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Abstract 
Host-microbial interactions are of major importance in the pathogenesis of inflammatory 
bowel disease (IBD). Toll-like receptors (TLR) are pattern recognition receptors which 
recognise conserved molecular patterns derived from micro-organisms. Crypt intestinal 
epithelial cells (IEC) were isolated form mucosal specimens of healthy controls and patients 
with IBD (ulcerative coliWLV8&DQG&URKQ¶VGLVHDVH). A population of IEC enriched for 
intestinal stem cells (ISC) were identified using Hoechst dye exclusion and by their 
adherence to cultured primary intestinal myofibroblast cell monolayers.  
 
Compared to healthy control colon, TLR2 and TLR4 mRNA and surface protein were 
significantly up-regulated in crypt IEC isolated from the inflamed mucosa of UC and &URKQ¶V 
colitis. Compared to healthy control ileum, TLR4 mRNA was significantly up-regulated in 
crypt epithelial cells isolated from the inflamed mucosa of &URKQ¶VLOHLWLV. TLR2 and TLR4 
mRNA expression from histologically normal and inflamed colonic mucosa in UC did not 
significantly differ, and expression of TLR4 transcripts was significantly greater in crypt IEC 
isolated from histologically normal proximal colonic mucosal samples compared to healthy 
controls. Myofibroblast-adherent crypt cells expressed TLR2 and TLR4 protein to a greater 
level than the underlying myofibroblasts. Hoechst-effluxing putative intestinal stem cells 
expressed both TLR2 and TLR4 transcripts and protein, and TLR3 and TLR5 transcripts.  
 
In conclusion, crypt intestinal epithelial cells up-regulated TLR2 and TLR4 expression in UC 
DQG&URKQ¶VFROLWLVDQGXS-UHJXODWHG7/5H[SUHVVLRQLQ&URKQ¶VLOHLWLV7/5DQG7/5ZDV
expressed constitutively in crypt IEC from histologically normal mucosa, suggesting 
differential TLR expression may in part be a primary event in UC. This provides further 
insights into the pathogenesis of IBD. Putative intestinal stem cells expressed TLR2, TLR3, 
TLR4 and TLR5, suggesting that direct microbial sensing by ISC may be important in 
maintaining intestinal homeostasis and in regulating ISC function.  
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Chapter 1: Introduction 
 
1.1 The gastrointestinal tract 
The gastrointestinal tract is primarily an organ responsible for the digestion and absorption of 
nutrients, vitamins, minerals, electrolytes and water from the diet in a controlled and orderly 
manner as it passes from the mouth to the anus. It is responsible for the expulsion of faecal 
waste as a controlled and socially acceptable process and is controlled by a complex system 
involving neural, hormonal and nutrient (peptide and lipid)-mediated signals. Along its 
passage through the gastrointestinal tract the nutrient-containing fluid is mixed with digestive 
enzymes and other active secretions produced by various glands and structures, including 
the submandibular and parotid salivary glands, gastric glands, pancreas, liver and 
gallbladder, intestinal brush border cells and mucus-secreting colonic cells (1).  
 
Nutrients are absorbed across the epithelial cells of the proximal small bowel. The distal 
ileum is responsible for the absorption of a small number of nutrients such as fat-soluble 
vitamins, bile acids and vitamin B12, with the colon responsible for the absorption of 
electrolytes and water. The gastrointestinal tract also provides an initial line of defence 
against enteric infection or harm by preventing access to the body by invading micro-
organisms and toxins. This includes vomiting following the ingestion of harmful substances 
and the provision of a barrier to active and passive movement of substances and organisms 
across the epithelial layer.  
 
It is becoming increasingly clear that the gut plays a key role in both the active immune 
response to infection and in the active maintenance of tolerance to antigens derived from 
beneficial, commensal micro-organisms resident in the intestinal tract and from food 
antigens. The gut is considered a secondary lymphoid organ, the so-called gut-associated 
lymphoid tissue (GALT), and plays a key role in the pathogenesis of inflammatory conditions 
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of the intestinal tract. The epithelial cells, once considered to be immunologically inactive, 
are increasingly being implicated in the pathogenesis of chronic inflammatory diseases of 
the bowel.  
 
1.1.1 Anatomy 
The digestive tract extends from the mouth to the anus and includes the pharynx, 
oesophagus, stomach, duodenum, small intestine (jejunum and ileum), colon, rectum and 
anus. The gastrointestinal tract (GIT) is lined with mucus membrane (mucosa), which is of 
stratified squamous type in the mouth, pharynx, oesophagus and anus (due to considerable 
mucosal abrasion at these sites) and columnar type in regions devoted to digestion and 
absorption. Muscle tissue in squamous mucosal regions of the GIT consists of striated 
muscle fibres, compared to the smooth muscle found throughout the rest of the gut. The 
absorptive surfaces in the small intestine are folded to reveal finger-like projections known 
as villi which increase surface area. Microscopically epithelial cells express microvilli which 
form the brush border, further increasing surface area and providing the site for small 
molecule transport. Between small bowel villi there are epithelial invaginations into the 
underlying layer (known as the lamina propria) called crypts of Lieberkühn. These contain 
the epithelial stem cells at their bases which replenish cells as they migrate from crypt to 
villus tip before being shed into the gut lumen.  
 
The GIT is composed of a number of layers. The innermost layer is the mucosa, which 
consists of an intestinal epithelial cell (IEC) layer covering the underlying lamina propria 
(LP). The LP is rich in stromal cells like myofibroblasts, which secrete extra-cellular matrix 
and growth factors, and cells of the innate and adaptive immune system like dendritic cells 
(DC), macrophages and lymphocytes (which are also found situated between epithelial cells 
of the mucosa). The LP also contains blood vessels, nerves, lymphatics and more organised 
lymphoid structures including O\PSKRLGIROOLFOHVDQG3H\HU¶VSDWFKHV33 
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The mucosa is separated from the underlying submucosa by a thin layer of smooth muscle 
known as the muscularis mucosae. Beneath the submucosa is the thicker muscle layer 
called the muscularis propria which comprises the inner circular and outer longitudinal layers 
of smooth muscle.  These act to move intestinal contents along the GIT, a process termed 
peristalsis. The outer layer of the gut is known as the serosa.  
 
The intrinsic nerves of the gut are known as the enteric nervous system and comprise of the 
P\HQWHULF$XHUEDFK¶VSOH[XVVXSSO\LQJWKHPXVFXODULVSURSULDDQGWKHVXEPXFRVDO
0HLVVQHU¶VSOH[XVVXSSO\LQJWKHPXVFXODULVPXFRVDH7KHVHLQWULQsic nerve fibres convey 
excitatory and inhibitory signals to smooth muscle fibres. The input of these plexuses comes 
from the autonomic nervous system and from the intrinsic chemoreceptors and 
mechanoreceptors which have their sensory terminals in the epithelial sheet. Secreted 
peptides like gastrin, secretin, cholecystokinin, somatostatin, vasoactive intestinal peptide 
and glucagon-like peptide act as hormones in the regulation of gut function over longer time 
periods compared to the nervous control which acts rapidly. The pharynx, upper oesophagus 
and anus are under exclusive neuronal control, whereas hormonal control plays a greater 
role in gastric, pancreatic and biliary secretion (1).  
 
1.1.2 Function 
The digestive process starts with the grinding of food in the mouth and mixture with salivary 
enzymes from the salivary glands. After passage through the pharynx and oesophagus this 
material enters the stomach where it is acted upon by gastric acid and proteases. Digestion 
here is limited and the stomach functions partly as a storage structure for this material, 
known as chime, until it is passed steadily into the duodenum. Here it is mixed with biliary 
and pancreatic secretions which contain a high concentration of digestive enzymes, bile 
acids and phospholipids to aid digestion and absorption. The majority of the absorption 
occurs in the proximal small bowel although colonic bacteria provide critical nutritional 
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actions by fermenting dietary fibre and producing short chain fatty acids and vitamins (such 
as vitamin K).  
 
As shall be discussed, beyond that of a simple barrier to the movement of large molecules 
and micro-organisms, the gut plays a key role in antigen recognition, generation of antigenic 
tolerance, initiation of innate immune responses and regulation of adaptive responses to a 
variety of antigens.   
16 
 
1.2 Inflammatory bowel disease 
1.2.1 Clinical introduction 
The inflammatory bowel diseases are a group of chronic conditions affecting the 
gastrointestinal tract characterised by a relapsing and remitting course. The two best 
FKDUDFWHULVHGLQIODPPDWRU\ERZHOGLVHDVHV,%'DUH&URKQ¶VGLVHDVH&'DQGXOFHUDWLYH
colitis (UC). Although CD and UC share a number of similar clinical features (such as 
symptoms, associated extra-intestinal manifestations and response to immunosuppressive 
therapies), clinical experience has led to wide acceptance that CD and UC are two separate 
conditions (2), as shown in table 1.1. 
 
7DEOH&OLQLFDOIHDWXUHVRI&URKQ¶VGLVHDVHDQGXOFHUDWLYHFROLWLV 
Feature CURKQ¶VGLVHDVH Ulcerative colitis 
Distribution Patchy and segmental Continuous 
Anatomical location Mouth to anus Rectum  
Predilection to terminal ileum 
DQG3H\HU¶VSDWFKHV 
Proximal extension 
Mural involvement Transmural inflammation Mucosal inflammation 
Histological hallmarks Macrophage infiltration and 
granulomas 
Neutrophilic infiltration with 
crypt abscesses 
Response to surgery Non-curative with 
anastamotic recurrence 
Curative 
Cytokine profile TH1/TH17 cell cytokines TH2 cell cytokines 
Effect of smoking Exacerbates Protective 
 
 
The United Kingdom, Northern Europe and North America have historically been considered 
the geographic regions associated with IBD, creating the so-called North-South divide. In 
Europe, the incidence of UC is 8.7-11.8 cases per 100,000 person-years and CD 3.9-7.0 
cases per 100,000 person-years, with a prevalence of 21.4-243 and 8.3-214 cases per 
100,000 persons, respectively. Thus, between 50,000 and 68,000 new cases of UC and 
23,000 to 41,000 new cases of CD are diagnosed each year in Europe (3). IBD is more 
common in Western Europe, a phenomenon called the East-West divide. 
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IBD is rarer in other continents with the exceptions of Australia, Israel and South Africa, 
although the incidence is increasing in Japan, South East Asia, North India and Latin 
America. Although IBD has been considered a disease of the developed world, the incidence 
in developing worlds is increasing. In addition, Asian immigrants moving to the UK 
demonstrate a sharp rise in incidence of IBD and in some cases show higher incidence than 
the indigenous European population (4). This may in part represent diagnostic inaccuracies 
(dysentery and intestinal tuberculosis can mimic UC and CD respectively) but may suggest 
environmental factors. Indeed, the high prevalence of intestinal helminths in the developing 
world may play a role in modulating intestinal immune responses and protecting from IBD 
(5).  
 
The peak age of onset of IBD is in persons aged 15 to 30 years, although a second peak in 
incidence in middle age is reported. There is a slight female preponderance to CD especially 
in late adolescence and adulthood, possible suggesting a hormonal influence, while the 
incidence of UC has a male preponderance. Men are particularly more likely to develop UC 
in the later decades (3, 6).  
 
&URKQ¶VGLVHDVHJHQHUDOO\DIIHFWVWKHLOHXPDQGSUR[LPDOFRORQDOWKRXJKDQ\SDUWRIWKH
gastrointestinal tract from mouth to anus can be involved. Classically the intestinal 
involvement of CD is discontinuous, with so-called skip lesions identifiable with intervening 
regions of macroscopically normal bowel. The intestinal inflammation of CD is transmural, 
affecting all layers of the gut, and typified by granulomas (in up to 50% of cases), strictures 
and fistulae. Fistulae take the form of internal fistulae, for example enterocolic, or external, 
such as enterocutaneous and peri-anal fistulae.  
 
By contrast, UC is a disease which always involves the rectum and extends proximally to a 
greater or lesser degree to involve the colon. The entire colon may be involved, a pan-colitis, 
and if this results in inflammation of the ileocaecal valve, incompetence of this valve can 
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result in back-wash ileitis. However, the small bowel is not inflamed in UC. The inflammation 
in UC is continuous and histologically confined to the mucosa. Strictures and fistulae are not 
seen in UC and granulomas are extremely uncommon, though have been reported in the 
peri-crypt location.  
 
There are many extra-intestinal manifestations of IBD such as skin conditions (oral mucosal 
granulomas, erythema nodosum and pyoderma granulosum), ocular manifestations 
(episcleritis and uveitis), HLA-B27 positive arthropathy and oral aphthous ulceration. In 
addition, cholesterol gallstones and oxalate renal calculi are associated with terminal ileal 
CD, and both types of IBD are associated with anaemia, osteoporosis and a pro-coagulant 
state predisposing to venous thromboembolism. Primary sclerosing cholangitis (PSC) and 
autoimmune liver disease can progress to cirrhosis, cholangiocarcinoma and primary 
hepatoma (7). There are a number of recognised risk factors for the development of IBD 
(table 1.2) (8). 
 
Table 1.2 Clinical risk factors for the development of inflammatory bowel disease 
Risk factor &URKQ¶VGLVHDVH Ulcerative colitis 
Smoking Exacerbates Protective 
Appendicectomy Future risk Protective 
Oestrogens Possible No 
Peri-natal infection Possible No 
Neonatal infection/antibiotics Possible No 
Diet (sugars, fats) Possible Possible 
 
Clinically, UC presents usually with bloody diarrhoea which is classically painless. 
Abdominal pain in the context of UC is suggestive of toxic colitis and impending perforation 
RIWHQORFDOLVHGRYHUWKHFDHFXP7KHSUHVHQWDWLRQRI&URKQ¶VGLVHDVHGHSHQGs on the 
disease location and phenotype. CD phenotype is generally classified as inflammatory, 
stricturing or fistulating (9). Pain is a prominent feature and often is accompanied by 
diarrhoea which may be secretory or steatorrhoea. Cutaneous or peri-anal fistulae are 
common to CD. Both conditions are associated with extra-intestinal manifestation which may 
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pre-date the intestinal symptoms and may be associated with constitutional symptoms such 
as weight loss and fatigue which may be related to systemic inflammation and anaemia.  
 
In addition to the risk of cholangiocarcinoma and hepatocellular carcinoma in the context of 
IBD-associated chronic liver disease, patients with IBD have an association with other 
intestinal malignancy, notably colorectal carcinoma is those with extensive, active, 
pseudopolyp-forming disease, particularly in those who smoke or have a family history of 
colorectal carcinoma, and distal-predominant small bowel lymphoma in CD.  
 
1.2.2 Pathogenesis  
'HVSLWHH[WHQVLYHUHVHDUFKRYHUUHFHQWGHFDGHVWKHDHWLRORJ\RI³LGLRSDWKLF,%'´UHPDLQV
incompletely understood. Granulomas (aggregations of immune cells with a centrally located 
core containing numerous macrophages surrounded by lymphocytes) are the hallmark of CD 
being present in 50-87% of intestinal biopsies and 20-38% of regional lymph nodes (10). 
Granulomas may represent a pathological extension of the normal function of the 
macrophage to defective intracellular killing by neutrophils and macrophages (11). More 
recently, the concept of defective immune responses in patients with CD were shown 
following trauma to the rectum, ileum and skin, resulting in reductions in neutrophil 
accumulation and pro-inflammatory cytokines interleukin (IL)-8 and IL-ȕSURGXFWLRQ(12). In 
addition, injection with heat-killed Escherichia coli resulted in reduced local inflammatory 
responses in CD (12). This suggests defective innate immune function results in 
accumulation of intracellular antigen leading to an over-active adaptive response attempting 
to clear foreign material.  
 
A recent review suggests that IBD results from a number of pathological processes observed 
in clinical studies (13):  
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1) invasion of the intestine by pathogenic or commensal bacteria (including 
Mycobacterium avium subspecies paratuberculosis (MAP), adherent invasive E. coli 
(AIEC), Bacteroides fragilis); 
2) alterations in the commensal flora of the gut (dysbiosis), resulting in higher bacterial 
numbers and reduced microbial diversity, with a predilection of sulphate-reducing 
species and loss of protective short chain fatty acid-producing species;  
3) host genetic defects in containing commensal bacteria (defective microbial killing, 
UHGXFHGĮ-defensin 5 production, reduced nicotinamide adenine dinucleotide 
phosphate (NADPH)-dependent superoxide production); and  
4) defective host immunoregulation (abnormal antigen processing and presentation, 
defective innate and adaptive immune regulation, overly aggressive T cell responses, 
host-microbial antigenic mimicry leading to autoimmune responses, mutations in 
pattern recognition receptor genes like nucleotide oligomerisation domain-2 (NOD2), 
autophagy and toll-like receptors).  
 
In support of the role of commensal micro-organisms in the pathogenesis of IBD serological 
markers against various microbes have been reported. Anti-Saccharomyces cerevisiae 
antibody (ASCA) production is widely reported LQ&URKQ¶VGLVHDVH. ASCA levels have been 
associated with disease progression (14) and, in combination with other serological markers, 
associated with complicated disease and the requirement for surgery (15). IBD patients 
display serological responses to other bacterial antigens, such as Escherichia coli outer 
membrane porin C (Omp-C), Pseudomonas fluorescens (I2) and flagellin (CBir1), which may 
be associated with phenotype and severity of disease (16-18). For example, seropositivity 
for anti-CBir1 antibodies is associated with small bowel, internal penetrating and 
fibrostenotic CD (18). These antibodies are more common in patients with IBD-associated 
genetic mutations, such as NOD1 and NOD2 polymorphisms (19), hinting that these 
antibodies are produced following a loss of tolerance to commensal micro-organisms due to 
defects in the innate immune system.  
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Similarly, the atypical peri-nuclear anti-neutrophil cytoplasmic antibody (pANCA) has been 
shown to be positive in IBD, especially UC, and may represent cross reaction with a 
bacterial antigen rather than an auto-antigen (20). In support of this, atypical pANCA auto-
antibodies react to KXPDQȕ-tubulin isotype 5 (TBB-5) and cross reacts with the microbial 
division protein FtsZ which shares high structural homology with TBB-5 (21).  
 
During active IBD, macrophages, dendritic cells and mucosal B lymphocytes over-produce 
pro-inflammatory cytokines including IL-1, IL-6, IL-8, IL-12 and IL-23, leading to the 
recruitment of neutrophils, T cells and monocytes and subsequent stimulation of 
differentiation and proliferation of T cells. ,Q&URKQ¶VGLVHDVH7KHOSHUFHOOUHVSRQVHVDUH
polarised to type 1 (TH1) and TH17 cells, leading to an up-regulation of IL-17, IL-23 and 
interferon gamma (IFN-ȖZKHUHDVLQXOFHUDWLYHFROLWLV7H2 cells, IL-5 and transforming growth 
factor beta (TGF-ȕpredominate (2).  
 
This loss of tolerance to intestinal flora and over-activation of adaptive immune responses 
result in chronic intestinal inflammation, the hallmark of the pathogenesis of IBD (22). It is 
interesting that IBD occurs in regions of the gut with the highest bacterial colonisation and 
that faecal diversion of intestinal contents away from inflamed bowel results in marked 
LPSURYHPHQWRILQIODPPDWLRQLQ&URKQ¶VGLVHDVH (23).  
 
1.2.3 Genetics of inflammatory bowel disease 
1.2.3.1 Innate immunity 
The observation that CD and UC run in families speculated at a genetic aetiology to IBD. 
Historical reports of higher rates of concordance in monozygotic twins in CD rather than UC 
suggested a stronger genetic component to the former (24). Although 80% of families with 
IBD tend to a similar phenotype, the remaining family cohorts reveal mixed groups of 
relatives with some members having CD and others UC, meaning there must be common 
genes to both conditions (25).  
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Over the last decade there has been a wealth of interest and a vast expansion in the 
identification of genetic polymorphisms predisposing to or protecting from IBD. The first to be 
identified were three mutations in the NOD2 (Caspase recruitment domain-15, CARD15) 
gene (26, 27). These mutations (Arg702Trp, Gly908Arg and Leu1007fsinsC) are likely to 
affect ligand-receptor interaction and are highly associated with susceptibility to small bowel 
and stenosing &URKQ¶s disease in a Caucasian (but not African or Oriental) population. 
Carriage of a heterozygous single nucleotide polymorphism (SNP) in the non-Jewish 
population equates to an odds ratio of 2.2-4.09 for developing CD; homozygosity or 
compound heterozygosity is associated with an odds ratio of 17.1 (28). Interestingly, NOD2 
mutations affect disease phenotype independently of smoking status and do not influence 
extra-intestinal manifestations (29).  
 
However, despite the clear relative risk of CD in NOD2 mutations, the absolute risk of IBD in 
carriers is small. Also, given that NOD2 mutations have a low penetrance and that these 
mutations are restricted to certain racial groups, NOD2 mutations cannot fully explain 
genetic predisposition to CD.  
 
The other main association with CD in the innate immune system relates to the autophagy 
genes, ATG16L1 and IRGM (30-32). A SNP in the ATG16L1 gene (Ala281Thr) located near 
the N-terminus of the tryptophan-aspartate (WD) repeat domain of the protein results in loss 
of function affecting primarily intestinal epithelial cells (IEC), antigen presenting cells (APC)  
and CD4+ and CD8 + T cells. Autophagy is a cellular process responsible for removal of 
waste organelles and is involved in the starvation response, though more recently it has 
been implicated in removal of long-lived proteins, aggregated/misfolded proteins, apoptotic 
bodies (which are pro-inflammatory) and intracellular pathogens such as Mycobacterium 
tuberculosis and intracellular Salmonella typhimurium (33, 34).  
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The defects in NOD2, ATG16L1, and IRGM genes represent dysregulation of the innate 
immune system. Their association with CD (but not UC) may indicate that defects in 
intracellular killing of bacteria are key features of CD which may lead to the observed TH1 cell 
polarity.  
 
As key pathogen sensors of the innate immune system, Toll-like receptor (TLR) genes play a 
role in IBD susceptibility. Two mis-sense mutations in the TLR4 gene, Asp299Gly and 
Thr399Ile, are associated with interrupted responses to lipopolysaccharide (LPS) in the 
human respiratory tract, with the former mutation interrupting TLR4 signalling (35). Both 
mutations are associated with CD (36) and the Asp299Gly mutation has been associated 
with both CD and UC, particularly in those with NOD2 mutations (37, 38). However, the 
association with UC is not a consistent finding (39).  Association has also been made 
between the TLR signalling molecule TIRAP (Toll-IL-1 receptor domain containing adaptor 
protein) and CD susceptibility (39).  
 
TLR5 recognises the ligand flagellin, a component of motile bacteria. Dominant negative 
mutations in the TLR5 gene are associated with reduced serological responses to flagellin 
and protection from the development of CD in the Jewish population (40). However, the 
prevalence of this mutation in the non-Jewish and UC populations were not different from 
healthy controls. Polymorphisms in the TLR9 promoter region (-1237 C/T) and the TLR9 
gene coding region (2848 G/A) are associated with CD in a German cohort (41).  
 
Other mutations to specific genes which logically link to the pathogenesis of IBD include: 
neutrophil cytosolic factor 4 (NCF4, involved in NADPH-dependent superoxide production in 
phagolysosomes) and CD (31); tumour necrosis super-family member 15 (TNFSF15) in 
Asians and Europeans and CD (42); TUNCAN (CARD8), a negative regulator of NF-ț%
signalling, and non-colonic CD (43); and E-cadherin (CDH1) polymorphisms (regulators of 
intestinal barrier function) and CD (44).  
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1.2.3.2 Adaptive immunity 
Although genetic polymorphisms in the innate immune system are associated with primarily 
CD, genes responsible for adaptive immune response are associated with both CD and UC. 
CD4-positive TH cells have traditionally been sub-divided into two main phenotypical groups: 
TH1 and TH2 cells. TH1 celOVVHFUHWH,)1ȖDQGDUHSULPDULly responsible for facilitating cell-
mediated immunity, including the activation of macrophages. By contrast TH2 cells secrete 
IL-4, -5, -6 and -10 and facilitate B cell-mediated antibody production (45). IL-4 is the key 
cytokine responsible for the differentiation of naïve T cells into the TH2 cell phenotype (via the 
transcription factors GATA-3 and STAT6), whereas IL-12 (a heterodimer comprising p35 and 
p40 subunits) drives TH1 cell differentiation (via the transcription factors STAT1, STAT4 and 
T-bet). For many years it was assumed that UC was mediated by TH2 FHOOVDQG&URKQ¶V
disease by TH1 cells (46).  
 
More recently a third phenotype of CD4-positive TH cell has been described, the TH17 cell. 
Differentiation into the TH17 cell phenotype is driven by IL-23, TGF-ȕ,/-6 and the 
transcription factor RORc (46). Interestingly, IL-23 is a member of the IL-12 cytokine family 
and has a heterodimeric structure, comprising the p40 subunit (common to IL-12) and a 
unique subunit p19. TH17 cells secrete IL-17 and other pro-inflammatory cytokines and are 
responsible for the immune response against extracellular micro-organisms (47).  
 
IL-17 is over-expressed in the LP of patients with IBD (48) and polymorphisms of the IL-23 
receptor (IL-23R) are associated with both CD and UC (49). Although the IL-23R Arg381Gln 
mutation protects against CD (relative risk, RR=0.38) and UC (RR=0.73) there is no 
association with disease phenotype or with NOD2 mutations (50). Polymorphisms in key 
components of IL-23 signalling pathway, STAT3 and Janus kinase-2 (JAK2) genes, and in 
the IL-12B gene are associated with CD (51) and, with the exception of JAK2, with UC (52, 
53). These ³SURWHFWLYH´PXWDWLRQVLQWKHVLJQDOOLQJSDWKZD\IRU,/-23 may reduce IL-23-
mediated susceptibility to IBD and may further suggest a role for IL-17 in the pathogenesis of 
25 
 
IBD. Indeed, anti-p40 (54) and anti-p19 (55) antibodies which attenuate IL-17 signalling have 
shown promise in the treatment of IBD humans and mice respectively. 
 
1.2.3.3 Disease phenotype 
A group of genetic polymorphisms impact on disease phenotype rather than susceptibility 
per se. Individuals with fHZHUFRSLHVRIWKHKXPDQȕ-defensin-2 gene have been associated 
with a predisposition to colonic CD (56). The TT polymorphism of the CD14 gene promoter is 
associated with a higher cumulative steroid doses in UC (57) and is seen more commonly in 
association with one or more NOD2 mutation in CD patients (58). In a Greek study, CD14 
promoter polymorphisms were also associated with susceptibility (38).  
 
The NOD1 deletion mutation, ND1 + 32656*1, is associated with early-onset CD and extra-
intestinal manifestation of IBD (59). Mutations in the ATP binding cassette B1/multi-drug 
resistance gene ABCB1/MDR1 are associated with UC, particularly the extensive-disease 
phenotype (60). The Asp299Gly and Thr399Ile TLR4 gene mutations are associated with 
stricturing CD particularly in NOD2 wild types, whereas wild type TLR4 in combination with 
common NOD2 mutations predicted penetrating disease in this cohort (36). Finally, 
polymorphisms in TLR genes impact on phenotype. TLR1 Arg80Thr and TLR2 Arg753Gly 
mutations predispose to pancolitis in UC, while there are negative associations between 
TLR6 Ser249Pro and proctitis in UC and between TLR1 Ser602Ile and ileal disease in CD 
(61).  
 
In addition to mutations associated with IBD in single genes, we see patterns of disease 
association extending over genomic regions containing several genes, such as the IBD5 
locus on chromosome 5q31 and CD susceptibility (62). OCTN1/2 (SLC22A4/5 solute carrier 
genes) within the IBD5 locus have been associated with CD (63) and UC (64), possibly in 
early onset of disease in children with lower weight, height and body mass index (BMI) (65). 
Similarly, mutations in the 5q13.1 region of the 1.23Mb gene desert are associated with CD 
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and most likely relate to the prostaglandin receptor EP4 (PTGER4) that resides in the 
closest associated region (66).  
 
1.2.3.4 Ulcerative colitis 
The genetic basis contributing to the pathogenesis of ulcerative colitis has not always been 
studied alongside that of CD (67). However, with the emergence of large-scale genome-wide 
association studies (GWAS) several genetic mutations and single nuclear polymorphisms 
(SNP) have been described in patients with UC from the original CD cohorts. IL-23R (49) 
and IL-12B (52, 53) are important genes in UC pathogenesis. The HECT domain and RCC 
domain-2 (HERC2) and STAT3 have stronger association with UC than with CD (53).  
 
The association with IL-10 is interesting in that mice deficient in IL-10 develop spontaneous 
enterocolitis, with associated crypt enlargement and branching, reduced goblet cells and 
loss of epithelial cells (68). Recovery and prevention of colitis was dependent on IL-10 
production by CD4+CD25+ regulatory T cells and induction of the colitis was prevented by 
rearing mice in germ-free conditions, implicating microbial factors in the pathogenesis of this 
model (69). IL-10-knock out mice are deficient in TGF-ȕ6PDGVLJQDOOLQJDQGIDLOWRLQKLELW
pro-inflammatory gene expression in intestinal epithelial cells after colonisation with 
colitogenic bacteria, which are likely to prevent tissue healing and Treg cell generation and 
to exacerbate inflammation (70).  
 
How IL-10 relates to the pathogenesis of human colitis remains unclear. Patients with UC 
show high rather than low levels of IL-10 mRNA expression in mucosal biopsies (71). The 
efficacy of human recombinant IL-10 in inducing remission or preventing post-operative 
recurrence of CURKQ¶VGLVHDVH has been disappointing (72, 73). Given that IL-10 may play a 
more pathogenic role in UC than CD, the benefits of IL-10 therapy in UC may warrant 
investigation.  
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Despite the significant advances in the understanding of the genetic basis of IBD, our current 
understanding incompletely explains the disease heritability. How far knowledge of the 
common mutations associated with small increases in disease risk will take us to 
understanding the pathogenesis of IBD and whether this will translate this into effective, safe 
therapies remains to be seen.  
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1.3 Immunology 
The body is protected from infectious organisms and harmful external substances like toxins 
by a variety of physical, functional, chemical and cellular mechanisms. These make up the 
immune system and constitute varying levels of protection of the host from illness or harm 
(74).  
 
When an individual first encounters a pathogenic organism or toxin, the first steps in the 
defence of the host are the physical and chemical barriers that prevent entry. These barriers 
include the epithelial layers of the skin and the mucosal linings of the intestinal, respiratory 
and urinary tracts and the eyes and nasal surfaces. Traditionally, these barriers are not 
considered parts of the immune response, but they do play a vital role in protecting the host 
from infection and, in essence, largely prevent the requirement for an active immune 
response in the majority of situations. It is only when the mucosal and epithelial barriers are 
breached that an active immune response is required (75).  
 
Similarly, the functional role of certain components of barrier to infection, such as peristalsis 
and mucus production in the intestine or the action of cilia of the respiratory tract, play an 
important role in reducing the burden on the immune system to protect the host.  
 
The immune system is broadly divided into two groups: innate and adaptive responses. The 
innate immune response recognises the presence of foreign, invading pathogens through a 
number of mechanisms and by a variety of white blood cells (leucocytes). This response is 
evolutionarily older and more primitive than the adaptive immune response, but reacts far 
more rapidly to invasion. Pathogens are recognised either through preformed, non-specific 
effector molecules resulting in the removal of the pathogen, or via activation of specific 
inherited receptors in the genome which remain evolutionarily conserved and which result in 
inflammation, recruitment and activation of effector cells to the site of invasion. Such 
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receptors are expressed by all cells of a particular type and trigger an immune response 
within hours of pathogenic invasion (76).  
 
The innate immune system recognises components of a broad class of pathogen, such as a 
protein or polysaccharide component on bacterial cell walls. Although it can recognise 
subclasses of pathogen by their antigens (for example the Gram positive bacterial cell wall 
components, lipoteichoic acid or phosphocholine) and can discriminate host from pathogen, 
it cannot discriminate between more closely related molecular structures and cannot 
differentiate different micro-organisms expressing the same cell wall structures. In addition, 
there is no amplification of the innate immune response to repeated exposure to the 
pathogen (74).  
 
By contrast, the adaptive immune system is a far more specific response to infection. 
Antigenic components of pathogens, following recognition by innate immune system cells, 
are transported to local lymphoid organs and presented to naïve B and T lymphocytes (45). 
This triggers clonal expansion and differentiation to effector cells and subsequent removal of 
the pathogen. Such adaptive immune system cells require receptors with unique specificity. 
These receptors are encoded in multiple gene segments, and require gene rearrangement 
and clonal expansion to provide a specific response (76). In addition, adaptive immune 
responses retain pathogen memory allowing a more rapid and effective adaptive response 
should that specific pathogenic antigen be encountered in the future. The trade off for such a 
complex and specific response is a delay of several days for the effectors of the adaptive 
response to become effective following antigen presentation to naïve lymphocytes. In many 
situations the innate immune response will clear pathogens successfully and the adaptive 
responses will remain primed for future encounter with the pathogen.  
 
Recently, a group of cells known collectively as the innate lymphoid cells (ILC) have been 
described. These cells are present in the mucosal tissue of the gut and play a role in innate 
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immune responses to infectious micro-organisms, in lymphoid tissue formation, in tissue 
remodelling after damage inflicted by injury or infection and in the homeostasis of tissue 
stromal cells. This cell group includes natural killer cells, lymphoid tissue-inducer cells and 
related cells producing inflammatory cytokines traditionally associated with TH1, TH2 and TH17 
lymphocyte phenotypes of the adaptive immune system. These evolutionarily conserved 
cells are vital for protective immunity and their dysregulation can result in immune pathology 
(77).  
 
Therefore the immune system is required to perform four main tasks to prevent harm. The 
first is immunological recognition whereby the infecting organism is detected by the immune 
system. The second is infection containment and elimination through effector functions, 
either humoral or cellular. However, the immune response must be kept under control, and 
therefore the third function is immune regulation. Failure of this function leads either to 
allergy and autoimmunity or the failure to mount an adequate immune response altogether. 
Fourthly, a unique feature of the adaptive immune response is memory, allowing the host a 
more rapid and stronger response to subsequent exposure (45).  
 
1.3.1 Mucosal immunity 
The gut-associated lymphoid tissue consists of lymphocytes at various sites throughout the 
gastrointestinal tract. Lymphocytes are found individually scattered between IEC and in 
ordered lymphoid aggregates (known as isolated lymphoid follicles, ILF) in the lamina 
propria (LP). In addition, lymphocytes aggregate LQ3H\HU¶VSDWFKHV (PP), sitting below the 
follicle-associated epithelium (FAE) and the dendritic cell-rich sub-epithelial dome (SED) in 
the LP, and are also found within mesenteric lymph nodes (MLN) (74).  
 
The traditional pathway for antigen presentation in the gut was reviewed by Mowat (78). 
Luminal antigen is transported unprocessed across the IEC barrier to DC within the SED 
which migrate to PP. The activated DC expresses co-stimulatory molecules and secretes 
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cytokines and chemokines. In addition, DC undertake antigen processing, resulting in 
antigen presentation in class II MHC molecules to naïve CD4+ T cells in the PP. B cells 
interact with DC and TH cells, resulting in differentiation and immunoglobulin (Ig) class 
switching to IgG.  
 
Lymphocytes primed in the PP drain via afferent lymphatics to the MLN for further 
differentiation, resulting in loss of L-selectin expression and up-UHJXODWLRQRIĮȕ-integrin 
and CCR9, which orchestrate homing to the gut mucosa following their return to the 
circulation via thoracic duct via interaction with MAdCAM-1 and CC-chemokine ligand 25 
(CCL25), respectively. This specific pattern of adhesion molecule and chemokine expression 
differs from other lymphocytes ZKLFKH[SUHVVĮȕ-integrin and CCR4 and which do not 
migrate to the gut mucosa (78).  
 
Activated lymphocytes arriving in the mucosa distribute to various compartments. B cells 
mature into IgA-secreting plasma cells and CD4+ T cells distribute throughout the LP along 
the crypt-villus axis. About half of mucosal T cells are CD8+ and represent either true 
effector (cytotoxic) cells or ³PHPRU\HIIHFWRU´FHOOV,QDGGLWLRQDSURSRUWLRQRI&'7FHOOV
in the LP are IL-10 and transforming growth factor (TGF)-ȕ-secreting Treg cells which help 
maintain oral tolerance to food and commensal micro-organisms (79).  
 
However, it is likely that antigen can take alternative routes leading to activation of naïve 
lymphocytes. Antigen can pass through or between IEC into the LP directly and bind to 
pattern recognition receptors (PRR) on DC. These APC may migrate directly to the MLN, 
bypassing the PP, and induce differentiation and migration of lymphocytes to the mucosa. 
The MLN would then be acting as a crossover point between peripheral and systemic 
immune systems and may explain the acquisition of systemic immunity to orally 
administered antigens. If in sufficiently high amounts, antigens may pass across the mucosal 
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barrier and enter either the lymphatic or venous systems directly and stimulate tolerogenic 
adaptive responses (78).  
 
Upon recognition of an invading pathogen the mucosal immune system switches from a 
tolerogenic to an inflammatory phenotype, up-regulating pro-inflammatory cytokines (IL-1, IL-
6, IL-8, IL-23, IL-12, IFN-ȖDQG,/-4) and co-stimulatory molecules (CD80, CD86 and CD40). 
This results in the activation and recruitment of innate cells and differentiation of T cells into 
effector lineages (TH1, TH17 and TH2 cells), clearing pathogenic organisms and acquiring 
immunological memory (45).  
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1.4 Pattern recognition receptors of the immune system 
Pattern recognition receptors (PRR) are components of the innate immune system which 
detect highly conserved, invariant pathogen-associated molecular patterns (PAMP) found in 
most micro-organisms. However, these PAMP are not unique to pathogenic micro-
organisms and can be found as cell wall components of many commensal gut bacteria. In 
addition, PRR have various endogenous (host-derived) ligands which are released during 
tissue destruction and apoptosis. These have been termed damage-associated molecular 
patterns (DAMP) DQGLQFOXGHKHDWVKRFNSURWHLQVȕ-defensins, fibronectin, hyaluronan 
fragments, heparin sulphate and extracellular fibrin.  
 
PRR can be categorised into three main groups: (1) secreted PRR (including collectins, 
ficolins and pentraxins) which bind to microbial surfaces and activate the classical and lectin 
complement pathways; (2) transmembrane PRR (including Toll-like receptors and C-type 
lectins) expressed on either the plasma membrane or in endosome organelles, and (3) 
cytosolic PRR (including RIG-I-like receptors (RLR) and NOD-like receptors (NLR)) (80).  
 
1.4.1 Toll-like receptors 
The Toll-like receptors were discovered in 1991 following the description of a homology 
between Toll, a transmembrane protein involved in embryogenesis in the fruit fly Drosophila, 
and the human IL-1R protein (81). The TLR family is a group of receptors with a common 
cytoplasmic Toll/IL-1 receptor (TIR) domain. A total of thirteen mammalian TLR have been 
identified, though only ten are found in humans (TLR1-10) (82). Each TLR is responsible for 
the recognition of distinct invariant microbial structure across bacterial, viral, fungal and 
protozoal species and are widely distributed in many tissues, especially epithelium, 
endothelium and myeloid cells (table 1.3) (83). 
 
 
34 
 
Table 1.3 Cellular expression, recognised ligands and gastrointestinal disease associations 
of Toll-like receptors in humans 
Toll-like receptor  Intestinal location  
 
Ligands  
 
GI associations  
 
TLR1 (heterodimer 
with TLR2)  
Ubiquitous  
 
Tri-acyl lipopeptides  
 
HCV  
 
TLR2  Myeloid, mast, NK, 
mDC, T cells  
Gram +ve bacteria 
LP, PGN, LTA, 
zymosan  
IBD, H. pylori, CRC, 
HBV, HCV, PBC  
TLR3 (intracellular)  mDC, NK  dsRNA  PBC  
TLR4  Mono,  mast, 
neutrophils, T cells, 
HSC  
 
Gram ±ve bacteria 
LPS, endogenous 
ligands  
 
IBD, H. pylori, CRC, 
PBC, PSC, HBV, 
HCV, ALD, NASH, 
HCC, cirrhosis, 
fibrogenesis, post-
OLT ACR 
TLR5  Epithelial, NK, DC, 
mono  
Bacterial monomeric 
flagellin  
IBD, PBC  
 
TLR6 (heterodimer 
with TLR2) 
Myeloid, mast, B 
cells  
 
Di-acyl lipopeptides  
 
HCV  
 
TLR7 (intracellular)  pDC, B cells, eosins  ssRNA  HCV  
TLR8 (intracellular)  Myeloid, T cells, NK  
 
ssRNA  
 
 
TLR9 (intracellular) pDC, B cells, NK  
 
Demethylated 
bacterial DNA CpG 
motifs  
Colitis, HCV, PBC, 
PSC  
 
TLR10  B cells, pDC  Unknown   
ACR Acute cellular rejection; ALD Alcoholic liver disease; CRC Colorectal cancer; DC Dendritic cell; DNA 
Deoxyribonucleic acid; dsRNA Double stranded RNA; Eosins Eosinophil; HBV Hepatitis B virus; HCC 
Hepatocellular carcinoma; HCV Hepatitis C virus; H. pylori Helicobacter pylori; HSC Hepatic stellate cell; IBD 
Inflammatory bowel disease; LPS Lipopolysaccharide; LTA Lipoteichoic acid; mDC Myeloid DC; Mono Monocyte; 
NASH Non-alcoholic steatohepatitis; NK Natural killer; OLT Orthotopic liver transplant; PBC Primary biliary 
cirrhosis; pDC Plasmacytoid DC; PGN peptidoglycan; PSC Primary sclerosing cholangitis; RNA Ribonucleic acid; 
ssRNA Single stranded RNA; TLR Toll-like receptor 
Modified from Testro and Visvanathan (82)  
 
TLR can be subdivided into two groups. TLR 1, 2, 4, 5 and 6 are expressed on the cell 
surface and recognise extracellular ligands, while TLR 3, 7, 8 and 9 are found within 
intracellular organelles. This intracellular location of the latter group means that their ligands, 
which closely resemble host endogenous ligands, require endosome-mediated 
internalisation and processing before TLR signalling is activated. Host nucleic acid is not 
accessible to these compartments so does not trigger TLR signalling.  
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TLR2 is generally regarded as the PRR for Gram positive bacteria and binds bacterial 
lipoproteins and peptidoglycan, though it also has a role in detecting Mycobacteria, 
spirochetes, fungi and hepatitis C, herpes simplex and cytomegalovirus. It also binds to 
endogenous DAMP ligands. TLR2 may heterodimerise with either TLR1 or TLR6 and the 
resulting complexes recognise bacterial triacylated and diacylated lipopeptides, respectively.  
 
TLR4 is the main Gram negative bacterial sensing PPR and is best known as the LPS 
receptor, though it also detects a range of endogenous DAMP ligands. TLR5 recognises the 
constant domain D1 of flagellin, a component of bacterial outer membrane involved in 
motility.  
 
TLR signal through one or both of two distinct pathways. The first requires the signalling 
molecule myeloid differentiation primary-response gene-88 (MyD88). Like the IL-1R and IL-
18R, all TLR except TLR3 and some TLR4 signals require MyD88. In its simplest pathway 
MyD88 is recruited to the intracellular TIR domain and acts as a recruitment factor for the IL-
1R-associated kinase 4 (IRAK4). This leads to attraction and binding of initially IRAK1 and 
subsequently two further molecules, tumour-necrosis-factor-receptor-associated factor 6 
(TRAF6) and transforming-growth-factor-ȕ-activated kinase 1 (TAK1). TRAF6 and TAK1 are 
activated by three ubiquitin factors, ubiquitin-conjugating enzyme E2 variant 1 (UEV1A), 
ubiquitin-conjugating enzyme 13 (UBC13) and evolutionarily conserved signal intermediate 
in Toll pathways (ECSIT) (84).  
 
Activated TRAF6 and TAK1 bind to several TAK1-binding proteins (TAB1-3) and activate 
various pro-inflammatory transcription factors including NF-ț%DQGWKH0$3.IDFWRUVS
and JUN N-terminal kinase (JNK). NF-ț%LVDFWLYDWHGE\SKRVSKRU\ODWLRQDQGGH-activation 
RILWVLQKLELWRUSURWHLQLQKLELWRURIț%,.%E\WKHSURWHLQFRPSOH[LQKLELWRURIț%NLQDVHV
ĮȕȖ,..Į,.%ȕDQG,.%Ȗ7KLVUHOHDVHV1)-ț%DQGDOORZVLWVQXFOHDUWUDQVORFDWLRQ-1.
and p38 are activated by MAPK kinases (MKK), including MKK7, MKK3, MKK4 and MKK6. 
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The activation of these transcription factors results in the production of IL-1, IL-6, IL-8, IL-12 
and TNF-Į0\'FDQDOVRFRXSOHWRLQWHUIHURQ-regulating factor 5 (IRF5) and, acting via 
TRAF6, represents a delayed source of TNF-Į (figure 1.1) (85). 
 
Figure 1.1 Intra-cellular signalling pathways of the Toll-like receptors 
 
Courtesy of Cell Signaling Technology® reference signal pathways (86) 
 
In the case of TLR7-9, the MyD88-IRAK4 pathways leads, through TRAF6 and TRAF3, to 
the activation of IRF7 (resulting in IFN-ĮSURduction) and IRF5 activation (leading to delayed 
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TNF-Į production). MyD88 can also directly translocate to the nucleus with IRF1 and 
produce IFN-ȕ (85).  
 
TLR2 and TLR4 require the bridging TIR adaptor protein TIRAP (also referred to as MyD88-
adaptor-like protein, MAL) for MyD88 recruitment. In addition TLR4 is associated with the 
MD2 protein, which is critical for its function, and both TLR2 and TLR4 require expression of 
CD14 for respective ligand binding.  
 
The second pathway for TLR signalling is known as the MyD88-independent pathway. TLR3 
signals through the molecule known as Toll/IL-1 receptor-domain-containing adaptor protein 
inducing interferon-ȕTRIF). This results in the attraction and activation of three pathways. 
Firstly TRAF3 acts through TRAF-family-member-associated-NF-ț%-activator-binding kinase 
1 (TBK1) to activate IRF3 and IRF7. Secondly, TRAF6 and receptor-interacting protein 1 
(RIP1) activate NF-ț%WKURXJK,.%LQDFWLYDWLRQ Thirdly, RIP1 activates FAS-associated 
death domain (FADD) to induce apoptosis. TLR4 also signals through the TRIF pathway (in 
addition to its MyD88-dependent signalling), requiring the TRIF-related adaptor molecule 
(TRAM) to attract TRIF to the intracellular TIR domain of its receptor before subsequently 
inducing TRIF-associated pathways analogous to TLR3.  
 
TLR signalling is subject to regulation at various levels (87). TIR-TIRAP binding requires 
%UXWRQ¶VW\URVLQHNLQDVHBTK)-dependent phosphorylation and SOCS1-dependent 
degradation. A short form of MyD88 (MyD88s) and FADD interfere with IRAK4 attachment to 
MyD88, and IRAK-M inhibits signalling by preventing the release of IRAK1 and IRAK4 from 
MyD88 which is required for their downstream functions (though IRAK-M is found 
predominantly in peripheral blood leucocytes rather than mucosal tissues). In addition, TLR3 
DQG7/5VLJQDOOLQJLVLQKLELWHGE\VWHULOHĮ- and armadillo-motif-containing protein (SARM) 
which prevents TRAF3, TRAF6 and RIP1 binding, and RIP3 is a negative regulator of RIP1 
function (85).  
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Several other intracellular negative regulators at various stages of TLR signalling have been 
described, including phosphatidylinositol 3-kinase (PI3K), Toll-interacting protein (TOLLIP), 
IRAK2c, IRAK2d and the TRAF6 inhibiting cysteine protease de-ubiquitylating enzyme A20. 
The molecule TRIAD3A targets TLR4 and TLR9 for degradation through ubiquitylation (87).  
 
In addition to the intra-cellular regulators, several transmembrane protein regulators of TLR 
signalling have been described. STL2 down-regulates NF-ț%VLJQDOOLQJDQGWKHWXPRXU-
necrosis-factor-related-apoptosis-inducing ligand UHFHSWRU75$,/5VWDELOLVHV,.%Į to 
prevent nuclear translocation of NF-ț%The single immunoglobulin IL-1R-related molecule 
(SIGIRR) has also been shown to interfere with TLR signalling at the IRAK level and 
SIGIRR-deficient mice show enhanced inflammation and reduced threshold for lethal 
endotoxin challenge (88). Soluble forms of TLR2 and TLR4 (sTLR2 and sTLR4) have been 
described which may clear free PAMPs and prevent membrane-bound TLR signalling.  
 
Finally, TLR can be down-regulated by anti-inflammatory cytokines like IL-10 and TGF-ȕ and 
in the case of intestinal epithelial cells, TLR4 responses are abrogated by lack of expression 
of the LPS co-receptor MD-2 (89).  
 
In summary, there has been great progression in the understanding of the mechanisms, 
actions, regulation and expression of the innate immune system pattern recognition 
receptors known as Toll-like receptors since their discovery two decades ago. TLR have 
emerged as the key receptors in the sensing of both pathogen- and damage-associated 
ligands and in the orchestration of the inflammatory response. However, TLR function has 
been shown to be for more complex and critical to the intestinal mucosa. Indeed, intestinal 
TLR play key roles in maintaining mucosal homeostasis and our understanding of their role 
in intestinal inflammatory diseases continues to expand.  
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1.5 Intestinal epithelial cells 
One of the remarkable aspects of the intestinal epithelium lies in its role in the innate and 
adaptive immune responses. In the face of such massive antigenic challenge, both from 
commensal bacteria and food sources, the mucosa maintains a state of immunological hypo-
responsiveness. However this is not an inactive state, but rather an active process of 
passivity to non-pathogenic antigens. In fact the epithelium remains primed to respond to 
pathogenic challenge.  
 
1.5.1 Barrier function of intestinal epithelial cells 
Although the skin is the most visible surface exposed to the external environment, the 
mucosal surfaces of the body have a much greater surface area, of which the intestinal 
mucosa comprises the majority. The intestinal mucosa is exposed to a vast array of dietary 
antigens in addition to the diverse micro-organisms of the intestinal flora. The adult human 
intestine is home to an estimated 1014 commensal bacteria (90) providing metabolic, 
nutritional and immunological benefits to the host (91).  
 
In its simplest role, the epithelial cells lining the gastrointestinal tract form a physical barrier 
to the movement of nutrient molecules and luminal commensal bacteria. Unlike the leaky 
characteristic of many mucosal surfaces, the intestinal epithelium regulates molecular 
passage based on size with a progressive decrease in permeability to larger molecules from 
crypt to villus.  
 
The mucosal surface is covered by a layer of mucus secreted from the gastric foveolar cells 
in the stomach and goblet cells in the intestine. Small molecules pass easily through this 
mucus layer whereas bulk fluid movement is limited, creating a thin unstirred layer adjacent 
to the mucosa protected from the mixing forces of luminal flow and peristalsis. This may aid 
nutrient absorption by preventing loss of the small nutrients released by the activity of brush 
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border enzymes (75). Defects in the mucus layer are implicated in the pathogenesis of 
murine models of intestinal inflammation as evident by the development of spontaneous 
colitis in Muc-2-deficient mice (92).  
 
Barrier function is regulated in part by the action of inflammatory cytokines such as TNF-Į
and IFN-Ȗ7KHHIIHFWVRI71)-ĮRQEDUULHUIXQFWLRQKDYHEHHQGHPRQVWUDWHGLQLQIODPPDWRU\
bowel disease and anti-TNF-ĮPRQRFORQDODQWLERG\WKHUDS\UHVWRUHVEDUULHUG\VIXQFWLRQLQ
&URKQ¶VGLVHDVH(93). Likewise, myosin light chain kinase (MLCK) expression and MLC 
phosphorylation are increased in patients with active disease and appears to correlate with 
disease activity, further suggesting a role for cytokines in epithelial barrier dysfunction (94).  
 
,QWHUHVWLQJO\ILUVWGHJUHHUHODWLYHVRISDWLHQWVZLWK&URKQ¶VGLVHDVHKDYHLQFUHDVHGLQWHVWLQDO
permeability despite being asymptomatic (95) and this may be related in part to the frame 
shift insertion at nucleotide 3020 of the NOD2 gene (96). Furthermore, during clinical 
UHPLVVLRQLQ&URKQ¶VGLVHDVHLQFUHDVHGLQWHVWLQDOSHUPHDELOLW\SUHGLFWVUHODSVHXVLQJWKH
lactulose-mannitol test (97).  
 
1.5.2 The role of intestinal epithelial cells in the immune response 
1.5.2.1 Recognition of commensal bacteria 
Mammals are born with a sterile intestinal tract and rapidly acquire their commensal flora 
following birth. The diversity of the commensal bacterial within the GI tract is greatest in the 
colon where anaerobic species such as Bacteriodes spp, Eubacterium spp, Bifidobacterium 
spp, Fusobacterium spp and Peptostreptococcus spp predominate over aerobic species 
such as Escherichia coli, Lactobacillus spp and Enterobacter spp. It appears that there is no 
pre-determined pattern of commensal acquisition but rather these colonies appear as a 
result of random environmental encounters, possible starting with the mode of delivery at 
birth and the composition of the maternal flora. While there is a great variability amongst 
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individuals in terms of the composition of flora, intra-individual composition varies 
remarkable little over time (98).  
 
Moreover, the presence of the flora is vital for normal GALT development. Mice reared in 
germ-IUHHHQYLURQPHQWVH[KLELWSRRUO\IRUPHG3H\HU¶VSDWFKHVDOWHUHGFRPSRVLWLRQRI&'
T cells and IgA-secreting B cells in the lamina propria and reduced cellularity of mesenteric 
lymph nodes and splenic tissue (99). The experimental introduction of polysaccharide from 
the commensal Bacteroides fragilis corrects the defect in peripheral lymphoid organs 
through TLR2 and TLR4 activation and NF-ț%VLJQDOOLQJ(100). Similarly, signalling through 
NF-ț%YLDTLR is important in maintaining intestinal homeostasis. IEC-specific deletion of 
IKK results in increased expression of pro-inflammatory cytokines and susceptibility to 
intestinal inflammation in disease models of radiation-injury, ischaemic colitis and chronic 
inflammation (101-103). NOD2 plays a role in immune tolerance to bacteria by decreasing 
the production of inflammatory cytokines in response to TLR2 and TLR4 activation (104-
106).  
 
To contain the growth of commensal bacteria, IEC secrete a broad range of antimicrobial 
peptides in the gut lumen, including defensins, cathelicidins and calprotectins which damage 
bacterial cell walls and interfere with bacterial metabolism (107, 108). Reduced antimicrobial 
SHSWLGHSURGXFWLRQKDVEHHQVKRZQLQFRORQLF&URKQ¶VGLVHDVH(109) and intra-luminal 
processing of Paneth cell-derived pro-human defensin-5 (pro-HD5) into active HD5 is 
impaired in the VPDOOLQWHVWLQHRISDWLHQWVZLWK&URKQ¶VGLVHDVH(110). Reduction in the 
production of Į-defensins in the small bowel (111) DQGȕ-defensins in the colon (56) may be 
partly a result of NOD2 gene mutations (112), though UHGXFHGLOHDOĮ-defensin production 
may simply occur due to loss of absolute epithelial cell numbers (113).  
 
Pathogenic bacteria adjacent to the epithelial layer are rapidly recognised, suggesting that a 
process of sampling of the luminal contents for foreign antigen occurs continuously. The 
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epithelium overlying PD\HU¶VSDWFKHVDQGLVRODWHGO\PSKRLGIROOLFOHV contain specialised 
epithelial cells known as microfold (m) cells which lack villi but demonstrate a folded 
structure at electron microscopy. M-cells sample and deliver antigen to DC in the sub-
epithelial dome (114) and this is enhanced by TLR2 and TLR4 activation (115).  
 
IEC themselves express pattern recognition receptors such as TLR and NLR (116) and MHC 
class II molecules (117), but they lack lymphocyte co-stimulatory molecules (118). During 
intestinal inflammation IEC up-regulate co-stimulatory molecules (119) and induce in vitro 
production of IFN-ȖZKHQFR-cultured with naïve CD4+ T cells (120).  
 
One of the fascinating aspects of mucosal immunity is its ability to discriminate between 
commensal and pathogenic bacteria, both of which may express similar PAMP. A traditional 
explanation for this is that pathogenic bacteria have evolved mechanisms to invade the host 
epithelial cell barrier and survive within host tissues, and it is these factors that are 
recognised by the immune system. By contrast commensal bacteria lacking these virulence 
factors and pathogenicity genes do not survive in host cells or disseminate throughout tissue 
and fail to elicit an immune response.  
 
Commensal bacteria can also produce anti-inflammatory molecules, such as the short-chain 
fatty acid butyrate, which inhibits pro-inflammatory cytokine expression and augments IL-10 
production (121). Butyrate is reported to induce epithelial cell maturation along the crypt-
villus axis and induces human epithelial cell line tolerance to LPS by down-regulating TLR4 
expression in HT-29 cells (122).  
 
Therefore in the normal state IEC possess the PRR to recognise bacterial PAMP and the 
intracellular signalling pathways to mount an innate immune response, but lack the co-
stimulatory molecules to modulate an adaptive response. Concomitantly, commensal 
bacteria lack innate immune system-activating pathogenic factors and dampen inflammatory 
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responses in IEC. It is only during intestinal inflammation that IEC express the necessary 
proteins allowing them at act as antigen-presenting cells and play a pro-inflammatory role in 
the immune response.  
 
1.5.2.2 Intestinal epithelial cell-dependent regulation of the mucosal immune response 
In healthy conditions, dendritic cells are capable of sampling commensal bacterial antigen 
and transporting it to mesenteric lymph nodes (123). This is partly undertaken by extending 
cellular processes between epithelial cells and into the lumen to directly sample antigen, 
which requires expression of the CX3CR1 chemokine receptor (124, 125). These DC also 
express CD70, a co-stimulatory molecule that binds T cell surface CD27 (124). Moreover, 
CCR6 is highly expressed by PH\HU¶VSDWFKDC and may be important in generating an 
effective immune response at this site. However, despite possessing the molecular 
requirements for initiating inflammation, mucosal DC do not normally activate innate immune 
responses. This is due to adjacent IEC producing tolerogenic signals.  
 
In vivo deletion of IEC-specific NF-ț%VLJQDOOLQJUHVXOWVLQHQKDQFHGH[SUHVVLRQRI'&-
derived pro-inflammatory cytokines (IL-12/23 p40, TNF-ĮDQG,/-17), loss of TH2 cell 
phenotype, reduced thymic stromal lymphopoietin (TSLP) production and the development 
of intestinal inflammation in NF-ț%NQRFN-out mice exposed to Trichuris helminthic infection 
(126). This demonstrates that IEC-specific NF-ț%DFWLYDWLRQLVDFULWLFDOVWHSLQPDLQWDLQLQJ
intestinal homeostasis, directing TH cell differentiation to the TH2 phenotype and mounting an 
appropriate immune response to Trichuris infection.  
 
TSLP promotes positive selection of CD4+CD25+FoxP3+ regulatory T cells and expression 
of cytotoxic T-lymphocyte-associated protein-4 (CTLA-4), a negative regulator of CD4+ T 
cell activation (127, 128). TSLP receptor knock out mice express high levels of IL-12/23 p40 
and IFN-ȖDQGdevelop a more severe DSS-induced colitis than wild type mice, suggesting 
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an immunomodulatory role for TSLP in gut mucosa in preventing TH1/TH17 cell-associated 
inflammation (129).  
In human studies, mucosal TSLP levels are enhanced in patients with ulcerative colitis, a 
condition associated predominantly with a TH2 cell phenotype (130). Conversely, patients 
ZLWK&URKQ¶VGLVHDVHGRQRW express TSLP, resulting in a TH1/TH17 cell-associated pro-
inflammatory response (131). Likewise, TSLP gene expression has been shown to be 
UHGXFHGLQKXPDQFRORQLF,(&LQSDWLHQWVZLWK&URKQ¶VGLVHDVH(132) resulting in a DC 
phenotype with up-regulated TLR2 and TLR4 expression and increased secretion of IL-6 
and IL-12 (133).  
 
IEC secrete other immunoregulatory cytokines which shape the immune response. TGF-ȕ
inhibits NF-ț%-dependent gene expression and limits cytokine expression from human 
blood-derived intestinal macrophages (134) and PXULQHWROHURJHQLF³UHJXODWRU\´DC (135). 
IEC induce CD103-positive DC through the production of TGF-ȕDQGUHWLQRLFDFLd (RA) 
which are capable of inducing de novo Treg cells with gut-homing properties that protect 
mice from experimental colitis and inhibit TH1/TH17 cell development (136). Murine CD103-
positive DC require tryptophan catabolism by the enzyme indoleamine-2,3-dioxygenase 
(IDO) to induce Treg differentiation (137). Furthermore, human IEC play a key role in 
modulating the differentiation of FoxP3+ Treg cell development in vitro, via CD103-positive 
CCR7-positive DC inductionDIXQFWLRQORVWLQSDWLHQWVZLWK&URKQ¶VGLVHDVH(132).  
 
Retinoic acid imprints the gut-KRPLQJUHFHSWRUV&&5DQGĮ4ȕ7-integrin on T cells (138, 139) 
and favours a Treg cell phenotype (140, 141). When compared to healthy controls, IEC from 
SDWLHQWVZLWKFRORQLF&URKQ¶VGLVHDVHVKRZUHGXFed transcription of TGF-ȕDQGDOGHK\GH
dehydrogenase-1A1 and -1A2 (ALDH1A1/2), the enzymes converting retinal to RA, even 
from regions of macroscopically inactive disease (132).  
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Therefore, IEC-derived TGF-ȕ5$DQG76/3SOD\ a key role in the differentiation of 
tolerogenic CD103-positive DC in the lamina propria of humans and mice. These DC 
express the MLN-homing CCR7 and drive tolerogenic FoxP3+ Treg cell differentiation. 
3DWLHQWVZLWK&URKQ¶VGLVHDVHDSSHDUXQDEOHWRLPSULQt DC with the ability to induce Treg 
cells. Interestingly, the probiotic commensal Lactobacillus paracasei increases levels of 
TGF-ȕDQG76/3DQGSURWHFWVPLFHIURPH[SHULPHQWDO'66-induced colitis (142).  
 
1.5.2.3 Intestinal epithelial cell-immune cell dysregulation in inflammatory bowel 
disease 
,Q&URKQ¶VGLVHDVHLQFUHDVHGQXPEHUVRI'&H[SUHVVLQJWKHFR-stimulatory molecule CD80 
(143), TLR2, TLR4 and CD40 (133) are observed in the mucosa. These are a likely source 
of increased TNF-ĮLQ&URKQ¶VGLVHDVH(144), and this may be due to lack of TSLP 
expression and subsequent failure to control DC-mediated inflammation (131). Indeed, anti-
TNF-ĮWKHUDS\is shown to reduce mucosal DC numbers (133). In patients with NOD2 gene 
mutations, DC show an impaired ability to induce TLR-mediated IL-17 expression in T cells, 
a process normally augmented by the NOD2 ligand muramyl dipeptide (MDP) (145).  
 
The role of DC in ulcerative colitis is less clear, though CD80+ DC-like cells have been 
described in association with lymphocytes in the colonic mucosa lymphoid aggregates (146) 
and peripheral blood-derived DC show increased lymphocyte stimulatory capacity (147). 
Macrophage-enriched clusters and cells with DC-like morphology derived from inflamed 
small and large bowel induce resting T cell proliferation to a greater extent than those from 
healthy controls (148).  
 
Whether the DC is a feasible target for therapeutic manipulation of the immune response 
remains to be seen. IL-10-WUHDWHG'&Į-dihydroxyvitamin D, mycophenylate mofetil and 
various immunosuppressants (like corticosteroids, tacrolimus, sirolimus and chloroquine) are 
known to act in various ways to reduce pro-inflammatory DC maturation, reduce co-
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stimulatory molecule expression and reduce IL-12 production (124). Indeed, IEC-derived DC 
tolerance may be an alternative approach to the treatment of IBD. Probiotics have an anti-
inflammatory action on intestinal mucosal DC in mice, protecting against TNBS-induced 
colitis though TLR2 and NOD2 pathways and Treg generation (149).  
 
Confluent cultured monolayers of the IEC line T84 express MHC class I and II molecules 
and can uptake and process antigen from the apical surface, suggesting that they can act as 
antigen presenting cells (150). However, their lack of or weak expression of co-stimulatory 
molecules suggests they cannot prime naïve T cells. ,Q&URKQ¶VGLVHDVHFRORQLF,(&RYHU-
express MHC class II molecules and localise exogenous antigens to the late endosome on 
their basolateral surface (151). Alloreaction with human IEC results in the proliferation of 
CD8+CD28+ effector T cells and CD8+CD28- Tregs (152). These CD8+CD28- Tregs have 
suppressive function in vitro, appear to require direct contact with IEC (through interaction of 
the CD8 ligand pg180 on IEC) for generation, and express CD101 and CD103 (152). 
Furthermore, the regulatory CD8+CD28- 7UHJFHOOLVGHIHFWLYHDQGOHVVDEXQGDQWLQ&URKQ¶V
disease and ulcerative colitis patients (153).  
 
In summary, it seems possible that gut-conditioned DC convert FoxP3- T cells into FoxP3+ T 
cells whereas IEC are important for expansion of pre-existing CD4+FoxP3+ T cells. IEC can 
modulate not just DC function but also regulate T cell function directly via MHC molecule 
expression. Altered IEC regulation of homeostatic balance between effector and regulatory 
cells may, in part, result in the inflammatory response seen in IBD.  
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1.6 The role of Toll-like receptors in inflammatory bowel diseases 
1.6.1 Human inflammatory bowel disease 
The altered expression of TLR in the mucosa of patients with IBD indicates a loss of 
tolerance to the luminal contents, though a primary causal link cannot made since TLR 
expression on IEC can be influenced by locally produced cytokines (154, 155). Therefore 
altered TLR expression may merely be a secondary phenomenon. Perhaps the most 
persuasive evidence for a direct role in human IBD is the association between genomic 
polymorphisms in TLR genes and susceptibility to or phenotype of IBD, as discussed in 
section 1.2.3.  
 
The most exciting avenue for future work in IBD will centre on the modulation of TLR 
signalling in therapeutics. TLR agonists and antagonists are being developed as treatments 
of cancer, allergic diseases and viral infections, and as adjuvants for vaccines (83).  
 
Given the differential expression of various TLR in intestinal inflammation, it would seem 
reasonable to investigate the therapeutic potential of blockage of the former and stimulation 
of the latter receptors in acute IBD. However, better characterisation of the expression of all 
TLR in active IBD, both CD and UC, is initially required.  
 
1.6.2 Animal models of inflammatory bowel disease 
Numerous experimental models of IBD have been used to further understand its 
pathogenesis and this has been extensively reviewed (156). Xavier and Podolsky suggest 
key lessons that have been learned from experimental models of IBD (157):  
 
1. Compromise of the epithelial barrier is sufficient to result in intestinal inflammation 
2. T cells have been implicated in many models and presumably promote inappropriate 
inflammatory responses 
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3. Haematopoietic cells mediate or regulate intestinal inflammation 
4. Various cytokines play key roles in certain models and chemokines may have a 
unique role in IBD 
5. The resident flora seems necessary for colitis induction (in most cases).  
 
The experimental induction of intestinal inflammation occurs through a number of 
mechanisms. The earliest models of colitis involved sensitisation to an antigen (such as 
OVA) followed by epithelial disruption with an agent like formalin and, finally, local or 
systemic re-administration of the antigen. Subsequent models involve primary defects in 
barrier function following administration of toxins like dextran sulphate sodium (DSS), acetic 
acid and carageenan. In time a number of murine gene knockout models have been 
developed which target specific genes like epithelial cell depletion of NEMO, 
multidrugresistant-Į-depletion (MDR-Į-/-), Muc2-/- and N-cadherin-/-. Other models involve 
depletion of regulatory T cells, including IL-10-/-, IL-2-/-, IL-5Į-/-, 7*)ȕ-/-7*)ȕ5-/- , 
CD45BRhigh transfer and SMAD3-/- mice. Finally models can induce inflammation by: 
increasing LPS responsiveness (macrophage and bone marrow STAT3-/- and A20-/- mice); 
impairing TLR responses (CdcsC3H/HeJBir mutant mice); increasing migration of T cells to the 
intestine (CD40L transgenic and SAMP1/Yit mutant mice), or T cell transfer into knock out 
mice (CD4+ CD62L+ T cell transfer from wild type into RAG-/- mice) (156).  
 
The flora has been shown to play a conflicting role in experimental colitis. Germ-free reared 
IL-10-deficient mice develop colitis only with the introduction of Escherichia faecalis. 
Likewise, TLR4-, TLR9- and MyD88-knockout mice are resistant to T cell-mediated and 
chronic DSS-induced colitis when reared in germ-free conditions (156).  Conversely, the 
development of colitis in the acute DSS model is worsened in germ-free environments and in 
TLR4-, TLR9- and MyD88-deficient mice (158). Indeed, NF-ț%DFWLYDWLRQin IEC has been 
shown to protect the intestinal mucosa from inflammation via production of type I interferons 
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(IFN-ĮȕDQG76/3ZKLFKUHGXFH,/-12/23 p40-induced TH1/TH17 cell responses, implicating 
TLR signalling as protective in some models of experimental colitis (156).  
 
Interestingly, the role of TLR signalling in experimental colitis has been investigated using 
various models. TLR9-/- mice are protected from developing chronic DSS colitis, as are mice 
subjected to chronic T-cell mediated models such as TLR4-/- mice in TNBS colitis and dual 
knock out MyD88-/- IL-10-/- mice (159).  
 
The most compelling evidence supporting a role for TLR signalling in the pathogenesis of 
IBD is derived from work investigating the effects of TLR agonists and antagonists on 
established murine models of colitis. Indeed, TLR ligands have been used in both 
prophylaxis and treatment of experimental colitis. Oral TLR2 and TLR4 ligands, and 
parenteral TLR3 and TLR9 ligands, prevent acute DSS colitis, while a TLR9 agonist has 
been shown to prevent chronic DSS colitis (159). Similarly, TLR4 (160) and TLR5 (161) 
agonists have been shown to protection against radiation-induced enteritis.  
 
However, TLR agonists administered during established colitis have very different effects. 
Rectal TLR5 and systemic TLR9 agonists aggravate established acute and chronic DSS-
induced colitis (159). Only the oral TLR2 agonist PCSK (Pam3CysSK4) has been shown to 
ameliorate established acute DSS colitis by enhancing epithelial barrier integrity (162, 163). 
By contrast TLR antagonists appear more effective in treating established colitis. Systemic 
administration of the TLR4 antagonist CRX-526 (a lipid A-mimetic) attenuated disease in the 
acute DSS colitis and spontaneous chronic MDR-Į-/- colitis models (164). Recently, a 
blocking monoclonal antibody against TLR4 improved acute DSS colitis but impaired 
mucosal healing (165).  
 
It would appear that TLR agonists and antagonists play a complex and variable role in the 
evolution of experimental colitis and have the potential for significant side effects. It is likely 
50 
 
that ligation of TLR in the absence of colitis protects against the development of 
inflammation, whereas once colitis is established, TLR agonists exacerbate while TLR 
antagonists ameliorate inflammation. The role of these and future TLR-manipulating agents 
in the management of acute and chronic IBD in humans is eagerly awaited. Perhaps TLR 
agonists may play a therapeutic role in preventing relapse in quiescent IBD, whereas TLR 
antagonists may be of benefit in reducing inflammation in acute exacerbations of IBD.  
 
1.6.3 Toll-like receptors-2 and -4 in human inflammatory bowel disease 
The main Gram-positive and Gram-negative bacterial-sensing pattern recognition receptors 
of the innate immune system are TLR2 and TLR4, respectively (82, 83). Inflammatory bowel 
diseases are widely regarded to result from an abnormal immune response to microbial 
components of the intestine. This results in the observed changes to the flora in IBD 
including increased bacterial numbers, reduced bacterial diversity, alterations in bacterial 
genus towards sulphate-reducing species at the expense of short chain fatty acid-producing 
species, and bacteria persistence/invasion of the mucosa and mesenteric lymph nodes (13).  
 
Genetic polymorphisms in the TLR2 receptor complex have been reported to significantly 
influence the phenotype of IBD (61). Similarly, polymorphisms in the TLR4 gene predispose 
to the development of FROLWLVLQERWK8&DQG&URKQ¶VGLVHDVH(36-38). Animal studies have 
shown that the presence of a bacterial flora is an important requirement in the development 
of experimental colitis (156, 157). TLR4- and MyD88-knock out mice are resistant to several 
types of experiments colitis such as chronic DSS-induced, TNBS-induced and IL-10-deficient 
models (159). These suggest altered TLR2 and TLR4 expression or function may be 
important events in the primary pathogenesis in IBD.  
 
The observation that TLR2 and TLR4 agonists prevent the induction of experimental colitis 
(159), and that a TLR4 antagonist (164) and an anti-TLR4 monoclonal antibody (165) 
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significantly reduce inflammation in established experimental colitis, suggest manipulation of 
TLR function and signalling may have therapeutic implications for human IBD.  
 
As will be discussed in chapter 4, TLRs have been reported to be expressed by human 
epithelial cancer cell lines, though the expression of TLR in primary human epithelial cells is 
less extensively reported. Given that the main cell type shown to have direct contact with the 
contents of the intestinal lumen (including the bacterial flora) is the intestinal epithelial cell, it 
seems reasonable to investigate the expression of TLR2 and TLR4 in primary human 
intestinal epithelial cells and to characterise any differential expression of TLR2 and TLR4 by 
these cells in IBD compared to normal epithelium.  
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1.7 Intestinal myofibroblasts, inflammation and the intestinal stem cell 
niche 
Myofibroblasts (MF) are mesenchymal cells responsible for the secretion of structural 
proteins, including the basement membrane fibrils, providing a supportive matrix in which the 
epithelial cells and gut immune cells reside. A sub-population of intestinal MF located in the 
peri-crypt region of the lamina propria, beneath the overlying epithelial cells, is referred to as 
the sub-epithelial MF (SEMF). These cells have a spindle shape when located around the 
crypt base and a more stellate appearance when located in the upper crypt and around the 
villi (166). In addition to their striking morphological appearance, SEMF are characterised by 
WKHH[SUHVVLRQRIWKHFHOOXODUPDUNHUVĮ-VPRRWKPXVFOHDFWLQĮ60$DQGYLPHQWLQPDUNHUV
associated with smooth muscle cells and fibroblasts respectively (167). However, MF have 
been phenotypically classified by their expression of cytoskeletal fibril proteins into several 
types including those which also co-express desmin (168).  
 
Electron microscopically the 18Co cell MF cell line demonstrate abundant, dilated rough 
endoplasmic reticulum, numerous Golgi, mitochondria, lysosomes and multivescicular 
bodies, and many caveolae occupying the sub-plasma membrane cytoplasm which may play 
a role in endocytosis (169).  
 
Myofibroblasts have a broad range of functions including but not limited to the secretion of 
extra-cellular matrix (ECM) proteins. The ECM is crucial as a provider of structural support to 
organs and tissues, and for cell layers to form such as the epithelium overlying the basement 
membrane. Cells attach to the ECM through a variety of receptors, including members of the 
integrin superfamily, and the ECM can transmit signals which alter cell behaviour and 
function. As a result, ECM proteins are key messengers in controlling cell differentiation, 
proliferation, survival, polarity and migration through their highly conserved structures and 
multiple distinct domains. Furthermore, many growth factors, for example fibroblast growth 
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factor (FGF) and vascular endothelial growth factor (VEGF), bind to ECM proteins to act as a 
growth factor reservoir; while other growth factors, like transforming growth factor (TGF)-ȕ
are actually presented to their receptor following binding to ECM proteoglycans (170).  
 
Myofibroblasts secrete collagen types I, III, IV and VIII and numerous glycoproteins such as 
the basement membrane constituent laminin-ȕODPLQLQ-ȖDQGILEURQHFWLQ,QDGGLWLRQ0)
secrete type I-III matrix metalloproteases (MMP), which degrade and remodel the ECM, and 
specific tissue inhibitors of MMP (TIMP) which regulate this process (167).  
 
The basement membrane has been shown to contain numerous pores. These are in 
continuity with tunnels within the ECM and it is through these pores that mononuclear cells 
and MF have been observed to migrate, following removal of the epithelial cell layer (171).  
 
The sub-epithelial MF is located immediately adjacent to the basement membrane and 
contributes to the stromal aspect of the region of the mucosa referred to as the stem cell 
niche. Its position around the crypt base places the SEMF in an ideal location to interact with 
the putative stem cell population (section 1.8). The interaction between the overlying IEC 
and the MF-derived ECM proteins is a key factor in maintaining IEC survival. Epithelial cells 
undergo rapid apoptosis within hours when removed from the underlying basement 
membrane, a process termed anoikis. This process can be either attenuated by exposing the 
cells to collagen I-coated membranes or when whole crypts are embedded in a collagen gel, 
or can be accelerated by pre-LQFXEDWLQJFHOOVZLWKDȕ-integrin blocking antibody (172). 
Interestingly, the crypt base appears particularly susceptible to apoptosis.  
 
A number of key signalling molecules are involved in the regulation of the stem cell 
population (173). Wnt signalling is perhaps the most widely characterised ISC signalling 
molecule. Upon ligation by a Wnt ligand, the Wnt receptors Fzd (Frizzled) and LRP (low 
density lipoprotein-related protein co-receptor) inactivate the destruction complex comprising 
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APC (adenomatous polyposis coli) and Axin, via a protein called Disheveled. This prevents 
WKHGHVWUXFWLRQRIDPROHFXOHFDOOHGȕ-Catenin, resulting in its translocation to the nucleus 
and activation of the transcription factors LEF (lymphoid enhancing factor) and TCF (T cell 
factor). The result of this cascade is the maintenance of the ISC in an un-differentiated state, 
and promotion of self renewal and proliferation within stem cells and progenitors, 
UHVSHFWLYHO\'HIHFWVLQ$3&DQGȕ-Catenin, resulting in over-expression of Wnt signalling, 
are associated with hereditary colorectal carcinoma syndromes. Wnt ligands are expressed 
in a gradient such that expression is greatest at the crypt and declines along the crypt-villus 
axis. Wnt also plays a role in compartmentalising Paneth and stem cells to the crypt base 
and is involved in specifying a secretory lineage of IEC (173).  
 
The PI3K/Akt signalling pathway plays a role in anti-apoptotic mechanisms, cell cycle 
progression and augmentation of the Wnt pathway, and disorders of this pathway result in 
LQWHVWLQDOKDPDUWRPDWRXVSRO\SIRUPDWLRQLQFOXGLQJ&RZGHQ¶VV\QGURPHand neoplastic 
conditions. Moreover, Notch signals result in stem cell proliferation and favour absorptive cell 
lineage differentiation (174). Conversely, bone morphogenetic protein (BMP) signalling 
suppresses cellular proliferation and induces differentiation towards a secretory lineage. 
BMP expression is greatest at the villus tip and decreases along the villus-crypt axis (the 
exact opposite of Wnt ligand expression). BMP signalling requires the SMAD4 protein and 
may inhibit PI3K/Akt signalling by enhancing the function of the PI3K inhibitor protein PTEN. 
Mutations in either SMAD4 or BMP receptor 1A (BMPR1A) result in the juvenile polyposis 
syndrome of the distal intestine (173).  
 
BMP antagonists are secreted only at the base of the crypt to prevent BMP-mediated 
differentiation. Importantly, BMP antagonists such as Noggin in mice (175) and Gremlin-1 
and -2 in humans (176) are expressed by SEMF. Murine SEMF have been reported to 
express mRNA for several Wnt ligands (such as Wnt2, 3, 4, 5A and 5B) while mRNA 
transcripts for Wnt receptors (Fzd1-7) were detected in SEMF and IEC (177). Similar mRNA 
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expression profiles have been reported in cultured human MF for Wnt ligands (Wnt2, 5A and 
5B) and Wnt receptors (Fzd1, 2, 4, 6, 7, 8 and LRP6), whereas human IEC express Wnt 
ligand receptors (Fzd1, 5, 7 and 8 and LRP6) but not Wnt ligands (178).  
 
These data suggest that MF residing within the stem cell niche play a vital role in maintain 
stem cells in an un-differentiated and proliferating state by secreting stem cell signalling 
factors which act in a paracrine effect on both ISC and local SEMF. This regulation acts 
through the BMP and Wnt pathways and is likely to regulate other pathways including 
PI3K/Akt signalling. These cells may also play a role in neoplastic conditions on the 
intestine.  
 
The role of MF proliferation and differentiation in intestinal fibrosis has recently been 
reviewed (179). Fibroblasts have been observed to contribute to the development of 
intestinal fibrosis via a number of pathways. Local proliferation of fibroblasts, fibroblast 
migration into regions of inflammation and myofibroblast differentiation from intestinal stellate 
cells all result in the expansion of the fibroblast population. In addition, bone marrow-derived 
MF are detected both in regions of inflammation/repair and normal mucosa in mice receiving 
gender-mismatched bone marrow stem cell transplantation and subject to TNBS-induced 
colitis (180). It is likely that a number of mechanisms exist which result in migration, 
proliferation and differentiation of fibroblasts in the intestinal mucosa, and these contribute to 
the processes of healing and fibrosis. These may be particularly relevant in fibrostenotic 
FRQGLWLRQVVXFKDV&URKQ¶VGLVHDVH 
 
The regulation of MF proliferation and differentiation is complex. Many growth factors 
including FGF-2, TGF-ȕSODWHOHW-derived growth factor, keratinocyte growth factor, insulin-
like growth factor and epidermal growth factor, are reported to play roles in the proliferation 
and activation of MF (179). It is noteworthy that pro-inflammatory cytokines known to be 
expressed in high levels in the mucosa of patients with IBD such as IL-1, IL-17 and TNF-Į
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are also implicated in the activation and proliferation of MF (177). This implies a possible 
MF-dependent mechanism for the development of fibrosis and stricturing in IBD and may 
SDUWO\H[SODLQWKHSURJUHVVLYHSKHQRW\SLFDOFKDQJHVVHHQLQ&URKQ¶VGLVHDVHRYHUWLPH
(181).  
 
In addition to the regulation of MF function by humoral factors of the immune system, there 
is an increasing body of evidence to suggest that MF play an active role in the immune 
response. The location of MF immediately below the antigen-sampling epithelial cells 
(including the microfold M-cells) and surrounded by antigen-responsive immune cells 
(including lymphocytes) provides the MF with an ideal environment in which to interact with 
these cellular compartments. Human cell lines of intestinal MF (CCD-18) and lung MF (CCD-
37), and cultured primary human intestinal MF have been shown to express mRNA for 
TLR1-9, NOD1 and NOD2, and to express protein for TLR2, TLR4 and several TLR-
associated signalling molecules (182). Although this has not been a consistently finding in all 
publications (183), these data suggest a role for MF in innate immune responses via 
recognition of specific PAMP epitopes.   
 
Myofibroblasts constitutively express both cyclo-oxygenase (COX)-1 and -2 enzyme 
isoforms (167). While COX-1 is constitutively expressed in many tissues and has a role in 
maintaining tissue homeostasis, COX-2 is the inducible isoform which is involved in the 
inflammatory response. In response to IL-17 and LPS, primary cultured colonic MF up-
regulate COX-2 mRNA and protein and PGE2 protein synthesis, implicating MF in the 
pathogenesis of gut inflammation (183). Myofibroblasts also constitutively secrete VEGF, 
which is over-expressed in active IBD and may play a role in the angiogenesis seen in the 
repair phase of the inflamed mucosa (184).  
 
Furthermore, MF may well partake in shaping specific adaptive immune responses to 
infection. Human myofibroblasts have been reported to up-regulate IL-23 p19 subunit mRNA 
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expression in response to incubation with IL-ȕDQG71)-ĮWKURXJK1)-ț%VLJQDOOLQJ(185). 
IL-23 p19 is a critical cytokine responsible for the differentiation of naïve CD4-positive T cells 
into the IL-17-secreting TH17 cell lineage in conjunction with TGF-ȕDQG,/-6. Moreover, TH17 
FHOOVDUHKHDYLO\LPSOLFDWHGLQWKHSDWKRJHQHVLVRI&URKQ¶VGLVHDVH(46). Interleukin-17 in 
turn has been shown to act directly on cultured MF and induce rapid secretion of IL-6 and 
the chemokines IL-8 and monocyte chemoattractive protein (MCP) -1 (186). Subsequently, a 
large number of cytokine and chemokine genes have been shown to up-regulate in cultured 
MF in response to IL-17 (166).  
 
Therefore, the intestinal MF is an important mucosal stromal cell for a number of reasons. 
MF secrete stem cell regulating factors and secrete components of the extracellular matrix, 
which is vital in providing structure to the intestinal wall, regulating the movement and 
attachment of cells, and binding inflammatory and growth factors. The interaction between 
the ECM and the overlying epithelial cells is crucial for their survival. Myofibroblast function 
is, in part, regulated by mucosal inflammatory mediators and may play an important role in 
regulating the immune response. Furthermore, the MF plays a pathological role in the 
formation of intestinal fibrosis in conditions such an inflammatory bowel disease.  
 
Although cultured intestinal MF have been reported to respond to a number of intercellular 
messenger molecules, including cytokines, the possible mechanisms by which the MF 
senses microbial antigens directly is not well investigated. Therefore the differential 
expression of TLR2 and TLR4 by primary cultured intestinal myofibroblasts from healthy 
controls and patients with IBD was investigated.  
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1.8 Putative intestinal stem cells 
The function of the intestinal stem cell is to maintain the integrity, and therefore functionality, 
of the intestinal epithelium. To achieve this, the stem cell must self-renew, proliferate and 
differentiate. Intestinal stem cells are located in a niche; comprising not only the proliferating 
epithelial cells but also mesenchymal cells such as myofibroblasts, enteric neurons, blood 
vessels and intra-epithelial lymphocytes, and extra-cellular matrix. Although the epithelial 
cells are separated from these cells by the basement membrane, epithelial-mesenchymal 
cross-talk is key to the maintenance and function of this niche (187).  
 
Schofield originally described haematopoietic stem cells as an essentially fixed tissue cell. 
Its maturation is prevented by its location in the stem niche and its progeny, unless able to 
occupy a similar location within the niche, will differentiate and proliferate into first-generation 
colony-forming cells (188). The intestine is interesting in that the epithelium can be 
separated into two compartments: functional and proliferative. The functional compartment 
comprises of cells unable to further proliferate, but rather contains predominantly mature 
absorptive columnar cells which populate the small bowel villi and luminal epithelium of the 
colon. The proliferative compartment is known as the crypt of Lieberkühn and contains the 
rapidly dividing cells which populate the functional compartment. Cells migrate from crypt to 
villus and are shed from the villus tip over a time course of approximately five days. The villi 
are polyclonal, potentially receiving cells from several adjacent crypts (187).  
 
Intestinal crypt cells differentiate into one of four mature lineages; columnar cells (known as 
enterocytes or colonocytes in the small and large bowel respectively), mucin-secreting 
goblet cells, hormone-secreting enteroendocrine cells and Paneth cells which secrete anti-
microbial peptides. The latter are noteworthy in that they are located deep in the crypts, in a 
region otherwise populated with undifferentiated stem cells, and that Paneth cells are only 
located in the small bowel and occasionally the proximal colon (108). Beneath the basement 
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membrane lie myofibroblasts. These cells maintain gut homeostasis through the secretion of 
a number of mediations including COX-2 and can regulate the immune response by 
secretion of signalling molecules such as TGF-ȕ,/-8, VEGF and chemokines and the 
expression of innate immune receptors (189).  
 
,Q3RWWHQDQG/RHIIOHUVXJJHVWHGWKDWWKH³VWHPQHVV´LQWKHLQWHVWLQHLVQRWDVLQJOH
property but rather a number of properties that a cell is capable of performing. Stem cells 
must be undifferentiated and capable of self-renewal and proliferation. Between the stem 
cells of the crypt (which divide but do not mature) and the mature lineage cells (which do not 
divide but are functionally competent) is a region of the crypt termed the transit amplifying 
region. This region contains celOVZKLFK³can under certain circumstances behave like actual 
stem cells while they undergo maturation under other conditions´DQGZKLFKVKRZVUDSLGFHOO
division and differentiation into functional cell lineages (190).  
 
Bjerknes and Cheng described the stems cell location as being at positions 1-4 in the crypt 
(labelling the most basal crypt cell as occupying position 1 and counting cells in an upwards 
direction from crypt to villus), with cells occupying position 5 or above being induced into 
differentiation (191, 192). Stem cells have been reported to number from between four and 
twenty cells per crypt.  
 
There are two current models of stem cell division in the intestine, deterministic and 
stochastic (187). The deterministic (or immortal) model describes a situation in which each 
stem cell divides into exactly one stem cell which remains within the niche and one daughter 
cell which leaves the niche; a process termed asymmetrical cell division. Under this model 
the stem cell is immortal and its genome is well protected from replication error because the 
stem cell retains the original template DNA strand whereas the daughter cell acquires the 
non-template strand. This has been demonstrated by 3RWWHQ¶VJURXSusing the labelling of 
stem cell DNA with tritiated thymidine (3HTdR) following radiation injury and by labelling 
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newly synthesised DNA strands with bromodeoxyuridine (BrdU). Template strands retain 
3HTdR in the stem cell zone (label-retaining cells) whereas newly synthesised BrdU-labelled 
strands are seen to migrate up the crypt (193). This work on label-retaining cells 
demonstrated that the dual 3HTdR- and BrDU-labelled cells (putative stem cells) on average 
UHVLGHDWWKH³´SRVLWLRQRIWKHFU\SWEDVH(193).  
 
The stochastic (or niche) model describes the result of stem cells division in terms of one of 
three outcomes: two stems cells (no daughter cell), one stem cell (and one daughter cell) or 
WZRGDXJKWHUFHOOVQRVWHPFHOO7KLVOHDGVWR³GULIW´LQWKHQXPEHURIGHVFHQGHQWRIHDFK
stem cell over time such that all stem cells within a given crypt are derived from a single 
common ancestral stem cell. Studies characterising the methylation patterns of CpG sites of 
non-expressed gene regions of stem cell DNA support this model and suggest that one stem 
cell has the potential to expand and replace the whole stem cell population stochastically 
(194).  
 
The issue of stem cell location within the crypt has led to differing reports in the literature 
regarding stem cell location. In particular, the character of the +4 position cells and the crypt-
based columnar cells (CBC), the latter originally described by Cheng and Leblond in 1974 
(195)LVGHEDWHG'HNDQH\¶VJURXSKDYHWDNHQWRXVLQJWKHWHUPVXSSHUDQGORZHUVtem cell 
zones (USZ and LSZ, respectively) (196) and suggest that the USZ may represent a 
quiescent reserve population whereas the LSZ contains cells which are active and more 
rapidly cycling (174).  
 
Identifying stem cells by the expression of a unique combination of markers has been a 
challenging area of intestinal stem cell research, though a number of intestinal stem cell 
markers have recently been described. The first was Musashi-1 (Msi-1) which is expressed 
in stem cells of the USZ and LSZ. Msi-1 is involved in asymmetrical cell division in neural 
stem cells of Drosophila (197) and acts as an RNA-binding protein in mammalian cells to 
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augment Notch signalling (198). Subsequently, Msi-1 has been reported as a stem cell 
marker in murine small and large intestine (199). Notch signalling up-regulates the 
expression of a transcription factor from the basic helix-loop-helix family, known as hairy and 
enhancer of split-1 (Hes-1). Hes-1 expression in the intestine commits cells to differentiate in 
to the columnar cell phenotype at the expense of secretory cell lineages. This occurs by the 
repression of math-1 expression, a key transcription factor for the secretory cell lineages 
(200).  Both Msi-1 and Hes-1 co-localise to cells in the stem cell zone and are best 
described as surrogate stem cell markers.  
 
A number of markers have been described which label the CBC cells of the LSZ specifically, 
such as: leucine-rich-repeat-containing G-protein-coupled receptor 5 (LGR5), CD133 
(prominin-ȕ-catenin, Ascl2 and SRY-box containing gene 9 (Sox9) (174). Conversely, B 
lymphoma Mo-MLV insertion region 1 homolog (Bmi1) and Doublecortin and CaM kinase-
like-1 (DCAMKL-1) mark the USZ, though Bmi1 is limited to the proximal small intestine and 
DCAMKL-1 may be a marker more of stem cell response to injury (196). Recently, a fraction 
of epithelial cells from mouse small intestine with stem cell properties have been reported to 
express the CD24(lo) and CD45-negative phenotype. These cells were enriched for LGR5 
and Bmi1 transcripts and generated organoid structures, including all four cell lineages, 
using Matrigel culture (201). However, approximately 30% of these cells express Paneth 
cell-associated lysozyme mRNA and protein, suggesting this sub-population of cells may not 
be homogeneous.  
 
Despite these advances in intestinal stem cell marker identification, these markers all 
represent intracellular proteins and are generally identified by immunostaining fixed 
histological tissue sections. An ideal combination of surface markers allowing positive 
cytological sorting of an enriched ISC population remains elusive. However, an alternative 
technique for isolating ISC has been described and uses the efflux properties on stem cells 
for the DNA-binding bis-benzimide blue fluorescent dye Hoechst 33342.  
62 
 
 
In 1996 Goodell et al. described a sub-population of murine bone marrow-derived 
haematopoietic cells which efflux Hoechst 33342 (202). When emission signal from live bone 
marrow-derived haematopoietic cells were viewed simultaneously following Hoechst 33342 
staining using the blue and red lasers on a linear scale of a flow cytometer, a population of 
cells with low signal in both emission wavelength channels and with a phenotype consistent 
with multipotent haematopoietic stems cells (HSC) was observed. These cells were 
subsequently shown to contain the vast majority of the HSC activity from murine bone 
marrow and to protect mice from lethal irradiation, even at low transplant cell numbers, by 
contributing to both the myeloid and lymphoid lineages (202). These cells are referred to as 
side population (SP) cells.  
 
SP cells with stem cell properties have been described in human breast (203), human 
prostate (204), murine liver (205) and murine skeletal muscle cells (206, 207). In 2005 
Dekaney et al described the isolation of murine SP cells from the jejunum of C57B1/6J mice 
using EDTA and dispase treatment followed by Hoechst 33342 staining (208). This yielded a 
mixed population of SP cells which were both CD45-positive and CD45-negative, and 
accounted for about 3% of the isolated epithelial cells. The CD45-negative SP cells were 
subsequently shown to stain negatively for common haematopoietic markers (Sca-1, Thy-
1.2, c-NLWDQG&'QHJDWLYHO\IRUWKHPHVHQFK\PDOPDUNHUĮVPRRWKPXVFOHDFWLQEXW
SRVLWLYHO\IRUȕ-integrin and the epithelial marker cytokeratin. These CD45-negative SP 
cells were enriched for Msi-1 mRNA expression, de-enriched for various mature epithelial 
lineage markers (intestinal trefoil factor, lysozyme and sucrase-isomaltase) and stained 
negatively for mesenchymal collagen IV mRNA expression (208).  
 
Subsequent work on isolated mouse jejunal IEC characterised a list of genes with enriched 
and de-enriched mRNA expression in CD45-positive SP compared to non-SP (NSP) cells in 
using micro array technology. Notch1 and fibroblast growth factor receptor-3 (Fgfr3, another 
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putative ISC marker) were shown to be enriched by four-fold and localise to the intestinal 
crypt base using immunohistochemistry (209).  
 
Most recently, SP cells of the human colon have been shown to express the epithelial-
VSHFLILFPDUNHU%HU(3&'DQGȕ-integrin, but not the haematopoietic stem cell 
marker CD34 (210). Moreover, these cells preferentially adhere to confluent myofibroblast 
PRQROD\HUVIRUXSWRGD\VLQDȕ-integrin-independent manner and were demonstrated to 
be Msi-1 positive using immunocytochemistry.  
 
The key feature in the identification of the SP is the ability of isolated cells to efflux the 
fluorescent dye Hoechst 33342. Hoechst 33342 readily binds to AT-rich regions of the minor 
groove of the DNA double helix and is used in cell cycle analyses (211). The efflux of 
Hoechst 33342 from the SP cells was initially thought to be a result of MDR-like pump 
action, however, bone marrow-derived cells from mice deficient in the MDR1a/1b gene were 
subsequently shown to efflux Hoechst 33342 and to demonstrate a side population of cells 
(212). Zhou et al. characterised the ATP binding cassette (ABC) transporter Bcrp1 (ABCG2) 
as being widely expressed in a variety of stem cell populations and identified ABCG2 as the 
molecular determinant of the side population (212). ATP depletion using 2-deoxyglucose 
with sodium azide, or reserpine, resulted in the abolishment of the SP. In addition, 
fumitremorgin C (FTC) (210, 213) and verapamil, a non-specific dihydropyridine calcium 
channel blocking agent (202, 204, 210), have been shown to block the ABCG2 pump and 
abolish the side population. These ABCG2-blocking agents allow identification of the side 
population and facilitate accurate SP cell sorting.  
 
Although the expression of ABCG2 is required to demonstrate a SP, mice deficient in both 
Mdr1a/b and Bcrp1 genes develop normal numbers of peripheral blood cells and 
demonstrate normal haematopoietic development (214). However, these bone marrow cells 
are more sensitive to the cytotoxic agent mitoxantrone in vitro than cells from mice 
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expressing either one of these genes, suggesting that these transporters play a role in 
providing environmental protection for the stem cell rather than being necessary for HSC 
development. Therefore, the SP likely represents a population of cells enriched with stem 
cell properties rather than representing a homogenous population of stem cells per se.  
 
Current evidence suggests that host-microbial interactions are important in the pathogenesis 
of IBD (13). Importantly, intra-epithelial neutrophil infiltration (cryptitis) and neutrophil crypt 
abscess formation are key histological features in IBD which result in epithelial cell loss and 
subsequent exposure of the underlying lamina propria to bacterial antigens (215). 
Regeneration of the epithelial barrier requires expansion and differentiation of the intestinal 
stem cell population. It is possible that the stem cell population, located in the base of the 
crypt, plays an important role in the pathogenesis of IBD through innate immune receptor-
mediated bacterial sensing. Therefore, the ability of this side population of cells (enriched for 
intestinal stem cells) to sense bacterial antigens by the expression of TLR2 and TLR4 was 
investigated.  
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1.9 Hypothesis 
Current evidence implicates epithelial cells in playing a key role in shaping the innate and 
adaptive immune responses of the intestinal mucosa. Toll-like receptors are important 
pattern recognition receptors which are indispensable in the developing gut-associated 
lymphoid tissue in early life and in maintaining intestinal homeostasis throughout life. 
Differential signalling through Toll-like receptors has been shown to prevent intestinal injury 
in a number of models of intestinal inflammation and to ameliorate established inflammation 
in models of colitis. Furthermore, Toll-like receptor expression has been demonstrated on 
human intestinal epithelial cells and differential expression of Toll-like receptors may 
contribute to the pathogenesis of human inflammatory bowel diseases.  
 
Recently, there has been interest in the role of intestinal myofibroblasts in mediating 
mucosal inflammation through the expression of innate immune system receptors, such as 
Toll-like receptors, and by the secretion of pro-inflammatory cytokines. Myofibroblasts also 
play a role in the pathogenesis of intestinal fibrosis in chronic inflammatory bowel diseases. 
Mediation of myofibroblast-induced intestinal fibrosis may, in part, be a result of toll-like 
receptor expression.  
 
Mucosal inflammation in inflammatory bowel disease results from abnormal immune 
responses to the intestinal flora. It is histologically identified by changes to epithelial crypt 
architecture and by inflammatory cell infiltration of the (usually sterile) crypts, forming crypt 
abscesses and cryptitis. Intestinal stem cells reside at the base of these crypts and are 
responsible for replenishing the epithelium following epithelial cell damage. These intestinal 
stem cells are surrounded and regulated by a variety of stromal cells, including intestinal 
myofibroblasts. It is unknown if intestinal stem cells directly recognise bacterial antigens 
through the expression of innate immune receptors, but their location at the crypt base 
places them in a prime position to response to bacterial antigens. Direct stem cell-mediated 
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bacterial antigen sensing may have key implications for mucosal homeostasis and 
inflammation.  
 
The hypotheses of this study are: (i) crypt intestinal epithelial cells and intestinal 
myofibroblasts in patients with inflammatory bowel disease differentially express Toll-like 
receptors-2 and -4 compared to healthy control subjects, and (ii) intestinal stem cells have 
the ability to directly sense bacteria through the expression of Toll-like receptors-2 and -4. 
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1.10 Aims 
The aims of this study are to characterise the expression of Toll-like receptors-2 and -4 in 
isolated crypt epithelial cells and primary intestinal myofibroblasts from patients with 
inflammatory bowel disease and to compare expression to healthy control subjects. 
Furthermore, this study will aim to isolate a sub-population of putative colonic intestinal stem 
cells based on their fluorescent dye efflux properties and characterise their expression of 
Toll-like receptors-2 and -4 in healthy control subjects.  
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Chapter 2: General methods and materials 
 
This chapter describes the methods and materials used in routine laboratory techniques. 
Specific techniques relevant to certain chapters will be described in detail in the relevant 
chapter.  
 
2.1 Cell counting and assessment of cell viability 
Cell counting and viability assessments were undertaken using a haemocytometer. Twenty 
PLFUROLWUHVȝORIVXVSHQGHGFHOOVZHUHPL[HGZLWKWU\SDQEOXH6LJPD-Aldrich 
Company Ltd, UK) in a 1:1 ratio. Two 12.5µl aliquots were added to the haemocytometer 
and the number of viable (unstained) and dead (stained) cells within the 25x25 square grid 
counted by light microscopy. Mean cell numbers were multiplied by the dilution factor (DF, in 
this 1:1 example the dilution factor is x2) to determine the concentration of cells per millilitre 
(ml) by the following formula: 
 
Cell concentration (x104/mL) = [(total cell count in grid 1) + (total cell count in grid 2)] x DF / 2  
 
2.2 RNA isolation 
Total RNA was isolated from cellular samples using the Qiagen RNeasy Plus Mini Kit 
4LDJHQ*HUPDQ\DVSHUWKHPDQXIDFWXUHU¶VLQVWUXFWLRQV%ULHIO\[6 cells were 
collected per tube. Cell membranes were disrupted by adding 600µl of Buffer RLT with 1% 
2-mercaptoethanol (M7522, Sigma) and mixing by pipette. The cellular lysate was 
homogenised using a Qiashredder spin column (79654, Qiagen, Germany) and 
centrifugation at 13,000 rpm for 2 minutes until all the lysate has passed through the column. 
The homogenised lysate was transferred to a genomic DNA (gDNA) Eliminator spin 
column® and centrifuged for 30 seconds at 13,000 rpm (>10,000g) to remove any 
contaminating gDNA. Genomic DNA binds to the column membrane whereas total RNA 
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passes through the membrane and into the flow-through. By discarding the gDNA column, 
contaminating gDNA is removed and total RNA is retained.  
 
Next, 600µl of 70% ethanol was added to the flow-through and mixed. This was transferred 
to an RNeasy spin column® and centrifuged for 15 seconds at 13,000 rpm (>10,000g). At 
this stage total RNA was bound ionically to the spin column membrane and required a 
number of subsequent wash steps for purification. Thus, 700µl of Buffer RW1® was added 
to the column and spun for 15 seconds at 13,000 rpm (>10,000g), followed by two further 
13,000 rpm (>10,000g) centrifugation steps using 500µl of Buffer RPE® each, for 15 and 
120 seconds respectively. The flow-through was discarded after each spin step.  
 
The spin column membrane containing bound total RNA was centrifuged dry for 1 minute at 
13,000 rpm (>10,000g) to minimise ethanol transfer from the Buffer RPE® wash steps. 
Finally, two elution steps each using 30µl of RNase-free water applied to the column and 
spun at 13,000 rpm for 1 minute were undertaken. Samples of total RNA were labelled and 
stored at -80oC in 20µl aliquots. 
 
2.3 Assessment of RNA quality 
2.3.1 Spectrophotometric analysis using Nanodrop® 
To assess protein and organic acid contamination of total RNA samples, spectrophotometric 
analysis was undertaken using the Nanodrop® spectrophotometer (Thermo Scientific, 
Loughborough, UK). A sample of total RNA was thawed at room temperature and a 1µl 
aliquot stored on ice for analysis. The absorbance of electromagnetic radiation (EMR) of 
260nm wave length is directly proportional to the concentration of the nucleic acid in solution 
and can be measured to calculate actual RNA concentration using the Beer-Lambert 
equation (216): 
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Absorbance = [Wavelength dependent coefficient] x [Path length] x [Solute concentration] 
       (AU)           (cm)  (g/L) 
 
Similarly protein absorbs EMR at 280nm and organic acids, such as phenolate and 
thiocyanates, absorb EMR at 230nm. By measuring the ratio of absorption at these 
wavelengths it is possible to quantify contamination by the corresponding organic 
compound. The Nanodrop® is also able to quantify accurately total RNA concentration in the 
sample. All total RNA samples were analysed by the Nanodrop® spectrophotometer prior to 
further experimentation using nucleic acid. 260:280 and 260:230 ratios of greater than 1.8 
were considered suitable for down-stream experimentation (217).  
 
A typical spectrophotometric trace using the Nanodrop® is shown. This trace provides a 
quantitative value for RNA concentration in addition to the indices of RNA purity, namely 
260:280 and 260:230 absorbance ratios (figure 2.1) 
 
Figure 2.1 Spectrophotometric trace using the Nanodrop® spectrophotometer 
 
Nanodrop® trace representing total RNA spectrophotometric properties. The absorbance at 260nm (A-260), A-
280, absorbance ratios and total RNA concentration are shown on the right of the panel.  
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2.3.2 Analysis of RNA integrity using Agilent 2100 Bioanalyser® 
In addition to spectrophotometric ratios, RNA quality has been historically assessed 
electrophoretically using an agarose gel and a fluorescent probe such as ethidium bromide. 
Typically two bands corresponding to the 28S and 18S ribosomal RNA (rRNA) species are 
analysed visually. High RNA quality is defined as a 28S:18S ratio greater than 2.0. However, 
it has been suggested that both spectrophotometric analysis (using a Nanodrop®) and 
electrophoretic analysis to calculate rRNA ratios are not sensitive enough to detect slight 
RNA degradation which may impact on the quality of down-stream applications (217).  
 
Micro-fluid capillary electrophoresis using the Agilent 2100 Bioanalyser® (Agilent 
Technologies, USA) assesses the quality of total RNA samples by creating an 
electrophoretic strip (figure 2.2). 
 
Figure 2.2 Micro-fluid capillary electrophoresis gel using the Agilent 2100 Bioanalyser® 
   
High quality nucleic acid                               Low quality nucleic acid 
Micro-fluid capillary electrophoresis gel of a range of RNA samples, from high quality (vertical lanes to the left of 
the panel) to low quality (vertical lanes to the right of the panel). Ribosomal 18S and 28S are shown for size 
comparison. Reproduced from Mueller et al.  2004 (218).  
 
Subsequently, the software assigns the RNA sample a RNA Integrity Number (RIN) ranging 
from 0 to 10, which represents low to high quality RNA, based on analysis of several aspects 
of the electrophoretic trace (figure 2.3).  
18S 
28S 
rRNA 
species: 
Direction of 
RNA migration 
during 
electrophoresis 
72 
 
Figure 2.3 Agilent 2100 Bioanalyser® fluorescent trace using micro-fluid capillary 
electrophoresis 
 
Agilent 2100 Bioanalyser® trace showing measured fluorescence of the RNA-binding Nano dye along the micro-
fluid capillary electrophoresis gel during RIN calculation. The size marker, 5S, 18S and 28S peaks are shown. 
Modified from Imbeau et al. 2005 (217). 
 
The RNA electrophoretic parameters analysed by the Agilent 2100 Bioanalyser® are: ratios 
RIWKHDUHDRIWKH6DQG6SHDNVWRWKHWRWDOFXUYHDUHD6SHDNKHLJKWµIDVW¶UHJLRQ
analysis (assessing the region between the 5S and 18S peaks for degradation products), 
and heights of a small size marker (219). This technique has been shown to demonstrate 
less inter-measurement variability and greater correlate with RNA quality and gene 
expression than other techniques using both cell lines and human tissue (217, 220).  
 
Therefore, prior to down-stream nucleic acid experimentation all total RNA samples were 
DQDO\VHGXVLQJWKH$JLOHQW%LRDQDO\VHUDFFRUGLQJWRWKHPDQXIDFWXUHU¶VLQVWUXFWLRQV
and the Agilent RNA 6000 Nano Kit. Briefly, a light-sensitive Nano Dye Concentrate was 
mixed with a gel matrix and added to a 12-sample chip. A 1µl aliquot of either a fixed-size 
ladder marker or a sample of template RNA was loaded into a chip well following heating at 
70oC for 2 minutes to minimise secondary structure. Up to twelve samples could be 
analysed on a single chip. The chip was vortex mixed (IKA - Model MS2-S8/MS2-S9) for 1 
minute at 2,400rpm and then inserted into the analyser. Acquisition of data was obtained 
18S 
28S 
5S 
Size 
marker 
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within 30 minutes of analysis. Samples of RIN >6.5 were considered suitable for down-
stream experimentation.  
 
2.4 Conventional reverse transcriptase polymerase chain reaction 
2.4.1 Reverse transcription using Qiagen QuantiTect RT kit 
Synthesis of complementary DNA (cDNA) from message RNA was undertaken using the 
Qiagen QuantiTect RT kit 4LDJHQ*HUPDQ\DFFRUGLQJWRWKHPDQXIDFWXUHU¶V
instructions. This protocol involved a further gDNA elimination step prior to reverse 
transcription and to ensure complete removal of genomic DNA from the sample. The gDNA 
elimination reaction involved adding up to 1µg RNA to 2µL gDNA Wipeout Buffer x7® and 
making the solution up to a volume of 14µL with RNase-free water. This was heated to 42oC 
for 3 minutes to eliminate residual gDNA through its DNase activity.  
 
Samples were then placed on ice and added to the reverse-transcription (RT) reaction 
components: Quantiscript reverse transcriptase® with RNase inhibitor (1µL); Quantiscript RT 
Buffer x5® including magnesium and deoxynucleotide triphosphates (dNTP) (4µL), and an 
RT Primer mix® (1µL). The final volume of 20µL was incubated at 42oC for 15 minutes 
before being placed at 95oC for 3 minutes to inactivate the RT. The 20µL samples were 
made up to 50µL with RNase-free water, pipette mixed and placed on ice for down-stream 
experimentation or stored at -80oC.  
 
The Quantiscript reverse transcriptase® has desirable enzymatic properties including 
functions such as a RNA-dependent DNA polymerase, hybrid-dependent exoribonuclease 
(RNase H) and DNA-dependent DNA polymerase. The first property allows cDNA 
transcription from the RNA template strand, while the second property subsequently 
degrades the RNA component of the newly synthesised RNA-DNA hybrid (but not the pure 
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un-hybridised RNA strands) to release cDNA. This avoids the need for a separate RNase H 
step prior to PCR (221).  
 
2.4.2 Primer design for RT-PCR 
In order to design reliable and specific primers for accurate PCR reactions, a number of 
rules were followed whenever possible. The proportion of guanine (G) and cytosine (C) 
bases was kept to between 40 and 60% of the sequence.  If possible, positioning G/C bases 
DWWKH¶HQGRIWKHVHTXHQFHZDVDYRLGHGWRUHGXFHWKHFKDQFHVRISULPHU-dimer formation. 
Self-annealing regions within each primer were avoided. Primers were designed to be intron-
spanning whenever possible. The melting temperature (TM) in oC was calculated using the 
following equation:  
 
TM = 4(G + C) + 2(A + T) 
 
where A and T represent adenine and thymine bases, respectively. Annealing temperatures 
(TA) were calculated as follows: 
 
TA = TM ± 5 
 
The annealing temperature of a primer pair was taken as the TA of the primer with the lowest 
value. The target TA range was 54-62oC.  
 
However, the equations above are only an approximation to the melting and annealing 
temperatures and, on occasion, manufacturers of oligonucleotides supply specifically 
measured melting temperatures with their synthesised primers. In such cases, if there was a 
GLVFUHSDQF\EHWZHHQWKHHVWLPDWHGDQGPDQXIDFWXUHU¶VFDOFXODWHG7M then the higher of the 
two was used. In some cases, primers were selected from published scientific articles. If the 
published primer pairs fulfilled many of the above criteria, and were cited in at least one 
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TXDOLW\VFLHQWLILFSXEOLFDWLRQWKH\ZHUHFRQVLGHUHGIRUXVH,QWKLVFDVHWKHDXWKRU¶VSURWRFRO
was initially followed and subsequently modified (if necessary) to optimise the PCR 
efficiency.  
Finally, primers were run through the National Institute for Health (NIH) PubMed Basic Local 
Alignment Search Tool (BLAST) to ensure accurate homology to the target sequence and 
confirm primer-sequence specificity (222).  
 
2.4.3 Conventional polymerase chain reaction 
2.4.3.1 Introduction to RT-PCR 
Polymerase chain reaction (PCR) is a process whereby segments of DNA (amplicons) are 
copied exponentially by a process of cycling reactions of different temperatures. This allows 
detection of the sequence from an initially small amount of template nucleic acid. During 
each cycle of the PCR protocol each double strand of DNA is separated (denatured) and a 
complimentary strand synthesised, resulting in a doubling of the amount of nucleic acid. 
Over a reaction of 35 cycles, the end amount of DNA is a 235-fold multiple of the starting 
amount of template.  
 
This process required primers, short sequences of DNA (oligonucleotides) which are 
designed to have complete homology with a specific DNA sequence of interest. Two primers 
are required which will anneal to each end of the region of interest, spanning the amplicon, 
and are of the correct orientation such that, when extension by the DNA polymerase enzyme 
RFFXUVWKHJHQHUHJLRQRILQWHUHVWLVFRSLHG'1$SRO\PHUDVHVDOZD\VH[WHQG'1$LQWKH¶
WR¶GLUHFWLRQ 
 
Each cycle has three steps. The first step is denaturation where the double-stranded DNA 
(dsDNA) melts and separates into two single-stranded (ssDNA) molecules. This occurs at 
approximately 94oC and at this temperature all enzymatic reaction (including polymerisation) 
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ceases. It is often referred to as the denaturation temperature (TD). The second step is the 
annealing step. The mixture is cooled to a predetermined temperature (TA), usually between 
54 and 60oC, in order that primers and DNA collide and hydrogen bonds between the stands 
are formed and quickly broken repetitively. When the primer collides with its homologous 
region of interest, the hydrogen bonds formed are stronger that those formed between non-
homologous interactions. This allows the primer to remain annealed to the DNA sequence 
long enough for the polymerase to attach and begin to copy the DNA strand. Once the 
sequence begins to elongate, the hydrogen bonds are so strong that the template and 
elongating copy strand will not denature at this temperature. Annealing takes only a few 
seconds and the annealing step need only last 15-30 seconds to avoid spurious primer 
annealing (216).  
 
Finally the target region of DNA is copied during the extension step. This occurs at 72oC and 
LQYROYHVH[WHQVLRQRIWKHFRSLHGVWUDQGLQWKH¶WR¶GLUHFWLRQZLWKFRXSOHGGHR[\QXFOHRVLGH
WULSKRVSKDWHG173PROHFXOHVDWWDFKHGWRWKHJURZLQJ¶HQGRIWKHFRPSOLPHQWDU\VWUDQG
DNA polymerases generally have a base insertion rate of 50 bases per second and the 
duration of the elongation step is usually only required to be 15-30 seconds, though longer 
times are required for longer amplicons. This three step cycle is repeated 35-45 times to 
exponentially amplify the template sequence.  
 
During RT-PCR reactions primers were used in the concentration of 1-2µM. Similarly, 
dNTPs were used at a concentration of 200µM. Magnesium ions (Mg2+) are critical for 
optimal PCR reactions. Mg2+ ions bind to template DNA, dNTPs and primers, and the 
Thermus aquaticus (Taq) polymerase requires free Mg2+ ions to function. Mg2+ ion 
concentration influences primer annealing, TM and product specificity with high 
concentrations leading to reductions in stringency (specificity) (216). For each RT-PCR 
reaction an Mg2+ ion dilution experiment was undertaken to identify optimal Mg2+ ions 
concentration for the reaction. This was usually within the range 1.5-3.5mM.  
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2.4.3.2 RT-PCR protocols 
Conventional RT-PCR was undertaken using the AmpliTaq Gold® DNA polymerase with 
GeneAmp® 10x PCR Gold Buffer kit (4311816, Applied Biosciences). Components of the 
RT-PCR reaction were added sequentially, for example nuclease-free water 16.25µl, 25mM 
MgCl2 2.5µl, 10x PCR Buffer 2.5µl, 10mM dNTP 0.5µl, 100µM sense primer 0.5µl, 100µM 
anti-sense primer 0.5µl, 5U/µl Taq polymerase 0.25µl and template cDNA 2.0µl to give a 
final volume of 25µl (for HPRT amplification).  
 
The volume of MgCl2 and nuclease-free water was dependent on the MgCl2 dilution test. This 
involves running parallel samples of cDNA for amplification with increasing concentration of 
MgCl2 in the buffer solution. The concentration of MgCl2 which resulted in the brightest band 
following electrophoresis was selected for future PCR reactions.  
 
$OOVDPSOHVZHUHUXQZLWKD³QR57´QHJDWLYHFRQWURO7KLVLVDVDPSOHwhere no RT enzyme 
was added to the mRNA sample during cDNA synthesis, theoretically resulting in the 
absence of cDNA synthesis. In such a sample, any detectable PCR product would indicate 
J'1$FRQWDPLQDWLRQ,QDGGLWLRQVRPHVDPSOHVZHUHUXQZLWKD³QRWHPSODWH control´. In 
these samples no cDNA sample was added to the PCR master mix. Again, any detectable 
product on the gel would indicate gDNA contamination as some stage of the protocol.  
 
Table 2.1 lists the RT-PCR protocol cycling conditions and the denaturing, annealing and 
elongation temperatures for all the primers used for conventional RT-PCR. The primer 
sequences used during conventional RT-PCR are shown in table 2.2. 
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Table 2.1 Cycling protocols for conventional RT-PCR primers 
Primer Stage 1 Stage 2: 
denaturation 
Stage 2: 
annealing 
Stage 2: 
elongation 
No. of 
cycles 
Stage 3 
HPRT 95oC 10 min 95oC 15 sec 60oC 30 sec 72oC 30 sec 40 72oC 20 min 
TLR2 95oC 10 min 94oC 15 sec 60oC 30 sec 72oC 30 sec 40 72oC 20 min 
TLR4 95oC 1 min 95oC 45 sec 54oC 45 sec 72oC 1 min 38 72oC 20 min 
HPRT, Hypoxanthine-guanine phosphoribosyltransferase; TLR, Toll-like receptor 
 
Table 2.2 Conventional RT-PCR primer sequences 
Gene Primer sequence Melting 
temperature (TM) 
Amplicon 
size  
HPRT GAC CAG TCA ACA GGG GAC AT (sense) 
CGA CCT TGA CCA TCT TTG GA (anti-sense) 
59.4oC 
57.3oC 
160bp 
TLR2 AGT TGA TGA CTC TAC CAG ATG (sense) 
GTC AAT GAT CCA CTT GCC AG (anti-sense) 
55.9oC 
57.3oC 
599bp 
TLR4 TGG ATA CGT TTC CTT ATA AG (sense) 
GAA ATG GAG GCA CCC CTT C (anti-sense) 
51.2oC 
58.8oC 
507bp 
bp, base pairs; HPRT, Hypoxanthine-guanine phosphoribosyltransferase; TLR, Toll-like receptor 
 
 
2.4.3.3 Separation of PCR products using agarose gel electrophoresis 
Following RT-PCR, nucleic acid amplicons were separated by agarose gel electrophoresis 
and visualised by the use of the fluorescent molecule ethidium bromide. Nucleic acids are 
negatively charged and will migrate towards the anode following the application of an electric 
field, with the rate of migration being proportional to the applied field strength. The shorter 
the nucleic acid sequence, the faster it migrates through the sieve-like agarose gel. 
Moreover, higher concentration agarose gels restrict the movement of larger nucleic acids to 
a greater degree and allow separation of shorter sequences, while lower concentration gels 
allow separation of longer sequences (216).  
 
In order to make a 1% agarose solution, 1g agarose (A9539, Sigma) was dissolved in 
100mL TAE solution (Tris, glacial acetic acid and EDTA, pH 8.0). This was heated for 2 
minutes on full power in an 800W microwave oven to fully dissolve the agarose. This was 
added to a gel cast and 10µL of 0.5mg/ml ethidium bromide added to the solution. This was 
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left for 30 minutes to set. The gel was submerged in the running tank with further TAE 
solution.  
 
To each 10µL PCR samples was added 2µL of anionic loading dye (161-0767, Bio-Rad 
Laboratories, California, US). These samples were transferred to consecutive wells in the 
agarose gel and run for 60-90 minutes with an applied electric field of 120V. The first well of 
each gel contained a 100 base pair ladder to allow sizing of amplified products. Bands were 
visualised using an ultraviolet (UV) trans-illuminator with appropriate eye protection.  
 
2.5 DNA sequencing using ABI PRISM BigDye Terminator® protocol 
Following agarose gel electrophoresis, PCR product bands were visualised under UV trans-
illumination. Using a scalpel blade, the band was cut from the gel and stored at 4oC until 
required. To extract the PCR product and dissolve the agarose gel the Qiagen MinElute Gel 
([WUDFWLRQNLW4LDJHQ*HUPDQ\ZDVXVHGDVSHUWKHPDQXIDFWXUHU¶VLQVWUXFWLRQV
The gel slice was weighed and 300µL of Buffer QG added per 100mg of gel. This was 
incubated at 50oC for 10 minutes until the gel had dissolved, with vortex mixing every 2-3 
minutes during the incubation. The Buffer GQ contains a pH indicator to ensure the solution 
remains below pH 7.5. Should the pH of the dissolved gel rise above this value, the buffer 
undergoes a colour change from yellow to orange/purple and the addition of 10µL of 3M 
sodium acetate is required to return the pH to its optimal level.  
 
Next, 100µL of isopropanol was added per 100mg of initial gel weight and this mixture 
transferred to a MinElute® spin column for centrifugation at 13,000 rpm for 1 minute. This 
column binds the DNA to the membrane and allows through passage of the dissolved gel. 
The membrane was washed with a further 500µL of Buffer GQ® spun at 13,000 rpm 
(>10,000g) for 1 minute, and then left to stand for 2-5 minutes with 750µL of Buffer PE® 
applied to the membrane before being spun at 13,000 rpm (>10,000g) for a further 1 minute.  
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To elute the DNA, 10µL of Buffer EB® (10mM Tris·Cl, pH 8.5) was added to the centre of the 
membrane and left to stand for 1 minute before centrifugation at 13,000 rpm (>10,000g) for 1 
minute. The average eluate volume was 9µL. The DNA eluate was used immediately for 
sequencing or stored at -20oC.  
 
Sequencing was undertaken using the BigDye Terminator® protocol (Applied Biosystems, 
US). Following DNA extraction from the agarose gel, the following were mixed: 
 
DNA eluate    0.5µL 
BigDye Ready Reaction Mixture®  0.5 µL 
1µM sense primer    1.5µL 
Better Buffer®    3.5µL 
Nuclease-free water    4µL 
Total     10µL 
 
The following PCR reaction was subsequently performed: 25 cycles of 96oC for 30 seconds, 
50oC for 15 seconds and 60oC for 4 minutes, followed by a single cycle of 28oC for 1 minute. 
Following this PCR reaction, the following were added to the 10µL PCR mixture: 
 
125mM EDTA  2µL 
3M sodium acetate 2µL 
100% ethanol  50µL 
Nuclease-free water 10µL 
Total   74µL 
 
This was vortex-mixed and incubated at room temperature for 15 minutes. Next, the solution 
was centrifuged at 13,000 rpm (>10,000g) for 20 minutes at 4oC (30 minutes for sequences 
over 600 bases). The supernatant was carefully aspirated and 70µL of 70% ethanol added 
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followed by centrifugation at 13,000 rpm (>10,000g) for 10 minutes at 4oC (15 minutes for 
sequences over 600 bases). The supernatant was carefully aspirated and a further ethanol 
wash and centrifugation was performed, as above, for sequences over 600 bases in length. 
Following aspiration of the ethanol, the pellet was dried with the tube lid open at 50oC for 10 
minutes.  
 
The pellet was stored at -20oC and transferred to the Post-Genomic Technologies Facility, 
University of Nottingham, for production of the BigDye® gel and subsequent reading of the 
sequence. Following sequencing analysis, a report is generated which provides the 
nucleotide sequence and allows assessment of the quality of the sequencing reaction. An 
example of the sequencing report for the HPRT housekeeping gene is shown, using 
Chromas 2 software (figure 2.4). 
 
Figure 2.4 HPRT gene sequencing using the BigDye Terminator® protocol technology and 
Chromas2 software  
 
 
A Chromas2 software readout of a section of the hypoxanthine guanine phosphoribosyltransferase (HPRT) 
sequence using BigDye® gel. Peaks represent individual nucleobases; A (adenine, green), C (cytosine, blue), G 
(guanine, black) and T (thymine, red). Successful sequencing reactions show clean sequences with discrete 
ordered peaks corresponding to the nucleotide sequence of the amplified product, as shown above.  
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In some cases rather than being sequenced from the gel, the PCR product was sequenced 
directly from the initial RT-PCR reaction mixture. In this case, the 10µL PCR product was 
mixed with 4µL of ExoSAP-IT (Exonuclease I and Shrimp Alkaline Phosphatase, GE 
Healthcare, UK) and incubated at 37oC for 30 minutes followed by 80oC for 15 minutes. At 
this stage 0.5µL of this mixture is added to the BigDye Ready Reaction mixture, 1µM sense 
primer, Better Buffer and Water and the protocol completed as above.  
 
2.6 Haematoxylin and eosin staining of cytospins and tissue sections 
Cytospin slides, stored at -20oC, were thawed for 30 minutes still wrapped in foil. They were 
then transferred to a metal slide rack and hydrated in running tap water for 5 minutes. The 
slides were transferred to pre-filtered haematoxylin for 15 minutes before being returned to a 
running water wash. The slides were then transferred to 1% acid alcohol for 10 seconds and 
0.5% ammoniated water for 30 seconds with a running water wash after each step.  
 
Finally, slides were transferred to eosin for 3 minutes, washed and then dehydrated in 
graded alcohols (50%, 70%, 80%, 90% and 100%) followed by three 1 minute treatments in 
xylene to make the slide hydrophobic so that a cover slip may be applied with resin. The 
specimens were covered by the drop of DPX (44581-500ML, Sigma) resin followed by a 
cover slip and allowed to dry overnight in a fume hood before being stored at room 
temperature.  
 
For whole bowel tissue sections, formalin-fixed, paraffin-embedded tissue sections, stored at 
room temperature, were placed into a metal rack and de-waxed by three treatments using 
xylene for 1 minute each. Tissue sections were then hydrated by sequential incubation in 
graded alcohols of reducing concentration (100%, 90%, 80%, 70% and 50%) for 1 minute 
each. Finally the slides were placed in distilled water for 5 minutes before staining with 
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haematoxylin and eosin, as described for cytospins. Tissue sections were covered using 
DPX mount and a coverslip.  
 
2.7 Immunocytochemistry 
Immunocytochemical (ICC) staining was undertaken using the avidin/biotin system. Avidin is 
a 68kDa glycoprotein with a very high affinity (1015M-1) for the small molecular weight vitamin 
biotin. This high affinity essentially produces irreversible binding of avidin to biotin, and this 
can be exploited by using biotin-conjugated (biotinlyated) enzymes such as horseradish 
peroxidase (HRP). In addition, avidin has four binding sites for biotin molecules (223).  
 
Monoclonal or species-specific polyclonal primary antibodies bind to a specific epitopes on 
target antigens (such as the extra-cellular domain of a toll-like receptor protein). These were 
applied to the tissue or cytological specimen following sequential blocking with hydrogen 
peroxide, normal serum, avidin and biotin solutions (to prevent non-specific staining by the 
secondary antibody or avidin/biotin complex). Following primary antibody incubation, a 
biotinylated secondary antibody reared in another species (for example horse) was applied. 
This binds to the primary antibody-antigen complex. The avidin/biotinylated-HRP complex 
was subsequently added to the specimen to bind to the secondary antibody. The detection 
of antibody binding waVYLVXDOLVHGE\DGGLQJ¶-diaminobenzidine (DAB), which turns 
brown in the presence of the antibody-bound horseradish peroxidise. The specimen was 
counter stained and viewed with the light microscope (figure 2.5).  
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Figure 2.5 Schematic of the immunoperoxidase staining technique  
 
Schematic diagram of immunoperoxidase staining using a primary unconjugated monoclonal antibody (black), a 
biotinylated secondary antibody (blue), the avidin/biotin (yellow)-horse radish peroxidase (HRP) complex (red) 
and the colorimetric reagent ¶-diaminobenzidine (DAB). In the presence of HRP, DAB turns a brown colour, 
allowing indirect visualisation of primary antibody-antigen binding.  
 
To perform ICC, slides stored at -20oC were thawed for 30 minutes (still wrapped in foil) and 
then transferred to a metal slide rack and hydrated in phosphate buffered saline (PBS) for 20 
minutes.  To prevent slides drying out, slides were laid in a slide incubation chamber 
surrounded by PBS-soaked paper towel. The area of the slide containing the adhered cells 
was highlighted with a wax pencil and then slides were blocked with 200µL neat avidin and 
biotin blocking solutions (SP-2001, Vector Labs) separately for 30 minutes each, and then 
wash in PBS twice for 5 minutes. Thereafter 200µL of blocking serum (5% horse serum in 
PBS) was applied to the cells at room temperature for 30 minutes and washed with PBS 
twice for 5 minutes.  
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The primary antibody was prepared from stock as shown in the following table. The normal 
serum block was removed and replaced with 200µL of primary antibody in PBS and 
incubated for 1 hour at room temperature. Negative control slides were also made by 
omitting the primary antibody and applying only PBS at this stage (table 2.3). 
 
Table 2.3 Working dilutions and DAB reagent detection times for the primary antibodies 
using in immunoperoxidase staining 
Primary antibody Dilution of stock antibody Duration of DAB detection 
Cytokeratin (Abcam) 1:400 2 minutes 
BerEP4 (Dako) 1:400 2 minutes 
Į-smooth muscle actin (Abcam) 1:500* 2 minutes 
Vimentin (Abcam) 1:40* 2 minutes 
Desmin (Abcam) 1:20* 2 minutes 
TLR2 (eBioscience) 1:50 4 minutes 
TLR4 (eBioscience) 1:50 4 minutes 
Lysozyme (Thermo Scientific) 1:100 2 minutes 
'$%¶-diaminobenzidine; PBS Phosphate buffered saline; TLR, Toll-like receptor 
* Initially stock antibody was diluted to 1:5 with PBS and 1% BSA before storage at -80oC 
 
Following incubation the slides were transferred back to the metal slide rack and washed 
twice for 5 minutes in PBS to remove unbound primary antibody. Next, peroxidise activity 
was blocked by incubating the slides in 0.3% hydrogen peroxide in methanol (2mL hydrogen 
peroxide and 198mL methanol) for 30 minutes. Thereafter slides were again washed twice 
for 5 minutes in PBS.  
The biotinylated secondary antibody (PK-6200 Vectastain ABC Universal kit, Vector Labs) 
was prepared in a 1:100 dilution in PBS with 5% blocking serum. This was added to the 
slides following their transfer back to the incubator chamber and left for 30 minutes at room 
temperature. The avidin/biotin-HRP complex (ABC) was prepared at the same time by 
adding 100µL each of reagents A and B to 5mL PBS and leaving for 30 minutes, as per the 
PDQXIDFWXUHU¶VLQVWUXFWLRQV 
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After the secondary antibody incubation step, the slides were washed twice for 5 minutes in 
PBS. The avidin/biotin complex was added to the slides and incubated for 30 minutes at 
room temperature followed by two 5-minute washes in PBS.  
 
To detect HRP activity, a solution of DAB was prepared (SK-4100 Vector peroxidise 
substrate kit, Vector Labs) by adding 100µL of Buffer pH 7.5, 200µL DAB stock solution and 
100µL hydrogen peroxide solution to 5mL distilled water. The DAB solution was applied to 
the slides and left for the indicated time (table) before rinsing under running tap water for 5 
minutes.  
 
The slides were counter-stained sequentially in Coles¶ haematoxylin for 2 minutes, 1% 
hydrochloric acid for 10 seconds and ammoniated water for 45 seconds, with a tap water 
wash step between each stain. Specimens were then dehydrated by passage through 
graded alcohol solutions (50%, 70%, 80%, 90% and 100%) and through xylene three times 
for 1 minute each. Finally, samples were mounted with DPX and a cover slip, and left to dry 
in a fume hood overnight.  
 
2.8 Statistical analysis 
Continuous quantitative data were analysed for Gaussian distribution using a Kolmogorov-
Smirnov test and by plotting data on a frequency-density histogram. Normally-distributed 
data were analysed using a paired or un-paired student t-test, as appropriate. Non-normal 
data were analysed using non-parametric testing, either a Wilcoxon or Mann Whitney U test. 
Any categorical data were analysed using a )LVKHU¶VH[DFWWHVW 
 
Statistical analyses were undertaken using two statistical software packages, SPSS (version 
19) and Graphpad Prism (version 5). All graphs were produced in Graphpad Prism except 
those relating to correlation calculations which were produced in SPSS. All statistical tests 
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were two-tailed and statistically significant results were those with p-values less than 0.05 
(5%).   
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Chapter 3: Isolation and characterisation of human crypt intestinal 
epithelial cells 
 
3.1 Introduction 
Intestinal epithelial cells form the largest area of any body surface. They function to provide 
key roles in the digestion and absorption of nutrients vital for host organism survival as well 
as providing a barrier to the migration of micro-organisms or toxins into the underlying host 
tissue (1). Recent work has demonstrated that the roles of the IEC go beyond these 
functions alone. IEC are now regarded to provide key roles in the immune response, 
modulating the adaptive immune response to tolerate commensal and food antigens and 
acting as innate immune system cells in times of inflammation (98).  
 
As will be further discussed in chapters 6 and 7, the mature functional epithelial cells are 
progeny of stem cells which reside in the base of the crypts of Lieberkühn (224). These stem 
cells have the capacity to populate the crypts of the intestine and the villi of the small 
intestine through rapid recycling and subsequent differentiation. Critically these stem cells 
can differentiate into all four mature lineages of IEC, namely columnar cells, Paneth cells (in 
the small intestine only), mucus-secreting goblet cells and enteroentocrine cells. This is a 
tightly regulated process which involves the secretion of various factors which regulate cell 
turnover and differentiation (174). The location of the stem cells within a niche is crucial to 
the stem cell response to injury and inflammation and plays a role in the pathogenesis of 
conditions such as inflammatory bowel disease (187). The niche is the term used to describe 
a functional location in which stem cells are surrounded by mesenchymal and vascular cells, 
extra-cellular matrix and numerous factors which regulate growth and differentiation.  
 
One challenging area of IEC research has been the difficulty in producing epithelial cell 
cultures. Numerous immortalised human cancer cell lines have been developed which 
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potentially can be maintained in culture indefinitely. However, these cell lines tend to 
proliferate independently of their surroundings, as is typical of neoplastic cells, and bear only 
modest relation to the original cell phenotype (225). In contrast, IEC in vivo differentiate and 
mature as a result of their interactions with surrounding cells and structures as they migrate 
from crypt to villus over the course of a few days. Therefore, the use of cell lines in the study 
of IEC physiology has its clear limitations.  
 
There have been several attempts to culture primary IEC over the last two decades. 
Whitehead et al. described the use of a collagen gel over a feeder layer of bovine aortic 
endothelial cells and demonstrated cell division at 7 days and survival to at least 16 days 
following isolation of human crypt cells (226). Collagen-coated surfaces have also been 
shown to facilitate murine colonic IEC proliferation for 10 days and survival for up to 35 days 
(227). The challenge has always been to isolate pure IEC from intestinal mucosa without 
mesenchymal or haematopoietic cell contamination, and to maintain viable and proliferating 
IEC in culture.  
 
This chapter describes the ex vivo method for isolating human small and large intestinal 
crypts and the disaggregation of these crypt cells into single cells. Unlike methods which 
isolate and culture whole crypts, the current technique isolates individual cells, allowing 
further study of these cells using techniques such as flow cytometry and fluorescence-
activated cell sorting (FACS). The protocol is a modified version of the method described by 
Bjerknes and Cheng in 1981 using murine small intestine (228) and later using human colon 
by Whitehead et al. in 1999 (229). More recently our laboratory has demonstrated isolation 
of individual human colonic IEC and with sufficient viability to allow subsequent flow 
cytometric analysis (210, 230).  
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3.2 Methods 
Primary human intestinal crypt epithelial cells were isolated from fresh full thickness small 
and large bowel resection specimens, as previously reported (210). Informed consent was 
obtained from patients prior to surgery to allow tissue samples to be included in the current 
study as part of the School of Clinical Sciences Tissue Bank, University of Nottingham. All 
patients received an information sheet prior to consent and were required to provide written 
consent for inclusion in the study. Permission to use tissue samples from the Tissue Bank 
was obtained following approval of the research project by the Research Ethics Committee. 
All patient data were pseudo-anonymised by entering data onto a secure database and 
assigning each case a unique, non-identifiable numerical code.   
 
3.2.1 Case selection 
All patients with inflammatory bowel disease (IBD), either ulcerative colitis RU&URKQ¶V
disease, undergoing operative bowel resection were considered for entry into the study. 
Data were collected on patient demographics (age, disease location and activity, current 
medical therapy, relevant past medical history, previous endoscopic evaluation of disease 
extend and activity, previous histological assessment for disease activity and exclusion of 
dysplasia, previous surgical interventions and proposed operative procedure). All patients 
were over 16 years of age. There was no upper limit of inclusion based on age.  
 
To act as controls, patients undergoing bowel resection for colorectal cancer were included. 
Macroscopically normal-looking tissue was taken at least 5cm from the margin of the cancer 
lesion. Similar demographic data were collected for control patients and those with a history 
of inflammatory bowel conditions (e.g. diverticular disease) were excluded. In addition, 
patients who had received pre-operative chemotherapy or radiotherapy of any type or 
duration were excluded to avoid any potential confounding factors, such as changes in gene 
and protein expression.  
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The anatomical location of specimen acquisition was recorded for every specimen. The post-
operative histopathology report was obtained to ensure the absence of dysplasia in either 
group (IBD or control). Any sample subsequently found to show features consistent with 
dysplasia was excluded from analysis.  
 
3.2.2 Tissue acquisition 
Full thickness fresh, unfixed specimens of small and large bowel were collected from the 
operatLQJWKHDWUHVRIWKH4XHHQ¶V0HGLFDO&HQWUH1RWWLQJKDP8QLYHUVLW\Hospitals NHS 
Trust, Nottingham UK. In the category III room in the Department of Histopathology 2cm x 
2cm square full thickness sections of bowel were cut from the specimen. This tissue was 
washed three times by gentle shaking in 20mL +DQNV¶%DODQFHG6DOW6ROXWLRQ+%66
without magnesium or calcium (Mg/Ca) (14180-46, Gibco, Invitrogen). Samples were then 
stored in 40mL F-12 with glutamine (21765, Gibco, Invitrogen) at 4oC. All collected 
specimens were stored at identical conditions for 12-14 hours until the intestinal epithelial 
cell isolation protocol (section 3.2.4) was undertaken. 
 
3.2.3 Tissue embedding in paraffin 
Prior to commencing the IEC isolation protocol, a small section of whole bowel 2mm x 2mm 
was cut and stored in 3.7% formaldehyde neutral buffer solution overnight (formalin, Sigma-
Aldrich) and then transferred to 70% ethanol. This was taken to the Department of 
Histopathology for paraffin embedding. The formalin-fixed, paraffin-embedded (FFPE) 
samples were stored in a dry location at room temperature until required. In some cases, 
strips of primary mucosal tissue were collected after each of the three EDTA/DTT protocol 
steps (see section 3.2.4). These were formalin-fixed and paraffin-embedded in preparation 
for later examination.  
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3.2.4 Intestinal epithelial cell isolation 
Strips of intestinal mucosa were cut from the remaining whole bowel specimen and washed 
gently five times in cold HBSS (without Mg/Ca) and then weighed. The mucosal strips were 
subsequently incubated in 40mL 1mM ethylenediaminetetraacetic acid (EDTA, Sigma-
Aldrich) and 0.05mM dithiothreitol (DTT, Acros Organics, New Jersey, US) (EDTA/DTT) at 
37oC in a shaking water bath for 30 minutes. EDTA/DTT solution was made freshly by 
adding 20mL of filter-sterilised stock 10mM EDTA (1.86g EDTA in 500mL HBSS without 
Mg/Ca, pH 7.0) and adding 2mL of fresh DTT (38.6mg DTT in 50mL HBSS without Mg/Ca) 
to 178mL HBSS (without Mg/Ca) and subsequent filter sterilisation through a 0.2µm filter.  
 
After 30 minutes incubation, the mucosal strips were shaken vigorously for 1 minute in cold 
HBSS (without Mg/Ca). The detached cells were retained in fluid suspension and the 
mucosal strips transferred to fresh HBSS (without Mg/Ca) for repeat vigorous shaking. The 
process of shaking in fresh media was repeated to a total of five times to ensure detachment 
of all loose epithelial crypt cells. This yield of suspended epithelial cells (still anatomically 
identifiable together in a crypt structure) was termed E1.  
 
The mucosal strips were returned to fresh EDTA/DTT for a further 30 minutes, after which 
the process of epithelial cell detachment by shaking was repeated, yielding an isolation of E2 
epithelial cells. This EDTA/DTT treatment with cell detachment was repeated for a third and 
final time, yielding E3 epithelial cells.  
 
Suspended crypts were transferred into 50mL falcon tubes and centrifuged at 1,000 rpm 
(800g) for 5 minutes. The supernatant was discarded and the pellet of cells re-suspended in 
40mL of filter-sterilised 0.25% pancreatin (0.1g porcine pancreatin, P-1500 Sigma, in 40ml 
HBSS with Mg/Ca). This was incubated at 37oC for 90 minutes with occasional mixing. This 
resulted in the disaggregation of crypt cells into individually isolated cells.  
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Following pancreatin treatment, samples were diluted two-fold with an equal volume (40mL) 
of cold HBSS (without Mg/Ca) and centrifuged at 1,000 rpm (800g) for 5 minutes. The 
supernatant was discarded and the cells re-suspended in 20mL EDTA/DTT solution and 
centrifuged at 1,000 rpm (800g) for 5 minutes. Again the supernatant was removed and the 
cells re-suspended in 20mL cold HBSS (without Mg/Ca) and centrifuged at 1,000 rpm (800g) 
for 5 minutes. Finally, the supernatant was removed and the pellet re-suspended in 5mL 
HBSS (without Mg/Ca) for cell counting using trypan blue exclusion. Cell suspensions were 
stored on ice for further down-stream experimentation.  
 
For E2 and E3 yields, after the shaking/detachment step and prior to the first centrifugation 
step, the suspension of cells was examined at x4 magnification under a light microscope to 
ensure continued crypt detachment. If intact crypts were visualised, the suspended cells 
were centrifuged and the protocol completed as described. If no crypts were identified, the 
sample was discarded.  
 
3.2.5 Cell counting 
Cell counting and viability was undertaken using a haemocytometer and 0.4% trypan blue 
exclusion, as described in section 2.1. On occasion, pancreatin-treated cells were observed 
to clump together, forming cellular aggregates. In these circumstances the suspended cells 
were passed through a 21 gauge needle several times before counting.  
 
3.2.6 Cytospin preparation 
Freshly isolated IEC and peripheral blood mononuclear cells, and cultured human epithelial 
cell lines, were suspended in HBSS (with Mg/Ca) medium to a concentration of 2.5x105 
cells/mL and adhered to glass slides using the Shandon Cytospin® 2 cytocentrifuge (Wolf 
Laboratories). SuperFrost plus® slides (Thermo Scientific) were labelled, covered in filter 
card and positioned in the metal grip, ensuring the hole in the card was aligned with the hole 
in the plastic cup. Two hundred microlitres of cell solution was transferred to each cup and 
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centrifuged at 800rpm (22.4g) for 10 minutes. The slides were removed and allowed to dry at 
room temperature. A diamond pencil was used to draw around the circle of attached cells. 
The slides were fixed in acetone for 5 minutes and allowed to dry at room temperature. 
Slides were wrapped in foil and stored at -20oC until further use.  
 
3.2.7 Immunocytochemistry 
Immunocytochemical staining was undertaken using the avidin/biotin system. The general 
protocol for immunocytochemical staining is described in chapter 2.7. In brief, frozen 
cytospin slides were thawed and hydrated in PBS. Endogenous peroxidase activity was 
quenched using 0.3% hydrogen peroxide in methanol and non-specific protein binding 
blocked using 5% normal horse serum in PBS. Cells were labelled with the murine anti-
human primary antibody at its optimal concentration as described in chapter 2.7 (determined 
initially by using serial dilutions of primary antibody) for 1 hour at room temperature. 
Biotinylated horse anti-mouse secondary antibody was applied followed by incubation with 
the avidin/biotin complex. Colour was developed using the Vector DAB peroxidise substrate 
before counter-staining with haematoxylin. Finally slides were dehydrated in graded ethanol, 
dipped in xylene and mounted using DPX mounting medium overnight.  
 
3.2.8 Cell viability analysis 
To assess the duration of cell viability, primary human crypt IECs were isolated and 
suspended in culture medium (HBSS (without Mg/Ca) with 10% FCS, 5ml of 200mM L-
glutamine, 50,000 units of  penicillin G (Britannia Pharmaceuticals Ltd, Surrey, UK), 50mg 
streptomycin sulphate (Sigma-Aldrich Company Ltd, Dorset, UK) and 24mg gentamicin 
(Roussel Laboratories, Uxbridge, UK) (P/S/G)). Cell suspensions were stored at 37oC and 
5% CO2 and viability by trypan blue exclusion was assessed daily over a period of up to 4 
days.  
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3.2.9 HT-29 and T84 human intestinal epithelial cell line culture 
HT-29 cells are a human colon adenocarcinoma grade II cell line. They are frequently used 
in vitro as a model representing luminal surface colonic epithelial cells in humans. By 
contrast, T84 cells are a human colonic adenocarcinoma cell line used in vitro to represent 
colonic epithelial cells derived from the crypt of the large bowel epithelium (89, 154, 231-
233).  
 
Cryovials of HT-29 or T84 cells of various passages were preserved in the liquid nitrogen 
store. As required, a cryovial was removed and rapidly thawed in a 37oC water bath. Cells 
were transferred to a T75 flask containing 20mL of media. The flask was incubated at 37oC 
and 5% CO2 overnight and media replaced with 14mL fresh media (500mL 'XOEHFFR¶V
Modified Eagles Media (DMEM) with 10% fetal calf serum, 5mL of 200mM glutamine and 1 
ampoule of Penicillin/Streptomycin/Gentamicin mixture) the following day, following 
confirmation that the revived cells had adhered to the flask using a light microscope. Media 
was changed three times weekly for the duration of the cell culture experiments with 14mL 
fresh media pre-warmed to 37oC. T84 cell culture medium was identical except 500mL 
DMEM Nutrient Mixture F-12 (DMEM/F-12) (1:1) (x1) (21331-020, Invitrogen) was used.  
 
Prior to media changes, HT-29 and T84 cells were examined under the light microscope. 
Cells were split prior to fully confluent growth, which was usually within 3-5 days. To split 
cells, medium was aspirated and the cells washed with 2mL 0.25% trypsin (Sigma-Aldrich) in 
Versine (0.02% EDTA in PBS, pH7.2). This was removed and replaced with a further 3mL of 
fresh 0.25% trypsin and incubated for 10 minutes at 37oC. Light microscopy was used to 
confirm cell detachment. Next 3mL of media was added to neutralise the trypsin and the 
6mL of cell suspension was collected and split equally (2mL) into three new T75 flasks each 
containing 13mL of fresh media. Alternatively, cells were counted and used immediately for 
further experimentation or centrifuged to adhere to cytospin slides.  
 
96 
 
For long-term storage, freezing mixture was prepared by mixing 550µL of dimethyl 
sulphoxide (DMSO) (Sigma-Aldrich) in 5mL FCS (Invitrogen). Cells were trypsinised, as 
described above, and the 6mL cell suspension centrifuged at 1,000rpm for 5 minutes. The 
supernatant was removed and the pellet re-suspended in 1mL of freezing mixture in a 1mL 
cryovial (Camlab). The cryovial was stored at -80oC overnight in a cardboard box filled with 
tissue paper and transferred to the nitrogen freezer the following day for permanent storage.  
 
3.2.10 Peripheral blood mononuclear cell isolation 
Peripheral blood mononuclear cells (PBMC) were used as positive controls for TLR2 and 
TLR4 expression. To isolate PBMC, whole blood was collected in sodium heparin tubes 
ȝ/KHSDULQSHUWXEHtransferred to a 50mL Falcon tube and diluted 1:1 with HBSS (with 
Ca/Mg) at room temperature. Next 5mL of Histopaque-1077 (H8889-100ML, Sigma) was 
added to a fresh 15mL Falcon tube and 10mL of diluted whole blood gently layered on top 
using a sterile Pasteur pipette. This was centrifuged at 2,000rpm (800g) for 20 minutes and 
the PBMC-containing white buffy layer (between the plasma, above, and the Histopaque, 
below) was transferred to a fresh Falcon tube.  
 
The PBMC were suspended in 5mL cold HBSS (with Ca/Mg) and centrifuged for 10 minutes 
at 1,800rpm (700g). The supernatant was removed and the PBMC re-suspended in 5mL 
cold HBSS (with Ca/Mg) and centrifuged at 1,600rpm (600g) for 10 minutes. The 
supernatant was removed and the cells finally re-suspended in 5mL cold HBSS (with Ca/Mg) 
and kept on ice until required or were centrifuged to adhere to cytospin slides.  
 
3.2.11 THP-1 human monocyte cell line culture 
THP-1 cells are a monocyte cell line (234). Cryovials of THP-1 cells of various passages 
were preserved in the liquid nitrogen store. As required, a cryovial was removed and rapidly 
thawed in a 37oC water bath and transferred to a Falcon tube containing 5mL medium 
(500mL RPMI 1640, 10% fetal calf serum, 5mL of 200mM glutamine, 1 ampoule of P/S/G 
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DQGȝPRO/ȕ-mercaptoethanol). The tube was centrifuged at 800rpm (300g) for 5 minutes 
and the supernatant removed. The pellet was re-suspended in 15mL fresh medium and 
added to a T75 flask. The flask was incubated at 37oC and 5% CO2 overnight and medium 
replaced the following day.  
 
THP-1 cells do not adhere to the T75 flask wall but remain in suspension during incubation. 
To replace the medium, the cell suspension was centrifuged in a falcon tube at 800rpm 
(300g) for 5 minutes. The supernatant was removed and the pellet re-suspended in 14mL of 
fresh medium in a fresh T75 flask. Media was changed three times weekly for the duration of 
the cell culture experiments with 14mL fresh medium pre-warmed to 37oC.  
 
Cells were split when the cell concentration reached 8x105 cells/mL using trypan blue 
exclusion. Cells were diluted to a concentration of 2-4x104 cells/mL (approximately 1:30 
dilution) and transferred to a fresh T75 flask. Alternatively, cells were counted and used 
immediately for further experimentation or centrifuged to adhere to cytospin slides.  
 
For long-term storage, freezing mixture was prepared by mixing 250µL of DMSO with 5mL 
THP-1 medium. Cells were centrifuged at 800rpm for 5 minutes and the supernatant 
removed. The cells were re-suspended in 1mL freezing mixture and transferred to a 1mL 
cryovial. The cryovial was stored at -80oC overnight in a cardboard box filled with tissue 
paper and transferred to the nitrogen freezer the following day for permanent storage.  
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3.3 Results 
3.3.1 Treatment with ETDA releases intestinal epithelial crypts 
On incubation of intestinal mucosa from the small and large bowel with EDTA, disruption to 
the IEC-lamina propria interface resulting in the release of IEC crypts into solution was 
evident (figure 3.1). Following the first 30-minute incubation the majority of cells (E1 cells) 
visible in solution using light microscopy were derived from the villus or luminal surface. 
There were very few crypts visible in suspension. In general these cells were discarded 
unless, as was occasionally seen, significant numbers of crypts were present in suspension. 
The majority of crypts were isolated following the second 30-minute EDTA incubation (E2 
cells) and could easily be seen in suspension in the mucosal tissue wash solution (figures 
3.1A and 3.1B). Following the third 30-minute incubation (E3 cells) washings were almost 
universally devoid of all cells and crypts, and were therefore discarded.  
 
Following pancreatin treatment crypt epithelial cells were seen to disaggregate into individual 
cells (figure 3.2). Mucosal strips cut from the whole bowel specimen were formalin-fixed and 
paraffin-embedded prior to treatment and after each 30-minute EDTA/DTT incubation step. 
These were sectioned and stained with haematoxylin and eosin. Figure 3.3A shows the 
appearance of the intact mucosa before EDTA incubation, with crypts visible as 
invaginations of IEC into the underlying lamina propria. Following EDTA treatment, loss of 
the crypts is clearly identified. The appearance of HPSW\³VSDFHV´LQthe underlying LP 
corresponds with regions in which the crypts previously resided (figure 3.3B). Similar 
appearances could be seen after EDTA treatment of the small intestinal mucosa (figure 3.4). 
 
3.3.2 Isolated and disaggregated cells stain positively for intestinal epithelial markers 
Isolated and disaggregated epithelial cells were centrifuged onto cytospin slides. The cells 
were labelled with murine anti-human antibodies to the epithelial markers: pan-cytokeratin 
(CK, P2871 Sigma Aldrich) and epithelial antigen (BerEP4, M0804 Dako). In addition, to 
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investigate the number of haematopoietic, non-epithelial (contaminating) cells isolated from 
mucosal preparations, cytospin slides were incubated with an anti-CD45 antibody (14-0459-
82, eBioscience). Furthermore, to confirm the reactivity of the antibodies, cytospin slides with 
the T84 human intestinal epithelial cell line and the THP-1 haematopoietic monocyte cell line 
were labelled. Additional slides without a primary antibody label were included with each 
experiment to act as negative controls.  
 
Primary isolated epithelial cells expressed the epithelial marker BerEP4 (figure 3.5A). 
Isolated cells were largely CD45-negative however the occasional CD45-positive cell was 
identified (figure 3.5B). To confirm the reactivity and specificity of the epithelial and 
haematopoietic antibodies, cytospin slides containing T84 epithelial cells and THP-1 
monocyte cells were made. T84 cells stained positively for CK (figure 3.6A) and BerEP4 
(figure 3.6B), but not for CD45 (figure 3.6C). By contrast, THP-1 cells stained negatively for 
BerEP4 (figure 3.7A) but positively for CD45 (figure 3.7B). A similar pattern of CD45-
positive, BerEP4-negative staining cells was seen for cytospin slides of primary PBMC (data 
not shown).  
 
To quantify the number of CD45-positive cells in the primary preparations, cytospin slides 
were blinded and the number of CD45-positive cells per 100 isolated cells was calculated. 
Cells were counted under a light microscope in replicates of ten high powered fields per slide 
and the average CD45-positive cell count calculated. This was repeated for ten sample 
slides for each of the following groups: healthy controls, ulcerative colitiVDQG&URKQ¶V
disease (figure 3.8). The proportion of CD45-positive cells (mean + SEM) was not 
significantly different between healthy controls (2.2% +0.25) and either patients with UC 
(1.9% +0.20, P=0.41) or patients with CD (2.2% +0.49, P=0.96). There was no difference 
between UC and CD patients (P=0.58).  
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Similarly, the number of BerEP4-positive cells per 100 isolated cells was calculated (figure 
3.9). Again there was no significant difference in the number of BerEP4-positive cells 
between healthy control subjects (97.4% +0.28) and either UC (97.8% +0.23, P=0.38) or CD 
(97.2% +0.47, P=0.62), or between patients with UC and CD (P=0.27).  
 
3.3.3 Disaggregated cells show a linear decline in viability following isolation 
To assess the viability of isolated and disaggregated cells in culture medium, cells were 
suspended in culture medium (HBSS (without Mg/Ca) with 10% FCS, 5ml of 200mM L-
glutamine, 50,000 units of penicillin G) and stored in an incubator at 37oC 5% CO2. Cell 
viability using trypan blue exclusion was assessed at 24 hour intervals. There was an 
observed decline in cell viability with time, from 58.5%+2.0 (mean+SEM) immediately 
following isolation to 33.8%+7.6 at 24 hours and 9.6%+3.7 at 48 hours (figure 3.10). 
Regression analysis showed a linear relationship between decline in viability and time since 
cell isolation (slope -24.46, R2=0.9944 and P=0.003).  
 
3.3.4 Viability of disaggregated cells is not influenced by patient demographics, tissue 
sample site, underlying diagnosis or severity of intestinal inflammation 
The viability of isolated cells was distributed normally (figure 3.11, Kolmogorov-Smirnov test 
for normality p=0.165). To assess the influence of cellular and subject demographic factors 
on the intestinal epithelial cell viability (at the time of isolation) a number of analyses were 
undertaken. Firstly, cell viability assessed by trypan blue exclusion was plotted against 
subject age. There was no relation between increasing age and cell viability (figure 3.12, 
R2=0.003, p=0.626). Similarly, cell viability did not correlate with either the total weight of the 
mucosal tissue removed from the whole bowel specimen prior to crypt IEC isolation 
(R2=0.005, p=0.52) or the cell count of isolated IEC in suspension following pancreatin 
treatment (R2=0.0002, p=0.973).  
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The viability of isolated intestinal epithelial cells was not significantly different between 
healthy control subjects (57.8%+1DQGSDWLHQWVZLWKHLWKHU&URKQ¶VGLVHDVH%+2.15, 
p=0.3) or ulcerative colitis (57.2%+1.82, p=0.785). Likewise, samples from CD or UC did not 
significantly differ significantly from each other (p=0.268). The cell viability was not different 
when cells derived from un-inflamed and inflamed tissue were compared (57.95%+1.36 
versus 59.42%+1.79 respectively, p=0.508), and this observation persisted when the viability 
of cells derived from colonic inflamed tissue was sub-divided using the histological system 
described by Riley et al (235). Using this grading system, inflammation was assessed on the 
basis of six factors: acute inflammatory cell (neutrophil) infiltrate, crypt abscess formation, 
mucin depletion, surface epithelial integrity, chronic inflammatory cell infiltrate and crypt 
architectural irregularities. The severity of acute inflammation was then graded as follows: 
none, mild, moderate or severe. To avoid having group of small numbers, samples were 
grouped into either mild/moderately inflamed or severely inflamed and compared to cells 
from normal tissue samples. No significant difference in cell viability was noted (ANOVA 
p=0.308). Furthermore, the cell viability of IEC isolated from the small bowel (59.15%+2.23) 
was not significantly different from cells isolated from the large bowel (58.54%+2.23, 
p=0.814).  
 
The viability of isolated IEC was not related to the following demographic features of the 
subject: hypertension (p=0.693), ischaemic heart disease (p=0.109), cerebrovascular 
disease (p=0.240), diabetes mellitus (p=0.566), obesity (p=0.666), peripheral vascular 
disease (p=0.768), osteoporosis (p=0.363), prior intestinal surgery (p=0.87), or use of the 
following medications at the time of surgery: 5-amino salicylic acid (p=0.541), thiopurines 
(p=0.349), corticosteroids (p=0.961), cyclosporine (p=0.353), methotrexate (p=0.129), anti-
71)ĮPRQRFORQDODQWLERG\WKHUDS\S 842) and antibiotic therapy (p=0.886).  
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3.3.5 Paneth cells are present in isolated epithelial cell preparations from the small 
intestine 
Cytospin slides from isolated crypt cells were stained for the Paneth cell marker lysozyme. 
Initially, cells isolated from small intestine preparations were labelled with a rabbit polyclonal 
antibody to lysozyme at a dilution of 1:200 (Thermo Scientific, RB-372-A) and developed 
using the Vector DAB system. Cytospin slides of isolated crypt cells derived from healthy 
small intestine revealed a minority sub-population of lysozyme-positive cells (figure 3.13). 
Lysozyme-positive cells were similarly observed on cytospin slides from patients with 
&URKQ¶VLOHLWLV/\VR]\PH-positive cells were not identified on cytospin slides of isolated crypt 
cells from the large intestine of healthy controls or SDWLHQWVZLWK8&RU&URKQ¶VFROLWLV.  
 
Paneth cell metaplasia in the colon is a recognised histological feature of inflammatory 
bowel disease, although its diagnostic value is unclear (215). Paneth cells were identified 
histologically as lysozyme-positive cells with a granular appearance located predominantly in 
the crypt base. To investigate the number of lysozyme-positive staining epithelial cells in the 
small and large bowel, whole bowel tissue sections from healthy controls and patients with 
inflammatory bowel disease were formalin-fixed and paraffin-embedded, sectioned and 
mounted onto glass histology slides before being stained with the anti-lysozyme antibody. 
Blinded sections were viewed at high power and the number of lysozyme-positive cells per 
crypt was calculated over at least five high power fields per section for at least two cases per 
disease group.  
 
Lysozyme-positive cells with secretory granules morphologically consistent with being 
Paneth cells were detected in the epithelial crypts of the small intestine of healthy controls 
DQGSDWLHQWVZLWK&URKQ¶VFROLWLVILJXUHThe number of lysozyme-positive epithelial 
cells per crypt in healthy control small bowel epithelium (2.2+0.2) was similar to the number 
RISRVLWLYHFHOOVLQLQIODPHG&URKQ¶VGLVHDVHVXEMHFWV+0.2, p=0.95), figure 3.15.  
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Lysozyme-positive cells with Paneth cell morphology were not detected in the bases of the 
crypts of the large intestine of healthy controls or patients with IBD (figure 3.16). Lysozyme-
positive cells were detected in the lamina propria of the small and large intestine sections 
from healthy controls and patients with IBD, and are likely to represent haematopoietic 
mononuclear cells. Rarely, lysozyme-positive cells were detected in the large intestine crypt 
of healthy controls and patients with IBD (less than one positively-staining cell per 20 crypts). 
These cells did not have Paneth cell morphological features, such as containing secretory 
granules, and likely represent intra-epithelial lymphocytes (figure 3.17). Furthermore, the 
number of these lysozyme-positive colonic crypt epithelial cells did not differ between 
healthy controls and patients with IBD-associated colitis of any degree of histological 
inflammation (Kruskal-Wallis test p=0.536).  
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3.4 Figures 
 
 
 
 
 
Figure 3.1 EDTA/DTT treatment releases epithelial cell crypts from the underlying lamina 
propria. Mucosal samples were treated with EDTA/DTT in a shaking water bath for 30 
minutes at 37oC. Following vigorous shaking, intact epithelial crypts were released from the 
underlying mucosa and visible in solution using light microscopy at low power (X10, A) and 
high power (X40, B) magnification.  
 
DDT, dithiothreitol; EDTA, ethylenediaminetetraacetic acid.  
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Figure 3.2 Isolated intestinal crypt cells disaggregate into individual cells following pancreatin 
treatment. Isolated intestinal epithelial crypts were treated with pancreatin for 90 minutes 
following whole crypt isolation, and viewed under light microscopy. Cells were seen either 
individually or in small clumps. Clumped cells were further disaggregated by passing the cell 
suspension through a 21-gauge needing using a 10mL syringe.  
 
DDT, dithiothreitol; EDTA, ethylenediaminetetraacetic acid.  
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Figure 3.3 EDTA/DTT treatment results in the loss of surface epithelial crypts from large 
intestine mucosal tissue. Colonic mucosal samples before and following EDTA/DTT 
treatment were formal-fixed and paraffin-HPEHGGHGEHIRUHFXWWLQJLQWRȝPWKLFNVHFWLRQV
and mounting on glass microscopy slides at low power (x10). Slides were stained with 
haematoxylin and eosin. Untreated colonic mucosa (A) shows an intact epithelium with 
visible crypt epithelial cells. Following EDTA/DTT treatment (B) there is loss of epithelial 
crypt cells from the underlying lamina propria. Empty structures previously containing crypts 
were identified (*). 
 
DDT, dithiothreitol; EDTA, ethylenediaminetetraacetic acid.  
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Figure 3.4 EDTA/DTT treatment results in the loss of surface epithelial crypts from small 
intestine mucosal tissue. Mucosal samples from the small intestine before and following 
EDTA/DTT treatment (three 30 minute incubations) were formal-fixed and paraffin-
embedded EHIRUHFXWWLQJLQWRȝPWKLFNVHFWLRQVDQGPRXQWLQJRQJODVVPLFURVFRS\VOLGHV
at low power (x10). Slides were stained with haematoxylin and eosin. Untreated colonic 
mucosa (A) shows an intact epithelium with visible crypt epithelial cells. Following 
EDTA/DTT treatment (B) there is loss of epithelial crypt cells from the underlying lamina 
propria. Empty structures previously containing crypts were identified (*). In untreated 
samples, eosin-staining Paneth cells are seen at the base of the small intestinal crypts (#).  
 
DDT, dithiothreitol; EDTA, ethylenediaminetetraacetic acid.  
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Figure 3.5 Isolated crypt cells express the epithelial-specific marker BerEP4, but not the 
haematopoietic marker CD45. Isolated intestinal epithelial cells were centrifuged onto 
cytospin slides and labelled with (A) anti-BerEP4 monoclonal antibody, (B) anti-CD45 
monoclonal antibody or (C) negative control (no primary antibody). Primary antibody 
colorimetric detection was undertaken using ¶-diaminobenzidine (DAB) substrate followed 
by haematoxylin counter-staining. Isolated crypt cells were strongly positive for the epithelial-
specific BerEP4, but negative for the haematopoietic marker CD45. However, the occasional 
CD45 positive staining crypt cell was noted (*, panel B). The absence of staining on the 
negative control slides excluded non-specific binding of the secondary antibody or 
avidin/biotin-conjugated horseradish peroxidise enzyme complex. 
A B 
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Figure 3.6 T84 cells express the epithelial-specific markers pan-cytokeratin and BerEP4, but 
not the haematopoietic marker CD45. Cells from the T84 intestinal epithelial cancer cell line 
were centrifuged onto cytospin slides and labelled with monoclonal antibodies to (A) human 
pan-cytokeratin, (B) BerEP4, (C) CD45, or (D) negative control (no primary antibody).  
Primary antibody detection required the ¶-diaminobenzidine substrate and haematoxylin 
counter-staining.  
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Figure 3.7 THP-1 cells express the haematopoietic marker CD45, but not the epithelial-
specific marker BerEP4. Cells from the THP-1 monocyte cell line were centrifuged onto 
cytospin slides and labelled with monoclonal antibodies to (A) BerEP4, (B) CD45 or (C) 
negative control (no primary antibody).  Primary antibody detection required the ¶-
diaminobenzidine substrate followed by haematoxylin counter-staining. THP-1 cells were 
positive for the haematopoietic marker CD45, but negative for the epithelial-specific marker 
BerEP4. 
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Figure 3.8 Isolated crypt cells from healthy controls and patients with inflammatory bowel 
disease include similar proportions of CD45-positive cells. Mucosal samples from healthy 
controls and patients with inflammatory bowel disease were treated with EDTA/DTT to 
release epithelial crypts which were subsequently disaggregated into individual cells using 
pancreatin. Isolated cells were centrifuged onto cytospin slides and stained with an anti-
&'PRQRFORQDODQWLERG\EHIRUHGHWHFWLRQXVLQJ¶-diaminobenzidine substrate. Cells 
were counter-stained with haematoxylin. CD45-positive-staining cells were counted per 
hundred cells using light microscopy.  
 
DTT, dithiothreitol; EDTA, ethylenediaminetetraacetic acid 
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Figure 3.9 Isolated crypt cells from healthy controls and patients with inflammatory bowel 
disease include similar proportions of BerEP4-positive epithelial cells.  
Mucosal samples from healthy controls and patients with inflammatory bowel disease were 
treated with EDTA/DTT to release epithelial crypts which were subsequently disaggregated 
into individual cells using pancreatin. Isolated cells were centrifuged onto cytospin slides and 
stained with an anti-BerEP4 DQWLERG\EHIRUHGHWHFWLRQXVLQJ¶-diaminobenzidine 
substrate. Cells were counter-stained with haematoxylin. BerEP4-positive cells were counted 
per hundred cells using light microscopy.  
 
DTT, dithiothreitol; EDTA, ethylenediaminetetraacetic acid 
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Figure 3.10 Intestinal crypt cell viability declines linearly with time following isolation from the 
underlying lamina propria. Intestinal crypt cells were isolated and suspended in cell culture 
medium for up to 48 hours. Cell viability was assessed by percentage trypan blue exclusion 
daily for 48 hours. A strong linear relationship between time since isolation and percentage 
cell viability was observed (R2=0.9944, p=0.0033). Dots represent mean cell viability and 
bars represent standard error.  
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Figure 3.11 Isolated crypt cell viability following acquisition is normally distributed. Intestinal 
epithelial cells were isolated and disaggregated before analysis of cell viability using trypan 
blue exclusion. Cell viability at the time of isolation was plotted on a frequency-distribution 
histogram and shown to be normally distributed (Kolmogorov-Smirnov test p=0.165). The 
normal curve is shown as a black line against the frequency distribution bars. 
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Figure 3.12 Initial intestinal crypt cell viability is independent of sample subject age. Intestinal 
epithelial cells were isolated and disaggregated before being suspended in medium. Cell 
viability assessed using trypan blue exclusion at the time of acquisition and plotted against 
subject age. Age did not determine initial cell viability (R2=0.003, p=0.626).  
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Figure 3.13 A sub-population of isolated normal small intestinal crypt cells are lysozyme-
positive. Cytospin slides of freshly isolated and disaggregated small intestinal cells were 
labelled with (A) no-antibody control serum or (B) a polyclonal antibody to lysozyme. Slides 
were sequentially incubated with a biotinylated secondary antibody, an avidin/biotin-
conjugated horseradish peroxidise enzyme complex and the ¶-diaminobenzidine (DAB) 
substrate. Slides were counter-stained with haematoxylin. Occasional brown-staining 
lysozyme-positive Paneth cells were seen at low power light microscopy (arrows, B).  
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Figure 3.14 Normal small intestinal crypt base epithelial cells express intracellular lysozyme. 
Whole bowel sections from the small intestine were formalin-fixed and paraffin-embedded 
before being sectioned and stained with (A and C) an anti-lysozyme antibody or (B and D) 
no-antibody control serum, and subsequently developed using ¶-diaminobenzidine (DAB) 
substrate and counter-staining with haematoxylin. Dark brown-staining lysozyme-positive 
cells were observed in both the base of the crypts (arrow) and in scattered cells of the 
lamina propria (arrowhead) (A, x10 magnification), but not on the no-antibody control slide 
(B). Weaker, non-specific staining of epithelial cells was noted (A and C). At a higher 
magnification (x40), dense lysozyme-staining crypt base cells (with cytoplasmic secretory 
granules, black arrow) were identified, interspersed between lysozyme-negative crypt base 
cells (white arrow, C). Lysozyme-positive lamina propria cells were also identified 
(arrowhead). A high power negative-control slide demonstrated no staining (D).  
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Figure 3.15 The number of lysozyme-positive crypt epithelial cells in small intestine crypts 
from healthy controls and SDWLHQWVZLWK&URKQ¶VLOHLWLV is similar. Whole bowel sections from 
WKHVPDOOLQWHVWLQHRIKHDOWK\FRQWUROVDQGSDWLHQWVZLWK&URKQ¶VLOHLWLVZHUHIRUPDlin-fixed 
and paraffin-HPEHGGHGEHIRUHȝPVHFWLRQLQJDQGVWDLQLQJZLWKDQDQWL-lysozyme antibody. 
The number of lysozyme-positive cells per crypt was counted by light microscopy on at least 
five high powered fields per slide.  
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Figure 3.16 Normal large intestinal crypt base epithelial cells do not express lysozyme. 
Whole bowel sections from the large intestine were formalin-fixed and paraffin-embedded 
before being sectioned and stained with (A and C) anti-lysozyme antibody or (B and D) no-
antibody control serum, and subsequently developed using ¶-diaminobenzidine (DAB) 
substrate and counter-staining with haematoxylin. Lysozyme-positive cells were not 
observed in the epithelium, but scattered lysozyme-positive cells were observed in the 
lamina propria (arrowheads) (A, x10 magnification). Weak, non-specific brown staining of 
epithelial cells is noted (A and C). At a higher magnification (x40), crypt base cells are 
lysozyme-negative (C). Low and high power negative-control slides demonstrated no 
lysozyme staining (B and D).  
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Figure 3.17 Colonic crypt base epithelial cells from inflamed ulcerative colitis contain 
lysozyme-positive cells without Paneth cell morphology. Whole bowel sections from the large 
intestine were formalin-fixed and paraffin-embedded before being sectioned and stained with 
anti-O\VR]\PHDQWLERG\DQGVXEVHTXHQWO\GHYHORSHGXVLQJ¶-diaminobenzidine (DAB) 
substrate and counter-staining with haematoxylin. Occasional (less than one cell per 20 
crypts) lysozyme-positive cells were observed in the epithelium (white arrow) at high power. 
These did not contain secretory granules and morphologically resembled lamina propria 
mononuclear cells (black arrow). 
5ȝP 
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3.5 Discussion 
The epithelium of the intestine has the fascinating ability to rapidly replenish itself over a 
period of five days due to the population of stem cell which reside at the base of the crypts of 
Lieberkühn (174). A key to the survival of intestinal epithelial cells is their interaction with the 
underlying basement membrane, which comprises structural proteins and growth factors. 
Attachment to this basement membrane is vital for cell viability and IEC rapidly undergo 
apoptosis when detached from this underlying structure (172). There is a need to advance 
our understanding of the biology of the ISC if the therapeutic potential of stem cell treatment 
in the intestinal tract is to be realised.  
 
Attempts at long term in vitro culture of intestinal epithelial cells have proved challenging 
(226, 227). However, the long term culture of murine intestinal epithelial organoids has 
recently been reported using techniques which are both dependent (236) and independent 
(237) of stromal niche cells. Such long term cultures may well lead to expansion in our 
understanding of stem cell biology, but it is unclear if they will be useful in experimentation 
into the functional state of epithelial cells in conditions such as inflammatory bowel disease. 
To understand the functional role of IEC in gut inflammation, primary cells from patients with 
IBD are required to be isolated and characterised rapidly ex vivo.  
 
In this chapter, primary crypt intestinal epithelial cells were isolated using a technique 
described by Whitehead et al. (229) and modified for use in our laboratory (210). During this 
technique, treatment with EDTA/DTT results in the detachment and isolation of intact 
epithelial crypts in solution. Thereafter, crypt cells are disaggregated into individual cells 
using porcine pancreatin. This results in a high crypt yield due to complete loss of crypt cells 
from the underlying lamina propria. Moreover, villus/luminal IEC could be largely discarded, 
allowing the crypt cells to be the main isolated cell type. 
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Consistent with previous reports demonstrating that IEC undergo rapid apoptosis following 
removal from the underlying basement membrane, it was shown that isolated crypt cell 
viability declines linearly with time. Almost all cells were non-viable within 48 hours of 
isolation and maintenance in cell culture medium. The mean viability of isolated epithelial 
cells was 58.5% as assessed immediately after isolation. To ensure consistency of results, 
all specimens were processed identically and all down-stream experiments were performed 
immediately following crypt cell isolation.  
 
Interestingly, the viability of isolated crypt cells was not dependent on patient baseline 
demographics, such as age, medical history or drug treatment using regression analysis. 
Likewise cell viability was not influenced by acquired mucosal tissue weight, underlying 
diagnosis (healthy control, CD or UC), severity of inflammation using the scoring system 
reported by Riley et al. (235) or whether the sample was of small or large bowel origin. It is 
unknown if the rates of apoptosis following isolation differ amongst specimens from patients 
with different baseline demographics, diagnoses or severity of underlying inflammation. 
There was no significant difference in cell viability (using trypan blue exclusion) amongst the 
groups studied.  
 
It was important to confirm that the isolated crypt cells represented a population of epithelial 
cells without significant numbers of contaminating non-epithelial cells. In normal healthy 
mucosa, intra-epithelial lymphocytes are visualised between epithelial cells at a frequency of 
up to 5 lymphocytes per 100 epithelial cells (215). Therefore, using EDTA/DTT treatment to 
isolate whole crypts, it would seem unlikely that this technique would yield a population of 
pure epithelial cells, but rather it would isolate a cell population containing a small proportion 
of non-epithelial cells. Moreover, neutrophil infiltration of the epithelium (cryptitis) and of the 
crypt lumen (crypt abscess) are characteristic features in the mucosa of patients with IBD 
and commonly observed in addition to the increased numbers of these cells present in the 
underlying lamina propria (215). Since both lymphocytes and neutrophils are known to 
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express TLR, it was crucial to investigate if the EDTA/DTT treatment resulted in the isolation 
of large numbers of these cells in addition to the epithelial cells isolated from inflamed 
mucosa. If this were the case, any differential expression of TLR in the isolated cells as a 
whole could be the result of non-epithelial (haematopoietic) cell contamination rather than 
differential expression in the epithelial cell population itself.  
 
To address this question, monoclonal antibodies directed against epithelial (BerEP4) and 
haematopoietic (CD45) markers were chosen and target specificity tested using human cell 
lines of epithelial (T84) and haematopoietic (THP-1) origin. Thereafter, cytospin slides 
prepared form healthy controls and patients with IBD were shown to comprise statistically 
similar numbers of CD45-positive cells (1.9-2.2%). Notably, this was at the reported 
frequency of less than 5 CD45-positive cells per 100 epithelial cells in healthy mucosa. 
Likewise, the numbers of BerEP4-positive (epithelial) cells were statistically similar on 
cytospin slides from healthy controls and patients with IBD (97.2-97.8%). This suggests that 
the current crypt cell isolation technique using EDTA/DTT yields a population of almost 
exclusively epithelial cells and which includes approximately two haematopoietic cells per 
100 isolated cells. More importantly, cellular isolates from patients with active IBD are not 
abundant with haematopoietic cells and, therefore, samples from healthy controls and IBD 
patient groups are comparable.  
 
Paneth cells are found in the base of the crypts of the small bowel and secrete the 
antimicrobial peptide lysozyme (108). Although their expression is almost universal in the 
bases of the crypts of the small bowel, Paneth cells are rarely present in the normal large 
intestine. However, Paneth cell metaplasia is a recognised consequence of chronic epithelial 
cell damage and is occasionally observed in the epithelium of the large intestine in IBD 
(215). Crucially, Paneth cells have been reported to sense bacteria via toll-like receptor 
signalling (238). Therefore, it was possible that Paneth cell metaplasia in the large intestine, 
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or Paneth cell expansion in the small intestine, could account for differential expression of 
TLR in isolated crypt cell preparations.  
 
To address this issue, cytospin slides of disaggregated crypt cells and slides of FFPE whole 
bowel sections were stained with a polyclonal antibody to lysozyme. Staining of cytospin 
slides from healthy small intestine DQG&URKQ¶VLOHLWLVdemonstrated lysozyme-positive cells 
which are likely to represent Paneth cells. However, due to the method of cytospin slide 
preparation (i.e. adherence of isolated cells into a glass slide by high speed centrifugation) 
the cellular morphology can be disturbed and it was not possible to definitively characterise 
the lysozyme-positive cells as Paneth cells on morphology alone. Importantly, cytospin 
slides from healthy large intestine and patients with IBD-associated colitis did not 
demonstrate lysozyme-positive cells.  
 
Immunohistochemical staining of FFPE whole bowel sections resulted in weak non-specific 
staining of epithelial cells despite numerous attempts to optimise the protocol and minimise 
this staining, including the use of longer serum, avidin and biotin blocking steps, and a 
shorter DAB substrate development step. Despite this weak staining, intense staining of cells 
with a typical granular Paneth cell appearance was demonstrated. These lysozyme-positive 
Paneth cells were easily identifiable and located exclusively in the bases of the small 
intestine crypts. These cells were also strongly eosin-staining on H&E slides, another feature 
of Paneth cells. When the numbers of positive-staining cells were counted in the normal 
small intestine epithelium, approximately 2 lysozyme-positive cells per crypt were identified. 
Statistically similar numbers of lysozyme-positive cells were identified in the crypts of 
VDPSOHVIURPSDWLHQWVZLWKLQIODPHGVPDOOLQWHVWLQDO&URKQ¶VGLVHDVHThis suggests that 
there is no significant expansion in the number of Paneth cells in the mucosa of &URKQ¶V
ileitis that would account for any differential TLR expression.  
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Lysozyme-positive cells with typical Paneth cell morphology were not observed in whole 
bowel sections of colonic tissue. Lysozyme-positive cells without secretory granules were 
rarely observed in the crypts of the large intestinal epithelium of healthy controls and patients 
with IBD at a frequency of less than one lysozyme-positive cell per twenty crypts. The 
number of these intra-epithelial lysozyme-positive cells was statistically similar in sections 
from patients with colitis compared to healthy controls. It is likely that these cells represent 
intra-epithelial lymphocytes, which are reported to express lysozyme (239). Indeed, 
lysozyme-positive mononuclear cells were present in the lamina propria of the small and 
large intestine regardless of the degree of inflammation, and had similar morphological 
appearance to intra-epithelial lysozyme-positive mononuclear cells in the lamina propria. In 
many specimens, no lysozyme-positive cells were identified in entire colonic tissue sections, 
both for healthy controls and patients with IBD. 
 
These data suggests that the reported occurrence of Paneth cells in the inflamed epithelium 
of patients with colonic IBD is unlikely to significantly contribute to changes in TLR 
expression in colonic crypt epithelial cell isolates from patients with inflammatory bowel 
disease.  
 
In summary, treatment of mucosal specimens with ETDA/DTT and pancreatin results in the 
isolation and disaggregation of crypt intestinal epithelial cells which contain minimal numbers 
of non-epithelial cells and which can be identified by their lack of expression of the epithelial 
marker BerEP4. The viability of the isolated cells was approximately 60%. The number of 
CD45-positive haematopoietic cells was not increased in crypt cells isolated from inflamed 
specimens compared to healthy control specimens and the number of epithelial Paneth cells 
was not significantly increased as a result if mucosal inflammation. Therefore, ETDA/DTT 
and pancreatin treatment of mucosal samples is an effective method of isolating a population 
of crypt intestinal epithelial cells suitable for down-stream comparative analysis. 
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Chapter 4: Expression of toll-like receptors-2 and -4 mRNA in crypt 
intestinal epithelial cells in health and inflammatory bowel disease 
 
4.1 Introduction 
4.1.1 The expression of Toll-like receptors on human intestinal epithelial cell lines 
The expression of Toll-like receptors in human IEC has been studied in both intestinal 
cancer cell lines and primary intestinal epithelial cells, although the majority of studies have 
characterised expression in the former. TLR4 has been the most extensively investigated 
TLR given its role in recognising LPS, the endotoxin associated with septic shock. Abreu 
reported Caco-2 HT-29 and T84 human cancer cell lines to be unresponsive to LPS (lack of 
IL-8 secretion and NF-ț%OXFLIHUDVHDFWLYDWLRQGXHWRORZ7/5PHVVHQJHU51$P51$
and protein expression and absence of the TLR4 accessory molecule MD-2 (89).  
 
Conversely, the HT-29 and T84 cell lines have been reported to actively express TLR2/3/4 
mRNA and surface TLR2 and TLR4 protein, though not CD14 mRNA or protein. TLR4 
ligation results in activation of different components of the MAP kinase pathway in different 
cell lines, namely p42/44 in T84 and p38 in HT-29 cells suggesting functional receptors in 
these cell lines (232). A foetal small bowel cell line (H4 cells) has also been shown to 
express TLR2 and TLR4 at both the mRNA and protein level (240).  
 
The cellular location of TLR expression has also been investigated. Flagellin has been 
demonstrated to stimulate TLR5-induced IL-8 production from confluent cultured and 
polarised T84 cells when applied to the basolateral membrane but not the apical membrane. 
Subsequently, TLR5 protein was demonstrated to reside only on the basolateral membrane 
(241). Following ligation, TLR2 and TLR4 receptors on confluent T84 cell cultures undergo 
basolateral scattering which results in apical hypo-responsiveness to subsequent apical 
stimulation (242). This may form part of the pathway for apical tolerance to bacterial antigens 
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in the gut. Intracellular cytoplasmic scattering of TLR2 and TLR4 following ligation has also 
been observed in SW480 cells (243).  
 
The expression of TLR2 and TLR4 in particular depend on a number of factors in cultured 
cell lines. Firstly the cell line phenotype is a key factor in receptor expression. The colonic 
SW480 line expresses TLR4 mRNA and protein to a greater level than HT-29 and T84 cells 
lines, which in turn have greater expression than Caco2 and HCT116 lines. This was 
reported to be due to variations in TLR4 promoter regulation by DNA methylation and 
histone deacetylation in these cell lines (233). This may explain differential responses of 
these cell lines to TLR ligands (122). TLR expression in SW480 and Colo205 lines has been 
suggested to most closely resemble expression in primary human colonic IEC at the 
genomic level, although TLR expression is still variable and no similar study has compared 
luminal surface versus crypt cell position or investigated optimal cell line models for small 
bowel IEC (243).  
 
It is generally accepted that TLR2 and TLR4 respond to extracellular ligands in humans, and 
that a cytoplasmic TLR2 or TLR4 location indicates cell immaturity. However it has been 
reported by Hornef et al. that a murine crypt cell line m-ICcl2 expresses peri-nuclear, 
cytoplasmic TLR4 and MD-2 proteins, and that co-localisation of LPS and TLR4 occurs 
adjacent to the Golgi organ (244) following clarithrin-mediated internalisation (245). Suzuki et 
al. report cytoplasmic staining of up-taken LPS in the human colonic epithelial cancer cell 
lines Colo205, HT-29 and SW480 with surface expression of TLR4 protein only observed in 
SW480 cells (246). In vitro IFN-ȖZDVVKRZQWRDXJPHQW/36UHVSRQVLYHQHVVDQGLQFUHDVH
total TLR4 protein levels in Colo205 and HT-27 cells, but not to increase their surface TLR4 
expression. This may suggest that Colo205 and HT-27 cells express intracellular TLR4 
which responds to LPS only after IFN-Ȗ-facilitated LPS uptake. By contrast, SW480 cells are 
primed to respond to extracellular LPS even in un-primed conditions (246).  
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To further investigate the role of TLR4 expression in differential cellular compartments, Latz 
et al. used the kidney cell line HEK293, which does not express TLR4, MD-2 or CD14, and 
transfected cells with fluorescently tagged TLR4, MD-2 and CD14 (247). Experiments 
showed continuous, rapid tracking of TLR4, MD-2 and CD14 to and from the plasma 
membrane and Golgi. Critically, MD-2 but not CD14 was shown to be required for LPS-
mediated signal transduction and this pathway also required translocation of MyD88 to the 
plasma membrane rather than the Golgi. Both the use of a non-internalisable stimulatory 
monoclonal anti-TLR4 antibody and the Golgi disrupting agent Brefeldin A did not reduce 
LPS-mediated signal transduction intensity, suggesting that it is the plasma membrane-
bound TLR4 that is site of inflammatory signal transduction whereas the Golgi directs TLR4 
cellular trafficking (247). Whether this is true for primary IEC remains unclear.  
 
In support of the more conventional view of surface TLR2 and TLR4 expression, surface 
TLR4 protein was reported by Takahashi et al. in SW480, T84 and HT-29 cells (233) and by 
Otte et al. in SW480 cells (243). Likewise surface TLR2 protein has been reported in low 
levels by Melmed et al. in Caco2 and T84 cells (231) and by Otte et al. in SW480 cells (243). 
Intracellular TLR4 has not been reported in primary human epithelial cells and it is unclear if 
the observations by Hornef et al. and Suzuki et al. bear any resemblance to human crypt 
IEC.  
 
Secondly, the maturation of the cell lines is critical in TLR expression. Cario showed that 
mature T84 cells express surface TLR2 and TLR4 protein while immature cells retain these 
in the cytoplasm (242). Butyrate (a short chain fatty acid produced in the human gut by the 
epithelial-adjacent commensal flora) induces maturation and differentiation of epithelial cells 
and results in loss of LPS responsiveness (122). Similarly prior treatment of HT-29 cells with 
butyrate results in loss of LPS-mediated, TLR4-dependent IL-8 production due to down-
regulation of TLR4 mRNA and protein expression (248). Interestingly, the harvesting of sub-
confluent cultures of HT-29 cells resulted in maintenance of LPS responsiveness whereas 
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culture to full confluence led to a loss of TLR4 signalling by similar mechanisms (248). It is 
possible that similar processes occur in the human gut as cells differentiate and migrate 
along the small bowel crypt-villous and large bowel crypt-luminal axes.  
 
Thirdly, cellular location along the crypt-villous axis influences TLR expression. Crypt IEC 
internalise peptidoglycan (PGN) which co-localises with PGN recognition protein-3 
(PGLYRP-3) and is held within an intracellular compartment before being subsequently 
exocytosed along the basolateral membrane. This was not observed in non-crypt IEC (249). 
The enhanced expression of TLR4 in crypt cells versus luminal cells would further support 
the concept of down-regulation of extracellular TLR with maturation (246). TLR4 and MD-2 
protein has been shown to be localised to the crypt IECs in mice (250) and a murine crypt 
cell line responds to LPS (244, 245).   
 
Fourthly, the expression of TLR may be mediated by the abundance of certain ligands, 
leading to receptor down-regulation and tolerance.  Otte et al. showed that SW480, Colo205 
and T84 cells were responsive (by the production of IL-8) to exposure to lipoteichoic acid 
(LTA), LPS and Gram positive (Staphylococcus aureus) and Gram negative (Escherichia 
coli) bacteria. Pre-incubation with these ligands blunted subsequent TLR- and IL-1-mediated 
responses which both signal through the common TIR domain, but not TNF-Į-mediated 
responses which have a different signalling cascade (243). Hypo-responsiveness was 
shown to be due to increased cytosolic expression of TLR2 and TLR4 protein and up-
regulation of TOLLIP mRNA and protein rather than by altered expression of total TLR2, 
TLR4, MyD88, IRAK molecules or TRAF6 (243). To the contrary, it has been reported that 
pre-incubation with LPS and IL-1 does not tolerise responsiveness to either ligand in HT-29 
or Caco-2 cells (122). Apical pre-stimulation of polarised HCA-7 cells with CpG-ODN, a 
TLR9 ligand, resulted in loss of subsequent response to TLR3, 5 and 9 ligands, whereas 
apical pre-stimulation with TLR3 and 5 ligands did not induce this loss of response (251). 
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This may be a contributory mechanism responsible for IEC tolerance to antigens expressed 
by the intestinal flora.  
 
Furrie et al. showed a rather variable response in differing cell lines to various TLR ligands 
and bacterial co-cultures. Caco-2 cell TLR expression was uninfluenced by bacterial flora co-
culture. However, HT-29 cells show increased TLR2 and TLR3 mRNA expression in 
response to Gram positive organisms but not individual TLR ligands, whereas TLR4 was up-
regulated by Enterococcus faecalis and lipid A but down-regulated by Escherichia coli. TLR1 
was up-regulated only by poly I:C (252). Nandakumar et al. showed that HT-29 and T84 
cells produce mRNA for TLR4 in response to Vibrio cholerae and Salmonella typhi and 
down-regulated TLR5 in response to Vibrio cholerae and enterohaemorrhagic Escherichia 
coli, with micro-organism also reducing TLR9 expression (253). How these in vitro 
observations relate to the in vivo state in humans is unclear.  
 
Finally, cytokine exposure influences expression of TLR. TNF-Į,)1-ȖDQG,)1-ĮXS-
regulate TLR4 and MD-2 mRNA to a variable degree, especially in HT-29 more than T84 
cells (154). Mueller et al. reported that the TH2 cell cytokines IL-4 and IL-13 down-regulate 
TLR3, TLR4 and MD-2 mRNA, whereas TLR2 and TLR5 mRNA were unaffected in a variety 
of human cell lines. In contrast, the TH1 cell cytokine IFN-ȖXS-regulates TLR2-5 and MD-2 
mRNA and TLR4 protein (155).  
 
In summary, it is clear that the use of human cell lines can yield a significant amount of data 
regarding the expression, location and function nature of TLR in IEC. However, the variability 
of differentiation, anatomical origin and extracellular environment during in vitro studies, in 
addition to the fact that these cells are cancer cell lines, limits the applicability of 
experimentation in these circumstances to cellular behaviour in human inflammatory 
disease. This has led to work on primary epithelial cells.  
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4.1.2 The expression of Toll-like receptors on human primary intestinal epithelial cells 
The literature on the expression of TLR in primary IEC is sparse. EDTA-isolated primary 
human colonic IEC have been shown to express mRNA for TLR1-9 but not TLR10 and with 
variable TLR7 expression (243). Böcker et al. investigated dispase-isolated primary epithelial 
cells and reported consistent expression of TLR4 and MD-2 mRNA with more variable TLR2 
mRNA expression (122). Conversely, Abreu et al. found low expression of TLR4 mRNA and 
no MD-2 mRNA in healthy subjects using laser capture microdissection (154).  
 
Immunohistochemical analysis of colonic biopsy samples from healthy subjects revealed 
expression of TLR2 and TLR4 protein mainly in the crypt IEC with gradual loss of expression 
along the crypt-luminal axis, whereas TLR3 protein was expressed mainly in the sub-apical 
cytoplasmic region in mature (luminal) colonocytes (252). Of note mononuclear lymphoid 
cells also stained for TLR2-4 protein and were localised to the peri-crypt region of the lamina 
propria.  
 
Additionally, TLR1/2 and TLR1/4 heterodimers, but not TLR3 or TLR5, have been shown to 
be expressed in the crypts of healthy small and large bowel, and these cells display an 
enteroendocrine phenotype (254). Conversely, isolated specimens of primary colonic 
mucosa were shown to respond to the TLR5 ligand flagellin only when applied to the 
basolateral but not the apical surface using an Ussing chamber (255) which is similar to that 
seen in equivalent experiments of cultured IEC lines (241). Primary IEC have been shown to 
express TLR8 mRNA and protein particularly at the luminal surface (256), and TLR9 mRNA 
but not protein (257).  
 
TLR2 and TLR4 proteins are expressed in the basolateral compartment of IEC from foetal 
small bowel, particularly in the crypt rather than villous region (240). Wolfs et al. report the 
intracellular expression of the TLR4 accessory protein MD-2 in Paneth cells of small bowel 
crypts in term infants and adults and it was postulated that this represented a role as a 
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locally secreted anti-LPS peptide (258). The observation that MD-2 is not expressed in 
premature infants implies that the immature bowel lacks the ability to sense colonic bacteria 
which may predispose to neonatal conditions like necrotising enterocolitis (NEC) which is 
thought to be an abnormal TLR-driven inflammatory response to the intestinal flora (259).  
 
4.1.3 The expression of Toll-like receptors in inflammatory bowel disease 
The epithelial cell expression of various TLR has been studied in the context of IBD. Cario 
and Podolsky showed immunohistochemically that TLR2 and TLR4 are minimally expressed 
in health and, DOWKRXJKDFWLYHXOFHUDWLYHFROLWLVDQG&URKQ¶VGLVHDVHGLGQRWLQIOXHQFH7/5
expression, TLR4 was significantly up-regulated in both diseases regardless of disease 
activity. Interestingly, TLR4 was located basolaterally in UC and apically in CD. TLR3 was 
expressed in healthy controls and significantly down-regulated in CD but not UC. Finally, 
TLR5 was expressed throughout the small bowel villous and large bowel luminal cells (but 
not in the crypt cells) and expression did not differ from controls in any disease state (260). 
To the contrary, in active UC Stanislawowski et al. report reduced mucosal TLR5 mRNA, by 
quantitative RT-PCR, and reduced cytoplasmic and basolateral TLR5 protein in epithelial 
cells by qualitative immunohistochemical staining (261).  
 
Hausmann et al. did not detect TLR2 or TLR4 protein in epithelial cells of colonic resection 
specimens using immunohistochemistry and, although they report a small number of TLR2 
and TLR4 protein positive cells in active IBD, these were identified as macrophages 
restricted to the peri-crypt region of the LP which were absent in healthy tissue (262). In a 
smaller study involving genomic expression Naik et al. showed qualitative, detectable TLR2 
expression regardless of disease state or activity but failed to detect TLR4 mRNA in healthy 
or diseased IEC, though TLR4 mRNA was detectable in LPMC in active colonic IBD (263). 
However, the small bowel lamina propria was not examined and therefore conclusions about 
LPMC in the small intestinal cannot be made.  Furthermore this study did not assess TLR 
protein expression in any cell type. Melmed et al. demonstrated TLR1, TLR2 and TLR6 
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mRNA expression in laser capture microdissected IEC of healthy subjects using quantitative 
PCR and noted a reduction in mRNA expression in TLR1 but not TLR2 or TLR6 in active UC 
(231).  
 
TLR8 mRNA is more highly expressed in EDTA-isolated IEC samples from active colonic 
IBD than inactive colonic IBD which in turn was greater than healthy epithelium (256). 
Interestingly TLR8 protein was only expressed in inflamed luminal IEC but not crypt cells and 
not in un-inflamed or healthy epithelium. Immunofluorescent staining for TLR8 varied 
between CD and UC, which a more diffuse intense staining in the former and more focal in 
UC. Sporadic cytoplasmic staining for TLR8 was only seen in inactive disease with the use 
of immuno-electron microscopy. Interestingly, TOLLIP mRNA expression was independent 
of intestinal inflammation (256).  
 
Pedersen et al. demonstrated expression of TLR9 mRNA in EDTA-isolated colonic IEC 
samples from healthy controls and IBD patients using quantitative PCR, and although TLR9 
protein was not detectable in healthy IEC using Western blotting, IEC from inflamed were not 
assessed for TLR9 protein (257). The authors suggested that TLR9 mRNA is down-
regulated in active versus inactive colonic IBD, though this comparison was made using 
whole mucosal tissue rather than isolated epithelial cells, thus any changes in TLR9 
expression may be explained by expression changes in resident LPMCs (shown in this study 
to express TLR9 mRNA).  
 
Therefore the current evidence on the expression of TLR in epithelial cells in IBD remains 
conflicting and controversial. Specifically, both TLR2 and TLR4 have been shown to be up-
regulated, unchanged and not expressed in epithelial cells in IBD. TLR3 and TLR5 are 
reported to be either unchanged or down-regulated depending on disease phenotype or 
publishing group. TLR1, TLR8 and TLR9 have single publications in this field and TLR7 has 
not been investigated in human IBD to date.  
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One of the interesting features of the current literature is that TLR2 and TLR4 appear to be 
expressed primarily in the crypt of the epithelium, with loss of TLR expression observed as 
cells migrate up the crypt towards the villi of the small intestine and luminal epithelium of the 
colon (240, 252). As discussed in sections 1.7 and 1.8, intestinal stem cells reside in the 
bases of these crypts of the small and large intestine. This region is referred to as the stem 
cell niche and comprises a variety of mesenchymal cells, including intestinal myofibroblasts, 
which regulation intestinal stem cell function through the secretion of intercellular messenger 
molecules (187). During intestinal inflammation, such as that seen in inflammatory bowel 
disease, there is often observed a dense inflammatory cell infiltrate surrounding the crypt 
bases, with further infiltration into the epithelium resulting in the formation of crypt abscesses 
and the distortion of the crypt architecture (215). Therefore, the epithelial crypt may play a 
key role in the pathogenesis of mucosal inflammation and for this reason intestinal epithelial 
cells of the crypt specifically were chosen to be studied.  
 
The aim of this chapter was to characterise the expression of TLR2 and TLR4 mRNA from 
isolated primary crypt intestinal epithelial cells and to quantitatively investigate for any 
differential expression in IBD compared to healthy controls.  
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4.2 Methods 
4.2.1 Gene expression profiling micro array using Ambion MessageAmp II® kit 
4.2.1.1 Introduction 
 To further characterise the expression of toll-like receptors in the crypt epithelial cells of 
control subjects and to compare this to the expression in patients with inflammatory bowel 
disease, an initial RNA gene expression micro array was undertaken. This technique allows 
rapid qualitative confirmation regarding the expression of TLR1-10 messenger RNA in 
primary crypt epithelial samples derived from small and large bowel tissue samples. In 
addition, semi-quantitative assessment of gene expression in IBD patients relative to the 
expression in healthy controls is possible. Finally, the differential expression of intracellular 
molecules known to be important in the TLR signalling pathway can be analysed in control 
and IBD samples using this method.  
 
4.2.1.2 Methodological overview 
A two dimensional micro array is a solid material which assays a large amount of biological 
material. It requires a glass, plastic or silicon slide (the biochip) to which the nucleic acid 
probes are bound. It differs from a macro array, which binds the probe to a membrane not a 
solid material. A micro array consists of thousands of oligonucleotide probes (also called 
reporters), each corresponding to a different gene in the genome or genomic region of 
interest. The probes are arranged on a grid in columns and rows as known as spots (or 
features) and can easily be located by their unique grid reference location.  
 
The probes are used to hybridise to target nucleic acid sample, either to complementary 
DNA (cDNA) or complimentary RNA (cRNA, also known as antisense RNA, aRNA), on the 
basis of their sequence homology. Detection of the probe-target hybridisation is achieved 
using fluorescent-, silver- or chemiluminescent-labelling of the target sequence to determine 
the relative abundance of the target molecule. DNA micro arrays can be used to measure 
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changes in expression levels, to detect single nuclear polymorphisms, or to genotype or re-
sequence mutant genomes.  
 
Micro array technology makes use of the binding of complementary nucleic acid sequences 
through the formation of hydrogen bonds between nucleotide base pairs (264). In a 
phenomenon similar to the binding of a primer to its DNA target sequence during PCR, the 
greater the sequence homology between the probe and the target sequence, the stronger 
the probe-target interaction between the two strands. Following this hybridisation process, 
non-bound and weakly bound targets can be easily washed away, leaving only 
complementary sequences bound to the probe and, therefore, bound to the micro array slide 
itself. Each gene feature on the slide consists of thousands of copies of the same identical 
probe and therefore the abundance of the labelled target sequence can be indirectly 
measured by quantifying the intensity of the signal from the labelling molecule.  
 
The most common measurement of target abundance is relative gene expression, whereby 
the expression of cDNA or cRNA is compared under various experimental conditions (for 
example, by comparing absolute gene expression in manipulated cells to expression in 
control cells) or by comparing samples from patients with a particular disease with those of 
healthy control cases. It is possible to quantitatively measure absolute target sequence 
expression levels obtained using chips with inbuilt control spots with standardised signal 
intensity, although this method is less commonly used (264).  
 
There are broadly two sub-types of micro array; spotted and oligonucleotide. In spotted 
micro arrays, the utilised probes are one of a number of possible molecules, such as 
oligonucleotides, cDNA molecules or small fragments of PCR products that correspond to 
specific mRNA sequences. The probes are synthesised prior to their deposition on the array 
surface and are then "spotted" onto the glass chip. This approach requires an array of fine 
needles controlled by a robotic arm that dips into wells containing DNA probes and then 
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deposits each probe at designated locations on the array surface. The resulting grid of 
probes represents the nucleic acid profiles of the prepared probes and is ready to receive 
complementary cDNA or cRNA targets derived from experimental or clinical samples. This 
technique can be produced in-house and customised for each experiment and is more cost 
effective.  
 
By contrast, oligonucleotide micro arrays are produced by a manufacturing technique where 
the oligonucleotide sequence is built and printed directly onto the micro array surface, rather 
than depositing the pre-synthesised intact probe onto the chip. One example of such a micro 
array is the Affymatrix GeneChipTM  which uses photo-labile blocking groups attached to 
nucleotide triphosphate molecules, masking filters and lasers to synthesise (nucleotide by 
nucleotide) the required probes directly onto the chip surface (264) . Oligonucleotide micro 
arrays are usually commercially produced and are often more expensive than spotted micro 
arrays.  
 
Micro array analysis can be undertaken using either a single- or two-channel protocol. In the 
single-channel method, target cDNA/cRNA is labelled with a single fluorophore and passed 
across the gene chip surface. The intensity of fluorescence at each spot relates to the 
relative expression of the corresponding gene. In this way, relative expression of several 
samples can be compared for differential gene expression or technique reproducibility.  
 
Two-channel protocols involve labelling two samples with different fluorophores initially and 
then mixing the samples together prior to their passage across the gene chip surface. 
Specific computer software measures the intensity of each fluorophore at each spot and 
calculates the relative expression of each gene on the micro array chip. Two samples 
expressing a gene equally would be expected to show a relative expression of 1, and values 
greater or lesser than this would indicate differential expression. In practice there is a certain 
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amount of noise in the system and relative expressions of 0.5 to 2 are taken as representing 
the boundaries of equivalent gene expression (264).  
 
The advantages of single-channel micro arrays are that an aberrant sample cannot affect the 
raw data derived from the other sample (as is the case with two-channel micro arrays) and it 
is easier for samples from different experiments to be compared, so long as all other 
experimental variables have been controlled. However, single-channel micro arrays require 
a single gene chip per sample so twice as many are required for comparison. Two-channel 
micro arrays are generally cheaper and allow a larger number of samples to be run on fewer 
gene chips.  
 
The major advantage of DNA micro array technology is the sheer number of genes that can 
be examined in a single experiment. Potentially the entire genome, whether it is of a bacteria 
or a human, can be analysed. Similarly this technique can be used to identify genomic 
regions of altered expression which are of potential interest for further (perhaps more robust 
and fully quantitative) characterisation, or be used in patients with a particular disease to 
identify abnormal sequences in genetic regions which potentially contain pathogenic 
mutations.  
 
4.2.1.3 Micro array RNA sample suitability and selection 
Gene micro array chips were produced in the Post-Genomic Technologies Facility of the 
University of Nottingham. Primary whole bowel samples were obtained during surgical 
resections and intestinal crypt cell samples were isolated using ETDA/DTT (section 3.2.4). 
Total RNA was isolated and its quality analysed using the Nanodrop® spectrophotometer 
and Agilent 2100 Bioanalyser (section 2.3). RNA samples of good quality (RNA 260:280 
ratio >1.8 and RIN >6.5) were considered suitable for micro array analysis.  
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Thirteen healthy control RNA samples (8 male (62%), mean age 72.8 years [SEM 2.16]) of 
JRRGTXDOLW\ZHUHSRROHGWRIRUPWKH³SRROHGFRQWUROVDPSOH´6DPSOHVRIȝJRNA from 
HDFKFDVHZHUHSRROHGWRJHWKHUWRIRUPWKH³SRROHGFRQWUROVDPSOH´7KHSRROHGFRQWURO
sample had an RNA concentration of 356.6ng/µL and a RIN of 8.2. The rationale of using a 
pooled control sample of this size as a control was to reduce the random variation in gene 
expression that may be present had a smaller numbers of control samples been used. The 
pooled control sample could be compared to individual healthy control samples (to ensure 
gene expression was similar) and to IBD patients (to characterise changes in TLR gene 
expression and identify other differential gene expression). 
 
Three individual control cases (2 male (67%), age 71.3 [7.42] years) and three cases from 
patients with ulcerative colitis (2 male (67%), age 34.3 [5.17] years) were initially chosen. 
These six samples were referred to as the ³test samples´. Amino allyl RNA was synthesised 
for each test sample and equal amounts of aaRNA from each test samples was mixed with 
aaRNA from the pooled control sample. Absolute values of gene expression were 
QRUPDOLVHGWRWKHWKUHHKRXVHNHHSLQJJHQHV+357*$3'+DQGȕ-actin. Gene expression 
in the UC patients was compared to expression in healthy controls.  
 
4.2.1.4 Protocol 
The Ambion MessageAmp II® aRNA amplification kit (265) uses a micro array protocol to 
amplify RNA based on the method devised in the Eberwine laboratory (266). The template 
RNA sample is hybridised to an oligo (dT) primer bearing a T7 promoter region. 
Subsequently, the ArrayScriptTM reverse transcriptase enzyme catalyses the first strand 
synthesis of full-length antisense cDNA. Next, RNA strand degradation (RNase H activity), 
second strand cDNA synthesis (DNA polymerase activity) and clean-up steps are 
undertaken to produce double-stranded cDNA. This cDNA is the template for linear 
DPSOLILFDWLRQXVLQJD751$SRO\PHUDVHZKLFKELQGVWRWKH7SURPRWHUUHJLRQDWWKH¶-
end of the antisense cDNA strand. Importantly, this amplification process transcribes 
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hundreds of thousands of copies of the antisense cDNA strand, producing antisense RNA 
(aRNA). From as little as 1µg of template RNA, 120µg of aRNA can be synthesised (figure 
4.1). 
 
During the aRNA synthesis stage, amino allyl uridine triphosphate (aaUTP) is included in the 
reaction mixture along with the T7 RNA polymerase and the regular (unmodified) nucleoside 
triphosphates (NTP). The amino allyl UTP molecule comprises a UTP molecule with an 
amino allyl side chain to which fluorescent molecules can be bound. During aRNA 
elongation, aaUTP molecules are randomly incorporated into the growing aRNA molecule in 
place of unmodified UTP.  
 
A further purification step is performed and, following completion of the amplification of the 
aRNA molecule, an N-hydroxysuccinimide (NHS) ester moiety conjugated to a fluorescent 
molecule (such as cyanine-3 or Alexa FluorTM 488 (AF488)) is bound to the aaUTP via the 
amino allyl side chain. The efficiency of NHS-dye conjugate inclusion in the aRNA molecule 
is determined using a frequency on incorporation (FOI) calculation derived from a 
spectrophotometric trace. For example, using cyanine-3: 
 
FOI = 58.5 x Absorbance at 550nm 
            Absorbance at 260nm 
 
FOI for AF488 was acquired from the online Invitrogen base:dye ratio calculator after 
calibration for background absorbance at the appropriate wavelengths 
(http://probes.invitrogen.com/resources/calc/basedyeratio.html). A target of 30-50 aaUTP 
molecules per 1000 nucleotides is desirable for cyanine-3, and >80 molecules per 1000 
nucleotides for AF488. At this stage the aRNA sample is ready for hybridisation to the micro 
array gene chip. From this stage, the hybridisation procedure was undertaken by the Post-
Genomic Technologies Facility, University of Nottingham. The Post-Genomic Technologies 
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Facility produce to order spotted oligonucleotide array chips with over 30,000 spots, each 
corresponding to a different gene of interest.  
 
For analysis of TLR mRNA expression, a two-channel micro array protocol was undertaken. 
Each individual test sample, whether from a control sample or an IBD patient, was labelled 
with the green cyanine-3 (Cy3)-conjugated NHS moiety. The pooled control sample was 
labelled with blue AF488-conjugated NHS moiety. Five hundred nanograms of aaRNA from 
each of the test sample were mixed with 500ng of aaRNA from the pooled controls sample 
and analysed on a gene chip. Therefore each individual gene chip would compare a test 
sample (either a control or IBD case) with the pooled control sample. Furthermore, the gene 
chips from control cases could be compared with the gene chips from individual IBD cases.  
 
The processing and data acquisition from the micro array chips following hybridisation 
requires the use of three software packages. Initially the arrayer produces a file containing 
information on each spot on the chip. This information includes a chip grid reference as to 
the location of each spot relative to a reference spot and other key information such as the 
corresponding gene name and accession number. There is also data on the average spot 
size (approximately 8µm) and spot spacing (approximately 165µm). This file is known as the 
gal file and requires Genepix Pro software v6.1 4200 (www.moleculardevices.com) for 
interpretation. Following hybridisation Genepix Pro® produces a file known as the gpr file, an 
adjusted gal file, containing data on location of the centre of each gene spot and actual spot 
diameters.  
 
In order to analyse specific fluorescent intensity at each and every spot, a second software 
package is required called J-express® (www.molmine.com). This filters the signal intensity 
data to allow exclusion of poorly hybridised spots and ensure all data analysis is performed 
on spots of good size, rounded shape and in which the majority of pixels within the included 
spots are above a given threshold.  
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Each spot contains a number of pixels which represent fluorescent intensity data. Thus each 
spot contains many pixels of information. The signal intensity of each spot is calculated 
individually as a median, rather than a sum or mean, of all the pixels contained within the 
spot. The software locates each spot by recognising the transition from the lower 
background signal intensity (between spots) to the higher signal intensity within a given spot. 
A circular boundary is marked around the spot and the mean (and standard deviation) of 
background signal intensity between spots is measured. A spot is only included in data 
analysis if >80% of its pixels are above the mean plus two standard deviations of the 
background signal intensity.  
 
The J-express® software also avoids the exclusion of a given spot should a signal be absent 
on one chip but present on another. This prevents the loss of data should there be no 
expression of the gene in only one sample, thus avoiding falsely excluding relevant data.  
 
The final software package required for micro array data analysis is the Ingenuity Pathways 
Analysis® programme (www.ingenuity.com). This can overlay expression data from the 
micro array to a continually updated database of signalling pathway molecules and gene 
function. It allows assessment of differential expression of key components of the signalling 
cascade. 
 
4.2.2 Conventional reverse transcriptase polymerase chain reaction 
Isolated and disaggregated IEC were collected using EDTA/DTT and pancreatin (section 
3.2.4). Isolated cells were suspended in HBSS (without Ca/Mg) medium and cell 
concentration calculated using trypan blue exclusion. Aliquots of 5x106 cells were collected 
for RNA isolation from each tissue specimen and RNA isolated immediately. After 
confirmation that the RNA quality was suitable for down-stream analysis (RNA 260:280 ratio 
>1.8 and RIN >6.5) cDNA was synthesised and amplified using conventional RT-PCR 
techniques, run on an agarose gel and identified bands were cut and sequenced.  
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4.2.3 Quantitative real-time reverse transcriptase polymerase chain reaction 
4.2.3.1 Introduction 
The molecular technique of polymerase chain reaction allows the exponential amplification 
of DNA for a variety of techniques such as gene sequencing and mutation analysis. The 
development of reverse transcription (RT)-PCR allows RNA material to be reverse-
transcribed into complementary DNA (cDNA) and provides a method for assessing gene 
expression.  
 
Traditional methods for the detection of RT-PCR amplicon sequences involve 
electrophoresis of the PCR product through an agarose gel and visualisation, or 
densitometry analysis, of the resulting band using ethidium bromide, an intercalating 
molecule which fluoresces after irradiation with UV light primarily when bound to nucleic 
acids. Southern blotting is an alternative technique for detecting DNA which suffers from the 
fact that it is time consuming and requires multiple handling steps, increasing the likelihood 
of contamination. In addition, PCR-enzyme-linked immunosorbent assay (ELISA) may be 
used to capture amplicon onto a solid phase and detected using the avidin/biotin or anti-
digoxigenin reported molecules (267).  
 
By contrast, real-time RT-PCR allows the detection of the fluorescent signal during the 
amplification process, in so-caOOHG³UHDOWLPH´7KLVKDVDOORZHGTXDQWLILFDWLRQRIQXFOHLFDFLG
concentration and has been largely due to the advances made in the chemistry of 
fluorogenic molecules, which have benefits over radiogenic oligoprobes in the avoidance of 
radioactive emission, ease of disposal and extended shelf life. In addition, the rapid speed of 
real-time RT-PCR analysis is largely the result of reduced cycle times, removal of post-PCR 
detection procedures and the use of sensitive methods to detect fluorogenic label emissions.  
 
In a similar principle to conventional RT-PCR, real-time RT-PCR depends upon the use of 
specific oligonucleotide probes (primers) which anneal to either end of the target sequence 
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to be amplified. In general the amplicon is shorter in base pair length that conventional 
primers and this increases efficiency of DNA synthesis during the rapid cycling steps.  
 
The most commonly used fluorogenic oligoprobes rely upon fluorescence resonance energy 
transfer (FRET), a spectroscopic process where energy is passed between molecules 
separated by a distance of 10-ǖQJVWURPc6RPHPROHFXOHVDFWDVQRQ-fluorescent 
quenchers, preventing the emission of FRET if located in close enough proximity the 
fluorogenic molecule. In such cases, once the fluorophore and quencher are sufficiently 
separated the fluorophore will produce a detectable emission. There are several different 
types of fluorogenic probes used in real-time PCR (267).  
 
The earliest and simplest fluorophores are the non-specific DNA-binding molecules including 
ethidium bromide, YO-PRO-1 and SYBR Green 1. These probes will fluoresce when in 
contact with and bound to the minor groove of the dsDNA strand (in the case of SYBR 
Green 1) upon exposure to a suitable wavelength of light. These probes bind to any dsDNA 
molecule present in the reaction solution and have the advantage that they require less 
specialist knowledge of fluorogenic probe design, are less expensive and do not need to be 
specifically matched to a sequence in the target nucleic acid.  
 
However there are certain disadvantages to non-specific fluorophores. Primers can self-
anneal and produce a dsDNA molecule known as a primer-dimer. Non-specific fluorophores 
will therefore also bind to primer-dimers in addition to amplified dsDNA, and emit a 
fluorescent signal which can cause difficulty in data interpretation. This is particularly 
troublesome with templates of low initial concentrations. To overcome this problem, use is 
made of the observation that the denaturing temperature of the primer-dimer is lower that of 
the complimentary primer-template melting temperature (TM). The addition of a short, higher 
temperature detection step, after the elongation step of the PCR cycle, can overcome this 
issue by measuring fluorescence when primer-dimer bonds have dissociated. Of additional 
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note, SYBR Green 1 fluorescence has been observed to increase non-specifically in the 
later cycles of no template controls (267).  
 
To overcome these non-specific probe-related problems a number of alternative probes can 
EHGHVLJQHG7KHVHLQFOXGHOLQHDUDGMDFHQW¶QXFOHDVHKDLUSLQVXQULVHDQGVFRUSLRQ
oligoprobes and have been reviewed by Mackay et al. and Giuliette et al. (267, 268). These 
probes are specific DNA-binding probes. They contain a fluorescent molecule with a closely 
positioned non-fluorescent quencher molecule, which prevents the emission of FRET. These 
probes also contain a sequence of nucleic acid which is specific for a region of the gene of 
interest. During the PCR reaction, the probe anneals to its target gene and the fluorophore 
and quencher become separated sufficiently that FRET emission is possible.  
 
One advantage of specific primers is that the concern of spurious primer-dimer fluorescent 
signal using non-specific probes is not an issue because these probes will not anneal to 
primer-dimers. Additionally, the sequence specificity to the complimentary gene sequence 
prevents the probes annealing to contaminating and/or non-amplified nucleic acid. However, 
these probes are expensive and much more challenging to design and manufacture.  
 
During real-time RT-PCR a thermal cycler is used to rapidly cycle the sample through pre-
specific and optimised denaturing, annealing and elongation temperatures, in much the 
same way as is undertaken for conventional RT-PCR. This allows separation of dsDNA 
strands, annealing of primers to complimentary gene regions and complimentary DNA strand 
synthesis, respectively. During this process, SYBR Green 1 fluorescent probe in the reaction 
mixture binds to the dsDNA as it is synthesised, resulting in a fluorescent emission. As the 
PCR process enters the linear phase of replication, the fluorescent intensity increased in 
direct proportion to the amount of synthesised dsDNA.  
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The point at which a given threshold value is reached is known as the threshold cycle (Ct) 
and each sample is assigned a Ct value. The more abundant the initial target cDNA 
concentration in the original sample, the earlier in the cycling reaction it will reach the 
threshold value and, therefore, the lower the measured Ct value. The threshold value is 
taken as ten standard deviations above the baseline fluorescence calculated during cycles 3 
to 15 and is, therefore, calculated for each experimental run. Thus, the relative amount of 
V\QWKHVLVHGGV'1$LVPHDVXUHGLQ³UHDOWLPH´UDWKHUWKDQEHLQJPHDVXUHGDWWKHHQGRIWKH
reaction when exhaustion of reaction components (such as dNTP) can influence final dsDNA 
calculation value.  
 
4.2.3.2 Quantification of relative gene expression using the Pfaffl method 
To investigate changes in gene expression, two quantification techniques are available. The 
first is relative expression, where the expression of the target gene is expressed relative to 
the expression of a reference gene, usually a ubiquitously expressed housekeeping gene 
such as HPRT or GAPDH. The second technique is absolute quantification and is based on 
an internal or external calibration curve to allow exact measurement of nucleic acid 
concentration. The latter method requires identical cycling efficiencies for target and 
standard cDNA samples and is a time-consuming and expensive method. However, it is 
necessary when calculating, for example, viral loads in virology (267). For most purposes, 
the first method of calculating relative gene expression (normalised to a housekeeping gene) 
is sufficient. It must be born in mind however that housekeeping gene expression may vary 
under experimental conditions (269, 270) although this is unlikely to be significant if all 
samples are treated in the same way using identical experimental methodologies.  
 
To calculate the PCR reaction efficiency, a standard curve is plotted during each real-time 
RT-PCR run to ensure efficient cDNA replication. An aliquot of high quality RNA is reverse 
transcribed into cDNA and serially diluted two-fold to obtain 1/2, 1/4, 1/8, 1/16 and 1/32 
dilutions of the original sample. Each serial dilution is run in triplicate alongside two negative 
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FRQWUROV³QRUHYHUVHWUDQVFULSWDVH´DQG³QRWHPSODWH´Fontrol samples) for each primer pair 
on every run to exclude DNA contamination or non-specific amplification.  
 
Following amplification, the Ct values for each serially diluted sample are plotted against the 
ORJDULWKPRIWKHGLOXWLRQIUDFWLRQWRSURGXFHWKH³VWDQGDUGFXUYH´6LQFHWKHGLOXWLRQIUDFWLRQis 
a logarithmic plot, the standard curve plot produces a straight line, the slope of which is 
related to the efficiency of the PCR reaction. The efficiency of the PCR run can be calculated 
by the following equation (271): 
 
Efficiency (E) = [10 (-1/slope) ] - 1 
By plotting a standard curve with each experimental run, the efficiency of each reaction 
could be measured to act as an internal inter-run control. Thereafter, samples were run in 
triplicate from cases with IBD and healthy controls to calculate the relative expression of the 
target genes, TLR2 and TLR4, to the housekeeping gene, HPRT. To calculate the relative 
expression of each target gene the following formula described by Pfaffl is used (272): 
 
Ratio(R) = (Etarget) ¨Ct(control ± sample) 
        (Ereference) ¨Ct(control ± sample) 
where target is the target gene; reference is the housekeeping gene; sample is the disease 
sample of interest, and control is the control sample.  
 
Using this equation, two difference R values can be calculated for a given sample. In the first 
instance, all samples from the disease group, for example active ulcerative colitis, are 
pooled to give a single group Ct value, and this normalised to a Ct from a pooled sample of 
healthy control cases. This gives a single relative expression of the target gene in diseases 
cases relative to controls but gives no measure of variability within the sample groups.  
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In the second calculation, a mean of the three triplicate samples for each diseased case 
(giving a mean Ct per case) is compared to a mean Ct value for the three triplicate samples 
for each control case. Thus, variation of target gene expression within each disease group is 
characterised.  
 
Finally, to investigate for the occurrence of primer-dimer formation, a melting curve analysis 
is undertaken for each set of primer pairs. Following the 40 cycles of cDNA amplification, the 
reaction mixture is cooled to 55oC and sequentially heated to 95oC at a rate of 0.5oC per 
second. At each 0.5oC increment, fluorescence is measured and plotted against 
temperature. In the ideal situation, there is a single peak at the dissociation temperature (TD) 
of the primer-template complex. Should primer-dimers occur, a smaller second peak at a 
lower temperature is seen, corresponding to the melting temperature of the primer-dimer 
complex (TM).  
 
If primer-dimer occurrence is detected on melting (dissociation) curve analysis, it can be 
negated by the inclusion of a fourth step in the real-time RT-PCR cycling protocol. Following 
the three traditional dissociation, annealing and elongation steps, an acquisition step is 
included which is set at a temperature above that required to dissociate the primer-dimers 
(i.e. above the TM) but below the dissociation temperature (TD) of the dsDNA molecule. At 
this temperature, the primer-dimer-SYBR Green 1 complex will dissociate (resulting in 
prevention of aberrant fluorescent signal from this complex) but the SYBR Green 1 molecule 
will remain bound to the synthesised dsDNA molecule and continue to produce a fluorescent 
signal (which thus reflects only the total dsDNA content). In such cases, fluorescence is 
measured at the end of this fourth (acquisition) step.  
 
4.2.3.3 Protocol for quantitative real-time RT-PCR 
For quantitative real-time RT-PCR, different primers were designed to those used in 
conventional PCR. Real-Time RT-PCR was undertaken using QuantiTect SYBR Green I® 
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technology (204141, Qiagen). Primers were designed to similar standards as conventional 
RT-PCR primers except that the amplicon length was kept shorter than 200 base pairs due 
to the rapid cycling step in real-time RT-PCR protocols. The Basic Local Alignment Search 
Tool was used to confirm primer specificity (222).  
 
For each primer pair, samples were initially run using the conventional RT-PCR protocol, 
described in section 2.4.3, and using cDNA from a TLR2- and TLR4-expressing cell line 
(T84 and THP-1 cells) as template to optimise annealing temperature conditions. Samples 
were run on a 1% agarose gel to confirm a single band of anticipated base length was 
visible, suggesting specific amplification of a single DNA sequence. Bands were cut and 
sequenced (section 2.5) to further ensure primer specificity for the gene of interest. Once the 
real-time primer specificity was confirmed and optimal cycling conditions characterised, 
samples were analysed on a Stratagene MX4000P real-time PCR cycler to undertake 
standard curve and melting (dissociation) curve analyses.  
 
For each real-time RT-3&5UHDFWLRQȝL of QuantiTect SYBR Green PCR Master Mix 
(providing a final concentration of 2.5mM MgCl2ZDVDGGHGWRȝL RIF'1$ȝL of 
ȝ0VHQVHSULPHUȝL RIȝ0DQWL-VHQVHSULPHUDQGȝL nuclease-free water, to 
PDNHDILQDOYROXPHRIȝL7KLVJDYHDILQDOSULPHUFRQFHQWUDWLRQRIȝ07KHVDPSOH
was thoroughly mixed and kept on ice until analysis.  
 
Samples were transferred to the Stratagene MX4000 real-time PCR cycler. The cycling 
conditions are shown in the table below for the respective real-time primers. A melting curve 
analysis and standard curve of serially diluted samples were performed for every real-time 
RT-PCR run (table 4.1). The sequences of the real-time RT-PCT primers are shown in table 
4.2. Real-time RT-PCR data were analysed using MxPro Mx3000P v4.01 software 
(Stratagene). The demographic data for the subjects included in the real-time RT-PCR 
analyses are shown in table 4.3.  
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Table 4.1 Cycling protocols for real-time RT-PCR primers 
Gene Stage 1 Stage 2: 
Denature 
Stage 2: 
Annealing 
Stage 2: 
Elongation 
Stage2: 
Acquisition 
step* 
No. of 
cycles 
Stage 3 
HPRT 95oC 15m 95oC 15s 60oC 30s 72oC 30s NR 40 95oC 1m 
TLR2 95oC 15m 95oC 15s 58oC 30s 72oC 30s 78oC 30s 40 95oC 1m 
TLR4 95oC 15m 95oC 15s 58oC 30s 72oC 30s NR 40 95oC 1m 
HPRT, hypoxanthine-guanine phosphoribosyltransferase; m, minute; NR, not required; s, second; TLR, Toll-like 
receptor 
* Only required when using TLR2 primers. Fluorescent measurement was taken at the end of this step (in other 
cases fluorescent measurement was taken at the end of the elongation step) 
 
 
Table 4.2 Real-time RT-PCR primer sequences 
Gene Primer Sequence Melting 
temperature (TM) 
Amplicon size 
(base pairs) 
HPRT GAC CAG TCA ACA GGG GAC AT (sense) 
CGA CCT TGA CCA TCT TTG GA (anti-sense) 
59.4oC 
57.3oC 
160bp 
TLR2 GGG TTG AAG CAC TGG ACA AT (sense) 
CTG CCC TTG CAG ATA CCA TT(anti-sense) 
57.3oC 
57.3oC 
134BP 
TLR4 CGG AGG CCA TTA TGC TAT GT (sense) 
TCC CTT CCT CCT TTT CCC TA (anti-sense) 
57.3oC 
57.3oC 
141BP 
Bp, base pairs; HPRT, hypoxanthine-guanine phosphoribosyltransferase; TLR, Toll-like receptor 
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Table 4.3 Demographic data for study subjects 
Demographic variable Large intestine Small intestine 
Healthy 
control 
Ulcerative 
colitis 
&URKQ¶V
colitis  
Healthy 
control 
&URKQ¶VLOHLWLV 
Number 11 18 11 7 7 
Age mean (SEM) years 70.5 (4.15) 51.5 (4.75)** 48.9 (4.10)** 74.1 (3.36) 44.3 (7.18)** 
Sex male/female (% male) 7/4 (64) 9/9 (50) 2/9 (18) 5/2 (71) 2/5 (29) 
Medications  
 5ASA 0 11 ** 3 0 0 
 Thiopurine 0 8 * 3 0 4 
 Corticosteroid 0 3 4 0 1 
 MTX 0 2 2 0 0 
 Anti-71)Į 0 0 6 * 0 2 
 Cyclosporine 0 1 0 0 0 
 Metronidazole 0 1 0 0 0 
Medical History  
 PSC 0 0 1 0 0 
 DM 2 1 1 2 0 
 NAFLD 0 0 1 0 0 
 Obesity 1 1 0 0 0 
 Osteoporosis 2 2 0 0 0 
 IHD 2 3 0 2 0 
 CVD 0 2 0 1 0 
 PVD 1 0 0 0 1 
 MS 0 1 0 0 0 
 IgA deficiency 0 0 1 0 0 
 Hyperchol 0 0 2 0 0 
 Hypothyroidism 0 0 1 0 1 
 Pernicious anaemia 0 0 1 0 1 
 Schizophrenia 0 0 1 0 1 
 Interstitial nephritis 0 0 0 0 1 
 Atrial fibrillation 1 0 0 1 0 
 COPD 1 0 0 0 0 
5ASA, 5-aminosalicylic acid (mesalazine); COPD, chronic obstructive pulmonary disease; CVD, cerebrovascular 
disease; DM, diabetes mellitus; Hyperchol, hypercholesterolaemia; IHD, ischaemic heart disease; MS, multiple 
sclerosis; MTX, methotrexate; NAFLD, non-alcoholic fatty liver disease; PSC, primary sclerosing cholangitis; 
39'SHULSKHUDOYDVFXODUGLVHDVH71)ĮWXPRXUQHFURVLVIDFWRU-Į.  
* p<0.05; ** p<0.01 versus healthy controls (Student t-test for continuous variables and )LVKHU¶VH[DFWWHVW for 
ordinal variables)
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4.3 Results 
4.3.1 Isolated intestinal crypt cells contain RNA of high quality which is not influenced 
by patient demographics, tissue sample site, underlying diagnosis or severity of 
intestinal inflammation 
RNA was isolated from 109 intestinal epithelial cell samples. The RNA 260:280 absorbance 
ratio was measured using the Nanodrop® spectrophotometer. This ratio is a measure of 
protein contamination of nucleic acid samples, with a higher the ratio indicating a purer RNA 
sample. RNA solutions of ratio >1.8 were considered suitable for down stream analysis. The 
mean 260:280 ratio was 2.1 with a standard error of 0.004. A histogram of the 260:280 ratio 
was plotted and showed an approximately normal (Gaussian) distribution (mean +SEM 
2.11+0.01; Kolmogorov-Smirnov test p=0.072).  
 
To further measure the quality of the isolated RNA samples from primary epithelial cells, 
samples were analysed using the Agilent 2100 Bioanalyser®. The Agilent 2100 
Bioanalyser® uses micro-fluid capillary electrophoresis to measuring a number of key 
aspects of the electrophoretic strip. Higher values indicate less degraded (higher quality) 
RNA samples and values >6.5 are considered suitable for downstream analysis (220). The 
RIN values were normally distributed (mean +SEM 7.69+0.11; Kolmogorov-Smirnov test 
p=0.548). When samples with a RIN <6.5 were excluded (n=12), the distribution of the 97 
remaining samples remained approximately normal (8.01+0.08; Kolmogorov-Smirnov 
p=0.357).  
 
To investigate the influence of various sample demographic factors on RNA quality, the RIN 
value and 260:280 ratio were compared to corresponding values including subject age, 
mucosal sample weight, isolated IEC concentration in suspension, cell viability using trypan 
blue exclusion, diagnosis, severity of tissue inflammation, medication use and concurrent 
medical conditions.  
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There was no correlation between the RIN and the age of the participant (figure 4.2, 
R2=0.011, p=0.27). Similarly, RIN was also not associated with mucosal tissue weight 
(R2=0.001, p=0.90) or cell viability (R2=0.021, p=0.125).  
 
7LVVXHVHFWLRQVRIȝPLQWKLFNQHVVZHUHIRUPDOLQ-fixed and paraffin-embedded, and 
subsequently stained with haematoxylin and eosin. The severity of inflammation of colonic 
specimens from patients with UC was assessed using the system described by Riley et al 
and graded as none, mild, moderate or severe (235). Small intestinal samples were graded 
as either un-inflamed (normal) or inflamed since a validated scoring system for the severity 
of small intestinal inflammation has not been reported. RIN values of isolated crypt IEC 
samples from histologically un-inflamed bowel (7.88+0.14) were similar to samples from 
inflamed bowel (7.46+0.17, p=0.058). Furthermore, if inflamed samples were sub-divided 
following histological assessment of the severity of inflammation into either mild/moderately 
inflamed (7.31+0.19) or severely inflamed (7.78+0.37), comparison with samples from un-
inflamed bowel revealed no significant difference of the RIN amongst these three groups 
(ANOVA test p=0.087).  
 
Sample RIN values of isolated crypt IEC samples from healthy controls (7.65+0.17) did not 
differ significantly from SDWLHQWVZLWK&URKQ¶VGLVHDVH (7.67+0.20, p=0.928) or UC 
(7.78+0.20, p=0.663). Likewise RIN values of isolated crypt IEC samples did not differ 
between &URKQ¶VGLVHDVHand UC (p=0.745). With regard to the anatomical site of the tissue, 
RIN values of isolated crypt IEC samples from the small and large bowel were similar 
(7.44+0.22 and 7.75+0.13, respectively, which were not significantly different, p=0.267). 
 
To compare the reliability of the Agilent 2100 Bioanalyser® measurements, RIN values were 
plotted against the corresponding 28S:18S ribosomal RNA ratios for each case. A higher 
RIN values should be associated with higher 28S:18S ribosomal RNA ratio. Indeed these 
variables were shown to highly correlate (figure 4.3, R2=0.448, p<0.001).  
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The RIN value was not influenced by a number of demographic variables, including a history 
of hypertension (p=0.953), ischaemic heart disease (p=0.823), cerebrovascular disease 
(p=0.399), diabetes mellitus (p=0.061), obesity (p=0.32), peripheral vascular disease 
(p=0.371), osteoporosis (p=0.287), prior surgery (p=0.881), or use of the following 
medications: aminosalicylic acid preparations (p=0.96), thiopurines (p=0.675), 
corticosteroids (p=0.177), cyclosporine (p=0.086), methotrexate (p=0.908), anti-71)Į
monoclonal antibody therapy (p=0.87) or systemic antibacterial therapy (p=0.247).  
 
4.3.2 Conventional and real-time RT-PCR primers are specific for human TLR2 and 
TLR4  
To ensure primer specificity and to optimise RT-PCR reaction conditions, human intestinal 
epithelial cells lines (HT-29 and T84 cells) were obtained which are reported in the literature 
to express both TLR2 and TLR4 transcripts (154, 231, 232, 252). The human monocyte cell 
line THP-1 was also used as a non-intestinal, TLR2- and TLR4-expressing cell control (233, 
240, 246, 248).   
 
T84 and HT-29 cells were cultured and RNA isolated using the Qiagen RNeasy Mini Elute 
Kit. RNA quality was analysed using the Nanodrop® spectrophotometer and Agilent 2100 
Bioanalyser®. Suitable samples were reverse transcribed into cDNA and subjected to 
conventional PCR amplification. Following agarose gel electrophoreses, bands were viewed 
using a UV-transilluminator and cut using a scalpel. Bands were sequenced using the ABI 
Prism BigDye Terminator® protocol.  
 
Agarose gel electrophoresis of cDNA samples from T84 cells revealed well demarcated 
amplicon bands for TLR2, TLR4 and HPRT at the expected base pair sizes (figure 4.4). 
Similar results were observed with the THP-1 monocyte cell line. However, these results 
could not be replicated with HT-29 cells, which showed variable and low level TLR2 and 
TLR4 transcript expression.  
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The bands at approximately 599bp, 507bp and 160bp were cut and sequenced. These 
sequences were confirmed as human TLR2, TLR4 and HPRT, respectively, using the 
National Centre for Biotechnology Information Basic Local Alignment Search Tool (BLAST) 
(222). Identical bands were observed when cDNA from primary human peripheral blood 
mononuclear cells (PBMC) was used as template (data not shown).  
 
Real-time RT-PCR requires the synthesis of shorter cDNA amplicons compared to 
conventional RT-PCT. Ideally amplicon length should be less than 200bp. Therefore, the 
primers used for conventional RT-PCR were unsuitable for real-time RT-PCR and alternative 
primers were designed. Following primers design, cDNA samples were amplified for TLR2 
and TLR4 using T84 cells and THP-1 cells as templates. Again PCR amplicons were run on 
a 1% agarose gel and bands were detected at the appropriate nucleotide sizes. Bands were 
cut and subsequent DNA sequencing confirmed specificity for human TLR2 and TLR4 
mRNA.  
 
4.3.3 Isolated intestinal crypt cells express TLR2 and TLR4 mRNA using RNA micro 
array 
To assess the efficiency of inclusion of the NHS-dye conjugate in the aRNA molecule during 
the RNA micro array protocol, a measurement known as the frequency of incorporation (FOI) 
was calculated. A target of 30-50 aaUTP molecules per 1000 nucleotides is desirable for 
cyanine-3 and >80 molecules per 1000 nucleotides for AF488 to indicate adequate dye 
inclusion. FOI for AF488 was assessed on the pooled samples and found to be satisfactory 
(116 dye molecules per 1000 nucleotide bases). The FOI values for the RNA micro array 
suggested adequate NHS-dye inclusion (table 4.4). 
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Table 4.4 RNA micro array frequency of NHS-dye incorporation  
 
Sample FOI of Cyanin-3 
Control 1 30.52 
Control 2 51.53 
Control 3 50.66 
Ulcerative colitis 1 54.04 
Ulcerative colitis 2 51.86 
Ulcerative colitis 3 50.00 
 
Analysis of the RNA micro array data confirmed the expression of RNA transcript for human 
TLR1-10 in the majority of 6 cases (three controls and three patients with ulcerative colitis). 
TLR7 mRNA was not detected in control cases and TLR1 and TLR10 transcripts were 
detected in only one UC patient. Several TLR gene transcripts were expressed in only two 
control or UC subjects, including TLR1, TLR3, TLR5 and TLR7. However TLR2 and TLR4 
transcripts were detected in all healthy control (C1-3) and UC (UC1-3) subjects (table 4.5). 
 
Table 4.5 Expression of TLR1-10 mRNA in primary crypt intestinal epithelial cells using 
micro assay technology 
 
RNA expression is given in fluorescent units per fluorescent unit of the housekeeping gene HPRT. Zero values indicate a gene-
spot fluorescent intensity of equal to or less than the background (inter-spot) chip intensity; implying non-expression of the 
corresponding gene.  
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The fluorescent intensity, and therefore RNA expression, of each micro array gene-spot 
(feature) can be normalised to the fluorescent intensity of one of several housekeeping 
genes. Using this method, TLR1-51$H[SUHVVLRQUHODWLYHWR+357*$3'+DQGȕ-actin 
was calculated. A similar pattern of expression was observed regardless of the chosen 
housekeeping gene. Therefore HPRT was chosen for all further micro array analyses.  
The median relative expression of TLR2 and TLR4, adjusted for HPRT expression, between 
healthy controls and patients with UC were compared (figure 4.5). There was no significant 
difference between healthy controls and UC subjects for either TLR2 (median [range] of 
relative expression 0.058 [0.013-0.111] versus 0.048 [0.047-0.785], respectively, p=0.45) or 
TLR4 (relative expression 0.032 [0.029-0.465] versus 0.046 [0.031-0.047], respectively, 
p=0.45).  
 
$³FRPSDULVRQDQDO\VLV´XVLQJWKH,QJHQXLW\3DWKZD\$QDO\VLV(IPA) software was 
undertaken to investigate the differential expression of multiple signalling molecules within 
the TLR signalling pathway at the RNA level. This analysis compares the expression of a 
given set of intracellular signalling molecules in the UC group relative to the healthy control 
group. Using this analysis the following molecules were shown to be up-regulated in the UC 
group: SITPEC (signalling intermediate in Toll pathway, evolutionarily conserved; also 
known as ECSIT, evolutionary conserved signalling intermediate in toll pathways) (relative 
expression 1.072), c-Jun (relative expression 1.113) and c-Fos (relative expression 1.269). 
,QDGGLWLRQ,ț.ȕUHODWLYHH[SUHVVLRQDQG,țȕĮUHODWLYHH[SUHVVLRQZHUH
significantly down-regulated in the UC group compared to the healthy control group (p<0.05 
for all). The location of these signalling molecules in the TLR signalling pathway is shown 
graphically in figure 4.6.  
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4.3.4 Isolated intestinal crypt cells express TLR2 and TLR4 mRNA using conventional 
RT-PCR 
To confirm the micro array findings in a larger cohort of subjects, and to investigate the 
H[SUHVVLRQRI7/5DQG7/5P51$LQVXEMHFWVZLWK&URKQ¶VGLVHDVHSrimary intestinal 
epithelial cells were isolated from colonic and small intestine specimens of healthy control 
subjects and SDWLHQWVZLWK&URKQ¶VGLVHDVHDQGXOFHUDWLYHFROLWLV&U\SWHSLWKHOLDOFHOOVZHUH
isolated and disaggregated, total RNA purified and complimentary DNA synthesised. 
Following amplification using conventional RT-PCR protocols, the PCR products were run on 
an agarose gel and visualised using a UV trans-illuminator.  
 
Primary intestinal epithelial cells from small and large bowel specimens were shown to 
express TLR2, TLR4 and HPRT transcripts (figure 4.7). This included small bowel samples 
IURPKHDOWK\FRQWUROVDQG&URKQ¶VGLVHDVHSDWLHQWVDQGFRORQLFVDPSOHVIURPKHDOWK\
controls and patients with both &URKQ¶VGLVHDVHDQGXOFHUDWLYHFROLWLV (n=5 for all groups).   
 
4.3.5 Patients with inflammatory bowel disease up-regulate TLR2 and TLR4 mRNA 
expression in intestinal crypt cells 
To determine whether the expression of TLR2 and TLR4 mRNA levels differ in subjects with 
inflammatory bowel disease compared to healthy control subjects, real-time RT-PCR 
analysis was undertaken. cDNA samples were analysed using the DNA-binding molecule 
SYBR Green as the fluorescent probe following amplification with specifically designed 
primers. cDNA samples from each subject (healthy controls and patients with IBD) were run 
in triplicate and the mean cycle threshold value for each case was calculated. Each mean 
value was compared to the pooled mean cycle threshold value for all healthy control 
samples. This allowed each case to be assigned a value corresponding to the gene 
transcript expression relative to the mean healthy control expression.  
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Initially, several quality control tests were undertaken. To investigate the efficiency of the 
PCR reaction, standard dilutions of pooled cDNA samples from primary crypt intestinal 
epithelial cells were plotted against cycle threshold on a logarithmic scale. This allowed 
derivation of the efficiency (E) of the PCR reaction from the slope of the plotted line using the 
equation: E=10(-1/slope). A typical standard curve for TLR2 is shown in figure 4.8. Similar 
standard curve analyses were obtained for TLR4 and HPRT primer pairs. Real-time RT-PCR 
runs were only considered suitable for analysis if the efficiency of the amplification was equal 
to 100% +10% (figure 4.8). 
 
To exclude the presence of undesirable oligonucleotide annealing and primer-dimer 
formation, a dissociation curve analysis was undertaken for each real-time RT-PCR run. 
Samples were healed from 55oC to 95oC in 0.5oC increments and the fluorescent intensity 
measured at every step. A typical dissociation curve for TLR4 PCR product is shown in 
figure 4.9, demonstrating optimal primer-template annealing and no primer-dimer formation 
(illustrated by the absence of a fluorescent peak at annealing temperatures lower that the 
main PCR product dissociation peak).  
 
Similar results were demonstrated with primers for HPRT (data not shown). However, the 
TLR2 primer pairs demonstrated evidence of primer-dimer formation at lower annealing 
temperatures (between 70oC and 77oC). This was mainly observed in standard samples of 
high dilution (i.e. low cDNA concentration) or in primary epithelial cell samples with low 
cDNA concentration (i.e. high cycle threshold values), as shown in figure 4.10. 
 
Primer-dimer oligonucleotide formation during real-time RT-PCR measurement steps is 
undesirable because SYBR Green fluorophore molecules can bind non-specifically to these 
dimers, resulting in measurement of erroneous fluorescent signal. To overcome this 
eventuality, a fourth (acquisition) step at 78oC was introduced to the cycling protocol 
following the three standard denature, annealing and elongation steps for the TLR2 primer 
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pairs. Fluorescent intensity was measured at the end of this fourth step. Repeat dissociation 
curve analysis using the modified four-step protocol resulted in the abolition of the primer-
dimer formation, as shown in figure 4.11. 
 
To exclude the possibility of non-specific cDNA amplification causing erroneous fluorescent 
signal during the PCR cycling protocol, wells with no nucleic acid (no template controls, 
NTC) and no cDNA (no reverse transcriptase controls, no RT) were included in all real-time 
RT-PCR runs. Control wells failed to show significant fluorescent signal, as shown for TLR2 
primers in figure 4.12. Similar results were obtained for HPRT and TLR4 primers.  
 
Following optimisation of real-time RT-PCR conditions, primary intestinal epithelial cell 
samples from healthy controls and patients with inflammatory bowel disease were examined. 
TLR2 and TLR4 expression levels were normalised to the expression of HPRT transcript in 
the corresponding sample. Thereafter all transcript levels were calculated as the expression 
level relative to the mean expression level from the pooled healthy control samples.  
 
In patients with ulcerative colitis (n=18, 9 males (50%), mean (SEM) age 51.5 (4.76) years), 
IEC from regions of histologically inflamed colon expressed significantly more transcripts for 
TLR2 (median relative expression [inter-quartile range] 3.18 [1.03-10.4], p=0.003) and TLR4 
(2.33 [1.15-4.45], p=0.024) compared to healthy controls (n=10, 6 males (60%), age 70.5 
(4.15) years). In regions of histologically normal (un-inflamed) colon, expression of TLR4 
mRNA transcripts was also higher compared to healthy controls (1.9 [1.69-4.31], p=0.017), 
but TLR2 mRNA transcripts were not significantly up-regulated (1.36 [0.75-5.77], p=0.254) 
(figure 4.13).  
 
Subsequently, inflamed samples were sub-classified by the severity of inflammation using 
the scoring system described by Riley et al. (235). For convenience and to avoid groups with 
small numbers, samples of either mild or moderate histological severity were combined to 
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form a single group. Severely inflamed UC samples showed significantly greater expression 
of TLR2 (10.4 [5.35-255.91], p=0.0002) and TLR4 (4.45 [1.75-7.56], p=0.031) transcripts 
compared to healthy controls. However, UC samples from mild/moderate histological 
inflammation did not show greater TLR2 transcript expression compared to healthy controls 
(1.06 [0.99-1.56], p=0.088) and, although there was a trend towards up-regulation of TLR4 
transcript, it did not reach statistical significance (2.12 [1.15-2.56], p=0.124) (figure 4.14).  
 
,QSDWLHQWVZLWK&URKQ¶Vcolitis (n=11, 2 males (18%), age 48.9 (4.10) years), IEC from 
regions of histologically inflamed colon expressed significantly more transcripts for TLR2 
(3.45 [0.8-5.4], p=0.012) and TLR4 (1.71 [1.0-4.32], p=0.042) compared to healthy controls 
(figure 4.15).  
 
,QWHVWLQDOHSLWKHOLDOFHOOVZHUHDOVRREWDLQHGIURPWKHVPDOOERZHORISDWLHQWVZLWK&URKQ¶V
ileitis (n=7, 2 males (29%), age 44.3 (7.18) years) and healthy controls (n=7, 5 males (71%), 
age 74.1 (3.36) years). All small bowel tissue samples isolated from patients with &URKQ¶V
disease were histologically and macroscopically inflamed. IEC from patients with &URKQ¶V
ileitis expressed significantly greater TLR4 transcripts compared to healthy controls (1.84 
[1.43-4.66], p=0.030) and, although there was a trend towards up-regulation of TLR2 mRNA, 
this did not reach statistical significance (1.72 [0.52-2.74], p=0.208) (figure 4.16).  
 
These data are summarised in the following table demonstrating the median expression of 
TLR2 and TLR4 mRNA in patients groups relative to healthy controls (table 4.6). 
 
 
 
 
 
162 
 
Table 4.6 Expression of TLR2 and TLR4 mRNA in patients with inflammatory bowel disease 
relative to expression in healthy control subjects 
Sample 
location 
Sample group N Relative TLR2 mRNA 
expression 
Relative TLR4 mRNA 
expression 
Median [IQR] p-value Median [IQR] p-value 
Large 
bowel 
Healthy control 11 1.0 [0.59-1.42] - 1.0 [0.82-1.37] - 
UC normal (UI) 5 1.36 [0.75-5.77] 0.254 1.90 [1.69-4.31] 0.017 
UC mild/mod inflamed 7 1.06 [0.99-1.56] 0.088 2.12 [1.15-2.56] 0.124 
UC severely inflamed 6 10.4 [5.35-255.9] 0.0002 4.45 [1.75-7.56] 0.031 
UC inflamed # 13 3.18 [1.03-10.4] 0.003 2.33 [1.15-4.45] 0.024 
CD inflamed 11 3.45 [0.8-5.4] 0.012 1.71 [1.0-4.32] 0.042 
Small 
bowel 
Healthy control 7 1.0 [0.77-1.22] - 1.0 [0.72-1.89] - 
CD inflamed 7 1.72 [0.52-2.74] 0.208 1.84 [1.43-4.66] 0.030 
&'&URKQ¶VGLVHDVH,45inter-quartile range; Mod, moderate; N, number of cases; UC, ulcerative colitis; UI, un-
inflamed (normal) 
 
# UC inflamed group is an amalgamation of the mild/moderate and severely inflamed UC groups (see text) 
 
P-values are calculated by Mann-Whitney test and compared to healthy control group  
 
It was noteworthy that colonic samples taken from healthy controls were collected from 
statistically older subjects (mean (SEM) age 70.5 (4.15) years) than the colonic samples 
from patients with either UC (51.5 (4.76) yearsS RU&URKQ¶VFROLWLV 
years, p=0.001). A similar observation was made when comparing the ages of small 
LQWHVWLQHKHDOWK\FRQWUROV\HDUVWRSDWLHQWVZLWK&URKQ¶VLOHLWLV
years, p=0.003).  
 
It is not known if TLR2 and TLR4 expression changes with age. If the expression of TLR2 
and TLR4 mRNA transcripts were to decline with age, this may explain the observed 
differences between (statistically younger) IBD patients and (statistically older) healthy 
controls. To investigate this possibility, the healthy control group was divided by age into two 
JURXSVRIHTXDOVL]H³\RXQJHU´DQG³ROGHU´FRQWUROV. The mean age of subjects in the 
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younger control group (n=5, age 61.2 (6.18) years) was statistically similar in age to patients 
with both UC (p=0DQG&URKQ¶VGLVHDVHS .108). When the relative expression of 
transcript between the younger and older healthy control groups was compared, there was 
no statistical difference in the expression of TLR2 mRNA (mean (SEM) relative expression 
1.21 (0.35) versus 0.83 (0.05), p=0.343, respectively) or TLR4 mRNA (0.98 (0.14) versus 
1.36 (0.36), p=0.384, respectively). Therefore, no change in TLR2 or TLR4 mRNA 
expression by age was observed.  
 
Within the group of patients with severely inflamed ulcerative colitis (n=6) there appeared to 
be a polarity in the group, with crypt cells from three patients expressing higher transcripts 
for TLR2 and, to a lesser extent, TLR4 mRNA than the remaining three subjects. However, 
when the absolute transcript expression values were tested there was no significant 
difference between the higher and lower expressing cases for TLR2 (p=0.1) or TLR4 (p=0.1) 
mRNA. Furthermore, although the higher expressing subjects were taking more thiopurine, 
methotrexate, corticosteroid and antibiotic therapy at the time of surgery than the lower 
expressing subjects, none of these differences were statistically significant (p>0.05 for all 
)LVKHU¶VH[DFWtests).  
 
4.3.6 Patients with isolated left-sided ulcerative colitis express similar levels of TLR2 
and TLR4 mRNA in un-inflamed and inflamed colon 
In a sub-group of patients with ulcerative colitis, five patients were identified with 
endoscopically and histologically isolated left sided colitis (Montreal classification E2 (9)). 
Two patients were receiving mesalazine, two were receiving mesalazine in combination with 
azathioprine, one was receiving corticosteroids and one patient was not receiving any 
pharmacological therapy at the time of surgery. Intestinal epithelial samples from 
histologically normal (right-sided) and inflamed (left-sided) regions of the colon were 
obtained and RNA isolated as described. Relative TLR2 and TLR4 mRNA expression from 
these paired samples was compared to the pooled sample of healthy control cases using 
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real-time RT-PCR. A Wilcoxon test was used to analyse these paired data, comparing 
normal (un-inflamed) to inflamed regions for each case.  
 
Relative TLR2 expression was similar in histologically normal and inflamed tissue (p=1.0). 
Likewise, there was no significant difference between TLR4 mRNA expression in 
histologically normal and inflamed, paired samples (p=0.625, figure 4.17).  
 
4.3.7 TLR2 mRNA expression is greater in the distal small intestinal and TLR4 mRNA 
expression is greater in the colon in healthy subjects 
Expression of Toll-like receptors has been reported to vary along the gastrointestinal tract. 
TLR2 mRNA is reported to be highest in the distal small bowel and TLR4 mRNA highest in 
the distal colon and stomach in mice (250). In a sub-group of small and large intestinal 
samples from healthy controls, real-time RT-PCR analysis was undertaken to compare TLR2 
and TLR4 mRNA expression in the small intestine compared to expression in the colon. 
Median [inter-quartile range] TLR2 mRNA expression was significantly higher in healthy 
small bowel (17.52 [12.52-19.70]) relative to healthy large bowel (1.0 [0.74-1.35], p=0.004). 
Conversely, TLR4 mRNA expression was significantly lower in healthy small bowel (0.20 
[0.08-0.38]) relative to healthy large bowel (1.0 [0.86-1.69], p=0.004), figure 4.18.  
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4.4 Figures 
 
 
 
 
Figure 4.1 Synthesis of anti-sense RNA using the Ambion MessageAmp II® aRNA 
amplification kit. (A) cDNA is synthesised from total RNA and cleaned, leaving dsDNA. (B) A 
T7 RNA polymerase synthesises anti-sense RNA (aRNA) from the anti-sense cDNA strand. 
The use of amino allyl UTP (aaUTP) at this step allows incorporation of aaUTP molecules 
into the elongating aRNA strand which is necessary for the subsequent conjugation of 
fluorescent dye to its aa side chain (265).  
 
 
aaUTP 
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Figure 4.2 The RNA Integrity Number values for mRNA samples isolated from intestinal 
crypt cells is independent of sample subject age. Intestinal crypt cells were isolated from 
mucosal samples. The Agilent 2100 Bioanalyser® was used to assess mRNA quality by 
ascribing a RNA Integrity Number (RIN) value to each sample. Thereafter, RIN values were 
plotted against patient age (years) for each sample case. Age did not influence the quality of 
the RNA sample as measured by the RIN (R2=0.011, p=0.27).  
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Figure 4.3 RNA Integrity Number and ribosomal RNA 28S:16S ratio values from intestinal 
crypt cell RNA samples show high correlation. Intestinal crypt cells were isolated and mRNA 
analysed using the Agilent 2100 Bioanalyser®. For each sample the RNA Integrity Number 
(RIN) and 28S:18S ribosomal RNA ratio (rRNAratio) was calculated and shown to highly 
correlate (R2=0.448, p<0.001).  
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Figure 4.4 T84 cells express TLR2 and TLR4 mRNA. T84 epithelial cancer line cells were 
cultured to act as positive TLR2 and TLR4 mRNA controls. Isolated mRNA from T84 cells 
was amplified using RT-PCR. Amplicon products were run on a 1% agarose gel and 
visualised with an UV-transilluminator. A 100 base pair (bp) nucleotide size ladder is shown 
(L). Samples examined for TLR2 and TLR4 were run in duplicate with appropriate internal 
and negative controls.  
 
Lanes 1 and 2: TLR2 (size 599bp) 
Lanes 3 and 4: TLR4 (size 507bp) 
Lane 5: HPRT (size 160bp) 
Lane 6: No RT control 
Lane 7: NTC 
 
HPRT, Hypoxanthine guanine phosphoribosyltransferase; No RT, No reverse transcriptase; 
NTC, No template control; TLR, Toll-like receptor 
 
 
500bp 
1000bp 
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Figure 4.5 Intestinal crypt epithelial cells from patients with ulcerative colitis express similar 
levels of TLR2 and TLR4 mRNA compared to healthy controls. The expression of TLR2 and 
TLR4 RNA in large intestinal epithelial cells from healthy control subjects (C) and patients 
with ulcerative colitis (UC) were analysed using an RNA micro array. RNA samples were 
analysed using the Ambion MessageAmp II® RNA micro array kit. Absolute fluorescent 
intensity of gene spots was expressed relative to absolute expression of the housekeeping 
gene hypoxanthine-guanine phosphoribosyltransferase (HPRT).  
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Figure 4.6 Intestinal epithelial cells from patients with ulcerative colitis show up-regulation of 
SITPEC, c-Fos and c-Jun, and down-regulation of ,ț%ĮDQG,ț.ȕ mRNA expression using a 
micro array pathway analysis. The Toll-like receptor signalling pathway is shown following 
overlay of relative RNA expression levels from controls and ulcerative colitis patients using a 
³FRPSDULVRQDQDO\VLV´LQWKHIngenuity Pathway Analysis® (IPA) software. Up-regulated 
signalling molecules in UC patients versus healthy controls are shown in red and down-
regulated molecule are shown in green. This figure is derived from the IPA® software 
canonical pathway building function and unique to the overlaid data. SITPEC, c-Fos and c-
Jun are up-UHJXODWHGLQ8&ZKHUHDV,ț%ĮDQG,țKȕDUHGRZQ-regulated in UC compared to 
control subjects (p<0.05 for all).  
 
,ț%Į,QKLELWRURINDSSD%-alpha; ,ț.ȕ,QKLELWRURINDSSD%NLQDVH-beta; SITPEC, signalling 
intermediate in Toll pathway, evolutionarily conserved.  
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Figure 4.7 Isolated primary intestinal epithelial cells express TLR2 and TLR4 mRNA. The 
expression of (A) TLR2, (B) TLR4 and (C) HPRT mRNA in isolated primary intestinal 
epithelial cells was examined using conventional RT-PCR with bespoke real-time PCR 
primers. The ladder marks (L) correspond to 100bp increments and demonstrates PCR 
bands at the expected sizes (TLR2 134bp; TLR4 141bp; and HPRT 160bp). Subsequent 
DNA sequencing confirmed specificity for human TLR2, TLR4 and HPRT respectively.  
 
Lane 1: Healthy control small bowel 
LDQH&URKQ¶VGLVHDVHinflamed small bowel 
Lane 3: Healthy control colon 
LDQH&URKQ¶VGLsease inflamed colon 
Lane 5: Ulcerative colitis inflamed colon 
Lane 6: No reverse transcriptase (negative) control 
Lane 7: No cDNA template (negative) control. 
 
Bp, base pairs; HPRT, Hypoxanthine guanine phosphoribosyltransferase; TLR, Toll-like 
receptor 
 
      L               1            2             3            4             5            6          7 
A 
B 
     L              1           2            3            4             5            6           7 
C 
    L               1            2             3             4             5             6           7 
500bp 
100bp 
500bp 
500bp 
100bp 
100bp 
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Figure 4.8 Standard curve analysis of TLR2 mRNA amplification using real-time RT-PCR 
and SYBR Green technology on serially diluted template mRNA from pooled primary crypt 
intestinal epithelial cells. To investigate the efficiency of the PCR reaction, standard dilutions 
(X-axis) of pooled cDNA samples from primary crypt intestinal epithelial cells were plotted 
against cycle threshold (Y-axis) on a logarithmic scale. This allowed derivation of the 
efficiency (E) of the PCR reaction from the slope of the plotted line using the equation: 
E=10(-1/slope).  
 
TLR, Toll-like receptor 
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Figure 4.9 Dissociation curve analysis of TLR4 mRNA expression by primary crypt intestinal 
epithelial cells using real-time RT-PCR. To exclude the presence of undesirable 
oligonucleotide annealing and primer-dimer formation, a dissociation curve analysis was 
undertaken for each real-time RT-PCR run. Samples were healed from 55oC to 95oC (X-
axis) in 0.5oC increments and the fluorescent intensity (Y-axis) measured at every step. A 
dissociation curve with a single peak was observed in the absence of primer-dimer formation 
(illustrated by the absence of a fluorescent peak at annealing temperatures lower that the 
main PCR product dissociation peak). 
 
RT-PCR, Reverse transcription polymerase chain reaction; TLR, Toll-like receptor
Single PCR 
product 
fluorescent 
peak  
174 
 
 
 
 
 
 
 
Figure 4.10 Dissociation curve analysis of TLR2 mRNA expression by primary crypt 
intestinal epithelial cells using real-time RT-PCR. During dissociation curve analysis, 
amplified cDNA samples using TLR2 primers were healed from 55oC to 95oC (X-axis) in 
0.5oC increments and the fluorescent intensity (Y-axis) measured at every step. A second 
fluorescent peak (at a lower annealing temperature that the main PCR product) was 
observed in cycling protocols generating primer-dimers.  
 
RT-PCR, Reverse transcription polymerase chain reaction; TLR, Toll-like receptor
Primer-dimer 
fluorescent 
peak (lower 
annealing 
temperature) 
PCR product 
peak (higher 
annealing 
temperature) 
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Figure 4.11 Dissociation curve analysis of TLR2 mRNA expression by primary crypt 
intestinal epithelial cells using real-time RT-PCR with the inclusion of a fourth (acquisition) 
step in the real-time RT-PCR protocol. During dissociation curve analysis, amplified cDNA 
samples using TLR2 primers with a  modified protocol, which included a fourth (acquisition) 
step, were healed from 55oC to 95oC (X-axis) in 0.5oC increments and the fluorescent 
intensity (Y-axis) measured at every step. A dissociation curve with a single peak was 
observed in the absence of primer-dimer formation (illustrated by the absence of a 
fluorescent peak at annealing temperatures lower that the main PCR product dissociation 
peak).  
 
RT-PCR, Reverse transcription polymerase chain reaction; TLR, Toll-like receptor
Single PCR 
product 
fluorescent 
peak  
Resolution of 
primer-dimer 
formation  
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Figure 4.12 Amplification plot of TLR2 mRNA expression by primary crypt intestinal epithelial 
cells using real-time RT-PCR. To exclude the possibility of non-specific cDNA amplification 
causing erroneous fluorescent signal during the PCR cycling protocol, wells with no nucleic 
acid (no template controls, NTC) and no cDNA (no reverse transcriptase controls, no RT) 
were included in all real-time RT-PCR runs in addition to wells containing cDNA from sample 
cases. The absence of fluorescent signal (Y-axis) in control wells indicated absence of non-
specific cDNA amplification.  
 
NTC, No template control; RT, Reverse transcription; TLR, Toll-like receptor
cDNA 
samples 
No 
template 
and no RT 
controls Threshold value 
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Figure 4.13 TLR2 and TLR4 mRNA expression is up-regulated in colonic epithelial cells from 
patients with inflamed ulcerative colitis, and TLR4 mRNA is up-regulated in normal (un-
inflamed) ulcerative colitis. The relative expression of (A) TLR2 and (B) TLR4 mRNA in 
isolated colonic intestinal epithelial cells from patients with ulcerative colitis (UC) was 
compared to healthy controls. UC samples were graded as un-inflamed (normal) or inflamed 
by histological assessment. Each data point represents the mean TLR2 or TLR4 mRNA 
expression of three samples per patient, expressed relative to a pooled sample of healthy 
controls using real-time RT-PCR. Horizontal bars represent median expression.  
# p=0.003; * p=0.024; ** p=0.017 
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Figure 4.14 Observed up-regulation of TLR2 and TLR4 mRNA expression in colonic 
epithelial cells from patients with inflamed ulcerative colitis is predominantly seen in samples 
from histologically severe disease. The relative expression of (A) TLR2 and (B) TLR4 mRNA 
in isolated colonic intestinal epithelial cells from patients with ulcerative colitis (UC), graded 
by severity of histological inflammation, was compared to healthy controls. UC samples were 
graded using the method described by Riley et al. (235). Samples of mild or moderate 
severity were combined to form a single group (Mild/Moderate). Each data point represents 
the mean TLR2 or TLR4 mRNA expression of three samples per patient, expressed relative 
to a pooled sample of healthy controls using real-time RT-PCR. Horizontal bars represent 
median expression.  
# p<0.001; * p=0.031; ** p=0.017 
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Figure 4.15 TLR2 and TLR4 mRNA expression is up-regulated in colonic epithelial cells from 
SDWLHQWVZLWKLQIODPHG&URKQ¶Vcolitis. The relative expression of (A) TLR2 and (B) TLR4 
mRNA in isolated colonic LQWHVWLQDOHSLWKHOLDOFHOOVIURPSDWLHQWVZLWK&URKQ¶VGLVHDVH(CD) 
was compared to healthy controls. Each data point represents the mean TLR2 or TLR4 
mRNA expression of three samples per patient, expressed relative to a pooled sample of 
healthy controls using real-time RT-PCR. Horizontal bars represent median expression.  
* p=0.012; # p=0.042 
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Figure 4.16 TLR4 mRNA expression is up-regulated in small intestinal epithelial cells from 
SDWLHQWVZLWK&URKQ¶Vileitis. The relative expression of (A) TLR2 and (B) TLR4 mRNA in 
LVRODWHGVPDOOLQWHVWLQDOHSLWKHOLDOFHOOVIURPSDWLHQWVZLWK&URKQ¶VGLVHDVHwas compared to 
the expression in healthy controls. Each data point represents the mean TLR2 or TLR4 
mRNA expression of three samples per patient, expressed relative to a pooled sample of 
healthy controls using real-time RT-PCR. Horizontal bars represent median expression.  
* p=0.030 
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Figure 4.17 Intestinal crypt epithelial cells from histologically normal and inflamed regions of 
large bowel express similar levels of TLR2 and TLR4 mRNA in patients with isolated left-
sided ulcerative colitis. Intestinal crypt epithelial cells were isolated from region of un-
inflamed (right-sided) and inflamed (left-sided) colon in patients with endoscopically and 
histologically confirmed left-sided ulcerative colitis (Montreal classification E2). The 
expression of (A) TLR2 and (B) TLR4 mRNA was calculated relative to expression from a 
pooled sample of healthy controls using real-time RT-PCR. Each data point represents the 
mean TLR2 or TLR4 mRNA expression of three samples per patient.  
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Figure 4.18 Healthy small bowel intestinal crypt epithelial cells express greater TLR2 mRNA 
but less TLR4 mRNA than healthy colonic intestinal crypt epithelial cells. The relative 
expression of (A) TLR2 and (B) TLR4 mRNA in isolated small intestinal epithelial cells from 
healthy controls was compared to their expression in colonic IEC from healthy controls. Each 
data point represents the mean TLR2 or TLR4 mRNA expression of three samples per 
subject, expressed relative to a pooled sample of healthy large bowel control subjects using 
real-time RT-PCR. Horizontal bars represent median expression. 
* p=0.004 
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4.5 Discussion 
In order to accurately and meaningfully assess the expression of any gene at the mRNA 
level it is important to obtain nucleic acid samples of high quality. Examination of the 18S 
and 28S ribosomal RNA species following electrophoresis and spectrophotometric analysis 
have historically been the two main methods used for assessing RNA qualitatively and 
quantitatively, respectively (216). Micro-fluid capillary electrophoresis is a recent technique 
that quantifies RNA quality and assigns a RNA Integrity Number (RIN) (218). RNA samples 
with a RIN above between 6 and 7 have been reported as being of suitable quality for down-
stream applications regardless of the length of storage at -80oC (220). Critically it has been 
demonstrated that relative gene expression declines with declining RIN values, whereas 
samples of similar RIN demonstrate comparable gene expression (217). 
 
With this in mind, primary IEC samples with a RIN >6.5 were considered suitable for down-
stream applications. RIN values were not significantly different amongst the healthy control, 
8&DQG&URKQ¶VGLVHDVHJURXSV)XUWKHUPRUH5,1YDOXHVZHUHVLPLODUUHJDUGOHVVRIWKH
degree of inflammation, small or large intestine origin, or various demographics including 
patient age, medical history, concurrent medication use, tissue sample weight or isolated 
IEC viability. Therefore, it was concluded that all isolated IEC RNA samples were of 
comparable quality and were suitable for subsequent qualitative and quantitative analysis. 
 
Several human intestinal cancer cell lines were used as positive controls for TLR2 and TLR4 
transcript expression, as reported in the literature. The human colon cancer cell line T84 and 
the human monocyte cell line THP-1 demonstrated high TLR2 and TLR4 mRNA expression 
using both conventional RT-PCR and real-time RT-PCR primer pairs. Subsequent 
sequencing confirmed primer pair specificity. Of interest, the colon cancer cell line HT-29 
demonstrated variable and inconsistent TLR2 and TLR4 expression. This observation has 
been previously reported (122) and may be due to a number of factors, including DNA 
methylation (233), its luminal rather than crypt origin (246, 249, 250), or due to confluent cell 
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monolayer culture growth (248). Indeed, down-regulation of TLR2 and TL4 expression by 
IEC as they differentiate and migrate along the crypt-villus axis may be one mechanism for 
the observed epithelial tolerance to commensal bacteria in the intestinal lumen.  
 
It was initially important to determine TLR2 and TLR4 mRNA expression by crypt IEC 
isolated from patients in this cohort. Therefore a spotted RNA micro array was undertaken 
using samples from healthy controls and patients with UC. A two-channel RNA micro array 
was chosen because it allows relative gene expression to be investigated between two 
sample groups using the minimal number of chips, thus minimising cost. Micro arrays have 
the advantage of allowing the analysis of a large number of genes during a single 
experimental run. Moreover, the gene-specific features on the micro array chip itself can be 
produced in a bespoke fashion to suit the specific interests of the researcher. Finally, it is 
possible to use the intensity of the fluorescent signal at the gene of interest to semi-
quantitatively characterise relative gene expression between two groups, a process which 
would generally require subsequent confirmation with fully quantitative methods such as 
real-time RT-PCR.  
 
To limit cost, three healthy controls and three patients with inflammatory UC were chosen for 
the micro array experiment. Expression of mRNA for TLR1-10 and several intracellular TLR-
associated signalling molecules was demonstrated. From this data further analysis using 
quantitative methods was deemed suitable and subsequently undertaken.  
 
To further investigate and verify the micro array data for TLR2 and TLR4 mRNA expression, 
conventional RT-PCR analysis on a larger number of crypt IEC samples from healthy 
controls and patients with IBD was undertaken, both on samples from the small and large 
intestine. This confirmed transcript expression of TLR2 and TLR4 in these patient groups.  
The expression of TLR2 and TLR4 mRNA in primary human IEC has previously been 
reported in a small number of publications. Otte et al. described EDTA-isolated colonic crypt 
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IEC expression of TLR1-9 transcripts, with variable expression of TLR7 and non-expression 
of TLR10 mRNA (243). Abreu et al. and Wolfs et al. used laser capture microdissection to 
demonstrate TLR4 mRNA expression in primary IEC, the former reporting expression in 
colonic IEC, and the latter demonstrating that TLR4 mRNA expression was limited to the 
crypts rather than the villi of the small intestine (154, 258). Bocker et al. used dispase to 
demonstrate TLR4 and variable TLR2 transcripts expression in isolated colonic crypt IEC 
from healthy mucosa (122).  
 
Therefore these data confirm previous reports in the literature and add to the current body of 
evidence on qualitative TLR2 and TLR4 mRNA expression in human primary IEC. It can be 
concluded that crypt intestinal epithelial cells of the small and large intestine express TLR2 
and TLR4 and have the potential to sense Gram-positive and Gram-negative bacterial cell 
wall components of the intestinal flora.  
 
To investigate differential expression of TLR2 and TLR4 transcript in crypt IEC in patients 
with UC compared to healthy controls, a semi-quantitative analysis using the RNA micro 
array data was undertaken. Expression of TLR2 and TLR4 mRNA was normalised to the 
housekeeping gene HPRT and compared between the UC and healthy control groups. No 
statistical difference in expression was detected between the two groups. There are a 
number of possible reasons to explain this observation. Firstly, TLR2 and TLR4 mRNA may 
not be differentially expressed in active UC. Secondly, the sample size (three samples per 
group) may have been too small to detect any differences in transcript expression at a 
statistically significant level. Thirdly, semi-quantitative analysis of relative gene expression 
using RNA micro array technology may be less accurate than fully quantitative methods, 
such as real-time RT-PCR, particularly when using mRNA samples from primary biological 
samples compared to cultured cell lines. Fourthly, mRNA samples from two of the three UC 
patients were from regions of only mild to moderate inflammation, as assessed by the Riley 
score (235). It is possible that differential expression of TLR2 and TLR4 mRNA is related to 
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the degree of inflammation such that a significant change in transcript expression is 
detectable only in the most severely inflamed tissue. Indeed, the relative expression in the 
patient with severely inflamed UC was greater than the expression in either of the mild to 
moderately inflamed patient samples.  
 
Therefore the analysis of a larger number of samples from a variety of disease activities was 
undertaken using real-time RT-PCR. Notably TLR2 and TLR4 mRNA was shown to be 
significantly up-regulated both in colonic crypt IEC from patients with inflamed UC and 
LQIODPHG&URKQ¶VFROLWLV&ULWLFDOO\ the expression of TLR2 and TLR4 transcripts in crypt IEC 
isolated from regions of severely active UC were up-regulated to a greater degree (10.4- and 
4.45-fold, respectively) than in crypt IEC from patients with mild to moderately inflamed UC 
(1.06- and 2.12-fold, respectively), suggesting gene expression of TLR2 and TLR4 was 
related, in part, to the severity of disease activity.  
 
Even more intriguing is the observation that TLR4 mRNA was up-regulated in crypt IEC 
derived from regions of histologically normal (un-inflamed) colon in UC. If TLR4 up-
regulation was purely a secondary phenomenon occurring in response to local mucosal 
tissue inflammation, relative TLR4 expression in normal UC tissue would be expected to be 
similar to TLR4 expression in healthy controls. The observation in this study that TLR4 was 
up-regulated in crypt IEC from normal (un-inflamed) UC mucosa suggests constitutive TLR4 
transcript expression in these patients.  
 
Furthermore, a sub-group of five UC patients with histologically and macroscopically left-
sided UC was collected. Paired samples of isolated crypt IEC mRNA expression for TLR2 
and TLR4 were analysed, comparing histologically normal (un-inflamed) right-sided samples 
with inflamed left-sided samples. Despite crypt IEC TLR2 and TLR4 mRNA expression in 
this sub-group being significantly up-regulated compared to healthy controls, there was no 
difference in expression between left- and right-sided samples for either TLR2 and TLR4, 
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suggesting similar expression of these genes in crypt IEC derived from normal and inflamed 
UC mucosa. This further suggests that TLR2 and TLR4 mRNA expression is constitutively 
expressed in colonic crypt IEC in patients with UC, and may be a primary event in the 
pathogenesis of ulcerative colitis. Interestingly, epithelial TLR4 over-expressing mice 
develop more severe experimental DSS-induced colitis than wild type mice, implying 
constitutive (pre-induction) TLR4 expression plays a role in colitis susceptibility (273), 
supporting the observation in this study that IEC from patients with UC expressed higher 
levels of TLR4 mRNA in regions of histologically normal colon.  
 
In support of TLR2 and TLR4 mRNA up-regulation being a secondary event in IEC, in vitro 
data has reported up-regulation of TLR2 and TLR4 mRNA in intestinal epithelial cell lines in 
response to pro-inflammatory cytokines. Differential expression of TLR2, TLR3 and TLR4 
mRNA has been reported in HT-29 and T84 cell monolayers in response to co-culture with 
various intestinal bacteria (252, 253)71)ĮDQG,)1Ȗare reported to up-regulate TLR4 
mRNA in HT-29 and T84 cell lines (154) DQG,)1ȖXS-regulates TLR2 to TLR5 mRNA and 
TLR4 protein in a variety of human IEC lines (155).  
 
Moreover, patients with active inflammatory bowel disease demonstrate higher levels of both 
peripheral blood and gut mucosal tissue pro-inflammatory cytokines (274). This observed 
systemic inflammatory response, which may result in elevated cytokine levels in the 
intestinal mucosa of un-inflamed bowel, may explain the up-regulation of TLR2 and TLR4 
mRNA in primary IEC isolated from histologically normal mucosa in patients with left-sided 
UC.  
 
It would seem conceivable that high levels of in vivo pro-inflammatory cytokines in the 
mucosa of patients with IBD could result in up-regulation of TLR2 and TLR4 expression. This 
may explain the greater up-regulation of TLR2 and TLR4 in crypt IEC derived from severely 
inflamed compared to mild or moderately inflamed mucosa observed in this study. It would 
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be interesting to investigate if TLR2 and TLR4 expression could be suppressed with 
successful immunosuppressive treatment for IBD, particularly following biological anti-71)Į
therapy, and to investigate whether there is a difference in the magnitude of suppression of 
TLR2 and TLR4 expression in patients who clinically respond to immunosuppressive 
treatment compared to the so-called non-responders.  
 
Toll-like receptors are reported to play a complex role in maintaining intestinal gut 
homeostasis. On one hand, TLR-mediated bacterial sensing is vital to the development of 
mature mucosal associated lymphoid tissue (99, 100) and TLR signalling protects mice 
against radiation-induced enteropathy (101), ischaemic-reperfusion injury (102) and chronic 
inflammation (103). TLR signalling facilitates bacterial sensing by intestinal epithelial m-cells 
which play a role in maintaining tolerance to intestinal luminal bacteria (115). Furthermore, 
oral TLR2 and TLR4 ligands and parenteral TLR3 and TLR9 ligands protect mice against 
DSS-induced colitis (159), and both TLR4 (160) and TLR5 (161) ligands protect against 
radiation-induced enteritis.  
 
On the other hand, intestinal inflammation has been shown to be in part mediated by 
enhanced IEC-associated TLR signalling. TLR-expressing IEC up-regulate their expression 
of T cell-associated co-stimulation molecules (119) and can induce naïve T cells to 
differentiate into a pro-LQIODPPDWRU\,)1Ȗ-secreting TH1 cell phenotype (120). Over-
expression of TLR2- and TLR4-SRVLWLYH'&LVUHSRUWHGLQWKHODPLQDSURSULDLQ&URKQ¶V
disease (133). TLR-knock out mice have been shown to be protected against various 
experimental models of colitis, while TLR5 and TLR9 ligands exacerbate established chronic 
DSS-induced experimental colitis (159). Furthermore, both a TLR4 antagonist (164) and an 
anti-TLR4 monoclonal antibody (165) are reported to improve inflammation in established 
acute DSS-induced colitis.  
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Therefore current literature suggests that epithelial TLR signalling maintains intestinal 
homeostasis and induces a tolerogenic state to luminal antigens in the healthy state, 
whereas TLR signalling exacerbates inflammation in the situation of established colitis. 
Given the observation in this study that TLR4 is constitutively expressed in crypt IEC in the 
colon of histologically normal UC patients, it is possible that TLR4 ligation may provide a 
therapeutic option in maintaining remission in quiescent disease. Conversely, the finding of 
marked up-regulatiRQRI7/5DQG7/5LQFU\SW,(&RISDWLHQWVZLWKERWK8&DQG&URKQ¶V
colitis, particularly in IEC derived from regions of severely inflamed mucosa, may suggest 
that blockade of TLR2 and TLR4 signalling could improve intestinal inflammation in active 
disease.   
 
Regarding the small intestine, quantitative real-time RT-PCR data demonstrated 
approximately two-fold up-regulation of TLR4 mRNA in the inflamed ileum of patients with 
&URKQ¶Vileitis. Although up-regulation of TLR2 mRNA was of a similar magnitude, it did not 
reach statistical significance. Up-regulation of both TLR2 and TLR4 transcripts LQ&URKQ¶V
LOHLWLVZDVOHVVPDUNHGWKDQLQ&URKQ¶VFROLWLVRU8&2QHSRVVLEOHH[SODQDWLRQLVWKDWPDQ\
of the patients included in this study required small intestinal resection for chronic stricturing 
&URKQ¶Vdisease rather than for treatment-refractory inflammatory disease. Indeed, 
HSLGHPLRORJLFDOGDWDVXJJHVWVWKDWPRVWSDWLHQWVZLWKLOHDO&URKQ¶VGLVHDVHSURJUHVVinitially 
from an inflammatory phenotype to either a fistulating or a stenosing phenotype over the 
disease course (181)&KURQLFVWULFWXULQJ&URKQ¶VGLVHDVHWHQGVQRWWRUHVpond to 
immunosuppressive or biological treatment, and symptoms from this disease phenotype are 
usually secondary to mechanical bowel obstruction rather than inflammation per se. 
7KHUHIRUHWKLVJURXSRISDWLHQWVZLWK&URKQ¶VGLVHDVHPD\QRWEHWKHPRVWsuitable for 
investigating TLR2 and TLR4 expression. Another explanation is that TLR2 and TLR4 over-
expression is less important in the pathogenesis oI&URKQ¶VLOHLWLVDQGRWKHUpathways play a 
more crucial role.  
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&URKQ¶VGLVHDVHLVFKDUDFWHULVHGE\so-called skip lesion, regions of transmural inflammation 
interspersed between regions of normal (un-inflamed) mucosa (2). Mucosal samples from 
regions of inflamed &URKQ¶VFROLWLV could easily be identified macroscopically and 
subsequently confirmed histologically. However, obtaining normal (un-inflamed) samples 
IURPSDWLHQWVZLWK&URKQ¶VFROLWLVis more challenging. Normal-appearing tissue can turn out 
to be microscopically inflamed. In addition, due to the intermittent nature of the disease, it 
was not possible to be certain that samples taken from a reportedly un-inflamed specimen 
were not actually taken from adjacent regions of inflamed mucosa. Therefore it was not 
SRVVLEOHWRREWDLQDUHOLDEOHJURXSRIFRORQLFFU\SW,(&IURPQRUPDO&URKQ¶VFROLWLVDQGthe 
HYDOXDWLRQRIWKHH[SUHVVLRQRI7/5DQG7/5LQQRUPDO&URKQ¶VFROLWLVZDVQRWSRVVLEOH 
 
The healthy control groups in this study were derived from patients undergoing surgical 
resection for colon cancer. Inflammatory bowel disease affects younger persons and it was 
not surprising that the IBD patient population was significantly younger than the healthy 
control population. Comparing non-age matched groups raises the possibility that inter-group 
differences are a result of age rather than disease process. To address this, two age groups 
of healthy control subjects were analysed. Younger controls (statistically similar in age to the 
IBD patients) expressed similar levels of TLR2 and TLR4 transcripts compared to statistically 
older controls. This suggests the expression TLR2 and TLR4 transcripts did not vary with 
age. Therefore it was concluded that the observed differences in expression were not age-
related.  
 
The data reported in this study are new in that quantitative expression of TLR2 and TLR4 
mRNA in a wide range of IBD patient groups has not been published. Naik et al. reported 
VLPLODUOHYHOVRI7/5P51$H[SUHVVLRQLQWZRSDHGLDWULFSDWLHQWVZLWK&URKQ¶VLOHRFROLWLV
compared to healthy controls, but mRNA expression was analysed by visually examining 
electrophoresis gel band width following conventional RT-PCR rather than using a fully 
quantitative method (263). Melmed et al. reported down-regulation of TLR1 mRNA, but no 
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differential expression of TLR2 or TLR6 mRNA, between paired un-inflamed and inflamed 
colonic IEC, isolated by laser capture micro-dissection, from two patients with UC (231). 
However, no healthy controls were used for comparison and the sample size was small in 
this study. Interestingly, mRNA for both TLR2 and TLR4 are reported to up-regulate in IEC in 
mice following induction of DSS colitis (250, 275).  
 
The final aspect of the characterisation of TLR2 and TLR4 mRNA expression in UC samples 
related to the comparison analysis in the IPA software using the RNA micro array data. 
Pathway analysis of the three cases of UC compared to the three healthy controls 
demonstrated up-regulation of two MAP kinase-associated signalling molecules, c-Jun and 
c-Fos, and up-regulation of the signalling molecule ECSIT (SITPEC) in the crypt IEC derived 
from the UC patients. Moreover, transcripts for the NF-ț%-regulating molecule ,ț%Įwas 
down-regulated in UC patients. Although differential expression of signalling molecules in the 
0$3NLQDVHDQG1)ț%SDWKZD\VDUHQRWXQLTXHWR7/5signalling, the up-regulation of 
ECSIT is intriguing. ECSIT is an intracellular signalling molecule of the TLR/IL-1 pathway 
(84) and has been implicated in TLR-dependent macrophage killing of bacteria via 
mitochondria-derived reactive oxygen species (276). These data suggest that the TLR 
signalling pathway is up-regulated in crypt IEC derived from patients with UC, though further 
investigation into the regulation and functional state of signalling molecules in the TLR 
pathway is clearly required.  
 
It has been reported in mice that TLR2 mRNA is predominantly expressed in the distal small 
intestine and the proximal colon, with TLR4 mRNA predominantly expressed in the distal 
colon (250). Although compartmental expression of TLR2 and TLR4 has not been reported 
in the human intestine, Bocker et al. reported predominant expression of TLR4 mRNA in the 
colon, with TLR2 mRNA expression being weaker and more variable (122). To address this 
question, samples of mRNA from normal distal small intestine and colon were analysed 
using real-time RT-PCR. The data showed that TLR2 mRNA is more than ten-fold higher in 
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the small intestine compared to the colon, whereas colonic TLR4 transcript expression is 
five-fold that of the small intestine. This is consistent with the mouse data suggesting 
compartmental TLR2 and TLR4 expression in the intestine with a shift from TLR2 to TLR4 in 
the distal large bowel (250).  
 
It is unclear why this pattern of TLR2 and TLR4 expression should be the case. The greatest 
burden of bacteria is found in the colon and it may be functionally more critical for the host to 
sense Gram-negative bacteria in this region to maintain homeostasis. Interestingly, the 
survival of Gram-negative bacteria in the ileal mucosa and their translocation to the 
mesenteric lymph nodes is well deVFULEHGLQ&URKQ¶VLOHLWLV (13). The relatively lower 
expression of TLR4 in the distal small bowel may increase the likelihood of mucosal invasion 
and immune system evasion by Gram negative bacteria, such as adherent invasive E coli, in 
LQGLYLGXDOVSUHGLVSRVHGWRGHYHORSLQJ&URKQ¶VGLVHDVH (277, 278). A higher baseline ileal 
TLR2 expression may also explain why the data in this study detected up-regulation only of 
TLR4 in CroKQ¶VLOHLWLV.  
 
The compartmentalisation of TLR4 to the colon is also interesting. Murine DSS-induced 
colitis results in predominantly distal colonic inflammation, the region of the colon with the 
highest expression of TLR4 mRNA and protein, and DCC colitis resembles UC more closely 
(250). The observation that a TLR4 antagonist (164) and an anti-TLR4 monoclonal antibody 
(165) improve inflammation in this experimental model support the concept that TLR4 plays 
a role in the pathogenesis of DSS colitis. In this study, the observed up-regulation of TLR4 
mRNA in crypt IEC from both normal and inflamed mucosal specimens in UC in this study 
provides further evidence to suggest that UC is in part mediated by TLR4-induced 
inflammation.  
 
In summary, EDTA-isolated crypt IEC from the small and large bowel contains high quality 
mRNA and expresses TLR2 and TLR4 transcripts. Quantitative real-time RT-PCR analysis 
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demonstrates significant up-regulation of TLR2 and TLR4 mRNA expression in inflamed UC 
DQG&URKQ¶VFROLWLVSDUWLFXODUO\LQ,(&GHULYHGIURPPXFRVDOUHJLRQVwith histologically 
severe disease activity. Similarly, TLR4 mRNA expression is up-regulated in crypt IEC 
GHULYHGIURPSDWLHQWVZLWK&URKQ¶VLOHLWLVInterestingly, compared to healthy controls TLR4 
mRNA is up-regulated in crypt IEC isolated from normal (un-inflamed) mucosa in patients 
with UC, suggesting constitutive TLR4 mRNA expression. Moreover, TLR2 and TLR4 mRNA 
is similarly expressed in paired crypt IEC samples isolated from histologically normal and 
inflamed mucosa in patients with left-sided UC, further suggesting constitutive TLR 
expression in UC patients. TLR2 mRNA is expressed to a greater level that TLR4 mRNA in 
crypt cells of the normal small intestine and this pattern is reversed in crypt cells of the 
normal colon. This may in part explain the distal anatomical distribution of colitis in UC. 
These data provide further insight into the role of TLR2 and TLR4 in the pathogenesis of 
IBD. 
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Chapter 5: Expression of Toll-like receptors-2 and -4 protein in 
crypt intestinal epithelial cells in health and inflammatory bowel 
disease 
 
5.1 Introduction 
The expression of Toll-like receptors in human epithelial cell lines and primary human 
intestinal epithelial cells at the genomic level has been discussed in chapter 4. However, to 
fully understand their roles in intestinal homeostasis and intestinal inflammation, TLR 
expression must also be analysed at the protein level.  
 
Regarding human cell lines, surface TLR4 protein expression has been reported in Caco-2, 
HT-29, T84 and SW480 cells (89, 231, 232, 243), though the TLR4-associated molecule 
MD-2 was inconsistently detected (89). TLR4 expression is reported to be dependent on the 
particular cell line studied, with greatest expression by SW480, lesser expression by HT-29 
and T84, and least expression by Caco-2 and HCT116 cells. This differential expression 
may be due to changes in TLR gene promoter methylation and histone deacetylation (233). 
TLR2 and TLR4 protein has also been reported in a foetal small intestine cell line (240).  
 
Functional TLR2 and TLR4 protein has been demonstrated in T84 and HT-29 cells. These 
cells were responsive to LPS as demonstrated by up-regulation of p42/44 (T84) and p38 
components of the MAPK pathway (HT-29), even in the absence of the TLR4-associated 
molecule CD14 (232). Functional TLR2 and TLR4 signalling has also been reported in T84, 
SW480, caco2 and Colo205 cells by demonstrating up-regulation of p-ERK1/2, down-
UHJXODWLRQRI,ț%ĮOLJDQGXSWDNHDVVD\VDQG/or production of IL-8 (122, 162, 242, 243, 246, 
248, 249); although non-responsiveness in cell lines has also been reported (89).  
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In primary intestinal tissue, TLR2 and TLR4 protein have been demonstrated to be 
expressed predominantly in the crypt cells of the colon using immunohistochemistry, with 
TLR3 protein expressed mainly on the luminal surface (252). TLR1/2 and TLR1/4 
heterodimers have been reported in small and large bowel epithelial cells, and their 
immunofluorescent co-localisation with serotonin-staining cells suggested an 
enteroendocrine phenotype to these TLR-expressing IEC (254). Immunohistochemical 
staining has demonstrated TLR2 and TLR4 protein expression in primary foetal small bowel, 
especially in the crypts (240).  
 
There are no functional studies investigating the response of primary intestinal epithelial 
cells to TLR2 and TLR4 ligands. Primary IEC have been reported to up-regulate DMBT1 
mRNA expression (a putative anti-microbial peptide) in response to TNF-Į (279) and to 
respond to a TLR8 ligand by secreting IL-8 (256), and primary mucosal samples respond to 
the TLR5 ligand flagellin when applied to the basolateral, but not apical surface (255). 
Despite the reporting of functional intracellular TLR4 protein in murine intestinal cell lines (m-
ICcl2 cells) (244, 245), primary IEC have not been reported to express intracellular TLR4 
protein. Indeed it is likely that surface rather than intracellular TLR4 protein is the key cellular 
location for LPS recognition (247).  
 
Regarding expression during intestinal inflammation, TLR2 and TLR4 protein has been 
reported to be expressed at low level in healthy colonic tissue, with TLR4 but not TLR2 up-
UHJXODWHGLQERWKXOFHUDWLYHFROLWLVDQG&URKQ¶VGLVHDVHUHJDUGOHVVRIGLVHDVHDFWLYLW\(260). 
However this is not been a universal observation (262). In another study, although both 
TLR2 and TLR4 protein were reported to be up-regulated in the mucosa of children with IBD 
using western blot analysis, the potential confounding contribution of lamina propria immune 
cells could not be excluded which prevents conclusions regarding the role TLR2 and TLR4 in 
IEC specifically from being made (280).  
 
196 
 
In summary, functional TLR2 and TLR4 protein has been demonstrated to varying degrees 
in human cells intestinal epithelial lines. Qualitative immunostaining has demonstrated TLR2 
and TLR4 protein to be expressed primarily in the crypt cells, though expression throughout 
all epithelial cells has also been reported. There is a paucity of data regarding the differential 
expression of these receptors in active IBD and to date there are no publications in this area 
using quantitative methods. The aim of this chapter was to investigate the expression of 
TLR2 and TLR4 protein in isolated crypt IEC and to quantitatively characterise their 
expression in IBD and healthy controls.  
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5.2 Methods 
5.2.1 Protein isolation and Bradford protein assay 
Following isolation of primary epithelial cells or cultured cell lines, cells were lysed and 
protein isolated for subsequent analysis using CelLytic M cell lysis buffer (C2978, Sigma) 
IROORZLQJWKHPDQXIDFWXUHU¶VLQVWUXFWLRQV6 cells were collected in solution and centrifuged 
for 3 minutes at 450g. The supernatant was removed and the cells washed three times in 
PBS. Following centrifugation, 125µL of CelLytic M was added to the pellet along with 
1.25µL of Phosphatase inhibitor cocktail 2 (P5726, Sigma) and 1.25µL of Protease inhibitor 
cocktail (P8340, Sigma) and the cells re-suspended.  
 
This cellular suspension was incubated for 15 minutes, followed by a centrifugation step at 
13,000 rpm (>10,000g) for 15 minutes to pellet the cellular debris. The protein-containing 
supernatant was removed and stored undiluted at -80oC until required.  
 
To measure the concentration of total protein in the lysate solution, a protein assay based on 
the Bradford method was used (216). A stock solution of 2mg/mL bovine serum albumin 
%6$ZDVVHULDOO\GLOXWHGLQWRWKHIROORZLQJFRQFHQWUDWLRQVȝJP/ȝJP/ȝJP/
ȝJP/ȝJP/DQGȝJP/LQ3%63XUH3%6ZDVXVHGDVDQHJDWLYHFRQWUROȝ/
aliquots of each diluted sample aQGȝ/RI&RRPDVVLH%OXHUHDJHQW(Biorad) were added 
to wells in a 96-well plate in duplicate. Coomassie Blue reagent is a triphenylmethane dye 
which actively binds to protein. Unbound Coomassie Blue reagent has a brown colour which 
changes to blue on protein binding. Of importance, the absorbance of light at 595nm (A595) 
of protein-bound Coomassie Blue reagent is linearly related to the protein concentration, 
within the range 0ȝJP/ to 200ȝJP/ of protein. With protein concentrations greater than 
ȝJPL the relationship becomes non-linear and therefore less accurate.  
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Using the Coomassie Blue reagent and serially diluted BSA samples it was possible to 
demonstrate this linear relationship between A595 and protein concentration (figure 5.1). 
 
8VLQJWKLV³VWDQGDUGFXUYH´WKHtotal protein concentration in primary IEC and cell line 
lysates could be directly derived from their individual A595 reading. Primary IEC and cell line 
lysates were analysed using this method. If the total protein concentration was greater than 
ȝJP/WKHDVVD\ZDVUHSHDWHGIROORZLQJVDPSOHGLOXWLRQZLWK3%6XQWLOWKHPHDVXUHG
A595 fell within the linear range. In such cases, calculation of the actual protein concentration 
was made multiplying the measured concentration by the dilution factor.  
 
5.2.2 Polyacrylamide gel electrophoresis and Western blotting 
Western blotting (WB) was undertaken following sodium dodecyl sulphate polyacrylamide 
gel electrophoresis (SDS-PAGE). Reagents for SDS-PAGE and Western blotting were made 
in stock solution prior to use and stored at room temperature. The following three stock 
solutions were required: 
 
 4x Resolving gel stock solution (containing 1.5M Tris and 0.4% SDS at pH 8.8): 
18.2g Tris-Cl (T3253, Sigma) and 4mL of 10% SDS (L4522, Sigma) were added to 
96mL dH2O and pH balanced to 8.8 using concentrated NaOH solution.  
 
 4x Stacking gel stock solution (containing 0.5M Tris and 0.4% SDS at pH 6.8): 6.05g 
Tris-Cl and 4mL of 10% SDS were added to 100mL dH2O and pH balanced to 6.8 
using concentrated NaOH solution. 
 
 5x SDS running buffer stock solution (containing 0.5% SDS): 1.5g Tris-Cl, 72g 
glycine and 50mL of 10% SDS solution made up to 1L with dH2O.  
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In addition, the following three reagents were made fresh for each run: 
 
 Transfer buffer (containing 48mM Tris, 39mM glycine, 0.05% SDS and 20% 
methanol at pH 9.2): 5.82g Tris-base (T6066, Sigma), 2.93g glycine (BP 381-1, 
Fisher), 0.5mL SDS and 200mL of methanol were made up to 1L with dH2O and pH 
balanced to 9.2 using concentrated NaOH solution. 
 
 Tween 20/Tris-buffered saline wash solution (TTBS, containing 100mM Tris, 150mM 
NaCl and 0.1% SDS): 12.1g Tris-Cl, 8.7g NaCl (S/3160/63, Fisher) and 1mL Tween 
20 (P1379, Sigma) were made up to 1L with dH2O and pH balanced to 7.5 using 
concentrated NaOH solution.  
 
 DPPRQLXPSHUVXOSKDWHVROXWLRQȝJDPPRQLXPSHUVXOSKDWH(161-0700, 
Biorad) LQȝOG+2O. 
 
To perform SDS-PAGE, glass plates and spacers were cleaned with 70% ethanol and 
assembled in the rack. A 10% resolving gel was made up by mixing the following: 5mL 30% 
acrylamide/0.8% bisacrylamide (161-0156, Biorad), 3.75mL 4x resolving gel stock solution, 
6.25mL dH22ȝ/DPPRQLXPSHUVXOSKDWHDQGȝ/7(0(' (NNN¶1¶-
tetramethylethylenediamine, T9281, Sigma). This was immediately poured between the 
glass plates to a mark 2cm below the top of the plates. Isopropanol (propan-2-ol, 
P/7507/PB17, Fisher) was layered on top of this, to a mark 1cm from the top of the glass 
plates. This was left to polymerise for 30 minutes at which point the isopropanol was 
removed with filter paper.  
 
A 5% stacking solution was mixed as follows: 0.65mL 30% acrylamide/0.8% bisacrylamide, 
1.25mL 4x stacking gel stock solution, 3.05mL dH22ȝ/DPPRQLXPSHUVXOSKDWHDQG
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ȝ/7(0('7KLVZDVimmediately layered on top of the set gel and allowed to polymerise 
following insertion of a Teflon comb.  
 
'XULQJWKLVVWHSȝJRIWRWDOSURWHLQIURPHDFKVDPSOHZDVPL[HGZLWK/DHPPOLEXIIHU
(161-0737, Bio-Rad, UK) in a 1:1 ratio and heated for 5 minutes at 100oC for soluble 
LQWUDFHOOXODUSURWHLQVHJȕ-actin) or 37oC for 10 minutes for hydrophobic transmembrane 
proteins (e.g. TLR2 or TLR4). The gels were placed facing in a tank of dilute 1x running 
buffer solution and the combs were removed. Protein samples were loaded into the wells 
and the gel run at 120-140V for 90-150 minutes depending on the molecular size of the 
protein.  
 
To perform the Western blot, two filters and one polyvinylidene difluoride (PVDF) membrane 
(RPN303F, GE Healthcare) were cut to the size of the gel. The gel was removed from the 
tank and glass plates, and soaked in SDS running buffer for 15 minutes. During this time the 
PVDF membrane was soaked in 100% methanol for 15 seconds and rinsed in dH2O for 2 
minutes before being soaked in transfer buffer for 10 minutes. Similarly, the filters and 
sponges were soaked in transfer buffer.  
 
Next the sponges, filters, gel and membrane were assembled, placed in a tank and filled 
with transfer buffer before undertaking electrophoresis at 90V, 0.2A for 50 minutes (figure 
5.2). 
 
To prevent non-specific antibody-protein binding, a 5% protein blocking solution was made 
by adding 2.5g Marvel to 50mL TTBS. The PVDF membrane was removed from the tank 
apparatus and incubated in this blocking solution for 30 minutes on a rocking platform at 
room temperature. Primary antibody solutions were made to the working concentrations and 
incubated as shown in table 5.1. 
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Table 5.1 Working dilutions and incubation protocols for primary antibodies used in Western 
blotting 
Antibody Dilution factor Incubation protocol 
ȕ-Actin (A5060, Sigma) 1:1,000 1 hour at room temperature 
TLR2 (14-9922, eBioscience) 1:250 18 hours at 4oC 
TLR4 (ab22048, Abcam) 1:250 18 hours at 4oC 
TLR, Toll-like receptor 
 
Following primary antibody incubation, the membrane underwent three 5-minute washes in 
TTBS. The biotinylated secondary horse anti-mouse/anti-rabbit antibody (Vectastain ABC 
Universal kit PK-6200, Vector Labs) was diluted to 1:100 in 5mL of 5% Marvel, and applied 
to the membrane for 30 minutes on a rocking platform at room temperature. During this 
incubation the avidin/biotin-HRP complex was prepared by adding 100µL each of reagents A 
and B to 5mL 3%6DQGOHDYLQJIRUPLQXWHVDVSHUWKHPDQXIDFWXUHU¶VLQVWUXFWLRQV
(Vectastain ABC Universal kit PK-6200, Vector Labs).  
 
After the secondary antibody incubation step, the membrane was washed three times for 5 
minutes in TTBS. The avidin/biotin-HRP complex was added to the membrane and 
incubated for 30 minutes at room temperature on a rocking platform followed by three 5-
minute washes in TTBS.  
 
To detect HRP activity, a solution of VIP reagent (Vector peroxidise substrate kit SK-4600, 
Vector Labs) was prepared by adding 150µL of each of reagents 1, 2 and 3 and 150µL of 
hydrogen peroxide solution to 15mL PBS. The membrane was immersed in the VIP solution 
for 1-5 minutes before quenching in dH2O for 5 minutes. The membrane was allowed to air 
dry before scanning.  
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5.2.3 Immunofluorescent staining 
Formalin-fixed, paraffin-embedded WLVVXHVSHFLPHQVZHUHFXWLQWRȝPWKLFNVHFWLRQVXVLQJ
the microtome and left to dry overnight on a SuperFrost plus® slide (Thermo Scientific). 
Slides were placed in a metal rack and successively transferred through three Xylene 
solutions for 2 minutes each. The sections were re-hydrated by transferring down through 
graded alcohol solutions (100%, 90%, 80%, 70% and 50%). Finally the slides were washed 
in dH2O.  
 
One percent citrate-based antigen retrieval solution (H-3300, Vector Labs) was made to 
300mL volume and the solution heated to 100oC in a conventional microwave oven. The 
slides were immersed in antigen retrieval solution at 100oC for 15 minutes and left to cool to 
room temperature for 30 minutes before being washed twice in PBS for 5 minutes.  
 
The slides were transferred to an incubation chamber containing PBS-soaked tissue paper. 
Around the tissue specimen a square was drawn using a wax pencil. Specimens were 
subject to three blocking steps. Firstly, the tissue specimens were incubated in neat avidin-
blocking solution (SP-2001, Vector Labs) for 30 minutes at room temperature and washed in 
PBS for 5 minutes. The slides were then incubated in neat biotin-blocking solution (SP-2001, 
Vector Labs) for 30 minutes at room temperature and washed in PBS for 5 minutes. Finally 
slides were incubated in 5% horse serum in PBS for 30 minutes at room temperature to 
block non-specific antibody binding.  
 
Thereafter, the slides were washed twice in PBS twice for 5 minutes and incubated with the 
primary antibody in a solution of 5% horse serum in PBS for 1 hour at room temperature as 
shown in table 5.2. 
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Table 5.2 Working concentrations of primary antibodies used for immunofluorescent staining 
Primary antibody Dilution of stock antibody 
Cytokeratin 1:400 
Į-smooth muscle actin 1:500* 
TLR2 (eBioscience) 1:50 
TLR4 (eBioscience) 1:50 
PBS Phosphate buffered saline; TLR, Toll-like receptor 
* Initially stock antibody was diluted to 1:5 with PBS and 1% BSA before storage at -80oC 
 
The slides were returned to the metal rack and washed three times in PBS for 5 minutes 
each. The secondary anti-mouse/anti-rabbit biotinylated antibody was prepared to a 1:400 
dilution using 5% horse serum in PBS. The slides were returned to the incubation chamber 
DQGȝ/VHFRQGDU\DQWLERG\solution applied to each slide for 30 minutes at room 
temperature.  
 
The slides were washed in three times in PBS and returned to the incubation chamber. 
Secondary antibody detection was undertaken using the Fluorescent Avidin kit (A-1100, 
Vector Labs). 7RHDFKVOLGHȝ/RI 5% solution of fluorescein avidin DCS (anti-mouse 
IgG) in 0.5M sodium chloride was added and incubated in the dark for 10 minutes at room 
temperature. Thereafter, the slides were washed twice in PBS for 1 minute only in the dark.  
 
)OXRUHVFHQWGHWHFWLRQZDVXQGHUWDNHQE\DGGLQJȝ/RI9HFWDVKLHOG0RXQWLQJ0HGLXPZLWK
4',6-diamidino-2-phenylindole (DAPI) (H-1200, Vector Labs) to the section, applying a 
22x22mm cover slip and leaving for 1 minute in position. The cover slip was then firmly 
positioned over the section to exclude any underlying bubbles.  
 
Fluorescently labelled, DAPI counter-stained slides were left in the dark for one hour before 
viewing. Images were generated in the Leica fluorescent microscope (Leica Microsystems) 
using Leica software (LAS AF v2.5.0). Slides were scanned with an exposure of 90ms for 
DAPI and 248ms for FITC. To reduce the initial background signal, the images were set to a 
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+10 background adjustment. No colour or contrast adjustments were made. Finally, images 
were saved and exported as JPEG files.  
 
5.2.4 Flow cytometry 
Crypt intestinal epithelial cells were isolated and disaggregated using EDTA/DTT and 
pancreatin (section 3.2.4), and peripheral blood mononuclear cells were isolated from whole 
blood using Histopaque and Ficoll density gradient centrifugation (section 3.2.10). Cell 
concentration was calculated using trypan blue exclusion. Five hundred thousand (0.5x106) 
cells were transferred to each flow cytometry tube and the volume made up to 0.5mL with 
flow cytometry medium (2% foetal calf serum in HBSS without calcium or magnesium). 
Tubes were centrifuged at x300g for 10 minutes at room temperature to pellet the cells 
before removal of the supernatant by pipette.  
 
Five microlitres of normal mouse serum was added to the tube and the tube flicked several 
times to loosen the pellet. Tubes were left for 15 minutes sitting over ice (approximately 
4oC). Thereafter no antibody, isotype antibody or primary antibody was added and incubated 
for 1 hour in the dark on ice at 4oC, as follows: 
 
1. No primary antibody 
2. Anti-BerEP4-FITC ȝ/ (F0860, Dako) 
3. Anti-BerEP4-FITC ȝ/,J*Dțisotype control-APC ȝ/ (17-4724, eBioscience) 
4. Anti-BerEP4-FITC ȝ/DQWL-TLR2-$3&ȝ/ (17-9922, eBioscience)  
5. Anti-BerEP4-FITC ȝ/DQWL-TLR4-$3&ȝ/ (17-9917, eBioscience) 
6. Anti-CD45-AF488 ȝ/ (304019, BioLegend) 
 
Next the cells were washed twice by adding 0.5mL of flow cytometry medium to the tube, re-
suspending the cells by flicking the tube and centrifugation at 300g for 10 minutes at room 
temperature. After decanting the supernatant, the cells were re-suspended in 0.5mL of 
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fixative solution (0.5% formaldehyde in PBS), wrapped in foil to protect from the light and 
stored at 4oC until analysis.  
 
A sub-group of isolated crypt cells (n=6, two colonic healthy controls, four &URKQ¶VFROLWLV
were analysed immediately following antibody-stained on the Beckman Coulter MoFlo cell 
sorter, without being fixed in formaldehyde. Unfixed BerEP4-positive cells were positively 
VRUWHGLQWRD)$&6WXEHFRQWDLQLQJȝ/RI)$&6PHGLXP(HBSS with calcium, 
magnesium and 10% FCS) on ice. Following sorting, the cells in suspension were 
transferred to an Eppendorf tube and centrifuged for 5 minutes at 1,000g using a 
microcentrifuge. Following removal of the supernatant, the cell pellet was resuspended and 
lysed in 600µl of Buffer RLT with 1% 2-mercaptoethanol. RNA was subsequently isolated 
using the Qiagen 51HDV\3OXV0LQL.LWDVSHUWKHPDQXIDFWXUHU¶VLQVWUXFWLRQVVHFWLRQ
RNA was stored at -80oC until analysis.  
 
A minimum of 20,000 total events per sample tube were collected for each subject 
undergoing flow cytometric analysis. Samples were initially analysed by forward and side 
scatter (which are measurements of cell size and density, respectively) to exclude dead cells 
(events adjacent to the zero points of both axes) and to exclude events considered to be 
clumped cells (events of large deflection on forward and/or side scatter).  
 
To identify positive events, samples were run both without primary antibodies (to assess 
cellular auto-fluorescence) and with relevant isotype control antibodies. All events in the 
isotype control antibody samples were gated into the lower left quadrant of the dot plot and 
these quadrants were applied to analyses of the primary antibody samples. Positive events 
in primary antibody samples were those lying in any of the other three quadrants. All flow 
cytometric data were analysed using Weasel v3 software.  
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The patient demographics for the subjects included in the flow cytometry analyses are 
shown in table 5.3.  
 
Table 5.3 Demographic data for flow cytometry study subjects 
Demographic variable Large intestine 
Healthy control Ulcerative colitis &URKQ¶VFROLWLV 
Number 7 4 8 
Age mean (SEM) years 73.4 (3.52) 50.5 (8.37)* 41.3 (5.63)*** 
Sex male/female (% male) 3/4 (43) 0/4 (0) 1/7 (13) 
Medications  
 5ASA 0 0 1 
 Thiopurine 0 0 1 
 Anti-71)Į 0 0 2 
Medical History  
 Venous thromboembolism 1 0 0 
 Diabetes mellitus 1 2 0 
 Osteoporosis 0 0 1 
 Ischaemic heart disease 0 2 0 
 MGUS 0 0 1 
 Hypercholesterolaemia 0 2 0 
 Hypertension 0 2 1 
 Chronic kidney disease 0 0 1 
 Prostate cancer 1 0 0 
5ASA, 5-aminosalicylic acid; MGUS, monoclonal gammopathy of uncertain significance71)ĮWXPRXUQHFURVLV
factor-Į 
* P<0.05 ** p<0.01 *** p<0.001 versus healthy controls 
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5.3 Results 
5.3.1 Isolated intestinal crypt cells express TLR2 and TLR4 protein  
To investigate the expression of TLR2 and TLR4 protein by intestinal epithelial cells, suitable 
positive controls cells were required. Peripheral blood mononuclear cells (PBMC) are 
reported to express TLR2 and TLR4 mRNA and protein. Furthermore, in this study PBMC 
were demonstrated to express TLR2 and TLR4 mRNA using RT-PCR (section 4.3.2). To 
investigate the functionality of commercial antibodies against human TLR2 and TLR4, 
protein lysates from PBMC were used as positive controls.  
 
PBMC were isolated and the total protein concentration of the cell lysate was calculated 
using the Bradford protein assay. Thereafter, 2ȝJRIWRWDOSURWHLQZDVloaded to each SDS 
PAGE well and electrophoresis undertaken. Protein was blotted onto a PVDF membrane 
and incubated with a polyclonal anti-ȕ-actin antibody or a purified anti-TLR2 or anti-TLR4 
monoclonal antibody. PBMC lysates were shown to express TLR2 and TLR4 proteins (figure 
5.3).  
 
Next, primary intestinal epithelial cells were isolated and protein lysates collected from the 
large intestine of KHDOWK\FRQWUROVDQGSDWLHQWVZLWK&URKQ¶VGLVHDVHDQGXOFHUDWLYHFROLWLV
7KHUHDIWHUȝJRIWRWDOSURWHLQZDVORDGHGWRHDFK6'63$*(ZHOODQGexamined using 
electrophoresis and Western blotting. Primary IEC samples from the large intestine of 
KHDOWK\FRQWUROVDQGSDWLHQWVZLWKDFWLYH8&RU&URKQ¶VGLVHDVHwere shown to express 
TLR2 and TLR4 proteins (figure 5.4).  
 
5.3.2 Pancreatin treatment does not affect expression of surface TLR2 or TLR4 protein  
To investigate the functionality of monoclonal antibodies to human TLR2, TLR4 and CD45 
using flow cytometry, PBMC were again chosen to act as positive control cells. Initially 
PBMC were incubated with either no antibody (control), allophycocyanin (APC)-conjugated 
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isotype control antibody or APC-conjugated anti-TLR2 primary antibody, without a preceding 
normal mouse serum blocking step. Importantly, cells were not permeabilised during this 
protocol. Therefore any primary antigen binding was due to surface protein expression and 
not intracellular protein binding.  
 
PBMC were shown to express surface TLR2 protein, confirming the functionality of the anti-
TLR2 antibody (figure 5.5A, C and D). Of note, the median fluorescent intensity (MFI) of the 
isotype antibody was greater than the no-antibody control, indicating non-specific isotype 
antibody binding by the PBMC (figure 5.5A, B and D). To address this issue, the protocol 
was modified to include a blocking step using normal mouse serum prior to the primary 
antibody incubation step. As a result of the addition of the serum blocking step, isotype 
antibody binding by PBMC was ameliorated (figure 5.6A-D). Therefore, all subsequent 
analyses were undertaken with a normal mouse serum blocking step prior to primary 
antibody incubation.  
 
Peripheral blood mononuclear cells were shown to express surface TLR4 protein, confirming 
the functionality of the anti-TLR4 antibody (figure 5.7). Furthermore PBMC express surface 
CD45 (figure 5.8) but not the epithelial-specific surface antigen BerEP4 (figure 5.9). These 
data are consistent with the cell surface marker expression profile characterised in PBMC 
using immunocytochemical staining (section 3.3.2).  
 
Pancreatin is a porcine-derived mixture of pancreatic enzymes and includes proteases, 
lipases and amylase. To investigate whether the pancreatin treatment step in the crypt cell 
isolation protocol resulted in either a reduction in the expression of surface TLR2 and TLR4 
protein expression or an alteration in the antibody-antigen binding affinity, isolated PBMC 
were either suspended in medium for 90 minutes at room temperature or treated with 0.25% 
pancreatin for 90 minutes before being re-suspended in medium. Thereafter PBMC were 
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incubated with an anti-TLR2-APC primary antibody, isotype-APC control antibody or no-
antibody control.  
 
Peripheral blood mononuclear cells treated in medium (figure 5.10A-C) or pancreatin (figure 
5.10D-F) demonstrated similar expression of surface TLR2 protein. The distribution of TLR2 
protein expression was similar in both medium-treated (figure 5.10G) and pancreatin-treated 
(figure 5.10H) cells. Median fluorescent intensity of TLR2 expression was 197.2 units in 
medium-treated cells and 236.1 in pancreatin-treated cells, suggesting there was no loss of 
surface TLR2 protein expression with pancreatin treatment (figure 5.10I). A similar result 
was observed with TLR4 expression (data not shown).  
 
5.3.3 Isolated intestinal crypt cells express BerEP4, but not CD45 protein 
BerEP4 is a surface antigen expressed on cells of epithelial origin. BerEP4 expression is 
used clinically to confirm the epithelial origin of malignant cells using a monoclonal mouse 
antibody raised in the MCF-7 cell line and directed against human BerEP4 (281). To 
characterise their BerEP4 expression, EDTA-isolated crypt cells were disaggregated using 
pancreatin and incubated with a FITC-conjugated anti-human BerEP4 antibody and 
examined using flow cytometry.  
 
Isolated crypt cells were shown to highly express BerEP4 (figure 5.11). The mean (SEM) 
number of BerEP4-positive events was 91.5+1.1%. To investigate the number of BerEP4-
positive events in cells isolated from tissue of varying degrees of inflammation, colonic crypt 
cells were isolated IURPKHDOWK\FRQWUROVDQGSDWLHQWVZLWK8&DQG&URKQ¶Vcolitis. The 
number of BerEP4-positive cells was similar in healthy controls (90.7+2.1%) compared to 
SDWLHQWVVXIIHULQJ&URKQ¶VGLVHDVH+2.1%, p=0.81) or UC (92.4+3.0%, p=0.66), figure 
5.12A.  
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Similarly, the expression of surface CD45 protein was investigated in isolated crypt cells. 
Isolated crypt cells were shown to be almost exclusively CD45-negative (figure 5.13). The 
overall number of CD45-positive cells was 2.2+0.4%. The number of CD45-positive isolated 
crypt cells was similar in healthy controls (1.5+0.4%) compared to patients suffering &URKQ¶V
disease (2.5+0.7%, p=0.26) or UC (2.4+1.3%, p=0.44), figure 5.12B.  
 
These observations were similar to the proportion of BerEP4-positive and CD45-positive 
cells calculated using immunocytochemical staining of cytospin preparations from healthy 
conWUROVDQGSDWLHQWVZLWKHLWKHU&URKQ¶VGLVHDVHRU8&VHFWLRQ 
 
5.3.4 BerEP4-positive crypt intestinal epithelial cells from patients with inflammatory 
bowel disease up-regulate TLR2 and TLR4 surface protein expression  
To characterise the surface expression of TLR2 and TLR4 protein in patients with 
LQIODPPDWRU\ERZHOGLVHDVHLQWHVWLQDOFU\SWFHOOVZHUHLVRODWHGIURPSDWLHQWVZLWK&URKQ¶V
disease and ulcerative colitis, and these were compared to isolated cells from healthy control 
subjects. To ensure only epithelial cells were analysed, all isolated cells were labelled with 
anti-human BerEP4. During analysis, median fluorescent intensity of TLR2 and TLR4 
antibody signal was measured on BerEP4-positive events only. By undertaking this gating 
step, all non-epithelial cells were excluded from the analysis, allowing a pure epithelial cell 
population to be characterised. Colonic BerEP4-positive IEC isolated from patients with UC 
demonstrated expression of surface TLR2 and TLR4 protein (figure 5.14). Similar results 
were seen with isolated BerEP4-positive IEC from the large bowel of patients with CD.  
 
The expression of TLR2 and TLR4 surface protein on BerEP4-positive IEC isolated from 
patients with IBD was compared to expression on cells isolated from healthy controls. 
BerEP4-positive colonic intestinal crypt epithelial cells from patients with histologically 
inflamed UC mucosa expressed greater surface TLR2 (median fluorescent intensity [inter-
quartile range] 89.1 [39.0-146.1]) than healthy controls (10.1 [2.4-29.0], p=0.006, figure 
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5.15A). Similarly, BerEP4-positive crypt IEC from patients with histologically inflamed UC 
mucosa expressed greater TLR4 surface protein (73.0 [31.1-179.4]) compared to healthy 
controls (12.1 [4.9-25.3], p=0.024, figure 5.15B).  
 
BerEP4-positive colonic crypt intestinal epithelial cells from the mucosa of patients with 
histologically inflamed &URKQ¶Vcolitis expressed greater surface TLR2 protein than healthy 
controls (65.8 [19.3-126.3] versus 10.1 [2.4-29.0] respectively, p=0.029, figure 5.16A) and 
greater surface TLR4 protein than healthy controls (69.7 [26.4-115.1] versus 12.1 [4.9-25.3] 
respectively, p=0.021, figure 5.16B). These data are summarised in table 5.4. 
 
Table 5.4 Expression of surface TLR2 and TLR4 protein in patients with inflammatory bowel 
disease relative and in healthy control subjects 
Site Group N TLR2 protein expression TLR4 protein expression  
Median  
[IQR] 
p-value # Median  
[IQR] 
p-value # 
Large 
bowel 
Healthy control 7 10.1  
[2.4-29.0] 
- 12.1  
[4.9-25.3] 
- 
Ulcerative colitis 
(inflamed) 
4 89.1  
[39.0-146.1] 
0.006 73.0  
[31.1-179.4] 
0.024 
&URKQ¶VGLVHDVH 
(inflamed) 
8 65.8  
[19.3-126.3] 
0.029 69.7  
[26.4-115.1] 
0.021 
# Mann-Whitney Test versus healthy controls 
IQR, inter-quartile range; N, number of cases 
 
There appeared to be a polarity of TLR2 and TLR4 protein expression within the group of 
patients with CrohQ¶VFROLWLV(n=8). Although IEC from cases expressing higher surface TLR2 
and TLR4 protein were more likely to not be receiving immunosuppressive treatment at the 
time of surgery (none of four cases receiving immunosuppressive treatment) compared to 
those cases with low surface TLR2 and TLR4 expression (three of four cases receiving 
LPPXQRVXSSUHVVLYHWUHDWPHQWWKLVGLIIHUHQFHZDVQRWVLJQLILFDQW)LVKHU¶VH[DFWWHVW
p=0.143).  
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5.3.5 Sorted BerEP4-positive intestinal epithelial cells express mRNA for TLR2 and 
TLR4 
In a sub-group of isolated crypt cell samples, BerEP4-positive cells were sorted using a 
fluorescence-activated cell sorting (FACS) cytometer (MoFlo cytometer, Beckman Coulter). 
After the crypt cell isolation, primary antibody staining and surface protein expression 
analysis steps, cells from six cases (two large intestine samples from healthy controls and 
four large intestine samples patients with &URKQ¶Vcolitis) were positively sorted for their 
BerEP4 expression and total RNA was subsequently isolated. RNA assessment using the 
Nanodrop® spectrophotometer revealed low concentrations of RNA (figure 5.17).  
 
Despite the low mRNA concentration and poor RNA quality, conventional RT-PCR from 
these BerEP4-positive sorted cell samples demonstrated expression of HPRT mRNA in all 
samples (figure 5.18). Furthermore, conventional RT-PCT analysis demonstrated expression 
of TLR4 transcripts in all KHDOWK\FRQWURODQG&URKQ¶VGLVHDVHODUJHLQWHVWLQHVDPSOHV. TLR2 
transcripts were demonstrated in all samples except one cDNA sample (from a patient with 
&URKQ¶VFROLWLV, figure 5.19).  
 
5.3.6 Intestinal epithelial cells express TLR2 and TLR4 protein along the crypt-villus 
axis, with greatest expression in the basal crypt cells of inflamed &URKQ¶Vileitis 
To investigate by anatomical location the expression TLR2 and TLR4 protein, full-thickness 
whole bowel from operation resection specimens were collected from healthy controls and 
patients with inflammatory bowel disease (n=15). Specimens were formalin-fixed and 
paraffin-emEHGGHGEHIRUHȝPVHFWLRQVZHUHPRXQWHGRQJODVVVLGHVVWDLQHGZLWKDQWL-
TLR2 or anti-TLR4 primary antibodies, followed by sequential incubation with a biotinylated 
secondary antibody, an avidin-FITC complex and a DAPI counter-stain (section 5.2.3). In 
addition control slides were also made, omitting the primary antibody step, to investigate for 
non-specific staining by the biotinylated secondary antibody or the avidin-FITC complex.  
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Weak TLR2 and TLR4 protein expression was demonstrated by intestinal epithelial cells of 
the colonic mucosa in healthy controls (figure 5.20). Patients with active ulcerative colitis 
(figure 5.21DQG&URKQ¶VFROLWLVILJXUH22) demonstrated stronger TLR2 and TLR4 
expression by crypt epithelial cells. Within the lamina propria, mononuclear cells were also 
observed to stain brightly for TLR2 and TLR4 both in the peri-cryptal region and also in 
extending into the upper third of the lamina propria. This was in contrast to the LP cell 
staining pattern in healthy controls which was less intense and less extensive within the LP.  
 
Examination of the small intestine demonstrated weak TLR2 and TLR4 protein staining by 
epithelial cells of healthy controls (figure 5.23), with more intense staining by epithelial cells 
from LQIODPHG&URKQ¶Vileitis (figure 5.24). Higher power images demonstrated that crypt 
base cells stained TLR2, and to a lesser extent TLR4 protein, more intensely than epithelial 
cells of the upper crypt (transit amplifying zone) or the villi (figure 5.25). Control slides 
demonstrated minimal fluorescent staining. 
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5.4 Figures 
 
 
 
 
Figure 5.1 Linear relationship between absorbance of light at 595nm and total protein 
concentration in solution using the Bradford assay. The absorbance of light (Y-axis) at 
595nm is directly proportional to the total protein concentration (X-axis, within the range 
<ȝJP/XVLQJVWDQGDUGGLOXWLRQVRIERYLQHVHUXPDOEXPLQDQGWKH&RRPDVVLH%OXH
reagent. The total protein concentration of an unknown sample can be extrapolating using 
the standard line shown above if it lies within the linear part of the standard curve.  
 
215 
 
 
 
 
 
Figure 5.2 Assembly of experimental components for Western blotting. To perform the 
Western blot, two 100% methanol-soaked filters and two 100% methanol-soaked sponged 
were positioned either side of the protein-containined polyacrylamide gel and the 
polyvinylidene difluoride (PVDF) membrane. The application of a current across this 
arrangement resulted in blotting of the protein bands onto the membrane for subsequent 
detection using colorimetric methods.  
 
Cathode 
Anode 
Sponge 
Filter 
Gel 
Membrane 
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Figure 5.3 Primary peripheral blood mononuclear cells express TLR2 and TLR4 protein. 
Peripheral blood mononuclear cells (PBMC) were isolated using Ficoll gradient 
centrifugation for total protein lysate collectionȝJRIWRWDOSURWHLQZDVORDGHGLQWRHDFK
SDS PAGE well prior to blotting onto a PVDF membrane. Protein expression was detected 
using membrane incubation with primary antibodies to (A) ȕ-actin, (B) TLR2 or (C) TLR4 
proteins and developing using Vector VIP peroxidase substrate. Bands were noted at the 
expected protein molecular weightVIRUȕ-actin (42 kDa), TLR2 (90kDa) and TLR4 (93kDa). 
Samples were run in duplicate (lanes 1 and 2).  
 
Da, Dalton; L, size ladder; PVDF, polyvinylidene difluoride; SDS PAGE, sodium dodecyl 
sulphate polyacrylamide gel electrophoresis; TLR, Toll-like receptor 
 
 
102 kDa 
76 kDa 
102 kDa 
76 kDa 
52 kDa 
38 kDa 
A 
B 
C 
  L                 1                2 
 L                  1                2 
  L                  1               2 
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Figure 5.4 Primary intestinal crypt cells express TLR2 and TLR4 protein. Primary intestinal 
crypt cells were isolated for total protein lysate collectionȝJRIWRWDOSURWHLQZDVORDGHG
into each SDS PAGE well prior to blotting onto a PVDF membrane. Protein expression was 
GHWHFWHGXVLQJPHPEUDQHLQFXEDWLRQZLWKSULPDU\DQWLERGLHVWR$ȕ-actin, (B) TLR2 or (C) 
TLR4 proteins and developing using Vector VIP peroxidase substrate. Bands were noted at 
WKHH[SHFWHGSURWHLQPROHFXODUZHLJKWVIRUȕ-actin (42 kDa), TLR2 (90kDa) and TLR4 
(93kDa).  
 
Lanes 1 and 2: Healthy large bowel 
Lanes 3 and 4,QIODPHG&URKQ¶Vlarge bowel 
Lanes 5 and 6: Inflamed ulcerative colitis large bowel 
 
Da, Dalton; L size ladder; PVDF, polyvinylidene difluoride; SDS PAGE, sodium dodecyl 
sulphate polyacrylamide gel electrophoresis; TLR, Toll-like receptor 
 
 
A 
B 
C 
52 kDa 
38 kDa 
102 kDa 
102 kDa 
76 kDa 
76 kDa 
  L              1       2       3       4         5        6 
  L              1       2       3       4         5        6 
  L                1        2        3       4         5       6 
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Figure 5.5 Peripheral blood mononuclear cells express surface TLR2 protein. Following 
Ficoll-gradient acquisition, PBMC were centrifuged to form a pellet in cytometry tubes, re-
VXVSHQGHGLQȝ/RIPHGLXPDQGincubated with (A) no primary antibody, (B) isotype-APC 
control antibody or (C) primary anti-TLR2-APC antibody, prior to analysis on a flow 
cytometer. The overlay histogram (D) illustrated the expression of surface TLR2 expression 
by PBMC and non-specific isotype antibody binding. The X-axes of panels A-C represent 
unused gates.  
 
 
Black: No antibody control 
Green: Isotype-APC antibody 
Red: TLR2-APC primary antibody  
 
APC, Allophycocyanin; PBMC, peripheral blood mononuclear cells; TLR, Toll-like receptor 
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Figure 5.6 Incubation with normal mouse serum ameliorates isotype control antibody 
binding. Following Ficoll-gradient acquisition and centrifugation, PBMC were exposed to a 
normal mouse serum block step prior to incubation with (A) no primary antibody, (B) isotype-
APC control antibody or (C) primary anti-TLR2-APC antibody, and subsequently analysed 
using flow cytometry. Dot plots (A-C) illustrate fluorescence. The overlay histogram (D) 
illustrated the surface binding of anti-TLR2 and isotype antibodies on PBMC following mouse 
serum blockade. The X-axes of panels A-C represent unused gates.  
 
 
Black: No antibody control 
Green: Isotype-APC antibody 
Red: TLR2-APC primary antibody  
 
APC, Allophycocyanin; PBMC, peripheral blood mononuclear cells; TLR, Toll-like receptor 
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Figure 5.7 Peripheral blood mononuclear cells express surface TLR4 protein. Following 
Ficoll-gradient acquisition and subsequent blocking with normal mouse serum, isolated 
PBMC were incubated with (A) no primary antibody, (B) isotype-APC control antibody or (C) 
primary anti-TLR4-APC antibody, and analysed using flow cytometry. The overlay histogram 
(D) illustrated the surface TLR4 expression by PBMC. The X-axes of panels A-C represent 
unused gates.  
 
 
Black: No antibody control 
Green: Isotype-APC antibody 
Red: TLR2-APC primary antibody 
 
APC, Allophycocyanin; PBMC, peripheral blood mononuclear cells; TLR, Toll-like receptor 
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Figure 5.8 Human peripheral blood mononuclear cells express surface CD45 protein. 
Following Ficoll-gradient acquisition and subsequent blocking with normal mouse serum, 
isolated PBMC were incubated with (A) no primary antibody or (B) primary anti-CD45-AF488 
antibody, and analysed using flow cytometry. The overlay histogram (C) illustrated the 
surface CD45 expression by PBMC. The Y-axes of panels A and B represent unused gates. 
 
 
Black: No antibody control 
Red: CD45-AF488 
 
AF488, Alexa Fluor-488; PBMC, peripheral blood mononuclear cells 
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Figure 5.9 Peripheral blood mononuclear cells do not express surface BerEP4 protein. 
Following Ficoll-gradient acquisition and subsequent blocking with normal mouse serum, 
isolated PBMC were incubated with (A) no primary antibody or (B) primary anti-BerEP4-FITC 
antibody, and analysed using flow cytometry. The overlay histogram (C) illustrated the 
surface BerEP4 expression by PBMC. The Y-axes of panels A and B represent unused 
gates. 
 
 
Black: No antibody control 
Red: BerEP4-FITC 
 
FITC, Fluorescein isothiocyanate; PBMC, peripheral blood mononuclear cells 
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Figure 5.10 Expression of surface TLR2 protein on human peripheral blood mononuclear 
cells is unaffected by pancreatin treatment. Following Ficoll-gradient acquisition, isolated 
PBMC were either suspended in medium for 90 minutes followed by incubation with (A) no 
primary antibody, (B) isotype-APC control antibody or (C) primary anti-TLR2-APC antibody; 
or treated with pancreatin for 90 minutes followed by incubation with (D) no primary 
antibody, (E) isotype-APC control antibody or (F) primary anti-TLR2-APC antibody. 
Subsequently cells were analysed on a flow cytometer. The overlay histograms illustrated 
the expression of surface TLR2 protein both after suspension in medium (G) or following 
pancreatin treatment (H). The comparative expression of surface TLR2 protein between 
medium- or pancreatin-treated PBMC was illustrated in histogram I. The X-axes of panels A-
F represent unused gates.  
 
 
Black: No antibody control 
Green: Isotype-APC antibody 
Red: TLR2-APC primary antibody in medium-treated PBMC 
Blue: TLR2-APC primary antibody in pancreatin-treated PBMC  
 
APC, Allophycocyanin; PBMC, peripheral blood mononuclear cells; TLR, Toll-like receptor 
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Figure 5.11 Isolated primary crypt cells express surface BerEP4 protein. Isolated intestinal 
crypt cells were incubated with normal mouse serum followed by either (A) isotype-FITC 
control or (B) primary anti-BerEP4-FITC antibody and analysed using flow cytometry. The 
overlay histogram illustrated the expression of BerEP4 on intestinal crypt cells (C). The Y-
axes of panels A and B represent unused gates.  
 
 
Black: Isotype-FITC control 
Purple: BerEP4-FITC 
 
FITC, Fluorescein isothiocyanate 
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Figure 5.12 Primary crypt cells show similar proportions of BerEP4-positive and CD45-
positive cells when isolated from healthy controls or patients with inflammatory bowel 
disease. Isolated intestinal crypt cells from healthy controls (n=7) or patients with 
LQIODPPDWRU\ERZHOGLVHDVH&URKQ¶VGLVHDVHQ RUXOFHUDWLYHFROLWLVQ were incubated 
with anti-BerEP4-FITC conjugated or anti-CD45-AF488 conjugated monoclonal antibodies 
and analysed using flow cytometry. The proportion of antibody-positive cells was calculated 
by comparing median fluorescent intensity of the primary antibody corrected by the 
respective isotype control antibody. There was no significant difference in the percentage of 
(A) BerEP4-positive or (B) CD45-positive cells amongst the groups.  
 
A 
B 
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Figure 5.13 The majority of isolated primary intestinal crypt cells do not express surface 
CD45 protein. Isolated intestinal crypt cells were incubated with normal mouse serum 
followed by either (A) isotype-AF488 control or (B) primary anti-CD45-AF488 antibody and 
assessed by flow cytometry. The overlay histogram illustrated the difference fluorescence 
between the anti-CD45 and the isotype control antibodies on isolated crypt cells (C). The Y-
axes of panels A and B represent unused gates.  
 
 
Black: Isotype-AF488 
Red: CD45-AF488 
 
AF488, Alexa Fluor-488 
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Figure 5.14 Isolated BerEP4-positive primary intestinal crypt cells express surface TLR2 and 
TLR4 protein. Isolated intestinal crypt cells from a patient with UC were incubated with anti-
BerEP4-FITC antibody followed by either anti-TLR2-APC or anti-TLR4-APC monoclonal 
antibodies and assessed by flow cytometry. BerEP4-positive events (left panel) represent 
intestinal epithelial cells. BerEP4-positive intestinal epithelial cells express both TLR2 (upper 
middle panel) and TLR4 (lower middle panel). Median TLR2 (upper right panel) and TLR4 
(lower right panel) surface protein expressions were calculated as the difference between 
the MFI of the primary antibody and the MFI of the isotype control antibody.  
  
 
Green: Isotype-APC 
Red: TLR2-APC 
Blue: TLR4-APC 
 
APC, allophycocyanin; MFI, median fluorescent intensity; TLR, Toll-like receptor; UC, 
ulcerative colitis 
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Figure 5.15 BerEP4-positive colonic intestinal epithelial cells from patients with ulcerative 
colitis up-regulate surface TLR2 and TLR4 protein expression. Isolated large intestinal crypt 
cells were stained with anti-BerEP4-FITC and either (A) anti-TLR2-APC or (B) anti-TLR4-
APC monoclonal antibodies, and analysed on a flow cytometer. Analysis was undertaken 
after positively gating on BerEP4-expressing epithelial cells and excluding BerEP4-negative 
cells. Each data point represents the difference in median fluorescent intensity (MFI) 
between the primary and isotype control antibodies. Horizontal bars represent median 
values for the group.  
* p=0.006; # p=0.024 
 
A 
B 
* 
# 
229 
 
M
ed
ia
n
 
Fl
u
o
re
sc
en
t I
n
te
n
si
ty
 
(M
FI
)
He
alt
hy
 
co
ntr
ol
Cr
oh
n'
s 
dis
ea
se
0
50
100
150
200
250
 
 
M
ed
ia
n
 
Fl
u
o
re
sc
en
t I
n
te
n
si
ty
 
(M
FI
)
He
alt
hy
 
co
ntr
ol
Cr
oh
n'
s 
dis
ea
se
0
50
100
150
200
 
Figure 5.16 BerEP4-positive colonic intestinal epithelial cells from patients with &URKQ¶V 
colitis up-regulate surface TLR2 and TLR4 protein expression. Isolated large intestinal crypt 
cells were stained with anti-BerEP4-FITC and either (A) anti-TLR2-APC or (B) anti-TLR4-
APC monoclonal antibodies, and analysed on a flow cytometer. Analysis was undertaken 
after positively gating on BerEP4-expressing epithelial cells and excluding BerEP4-negative 
cells. Each data point represents the difference in median fluorescent intensity (MFI) 
between the primary and isotype control antibodies. Horizontal bars represent median 
values for the group. 
* p=0.029; # p=0.021 
A 
B 
* 
# 
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Figure 5.17 Spectrophotometric trace of sorted BerEP4-positive cells using the Nanodrop® 
spectrophotometer. Intestinal epithelial crypt cells were isolated using EDTA/DTT and 
labelled with an epithelial-specific monoclonal antibody against BerEP4. Total RNA was 
isolated from sorted BerEP4-positive crypt cells using the Qiagen RNeasy Plus Mini Kit. 
Subsequently, the quality and quantity of RNA was assessed using the Nanodrop® 
spectrophotometer.  
 
DTT, Dithiothreitol; EDTA, Ethylenediaminetetraacetic acid 
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Figure 5.18 Sorted BerEP4-positive intestinal epithelial cells express HPRT mRNA. Isolated 
BerEP4-expressing intestinal crypt epithelial cells were sorted using FACS. Message RNA 
expression was analysed using conventional RT-PCR with agarose gel electrophoresis.  
 
Lanes 1-2: Healthy control colon 
Lanes 3-6&URKQ¶VGLVHDVH colon 
Lane 7: THP-1 monocyte cell line positive control 
Lane 8: No RT negative control 
Lane 9: No template negative control 
 
FACS, fluorescence-activated cell sorting; HPRT, hypoxanthine guanine 
phosphoribosyltransferase; L, 100 base pair ladder; RT-PCR, reverse transcriptase 
polymerase chain reaction 
 
 
 
 
 
 
 
 
 
 
    L        1        2        3        4        5        6        7        8        9 
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Figure 5.19 Sorted BerEP4-positive intestinal epithelial cells express TLR2 and TLR4 
mRNA. Isolated BerEP4-expressing intestinal crypt epithelial cells were sorted using FACS. 
Message RNA expression was analysed using conventional RT-PCR with agarose gel 
electrophoresis. PCR was undertaken using real-time RT-PCR primers for (A) TLR2 
(expected size 134bp) and (B) TLR4 (expected size 141bp).  
 
Lanes 1, 3 and 4&URKQ¶Vcolitis 
Lane 2: Healthy control colon 
Lane 5: THP-1 monocyte cell line positive control 
Lane 6: No RT negative control 
Lane 7: No template negative control 
 
BP, base pair; FACS, fluorescence-activated cell sorting; L, 100 base pair ladder; RT-PCR, 
reverse transcriptase polymerase chain reaction; TLR, Toll-like receptor 
 
   L                     1         2        3        4         5        6       7 
   L                    1         2         3         4          5        6        7 
500bp 
500bp 
100bp 
100bp 
B 
A 
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Figure 5.20 Intestinal epithelial cells from healthy control colon weakly express TLR2 and 
TLR4 protein. Full-thickness whole bowel was obtained from operation resection specimens 
of the colon before being formalin-fixed and paraffin-HPEHGGHGȝPVHFWLRQVZHUHPRXQWHG
on glass slides and stained with (top row) no primary antibody control, (middle row) anti-
TLR2 monoclonal antibody or (bottom row) anti-TLR4 monoclonal antibody. Slides were 
incubated with a biotinylated secondary antibody followed by an avidin-FITC conjugate and a 
DAPI counter-stain. Slides were viewed on a Leica fluorescent microscope (background 
adjustment: +10, colour adjustment: nil, exposure: 248ms).  
DAPI, 4',6-diamidino-2-phenylindole; FITC, Fluorescein isothiocyanate; TLR, Toll-like 
receptor
No 
primary 
antibody 
TLR2 
TLR4 
DAPI FITC Overlay 
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Figure 5.21 Intestinal epithelial cells from patients with ulcerative colitis express TLR2 and 
TLR4 protein. Full-thickness whole bowel was obtained from operation resection specimens 
of the colon before being formalin-fixed and paraffin-HPEHGGHGȝPVHFWLRQVZHUHPRXQWHG
on glass slides and stained with (top row) no primary antibody control, (middle row) anti-
TLR2 monoclonal antibody or (bottom row) anti-TLR4 monoclonal antibody. Slides were 
incubated with a biotinylated secondary antibody followed by an avidin-FITC conjugate and a 
DAPI counter-stain. Slides were viewed on a Leica fluorescent microscope (background 
adjustment: +10, colour adjustment: nil, exposure: 248ms).  
DAPI, 4',6-diamidino-2-phenylindole; FITC, Fluorescein isothiocyanate; TLR, Toll-like 
receptor 
 
 
No 
primary 
antibody 
TLR2 
TLR4 
DAPI FITC Overlay 
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Figure 5.22 ,QWHVWLQDOHSLWKHOLDOFHOOVIURPSDWLHQWVZLWK&URKQ¶VFROLWLVH[SUHVV7/5DQG
TLR4 protein. Full-thickness whole bowel was obtained from operation resection specimens 
of the colon before being formalin-fixed and paraffin-HPEHGGHGȝPVHFWLRQVZHUHPRXQted 
on glass slides and stained with (top row) no primary antibody control, (middle row) anti-
TLR2 monoclonal antibody or (bottom row) anti-TLR4 monoclonal antibody. Slides were 
incubated with a biotinylated secondary antibody followed by an avidin-FITC conjugate and a 
DAPI counter-stain. Slides were viewed on a Leica fluorescent microscope (background 
adjustment: +10, colour adjustment: nil, exposure: 248ms).  
DAPI, 4',6-diamidino-2-phenylindole; FITC, Fluorescein isothiocyanate; TLR, Toll-like 
receptor 
 
No 
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DAPI FITC Overlay 
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Figure 5.23 Intestinal epithelial cells from healthy control small intestine weakly express 
TLR2 and TLR4 protein. Full-thickness whole bowel was obtained from operation resection 
specimens of the small intestine before being formalin-fixed and paraffin-HPEHGGHGȝP
sections were mounted on glass slides and stained with (top row) no primary antibody 
control, (middle row) anti-TLR2 monoclonal antibody or (bottom row) anti-TLR4 monoclonal 
antibody. Slides were incubated with a biotinylated secondary antibody followed by an 
avidin-FITC conjugate and a DAPI counter-stain. Slides were viewed on a Leica fluorescent 
microscope (background adjustment: +10, colour adjustment: nil, exposure: 248ms).  
DAPI, 4',6-diamidino-2-phenylindole; FITC, Fluorescein isothiocyanate; TLR, Toll-like 
receptor 
No 
primary 
antibody 
TLR2 
TLR4 
DAPI FITC Overlay 
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Figure 5.24 ,QWHVWLQDOHSLWKHOLDOFHOOVIURPVPDOOLQWHVWLQDO&URKQ¶VGLVHDVHH[SUHVV7/5DQG
TLR4 protein. Full-thickness whole bowel was obtained from operation resection specimens 
of the small intestine before being formalin-fixed and paraffin-HPEHGGHGȝPVHFWLRQVZHUH
mounted on glass slides and stained with (top row) no primary antibody control, (middle row) 
anti-TLR2 monoclonal antibody or (bottom row) anti-TLR4 monoclonal antibody. Slides were 
incubated with a biotinylated secondary antibody followed by an avidin-FITC conjugate and a 
DAPI counter-stain. Slides were viewed on a Leica fluorescent microscope (background 
adjustment: +10, colour adjustment: nil, exposure: 248ms).  
DAPI, 4',6-diamidino-2-phenylindole; FITC, Fluorescein isothiocyanate; TLR, Toll-like 
receptor 
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Figure 5.25 TLR2 and TLR4 protein expression is greatest in the basal crypt epithelial cells 
LQVPDOOLQWHVWLQDO&URKQ¶VGLVHDVH. Full-thickness whole bowel was obtained from operation 
resection specimens of the small intestine before being formalin-fixed and paraffin-
HPEHGGHGȝPVHFWLRQVZHUHPRXQWHGRQJODVVVOLGHVDQGVWDLQHGZLWKtop row) anti-
TLR2 monoclonal antibody or (bottom row) anti-TLR4 monoclonal antibody. Slides were 
incubated with a biotinylated secondary antibody followed by an avidin-FITC conjugate and a 
DAPI counter-stain. Slides were viewed on a Leica fluorescent microscope (background 
adjustment: +10, colour adjustment: nil, exposure: 248ms).The expression of TLR2 and 
TLR4 protein was examined by comparing intestinal epithelial cells in the crypt base to 
epithelial cells further along the crypt-villus axis. Crypt base epithelial cells demonstrate 
greater TLR2 and, to a lesser extend TLR4 protein, than non-basal epithelial cells (white 
arrows).  
DAPI, 4',6-diamidino-2-phenylindole; FITC, Fluorescein isothiocyanate; TLR, Toll-like 
receptor 
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5.5 Discussion 
The demonstration of the up-regulation of TLR2 and TLR4 mRNA in crypt IEC of the large 
bowHOLQ8&DQG&URKQ¶VGLVHDVHchapter 4) gives insight into the pathogenesis of IBD in 
relation to TLR expression. However it was important to characterise TLR2 and TLR4 
expression at the protein level before more definitive conclusions can be drawn. To 
investigate the expression of TLR2 and TLR4 protein in crypt IEC Western blotting of whole 
cell lysate, single cell flow cytometry and full-thickness bowel section immunofluorescent 
staining were undertaken.  
 
Following the acquisition of monoclonal antibodies directed against extracellular epitopes of 
the TLR2 and TLR4 proteins, the function of these antibodies was tested. Peripheral blood 
mononuclear cells are commonly used as TLR2- and TLR4-expressing positive controls, and 
this study has demonstrated expression of TLR2 and TLR4 transcript in these cells (section 
4.3.2). Western blotting of whole cell lysate confirmed TLR2 and TLR4 protein expression in 
PBMC. Subsequently, TLR2 and TLR4 protein expression was demonstrated in whole cell 
lysate samples from primary colonic crypt cells derived from healthy controls and patients 
ZLWK8&DQG&URKQ¶VFROLWLV 
 
Demonstration of surface TLR2 and TLR4 protein expression using flow cytometry has not 
been reported in primary IEC. Melmed et al. used flow cytometry to analyse TLR4 surface 
protein expression in T84 and Caco-2 human intestinal cancer cells lines and reported low 
level expression in both cell lines (231). Otte et al. reported surface TLR2 and TLR4 protein 
expression on the SW480 intestinal cancer cell line, and demonstrated a reduction in 
expression following overnight incubation in the relevant receptor ligand (243). Surface TLR4 
expression using flow cytometry in a variety of cell lines has been reported by other groups 
(155, 233, 246).  
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Following acquisition using EDTA/DTT, crypt cells were disaggregated using pancreatin, a 
mixture of porcine pancreas-derived proteolytic enzymes, lipases and amylase. This enzyme 
mixture is used to break down the intercellular bonds between cells which release individual 
cells suitable for single cell analysis. However, it was important to investigate whether 
pancreatin treatment could result in either loss of surface TLR protein or could damage the 
extracellular antibody-specific epitope such that primary antibody binding would be impaired. 
Pancreatin- and medium-treated PBMC were shown to express similar levels of surface 
TLR2 and TLR4 protein, suggesting pancreatin treatment did not alter primary antibody 
binding.  
 
The BerEP4 surface protein is an epithelial antigen used in clinical laboratory practise to 
determine the epithelial origin of tumour cells (281). Crypt cells were shown to be 90-92.4% 
BerEP4-positive, confirming their phenotype as being epithelial-derived. This was consistent 
with the immunocytochemical data showing that approximately 97% of freshly isolated crypt 
cells stained positively for BerEP4 (section 3.3.2). The slightly lower BerEP4-positive rate 
may be a consequence of greater cell death during the flow cytometry protocol compared to 
the cytospin slide preparation undertaken for immunocytochemical staining. Of importance, 
the proportion of BerEP4-positive cells in cellular preparations was statistically similar in 
healthy controls compared to cell isolated form SDWLHQWVZLWK8&RU&URKQ¶VFROLWLV7KLV
suggests that the crypt cell isolation preparation yielded a similar proportion of epithelial cells 
in all groups and therefore these groups are comparable.  
 
In chapter 3 immunocytochemical studies were undertaken on isolated crypt cells to 
determine the number of CD45-positive cells. These experiments showed that between 
1.9% and 2.2% of all crypt cells were CD45-positive, with the numbers of CD45-positive 
crypt cells being statistically similar when comparing healthy controls to patients with IBD 
(section 3.3.2). To further quantify the number of CD45-positive cells present in preparations 
following EDTA/DTT and pancreatin treatment, isolated cells were labelled with a fluorescent 
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anti-CD45 antibody and examined by flow cytometry. The number of CD45-positive crypt 
cells ranged from 1.5% to 2.5%. There was no significant difference in the number of CD45-
positive cells in crypt cell preparations from healthy controls compared to patients with IBD. 
From these results it was concluded that crypt cells were predominantly of epithelial origin 
and that crypt cells isolated from the mucosa of patients with IBD did not yield greater 
numbers of haematopoietic cells. Therefore, EDTA and pancreatin treatment is a reliable 
method for isolating IEC. Furthermore, these isolated crypt cells are comparable between 
the different disease groups.  
 
To quantitatively analyse the surface expression of TLR2 and TLR4 protein on crypt IEC 
from patients with IBD, isolated crypt cells were dual labelled with fluorescent antibodies to 
the epithelial-specific marker BerEP4 and TLR2 or TLR4 proteins. The strength of this 
technique is that only crypt cells staining positively for BerEP4 were included in the analysis. 
This allowed all non-epithelial cellular events to be removed from the analysis of surface 
TLR2 and TLR4 protein expression.  
 
BerEP4-positive crypt IEC from patients with UC demonstrated greater expression of surface 
TLR2 and TLR4 proteins (8-fold and 6-fold, respectively) compared to healthy controls. 
Likewise, BerEP4-positive FU\SWFHOOVIURPSDWLHQWVZLWK&URKQ¶VFROLWLVdemonstrated greater 
expression of surface TLR2 and TLR4 proteins (6-fold and 5-fold, respectively) compared to 
healthy controls.  
 
These data supports the results from section 4.3.5, showing significant up-regulation of 
TLR2 and TLR4 mRNA transcripts in crypt cells from patients with UC and &URKQ¶VFROLWLV
Interestingly, the relative up-regulation of TLR2 and TLR4 mRNA transcripts in crypt cells 
from IBD patients was in the order of 2-fold to 3.5-fold, which is less than the relative up-
regulation at the protein level. It is possible that degradation of mRNA during the cell 
isolation protocol occurred at a more rapid rate than protein degradation, resulting in a 
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greater loss of transcripts during cell isolation and, therefore, a lesser observed difference 
between controls and patients with IBD. On the other hand, the samples for the transcript 
analysis and the surface protein analysis were collected at different times during the study 
period. Therefore, the observed differences in relative expression at the transcript and 
protein levels may simply reflect the fact that the samples were obtained from different 
groups of subjects.  
 
Following the labelling with anti-BerEP4 antibody and the analysis of surface TLR2 and 
TLR4 protein expression, isolated BerEP4-positive IEC were sorted using FACS. 
Subsequently, mRNA was isolated from these cells and TLR2 and TLR4 mRNA expression 
analysed by conventional RT-PCR. BerEP4-positive crypt IECs derived from healthy controls 
DQGSDWLHQWVZLWK&URKQ¶VFROLWLVZHUHVKRZQWRH[SUHVVERWK7/5DQG TLR4 transcripts. 
These data confirm TLR2 and TLR4 mRNA expression in BerEP4-positive colonic crypt 
intestinal epithelial cells of healthy controls and patients with IBD.  
 
This is the first study to report up-regulated surface TLR2 and TLR4 protein expression on 
crypt IEC of patients with IBD using flow cytometry. Qualitative expression of TLR2 and 
TLR4 protein by crypt IEC has been reported using immunohistochemistry in the adult small 
and large intestine (252, 254) and on the basolateral surface of foetal ileal epithelial cells 
(240). In IBD, Cario and Podolsky reported up-regulation of TLR4, but not TLR2, protein 
using immunohistochemistry by IEC of the small and large intestine of patients with UC and 
&URKQ¶VGLVHDVHUHJDUGOHVVRIGLVHDVHDFWLYLW\(260), though this is not a universal finding 
(262). Therefore reported data on the expression of TLR2 and TLR4 in IBD is limited.  
 
This study supports the report by Cario and Podolsky in suggesting up-regulation of TLR4, 
but conflicts with their report regarding TLR2 expression (260). Flow cytometry is a more 
accurate, quantitative method of assessing TLR2 and TLR4 protein expression and this may 
explain the observed conflicting expression of the former receptor. Interestingly, in mice 
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DSS-induced colitis resulted in IEC up-regulation of both TLR2 and TLR4 protein, as 
assessed by using Western blotting, and TLR4 protein was shown to be expressed further 
up the crypt with increasing disease severity using immunohistochemical staining (250).   
 
In this study, crypt epithelial cells were isolated at the time of surgical intestinal resection. 
Patients were therefore those with chronic IBD symptoms that required surgical resection 
due to either persisting disease activity despite maximal medical therapy or due to non-
response to medical therapy. This explains why some patients were taking several 
immunosuppressive medications at the time of surgery and why others were not. This is a 
reasonable group of patients with IBD to study because these patients usually have active 
disease and are therefore likely to show the biological changes associated with IBD.  
 
The number of isolated epithelial cells required to perform immunohistochemical staining, 
RNA isolation for transcript analysis and analysis of protein expression using western 
blotting and flow cytometry precluded using endoscopically-obtained biopsy specimens. 
There were no samples of crypt epithelial cells isolated from resected colectomy specimens 
undertaken for acute severe ulcerative colitis. This group would likely express the highest 
level of TLR2 and TLR4 and would be an interesting group to study. However, patients with 
acute severe colitis often have severe mucosal ulceration with extensive epithelial cell loss. 
Obtaining adequate numbers of crypt cells from such cases is challenging. Furthermore, 
patients with chronically active IBD rather than acute severe colitis are likely to represent a 
cohort of patients in which modulation of the inflammatory response through the use of novel 
agents (such as TLR-blocking agents) may be most suited.  
 
The functionality of TLR2 and TLR4 protein has not been reported in human primary IEC, 
though response to a TLR8 ligand is reported (256) and primary mucosal specimens are 
reported to respond to the TLR5 ligand flagellin following its application to the basolateral, 
but not the apical cell surface (255). Human intestinal epithelial cancer cell lines have been 
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shown to respond to TLR2 and TLR4 ligands (154, 231, 232, 242, 243, 246). Despite the 
micro array data in this study demonstrating up-regulation of the TLR-associated signalling 
molecule ECSIT mRNA in crypt cells from patients with UC, future work is required to 
investigate the functionality of these receptors in primary intestinal epithelial cells.  
 
Despite the quantitative flow cytometry data reported here demonstrating up-regulation of 
surface TLR2 and TLR4 protein on colonic crypt IECs in patients with IBD, the western blot 
protein bands RIZKROHFHOOO\VDWHVIURPSDWLHQWVZLWK8&DQG&URKQ¶VFROLWLVDSSHDUHG to be 
a similar size when compared to the protein bands from healthy controls. This may suggest 
that the total protein was similar in whole cell lysates isolated from healthy controls and 
patients with IBD, but surface protein expression was significantly greater in the latter. 
However, western blotting is a qualitative method of measuring total protein expression 
whereas flow cytometry is fully quantitative. Therefore, these discrepancies may be the 
result of the inherent differences of the two techniques.  
 
Trafficking of TLR4 protein from the cell membrane to the Golgi complex has been reported 
in TLR4-transfected HEK293 cells (247) and it has been shown that surface TLR protein, 
rather than cytoplasmic protein, is functionally active in SW480 and TLR4-transfected 
HEK293 cell lines (246, 247). Furthermore, Otte et al. demonstrated that although total TLR2 
and TLR4 protein levels were unchanged (using western blotting), surface TLR2 and TLR4 
protein expression was reduced (using flow cytometry) when SW480 cells were pre-exposed 
to TLR2 and TLR4 receptor ligands, suggesting that loss of surface protein is an IEC 
mechanism for acquiring tolerance to TLR2 and TLR4 ligands (243). Therefore, the up-
regulation of surface TLR2 and TLR4 protein in crypt IECs from patients with IBD 
demonstrated in this study may result from trafficking of protein from the cytoplasm to the 
(functionally relevant) cell surface and it suggests that this increased TLR2 and TLR4 protein 
expression occurs in the functionally relevant cellular compartment.  
 
245 
 
To further investigate the location of TLR2 and TLR4 protein expression within the crypt, 
immunofluorescent staining of whole bowel sections was undertaken. Intestinal epithelial 
cells were shown to express TLR2 and TLR4 protein throughout the crypt and this 
expression appeared to be localised to the cell membrane. Moreover, the intensity of 
staining appeared to be greater by colonic crypt IEC from patients with UC, and by both 
smaOODQGODUJHLQWHVWLQHFU\SW,(&IURPSDWLHQWVZLWK&URKQ¶VGLVHDVHWKDQLQKHDOWK\
controls. These data are consistent with the flow cytometry data, suggesting TLR2 and TLR4 
protein expression appears to be on the plasma membrane and are up-regulated in active 
IBD.  
 
TLR2 and TLR4 immunofluorescent staining by crypt epithelial cells is visible on both the 
apical and basolateral cell membrane, though it was not possible to determine if expression 
was greater in one of these two compartments. Predominantly basolateral TLR5 protein 
expression has been reported in confluent T84 cell monolayers (241) and primary mucosal 
samples (255). Apical to basolateral scattering of TLR2 and TLR4 protein following receptor 
ligation has been demonstrated in confluent monolayers of T84 (242) and SW480 cells (243) 
which may represent a mechanism of tolerance to luminal antigen in these IEC models. This 
study has demonstrated persisting apical TLR2 and TLR4 protein expression in active small 
and large intestinal IBD.  
 
An interesting observation from the IF images iVWKDWFU\SWEDVHGHSLWKHOLDOFHOOVLQ&URKQ¶V
ileitis appeared to stain TLR2 and TLR4 protein at a greater intensity than the remaining 
epithelial cells of the crypts. This region of the crypt is the location of both the putative 
intestinal stem cell (173) and the Paneth cell (108). Although Paneth cells are reported to 
demonstrate TLR-associated signalling (238), the expression of TLR2 and TLR4 by intestinal 
stem cells is unreported. This issue is addressed further in chapters 6 and 7.  
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In summary, intestinal mucosal treatment with EDTA/DTT and pancreatin results in the 
isolation of crypt intestinal epithelial cells with few contaminating non-epithelial cells. Staining 
with the epithelial-specific antibody BerEP4 allows the identification and sorting of a 
homogenous group of pure intestinal epithelial cells. Primary BerEP4-positive crypt intestinal 
epithelial cells demonstrate expression of TLR2 and TLR4 protein, which is in part 
expressed in the functionally active location of the cell membrane surface. Crypt IEC derived 
IURPSDWLHQWVZLWK&URKQ¶VFROLWLVDQG8&H[SUHVVVLJQLILFDQWO\PRUHVXUIDFH7/5DQG7/5
protein than IEC derived from healthy controls, and this may be important in the 
pathogenesis of colonic IBD. In the small intestinal crypts there is a population of crypt base 
cells which express greater TLR2 and TLR4 protein than the other crypt IEC and the nature 
of these cells requires further investigation. These data provide further insight into the 
pathogenesis of inflammatory bowel disease.  
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Chapter 6: Expression of toll-like receptors-2 and -4 by intestinal 
myofibroblasts and their interaction with intestinal crypt cells  
 
6.1 Introduction 
In section 1.7, the structure and function of the intestinal myofibroblast (MF) was introduced. 
Furthermore, the role of the intestinal MF in modulating the immune response and in the 
formation of fibrosis during inflammatory conditions of the intestine was discussed. Intestinal 
wall fibrosis is a recognised feature of chronic inflammatory bowel diseases. In UC fibrosis is 
limited to the mucosa and sub-mucosa, resulting in thickening of the muscularis mucosa with 
VWLIIHQLQJDQGVKRUWHQLQJRIWKHFRORQZKHUHDVLQ&URKQ¶VGLVHDVHWKHH[SDQVLRQRIWKH(&0
is trans-mural, resulting clinically in stricturing or penetrating (fistulating) disease (2). While 
PRVWSDWLHQWVLQLWLDOO\SUHVHQWZLWKLQIODPPDWRU\&URKQ¶VGLVHDVHDOPRVWDOOSDWLHQWV
progress to a penetrating or stricturing phenotype over the course of the disease (181). 
While there have been significant advances in the treatment of inflammatory and penetrating 
IBD in recent years, particularly with the introduction of biological therapies (282), there has 
been little development in the prevention or treatment of stricturing disease. Therefore, 
better understandings of the mechanisms which lead to MF-induced fibrosis are urgently 
required.  
 
Alpha-smooth muscle actin- and vimentin-positive MF have been identified in increased 
numbers in the mucosa of pDWLHQWVZLWKERWK8&DQG&URKQ¶VGLVHDVH(283). It has also been 
demonstrated that MF isolDWHGIURPSDWLHQWVZLWK&URKQ¶VGLVHDVHSUROLIHUDWHDWDJUHDWHU
rate than MF isolated from normal subjects or patients with UC (284). Furthermore, isolated 
MF from patients with IBD express higher levels of mRNA for MMP-1, MMP-3 and TIMP-1 
than do MF isolated from normal mucosa (285-287). These studies suggest that MF may 
play a role in the pathogenesis of stricturing and fibrosis in IBD.  
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There is evidence to suggest intestinal MF play a role in both intestinal mucosal homeostasis 
and in the regulation of the immune response (section 1.7). Indeed, MF may play a role in 
retaining inflammatory molecules and leukocytes within inflamed tissue, resulting in the 
transition from acute to chronic inflammation as is seen in IBD and the subsequent 
development of intestinal fibrosis.  
 
Recent work has investigated the interaction between isolated crypt epithelial cells and 
cultured MF monolayers in vitro. 7KH,(&DGKHUHWR0)PRQROD\HUVLQDȕ-integrin-
independent manner and remain viable for a number of days (210). Interestingly epithelial 
cells expressing the putative intestinal stem cell marker musashi-1 are over-represented in 
the adherent cell population, suggesting that stem cells may preferentially bind to MF layers. 
Furthermore, isolated cells with side population characteristics (a group of cells enriched 
with intestinal stem cells, chapter 7) were shown to adhere to MF layers (210). This suggests 
that IEC-MF co-cultures are a useful way of isolating an epithelial cell population enriched 
with putative stem cells from isolated crypt epithelial cells.  
 
The purpose of this chapter was to culture primary human MF from healthy controls and 
patients with active IBD. Given that MF appear to play a number of roles in shaping the 
immune response, such as recruiting and retaining immune cells in the sub-epithelial layer of 
the intestinal mucosa, producing pro-inflammatory and chemotactic cytokines and 
expressing innate immune system pattern recognition receptors, the differential expression 
of TLR2 and TLR4 mRNA and protein by MF was investigated in healthy controls and 
patients with IBD. Furthermore, the reported preferential interaction between cultured MF 
layers and ISC was used to investigate the expression of TLR2 and TLR4 in MF-adherent, 
stem cell-enriched intestinal crypt cells. 
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6.2 Methods 
6.2.1 Myofibroblast isolation 
The isolation of myofibroblasts from the lamina propria was originally described by Mahida et 
al (167). Mucosal strips were treated with EDTA/DTT to remove the overlying epithelium. 
Following the collection of the E3 crypt IEC by shaking (section 3.2.4), the remaining 
mucosal strips were washed a further five times in HBSS (with Mg/Ca). At this stage 
mucosal strips are completely depleted of the epithelial cell lining. The strips were cut into 
smaller (2-3mm) pieces and plated out into 60mm culture dishes in 7ml of medium (500mL 
RPMI 1640 containing filter-sterilised 10% FCS, 5mL of 200mM glutamine and 50,000 units 
of  penicillin G, 50mg streptomycin sulphate and 24mg gentamicin).  
 
This medium was changed twice weekly until at least three colonies of MF had formed on 
the base of the dish, which usually required 4-6 weeks culture. At this stage the mucosal 
strips were removed (and discarded) and the medium was replaced with complete MF 
medium (section 6.2.2). The medium was changed 3 times weekly until a confluent layer of 
MF was observed, usually requiring a further 4 weeks. At this stage, the cells were washed 
with 1mL of 0.1% trypsin and incubated with a further fresh 1.5mL of 0.1% trypsin for 15mins 
until cell detachment occurred.  
 
Following cell detachment, 2mL of MF medium was added to neutralise the trypsin and the 
cells were collected and transferred to a T75 flask pre-filled with 11mL of MF 
medium. Medium was changed three times weekly and cells cultured again until confluent 
over 1-2 weeks in preparation for further splitting, freezing or transfer to cover slips for use in 
experimentation.  
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6.2.2 Myofibroblast culture 
Complete MF medium was prepared as follows: 500mL RPMI 1640 (52400-041, Gibco, 
Invitrogen) with 0.2µm filter-sterilised 10% FCS, 5mL of 200mM glutamine, 50,000 units of  
penicillin G (Britannia Pharmaceuticals), 50mg streptomycin sulphate (Sigma-Aldrich) and 
24mg gentamicin (Roussel Laboratories) (P/S/G) and 5ml of non-essential amino acid 
(NEAA) mix (Gibco, Invitrogen).  
 
Prior to medium changes, MF cultures were examined under the light microscope to assess 
growth. Cells were split when 85-90% confluent, which was usually within 14 days. Medium 
was removed and cells briefly washed with 2mL 0.1% trypsin (Sigma-Aldrich) in Versine 
(0.02% ethylenediaminetetraacetic acid, EDTA, in phosphate buffered saline, PBS, pH7.2). 
This was removed and replaced with a further 3mL of fresh 0.1% trypsin and incubated for 
10 minutes at 37oC. Light microscopy was used to confirm cell detachment and 3mL of 
medium added to neutralise the trypsin, making total volume of 6mL. This fluid was split 
equally (3mL) into two new T75 flasks each containing 13mL of fresh medium.  
 
For RNA transcript expression analysis, cultured MF were isolated for total RNA isolation 
(section 2.2) at passage 3. For flow cytometric analysis of surface TLR2 and TLR4 protein 
analysis, cultured MF were isolated at passage 4 or 5. For crypt cell-MF co-culture 
experiments, isolated MF were transferred onto glass cover slips in 24-well plates at 
passage 2. Following cell detachment using trypsin, the 6mL volume of suspended cells was 
made up to 25mL with MF media and mixed thoroughly. For each plate, 12 cover slips were 
sterilised in 100% ethanol and dried at room temperature before being placed individually 
into wells. Into each cover slip-containing well, 2mL of suspended MF were added. Cells 
were left to adhere to the cover slip over night. The medium was replaced with fresh medium 
24 hours later. Thereafter media was replaced every 2-3 days.  
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6.2.3 Intestinal epithelial cell-myofibroblast co-culture experiments 
Myofibroblasts were grown until confluent on cover slips and cultured for a further minimum 
period of 7 days before being considered suitable for use in co-culture experimentation. IEC 
were isolated from the mucosa of large bowel tissue resections. IEC were counted using 
trypan blue exclusion and suspended in complete MF medium at a concentration of 0.25x106 
viable cells/mL.  
 
To each cover slip-containing well, 1mL of suspended IEC was added and incubated for 30 
minutes at 37oC. The medium was then replaced three times to remove non-adherent 
epithelial cells. Finally, the cover slips were fixed in cold acetone for at least 1 minute and 
stored at -20oC until required.  
 
6.2.4 Immunocytochemical staining of myofibroblasts and intestinal epithelial cell-
myofibroblast co-culture experiments 
Cover slips stored at -20oC were thawed for 30 minutes at room temperature and hydrated in 
PBS for 20 minutes. Non-specific blocking was undertaken with 5% serum (S-2000, Vector 
Labs), 25% avidin block and 25% biotin block (SP-2001, Vector Labs). The cover slips were 
then incubated with the primary antibody for 1 hour at room temperature at the following 
dilutions: 
 
Cytokeratin    1:400 
BerEP4 (Epithelial antigen)   1:400 
Į-smooth muscle actin   1:500 
Vimentin     1:40 
Desmin     1:20 
CD45      1:400 
TLR2      1:250 
TLR4      1:250 
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Following a 0.3% hydrogen peroxide in methanol peroxidase blocking step, the biotinylated 
secondary antibody was applied for 30 minutes. Following incubation with the avidin/biotin 
mixture (PK-6200, Vector labs) for 30 minutes, the cover slips were developed using the 
DAB substrate (SK-4100, Vector labs) for 2-4 minutes, all at room temperature.  
 
Cover slips were counter stained in haematoxylin for 2 minutes, in 1% acid alcohol for 10 
seconds and in ammoniated water for 60 seconds. The cover slips were dehydrated in 
graded alcohol solution and three xylene solutions before being mounted on a new slide with 
DPX and dried overnight in a fume hood.  
 
6.2.5 Flow cytometric analysis of myofibroblasts 
Confluent myofibroblasts layers were cultured in T75 flasks. The medium was removed and 
the cells washed briefly in 0.1% trypsin. Cells were then incubated in 3mL fresh 0.1% trypsin 
for 10 minutes at 37oC. Once cell detachment was confirmed with light microscopy, 3mL 
medium was added to neutralise the trypsin and cell concentration calculated by trypan blue 
exclusion. 50x103 cells were added to each FACS tube and centrifuged for 5 minutes at 
300J7KHVXSHUQDWDQWZDVUHPRYHGDQGȝ/PRXVHVHUXPDGGHGIRUPLQXWHVDWoC. 
Thereafter, isotype or primary antibodies were added to the tubes as follows: 
 
Tube 1: No primary antibody 
Tube 2: BerEP4-),7&ȝ/ 
7XEH,J*Dț-$3&LVRW\SHȝ/ 
Tube 4: Anti-TLR2-$3&ȝ/ 
Tube 5: Anti-TLR4-$3&ȝ/ 
Tube 6: Anti-CD45-$)ȝ/ 
 
Cells were incubated for 1 hour at 4oC in the dark. The cells were washed twice in 0.5mL of 
cold HBSS (FACS) medium (2% foetal calf serum in HBSS without calcium or magnesium) 
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followed by centrifugation for 5 minutes at 300g. Finally the cells were re-suspended in 
0.5mL FACS fixative (0.5% formaldehyde in HBSS (without Ca/Mg) with 2% FCS) and 
stored at 4oC in the dark until analysis.  
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6.3 Results 
6.3.1 Primary isolated myofibroblasts in long-term culture show typical morphological 
features and express typical markers of intestinal myofibroblasts 
Mucosal tissue from healthy controls and patients with inflammatory bowel disease were 
treated with EDTA/DTT to remove the epithelial cell layer and expose the microscopic 
channels in the underlying basement membrane and lamina propria. Following a period of 
tissue culture, colonies of intestinal myofibroblasts were isolated and cultured in T75 flasks 
over a period of several weeks until fully confluent.  
 
Prior to fully confluent growth, myofibroblast cells could be seen under light microscopy to 
form the characteristic spindle shapes described during myofibroblast isolation from various 
tissues (figure 6.1A). As cultured cells approached confluent growth, myofibroblasts were 
observed to form complex colonies of spindle-shaped cells (figure 6.1B).  
 
Primary cultured intestinal myofibroblasts were demonstrated to positively stain for the MF-
DVVRFLDWHGPDUNHUVĮ-smooth muscle actin, vimentin and desmin (figure 6.2). Moreover, 
cultured MF did not stain for the epithelial cell marker BerEP4 (figure 6.3).  
 
6.3.2 Intestinal myofibroblasts in long term culture express TLR2 and TLR4 protein 
To investigate the reported expression of TLR2 and TLR4 in intestinal myofibroblasts, 
primary isolated colonic myofibroblasts from healthy controls were initially cultured until 
confluent in T75 flasks. The myofibroblasts were trypsinised and the cells collected. Protein 
lysates were obtained and the total protein concentration measured using the Bradford 
DVVD\'XSOLFDWHWRWDOSURWHLQVDPSOHVRIȝJDQGȝJZHUHORDGHGLQWRZHOOVDQG
analysed using SDS-PAGE and Western blotting, using anti-ȕ-actin, anti-TLR2 and anti-
TLR4 antibodies.  
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Intestinal myofibroblast samples were shown to express TLR2 and TLR4 protein by western 
blotting (figure 6.4). It was noted that TLR2 and TLR4 protein expression was lower than in 
LQWHVWLQDOFU\SWFHOOV&KDSWHUILJXUH3URWHLQEDQGVZHUHYLVLEOHXVLQJȝJRIWRWDO
SURWHLQEXWEDUHO\YLVLEOHXVLQJȝJRIWRWDOSURWHLQ 
 
To further examine the expression of TLR2 and TLR4 protein, intestinal myofibroblasts from 
the small and large bowel of healthy controls were cultured on coverslips until the observed 
growth was confluent by light microscopy. Following acetone fixation, the coverslips were 
stained with monoclonal antibodies to TLR2 and TLR4. Colonic intestinal MF expressed both 
TLR2 and TLR4 protein immunocytochemically (figure 6.5). Similar results were seen with 
intestinal MF derived from healthy small intestine.  
 
6.3.3 Patients with inflammatory bowel disease differentially express TLR2 and TLR4 
mRNA, but not protein in intestinal myofibroblasts 
To investigate whether intestinal myofibroblasts from patients with active inflammatory bowel 
disease differentially express TLR2 and TLR4, myofibroblasts IURPSDWLHQWZLWK&URKQ¶V
disease and ulcerative colitis were isolated and cultured in T75 flasks. Following the 
establishment of long term cultures, myofibroblasts were isolated for RNA isolation at 
passage 3 and for flow cytometric analysis at passages 4-6. Long term cultures were 
established from at least three subjects for each group.  
 
Following RNA isolation using the RNeasy Plus Mini kit, samples were reverse transcribed 
into cDNA and analysed using SYBR Green real-time RT-PCR to calculate the mRNA 
expression in IBD patients relative to a pooled sample of healthy control myofibroblasts. To 
analyse differential protein expression, cells were collected and stained with monoclonal 
APC-conjugated antibodies to TLR2 and TLR4 before being analysed on a flow cytometer. 
The measured median fluorescent intensity (MFI) for the isotype control antibody was 
subtracted from the MFI of the primary antibody to correct for non-specific antibody binding.  
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Compared to healthy controls, small intestinal myofibroblasts isolated from patients with 
&URKQ¶Vileitis showed a trend towards up-regulated expression of TLR2 mRNA (relative 
expression median [range] 4.80 [4.32-7.02] versus 1.0 [0.89-1.12], p=0.100) and TLR4 
mRNA (2.95 [2.52-3.41] versus 1.0 [0.64-1.54], p=0.100), figure 6.6. At the protein level 
using flow cytometry, a similar trend was observed in small intestine MF from patients with 
&URKQ¶Vileitis, but this did not reach statistical significance for either TLR2 (MFI [range] 31.1 
[17.7-48.0] versus 21.4 [1.7-24.8], p=0.400) or TLR4 (35.2 [19.8-55.1] versus 29.7 [0.0-34.1], 
p=0.400), figure 6.7.  
 
Regarding myofibroblasts from the large intestine, samples from patients with ulcerative 
colitis significantly down-regulated TLR2 mRNA (relative expression 0.32 [0.30-0.33] versus 
1.0 [0.43-1.41, p=0.009) but not TLR4 mRNA (0.47 [0.36-0.77] versus 1.0 [0.14-3.39, 
p=0.776). There was no differential expression of TLR2 mRNA (0.62 [0.49-0.64] versus 1.0 
[0.43-1.41, p=0.282) or TLR4 mRNA (2.06 [1.67-5.65] versus 1.0 [0.14-3.39, p=0.085) in 
FRORQLFP\RILEUREODVWVIURPSDWLHQWVZLWK&URKQ¶Vcolitis compared to healthy controls (figure 
6.8).  
 
The patterns of TLR2 and TLR4 protein expression by flow cytometry in colonic 
myofibroblasts from patients with IBD were similar to the patterns of mRNA expression 
(figure 6.9). There was no significant difference in TLR2 or TLR4 expression in 
myofibroblasts from HLWKHU&URKQ¶Vcolitis or ulcerative colitis compared to MF from healthy 
controls (p>0.05 for all analyses). There data are summarised in tables 6.1 and 6.2. 
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 Table 6.1 Expression of TLR2 and TLR4 mRNA by intestinal myofibroblasts isolated from 
patients with inflammatory bowel disease relative to expression in healthy controls 
Relative mRNA expression TLR2 TLR4 
Sample 
site 
Disease group N Median 
[range] 
P-value * N Median  
[range] 
P-value * 
Small 
bowel  
Healthy control 3 1.0  
[0.89-1.12] 
- 3 1.0  
[0.0.64-1.54] 
- 
&URKQ¶Vileitis 3 4.80  
[4.32-7.02] 
0.100 3 2.95  
[2.52-3.41] 
0.100 
Large 
bowel 
Healthy control 9 1.0  
[0.43-1.41] 
- 8 1.0  
[0.14-3.39] 
- 
&URKQ¶Vcolitis 3 0.62  
[0.49-0.64] 
0.282 3 2.06  
[1.67-5.65] 
0.085 
Ulcerative colitis 3 0.32  
[0.30-0.33] 
0.009 3 0.47  
[0.36-0.77] 
0.776 
* versus healthy control; N, number of samples 
 
Table 6.2 Expression of surface TLR2 and TLR4 protein on intestinal myofibroblasts isolated 
from patients with inflammatory bowel disease and healthy controls subjects 
Median fluorescent 
intensity 
TLR2 TLR4 
Sample 
site 
Disease group N Median 
[range] 
P-value * N Median 
[range] 
P-value * 
Small 
bowel  
Healthy control 3 21.4 
[1.7-24.8] 
- 3 29.7  
[0.0-34.1] 
- 
&URKQ¶Vileitis 3 31.1  
[17.7-48.0] 
0.400 3 35.2  
[19.8-55.1] 
0.400 
Large 
bowel 
Healthy control 5 12.8  
[4.3-25.4] 
- 5 9.5  
[4.7-28.2] 
- 
&URKQ¶Vcolitis 3 28.2  
[0.0-31.4] 
0.571 3 26.7  
[0.0-38.8] 
0.786 
Ulcerative 
colitis 
3 7.3  
[0.0-23.7] 
0.786 3 3.9  
[0.0-33.6] 
0.571 
* versus healthy control; N, number of samples 
 
6.3.4 BerEP4-positive intestinal crypt cells adhere to intestinal myofibroblast layers 
To investigate their interaction with isolated intestinal epithelial crypt cells, primary normal 
colonic myofibroblasts were cultured until confluent on glass coverslips. Intestinal crypt 
epithelial cells Q >QRUPDOFRORQ&URKQ¶VLOHLWLV&URKQ¶VFolitis 5, UC 7]) were isolated 
using EDTA/DTT and disaggregated into individual cells using pancreatin (section 3.2.4). 
Isolated crypt cells were suspended in myofibroblast medium and co-cultured on 
myofibroblast monolayers for 30 minutes, before non-adherent cells were removed by 
washing. Coverslips were then fixed in acetone and labelled with a monoclonal antibody to 
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BerEP4, before development using the DAB substrate and counter-staining with 
haematoxylin.  
Prior to acetone fixation coverslips were examined by light microscopy. Small intestinal 
epithelial cells were seen to adhere to the underlying myofibroblast monolayer (figure 6.10). 
Intestinal cells were noticeably smaller than the underlying intestinal myofibroblasts.  
 
Following acetone fixation, coverslips were stained with the epithelial-specific monoclonal 
antibody to BerEP4. Intestinal crypt cells stained positively for BerEP4 (n=16), but 
myofibroblasts were BerEP4-negative (figure 6.11A and B). Examination of adherent 
BerEP4-positive cells under high power magnification (x40) demonstrated occasion spur-like 
processes extending out from the membrane of the adherent epithelial cell (figure 6.11C and 
D).  
 
6.3.5 Adherent intestinal crypt cells and intestinal myofibroblasts express TLR2 and 
TLR4 protein 
Epithelial cells adhering to myofibroblast monolayers have been reported to represent a 
population of epithelial cells enriched for the expression of the intestinal stem cell marker 
musashi-1 (210). To investigate if these adherent epithelial cells expressed TLR2 and TLR4 
protein, coverslips containing co-cultured intestinal myofibroblast and intestinal epithelial 
cells Q >QRUPDOFRORQ&URKQ¶VLOHLWLV&URKQ¶VFROLWLV8&@were stained with 
monoclonal antibodies to TLR2 and TLR4 and acetone-fixation. Coverslips were developed 
using DAB substrate and counter-stained with haematoxylin.  
 
Adherent epithelial crypt cells were shown to stain positively for TLR2 and TLR4 protein 
(n=20). The underlying myofibroblasts were also positive-staining for TLR2 and TLR4 
protein, but the staining of the MF was less intense than the staining of the adherent 
epithelial crypt cells (figure 6.12).  
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6.4 Figures 
 
 
 
Figure 6.1 Cultured primary colonic myofibroblasts display a spindle-shaped morphology. 
Primary human mucosal samples were treated with EDTA/DTT to remove the overlying 
epithelial cell layer. The residual mucosa was cultured until migrating MF formed colonies on 
the growth plate. The mucosal tissue samples were discarded at this stage and the MF 
colonies were further cultured until fully confluent, before being transferred to T75 flasks for 
long term culture. MF cultures display a typical spindle shape (A) when examined by light 
microscopy and form complex colonies in long term culture (B).  
 
DTT, dithiothreitol; EDTA, ethylenediaminetetraacetic acid; MF, myofibroblast 
 
 
 
 
 
 
 
A 
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Figure 6.2 Cultured primary colonic myofibroblasts H[SUHVVĮ-smooth muscle actin, vimentin 
and desmin. Primary human intestinal MF colonies (n=5) were cultured on glass coverslips 
until fully confluent, before being acetone-fixed. Coverslips were stained with (A) no primary 
antibody, (B) anti-Į-smooth muscle actin, (C) anti-vimentin, or (D) anti-desmin antibodies 
and developed using DAB substrate. CXOWXUHGSULPDU\KXPDQ0)VWDLQHGSRVLWLYHO\IRUĮ-
smooth muscle actin (A), vimentin (B) and desmin (C).  
 
'$%¶-diaminobenzidine; MF, myofibroblast 
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Figure 6.3 Cultured primary colonic myofibroblasts do not express BerEP4. Primary human 
intestinal MF (n=5) were cultured until fully confluent on glass coverslips and fixed in 
acetone. Coverslips were stained with (A) no primary antibody or (B) anti-BerEP4 
monoclonal antibody, and developed using DAB substrate before counter-staining with 
haematoxylin. Cultured primary human MF did not express BerEP4.  
 
'$%¶-diaminobenzidine; MF, myofibroblast 
 
 
 
 
 
 
 
 
 
A 
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Figure 6.4 Cultured primary colonic myofibroblasts express TLR2 and TLR4 protein. Primary 
intestinal myofibroblasts were cultured until fully confluent in T75 flasks. Cells were collected 
DQGO\VHGIRUWRWDOSURWHLQTXDQWLILFDWLRQXVLQJWKH%UDGIRUGDVVD\7KHH[SUHVVLRQRI$ȕ-
actin, (B) TLR2 and (C) TLR4 protein was examined using SDS PAGE and Western blotting. 
'XSOLFDWHVDPSOHVRIȝJODQHVDQGRUȝJODQHVDQGRIWRWDOSURWHLQZHUH
loaded into adjacent wells. Bands were noted at the expected protein molecular weights for 
ȕ-actin (42 kDa), TLR2 (90kDa) and TLR4 (93kDa). TLR2 and TLR4 expression was shown 
WREHH[SUHVVHGDWORZOHYHOVSDUWLFXODUO\LQWKHȝJODQHV 
 
Da, Dalton; L, size ladder; SDS PAGE, sodium dodecyl sulphate polyacrylamide gel 
electrophoresis; TLR, Toll-like receptor
52 kDa 
38 kDa 
102 kDa 
102 kDa 
76 kDa 
76 kDa 
  L                      1           2          3          4 
  L                      1           2          3          4 
  L                      1           2          3          4 
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A 
C 
263 
 
 
    
         
       
 
Figure 6.5 Cultured primary normal colonic myofibroblasts express TLR2 and TLR4 protein. 
Primary human intestinal MF isolated from healthy control large bowel mucosa (n=3) were 
cultured until fully confluent on glass coverslips and fixed in acetone. Coverslips were 
stained with anti-TLR2 or anti-TLR4 monoclonal antibodies, developed using DAB substrate, 
counter-stained with haematoxylin and viewed by light microscopy. Cultured primary MF 
expressed both TLR2 at low (X10) and high (x40) power (A and B, respectively) and TLR4 at 
low and high power (C and D, respectively). Low and high power no-antibody control slides 
are also shown (E and F, respectively). 
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Figure 6.6 6PDOOLQWHVWLQDOP\RILEUREODVWVIURPSDWLHQWVZLWK&URKQ¶Vileitis trend towards up-
regulation of TLR2 and TLR4 mRNA expression. Primary small intestinal myofibroblasts 
from healthy controls and patients with CD were cultured in T75 flasks until cell monolayers 
were fully confluent. At this stage MF were collected for mRNA isolation, cDNA synthesis 
and subsequent analysis of (A) TLR2 and (B) TLR4 expression relative to HPRT using real-
time RT-PCR. Each data point represents the mean TLR2 or TLR4 mRNA expression of 
three triplicate runs per sample, expressed relative to the pooled healthy control small bowel 
samples. Horizontal bars represent median expression for the group. 
 
 
&'&URKQ¶VGLVHase; HPRT, Hypoxanthine guanine phosphoribosyltransferase; RT-PCR, 
reverse transcriptase polymerase chain reaction; TLR, Toll-like receptor
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Figure 6.7 Small intestinal myofibroblasts from healthy controls and SDWLHQWVZLWK&URKQ¶V
ileitis express similar levels of surface TLR2 and TLR4 proteins. Primary small intestinal 
myofibroblasts from healthy controls and patients with CD were cultured until cell 
monolayers were fully confluent. At this stage MF were collected, stained with either (A) anti-
TLR2 or (B) anti-TLR4 APC-conjugated monoclonal antibodies and subsequently examined 
by flow cytometry. Each data point represents the difference in median fluorescent intensity 
between the primary and isotype control antibodies. Horizontal bars represent median 
expression for the group. 
 
$3&DOORSK\FRF\DQLQ&'&URKQ¶VGLVHDVH0)P\RILEUREODVWV7/57ROO-like receptor 
 
 
A 
B 
266 
 
 
 
 
R
el
at
iv
e 
TL
R
2 
ex
pr
es
si
o
n
He
alt
hy
 
co
ntr
ol
Cr
oh
n'
s 
dis
ea
se
Ulc
er
ati
ve
 
co
liti
s
0.0
0.5
1.0
1.5
 
 
R
el
at
iv
e 
TL
R
4 
ex
pr
es
si
o
n
He
alt
hy
 
co
ntr
ol
Cr
oh
n'
s 
dis
ea
se
Ulc
er
ati
ve
 
co
liti
s
0
2
4
6
 
Figure 6.8 Colonic myofibroblasts from patients with ulcerative colitis down-regulate TLR2 
mRNA expression. Primary colonic myofibroblasts from healthy controls and patients with 
IBD were cultured until cell monolayers were fully confluent. At this stage MF were collected 
for mRNA isolation, cDNA synthesis and subsequent analysis of (A) TLR2 and (B) TLR4 
expression relative to HPRT using real-time RT-PCR. Each data point represents the mean 
TLR2 or TLR4 mRNA expression of three triplicate runs per sample, expressed relative to 
the pooled healthy control large bowel samples. Horizontal bars represent median 
expression for the group. 
* p=0.009 
 
HPRT, hypoxanthine guanine phosphoribosyltransferase; IBD, inflammatory bowel disease; 
RT-PCR, reverse transcriptase polymerase chain reaction; TLR, Toll-like receptor 
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Figure 6.9 Colonic myofibroblasts from patients with inflammatory bowel disease express 
similar surface TLR2 and TLR4 proteins compared to healthy controls. Primary colonic 
myofibroblasts from healthy controls and patients with IBD were cultured until cell 
monolayers were fully confluent. At this stage MF were collected, stained with either (A) anti-
TLR2 or (B) anti-TLR4 APC-conjugated monoclonal antibodies and subsequently examined 
by flow cytometry. Each data point represents the difference in median fluorescent intensity 
between the primary and isotype control antibodies. Horizontal bars represent median 
expression for the group. 
 
APC, allophycocyanin; IBD, inflammatory bowel disease; MF, myofibroblasts; TLR, Toll-like 
receptor 
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Figure 6.10 Isolated colonic crypt cells adhere to cultured intestinal myofibroblast layers. 
Primary normal colonic myofibroblasts were cultured on glass coverslips until fully confluent. 
Primary normal small intestine crypt cells were isolated from mucosal samples using 
EDTA/DTT and disaggregated using pancreatin, before being added onto the confluent 
myofibroblast monolayer. After a 30 minutes period of co-culture, non-adherent intestinal 
crypt cells were removed by washing and the coverslip viewed with the light microscope at 
high power (x40). Intestinal crypt cells (*) were seen to adhere to the underlying 
myofibroblast monolayer (#). Notably, the myofibroblasts were much larger in size than the 
adherent intestinal crypt cells.  
 
DTT, dithiothreitol; EDTA, ethylenediaminetetraacetic acid 
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Figure 6.11 Colonic crypt cells adherent to myofibroblast monolayers are BerEP4-positive 
and demonstrate spur-like cytoplasmic projections. Primary normal colonic myofibroblasts 
were cultured until fully confluent on glass coverslips. Isolated and disaggregated normal 
colonic crypt cells were co-cultured on myofibroblast monolayers for 30 minutes and 
subsequently the non-adherent cells removed by washing (n=10). Coverslips were fixed in 
acetone, incubated with an anti-BerEP4 monoclonal antibody, developed using DAB 
substrate and finally counter-stained with haematoxylin. Brown-staining BerEP4-positive 
intestinal epithelial cells were seen to adhere to the much larger underlying myofibroblasts 
(A and B). Haematoxylin-staining myofibroblast nuclei were marked (#). In some cases, 
spur-like projections were seen extending from the epithelial cell cytoplasm (C and D, 
arrows).  
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Figure 6.12 Co-cultured colonic crypt cells and colonic myofibroblasts express TLR2 and 
TLR4 protein. Primary normal colonic myofibroblasts were cultured until fully confluent on 
glass cover slips. Isolated and disaggregated colonic crypt cells IURPDSDWLHQWZLWK&URKQ¶V
colitis were co-cultured on myofibroblast monolayers and subsequently the non-adherent 
cells removed by washing (n=10). The cover slips were fixed in acetone and stained with 
either (A) no primary antibody, (B-D) anti-TLR2 antibody or (E and F) anti-TLR4 antibody. 
Cover slips were developed using DAB substrate and counter-stained with haematoxylin. 
TLR2- and TLR4-positive intestinal crypt cells (*) were seen to adhere to myofibroblasts (#), 
which were also TLR2- and TLR4-positive. Adherent intestinal crypt cells demonstrated 
stronger staining for TLR2 (B-D) and TLR4 (E and F) than the underlying myofibroblasts.  
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6.5 Discussion 
Primary intestinal myofibroblasts were successfully cultured from the small and large 
intestine of healthy controls and patients with inflammatory bowel disease, and maintained in 
culture for a period of several months. The cultured MF demonstrated typical spindle-shaped 
morphology and expressed the MF-DVVRFLDWHGLQWUDFHOOXODUPDUNHUVĮ-smooth muscle actin, 
vimentin and desmin, but not the epithelial-specific marker BerEP4. 
 
Primary MF monolayer cultures from the normal small and large intestine were shown to 
express TLR2 and TLR4 protein using whole cell lysate Western blotting, 
immunocytochemical staining of cultured MF colonies on coverslips and flow cytometric 
analysis of individual intestinal MF, supporting the report by Otte et al. that primary cultured 
intestinal MF express TLR2 and TLR4 transcripts (182). This suggests that primary human 
intestinal MF have the ability to sense bacterial ligands in the lamina propria via TLR2 and 
TLR4, and therefore may play a role in mediating the mucosal inflammatory response 
through TLR signalling. Indeed primary cultured large intestinal MF cells have been reported 
to respond to the TLR4 ligand LPS by expressing COX-2 (183).  
 
Notably, primary cultured MF expressed less total TLR2 and TLR4 protein than isolated 
intestinal crypt cells, as assessed by Western blotting. Protein bands of the expected size 
were easily identified on western blots using primary intestinal crypt cell lysates after loading 
ȝJRIWRWDOSURWHLQZKHUHDVSURWHLQEDQGVIURP0)O\VDWHVXVLQJȝJRIWRWDOSURWHLQ
were barely visible and ȝJRIWRWDOSURWHLQZDVUHTXLUHGIURP0)ZKROHFHOOO\VDWHVWR
demonstrate bands of similar width. Moreover, when normal colonic crypt cells were co-
cultured on normal colonic MF monolayers, immunohistochemical analysis of TLR2 and 
TLR4 protein expression showed that crypt cells stained more intensely than the underlying 
MF cells. Conversely, median fluorescent intensity of surface TLR2 and TLR4 protein 
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expressions using flow cytometry were statistically similar between normal colonic crypt cells 
and normal colonic MF (p=1.0 and p=0.876, respectively).  
 
The intestinal epithelial cell-myofibroblast co-culture experiments demonstrated that 
adherent crypt cells are markedly smaller than the underlying MF cells. Conversely, when 
MF were harvested using trypsin and analysed by flow cytometry they were smaller (as 
assessed by forward scatter on the flow cytometer) than isolated crypt cells, suggesting that 
harvested MF round up and significantly reduce in size following trypsinisation. This could 
result in increased density of surface TLR2 and TLR4 expression following MF harvest. 
Myofibroblasts in culture took on a classical spindle-shaped appearance and were much 
larger in size than isolated crypt cells. Therefore, the observations that total TLR2 and TLR4 
protein is less in MF than IEC (as assessed by western blotting) and that cultured MF cells 
are larger than isolated crypt IEC suggests that surface TLR2 and TLR4 expression is less 
dense in MF. This is supported by the IEC-MF co-culture immunostaining experiments which 
demonstrated more intense staining of the adherent crypt cells compared to the underlying 
MF monolayer cells.  
 
When prLPDU\LOHDO0)FXOWXUHVIURPSDWLHQWVZLWK&URKQ¶VLOHLWLVZHUHFRPSDUHGWRVPDOO
intestine MF cultures from healthy controls, there was a trend towards up-regulation of TLR2 
and TLR4 transcripts and, to a lesser extent, up-regulation of surface TLR2 and TLR4 
proteins. However, there was no differential expression of TLR2 or TLR4 between intestinal 
0)GHULYHGIURPSDWLHQWVZLWK&URKQ¶VFROLWLVFRPSDUHGWRKHDOWK\FRQWURO colonic MF at 
either the transcript or protein level. There was a statistically significant down-regulation of 
TLR2 mRNA transcript in intestinal MF from patients with UC compared to healthy controls. 
However TLR4 mRNA expression was similar between the two groups and there was no 
significant difference in the expression of surface TLR2 or TLR4 protein on intestinal MF 
from patients with UC compared to healthy control colonic MF.  
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There are several explanations for these data. Firstly it is possible that, while intestinal MF 
certainly demonstrated both TLR2 and TLR4 transcript and protein expression, they do not 
differentially express these receptors during states of mucosal inflammation. However, 
trends in expression between groups were observed, and it is possible that the small number 
of specimens in each disease group (n=3 for IBD groups) may have contributed to a lack of 
statistically significant differences.  
 
It is important to note that the MF isolated for TLR2 and TLR4 transcripts and protein 
expression analyses were collected following a prolonged period of cell culture in an ex vivo 
environment (several weeks or months). This ex vivo culture period may have a significant 
bearing on the expression of TLR2 and TLR4. Therefore, any differential expression 
amongst the groups may have been diminished as a result of long term cell culture. 
However, primary cultured intestinal MF from healthy controls and patients with UC and 
&URKQ¶VGLVHDVHwere reported to demonstrate GLVWLQFWSDWWHUQVRI7*)ȕLVRIRUPH[SUHVVLRQ
which were sustained through several MF passages (284). Whether sustained expression is 
also true of TLR2 and TLR4 remains unknown.   
 
However, looking more generally at the trends in TLR2 and TLR4 expression, it is interesting 
than small and large LQWHVWLQDO0)GHULYHGIURPSDWLHQWVZLWK&URKQ¶VGLVHDVHWHQGHGWRXS-
regulate TLR2 and TLR4 expression, whereas colonic intestinal MF derived from patients 
with UC tended to down-regulate TLR2 and TLR4 expression. Intestinal MF are associated 
with the formation of intestinal fibrosis and are reported to be expressed in greater numbers 
(283) and with greater proliferative capacity (284) in the mucosa in IBD, particularly in 
&URKQ¶VGLVHDVHZKLFKLVDVVRFLDWHGZLWKLQWHVWLQDOVWULFWXUHV(2). It is possible that TLR2 and 
TLR4 signalling plays a role in regulating intestinal MF function and the burden of mucosal 
antigens in inflamed mucosa may play a role in mediating the innate and adaptive immune 
responses through direct bacterial sensing. The observation that TLR2 and TLR4 may be 
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up-UHJXODWHGLQLQWHVWLQDO0)RISDWLHQWVZLWK&URKQ¶VGLVHDVHUHTXLUHVIXUWKHULQYHVWLJDWLRQ
before their role in mediating intestinal fibrosis can be more fully understood.  
 
On the contrary, intestinal fibrosis in UC is unusual and generally limited to the mucosa and 
sub-mucosa. The down-regulation of TLR2 mRNA by intestinal MF in this study may occur 
as a tolerogenic response to increased bacterial antigenic exposure in the lamina propria 
following loss of the overlying epithelium. The relative hypo-responsiveness of mucosal MF 
to bacterial antigens may explain why colonic stricturing is less common in patients with UC 
FRPSDUHGWR&URKQ¶VGLVHDVH (2).  
 
It has previously been shown in this laboratory that intestinal crypt cells expressing the 
intestinal stem cell marker musashi-1 (Msi-1) represent less than 1% of the total isolated 
crypt cell population. However, co-culturing isolated and disaggregated intestinal crypt cells 
with confluent intestinal MF monolayers results in the adherence of a population of crypt 
cells to the MF monolayer which express Msi-1 in approximately 60% of cells (210). This 
suggests that intestinal stem cells preferentially adhere to MF monolayers. This technique 
provides a convenient way of isolating a sub-population of crypt cells enriched with stem 
cells for subsequent analysis.  
 
This study demonstrated adherence of BerEP4-positive crypt intestinal epithelial cells to 
primary colonic MF monolayers. These adherent IEC are much smaller than the underlying 
intestinal MF and display slender processes which extend towards the MF monolayer, as 
previously observed using electron microscopy (210). Myofibroblast-adherent crypt cells 
expressed TLR2 and TLR4 protein, suggesting that the sub-population enriched for intestinal 
stem cells also expressed TLR2 and TLR4 protein. Moreover, TLR2 and TLR4 staining was 
more intense in the adherent crypt cells compared to the underlying MF, suggesting greater 
TLR2 and TLR4 expression by the adherent stem cell-enriched population than by the 
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underlying MF monolayer, though this may reflect down-regulation of TLR2 and TLR4 by MF 
following a relatively prolonged period of cell culture, as previously discussed.  
 
To further isolate a population of cells enriched with an intestinal stem cell phenotype and to 
discuss the implications of TLR2 and TLR4 expression by intestinal stem cells, further 
studies were undertaken on isolated intestinal crypt cells. Intestinal stem cells were identified 
by their ability to efflux the fluorescent DNA-binding dye Hoechst 33342, identifying a stem 
cell-enriched group of cells known as the side population. This work is discussed in detail in 
chapter 7.  
 
In summary, primary intestinal myofibroblast cultures were successfully maintained over a 
period of several months. These cultured cells demonstrated the typical morphology and 
expressed typical MF-associated intracellular markers. Primary cultured intestinal 
myofibroblasts expressed TLR2 and TLR4 transcript and surface protein, suggesting that 
they may play a role mediating mucosal inflammation by sensing bacteria that penetrate the 
epithelial barrier via TLR2 and TLR4 signalling. In a subsequent small study, intestinal 
myofibroblasts isolated from patients with UC down-regulated TLR2 mRNA expression. 
There was a trend towards up-regulation of TLR2 and TLR4 in intestinal MF from patients 
ZLWK&URKQ¶VLOHLWLV7KLVPD\EHan important mechanism in the pathogenesis of 
myofibroblast-mediated fibrosis and stricturing in distal ileum of patients with &URKQ¶V
disease. Finally, co-culturing intestinal crypt cells onto MF monolayers is known to result in 
the adherence of a sub-population of IEC enriched for intestinal stem cells. These adherent 
cells were shown to express TLR2 and TLR4 protein, suggesting intestinal stem cells are 
also TLR2- and TLR4-expressing cells.  
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Chapter 7: Isolation and characterisation of putative stem cells in 
the human large bowel and their expression of Toll-like receptors 
 
7.1 Introduction 
The location, function and regulation of the intestinal stem cell (ISC) were introduced in 
section 1.8. The ISC is responsible for the repletion of the epithelial layer every five days and 
play a key role in the mucosal response to epithelial injury (187). Identification of ISC has 
relied on the retention of tritiated thymidine (3HTdR) labelled DNA (193) and 
immunohistochemically staining a number of intracellular protein ISC markers (174). This 
has precluded the isolation and sorting of ISC to allow their better characterisation.  
 
The identification of a side population of cells, initially in murine bone marrow (202) and 
subsequently in the small intestine of mice (208) and the human colon (210), has enabled 
researchers to sort a population of cells highly enriched with stem cell properties. This 
technique relies on the observation that side population cells, but not other non-stem cells, 
efflux the DNA-binding fluorescent dye Hoechst 33342, a process which is ameliorated by 
the ABCG2 pump-blocking agents, verapamil and fumitremorgin C (212).  
 
Current evidence suggests that host-microbial interactions are important in the pathogenesis 
of IBD (13). Importantly, intra-epithelial neutrophil infiltration (cryptitis) and neutrophil crypt 
abscess formation are key histological features in IBD which result in epithelial cell loss and 
subsequent exposure of the underlying lamina propria to bacterial antigens (215). 
Regeneration of the epithelial barrier requires expansion and differentiation of the intestinal 
stem cell population. Therefore it is possible that the stem cell population, located in the 
base of the crypt, plays an important role in the pathogenesis of IBD through innate immune 
receptor-mediated bacterial sensing.  
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To date there is no published data describing the expression of toll-like receptors in this stem 
cell-enriched side population of cells. This study has demonstrated that unselected intestinal 
crypt epithelial cells express TLR2 and TLR4 transcripts and protein (chapters 4 and 5), but 
it is unclear if these TLR-expressing IEC are derived from intestinal crypt cells with stem cell 
properties. The aim of this chapter was to isolate normal colonic intestinal side population 
cells and to investigate their expression of TLR2 and TLR4 mRNA and protein. 
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7.2 Methods 
7.2.1 Isolation of side population cells by Hoechst 33342 dye efflux 
Stock solutions of the key reagents were made and stored at 4oC in the dark. A stock 
solution of x100 (5mmol/L) verapamil (V4629, Sigma-Aldrich) was made by adding 49.1mg 
verapamil hydrochloride to 20mL 95% ethanol. A stock solution of x100 (1mmol/L) 
fumitremorgin C (ALX-350-127, Alexis Biochemicals) was made by adding 0.25mg of FTC to 
ȝ/GLPHWK\OVXOIR[LGH'062Finally, a stock solution of x200 (0.5mg/mL) Hoechst 
33342 was made by adding 2.5mg Hoechst 33342 (bisBenzimide H 33342, B2261-25MG, 
Sigma) to 5mL of distilled water.  
 
Disaggregated IEC were isolated using EDTA/DTT and pancreatin. The cells were counted 
using trypan blue exclusion and 106 cells transferred to each of a dozen clean 15mL BD 
FalconTM tubes. The cell suspension volume was made up to 2mL/tube with pre-warmed 
(37oC) DMEM (FACS) medium (500mL '0(0ZLWKȝPILOWHU-sterilised 2% FCS and 
10mM (1.19g) HEPES) to give a cell concentration of 0.5x106 cells/mL.  
 
To identify the SP, one of two ABCG2-blocking agents was added to a tube of isolated crypt 
cells. The cells in this tube were used only to demonstrate the presence of the ABCG2 pump 
(by demonstrating its blockade resulted in loss of its dye efflux properties using the blocking 
agent), but these cells were not used for either cell surface TLR2 or TLR4 expression 
analyses or for RNA isolation. Either ȝ/RIstock verapamil or ȝ/RIVWRFNfumitremorgin 
C was added to these tubes and incubated in a shaking water bath at 37oC for 15 minutes, 
with manual inversion twice during this incubation. During this period the remaining cell-
containing tubes (unexposed to verapamil or fumitremorgin C) were kept at 37oC in a water 
bath. Following the verapamil/FTC incubation stepȝ/RIthe stock solution of Hoechst 
33342 was added to all tubes, giving a working concentration of Hoechst 33342 of ȝJP/ 
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Initially, preliminary experiments were undertaken to identify the optimal conditions for 
Hoechst 33342 staining of isolated IEC. Hoechst 33342 concentrations of 2.5-ȝJP/ZHUH
incubated with IEC for 30, 60 and 90 minutes in a shaking water bath at 37oC. Hoechst 
FRQFHQWUDWLRQRIȝJP/UHGXFHG,(&YLDELOLW\DVGLG incubation times beyond 30 
minutes. Therefore all subsequent experiments were run with Hoechst 33342 incubation at 
ȝJP/IRUPLQXWHVTubes were mixed by inversion twice during this 30 minutes 
incubation.  
 
Following the Hoechst 33342 incubation step, all tubes were placed on ice for 30 minutes 
and kept at below 4oC thereafter. Following cooling, the tubes were centrifuged at 800rpm 
(300g) for 5 minutes at 4oC and the supernatant removed. Cell pellets were re-suspended in 
0.5mL of HBSS (FACS) (500P/+%66ZLWK&D0JZLWKȝPILOWHUVWHULOLVHG)&6DQG
10mM HEPES (1.19g) at pH 7) and maintained at 4oC until analysis. Immediately prior to 
F\WRORJLFDODQDO\VLVȝ/RISURSLGLXPLRGLGH(PI) was added to the cell suspension to allow 
exclusion of non-viable cells.  
 
Using a Beckman Coulter MoFlo cell sorter, Hoechst 33342 dye excitation at wavelength 
405nm using violet light (405nm) was undertaken, followed by measurement of fluorescent 
emission at two wavelengths using a 450/50nm Band Pass (BP) blue optical filter and 
620nm Long Pass (LP) red optical filter. For subsequent RNA isolation or assessment of cell 
surface marker expression, cells from both the side population (SP) and epithelial cells from 
outside the side population region (non-side population cells, NSP) were sorted into 
LQGLYLGXDO)$&6WXEHVFRQWDLQLQJȝ/RIFKLOOHG+%66 (FACS) medium on ice until 
required.  
 
Viable crypt cells were initially identified using forward and side scatter analyses. Non-viable 
cells (adjacent to the intersection of the X- and Y-axes) and clumped cells (with large 
deflection on forward and/or side scatter) were excluded from analysis and cell sorting. 
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Viable cells were further analysed for clumping by viewing gated cells simultaneously in the 
blue linear (FL7-Height) and blue area (FL7-Area) channels. Single cells were those with 
equal signal in both FL7-Height and FL7-Area channels, whereas clumped cells 
demonstrated higher signal in the FL7-Area channel than the FL7-Height channel and were 
therefore excluded. Cell viability was further analysed by PI uptake. PI is a non-membrane 
permeable fluorophore and is only up-taken by non-viable cells with permeable cell 
membranes. Cells demonstrating high PI fluorescence in the FL2 channel were therefore 
excluded as non-viable.  
 
Finally cells were analysed in the red (FL10 log) and blue (FL7 log) channels for Hoechst 
33342 fluorescence. Two tubes were analysed to demonstrate ABCG2 blockade, indicating 
cells with a stem cell phenotype. The first contained Hoechst 33342-stained crypt cells and 
the second tube contained Hoechst 33342-stained crypt cells pre-incubated with 
verapamil/fumitremorgin C. If the former tube demonstrated a proportion of cells with low 
signal in both the blue and red channels (known as the Hoechst 33342-low region, indicating 
Hoechst 33342 efflux) and the latter tube demonstrated amelioration of events in this 
Hoechst 33342-low region (indicating loss of Hoechst 33342 efflux), this suggested that cells 
in the Hoechst 33342-low region expressed functional ABCG2 pumps (i.e. demonstrating 
these cells to have side population characteristics, figure 7.1).  
 
In this case, a gate was drawn around the Hoechst 33342-low region to identify the stem 
cell-enriched side population of cells. Subsequently, tubes incubated with Hoechst 33342 
(but not verapamil/fumitremorgin C) were analysed in an identical manner, and cells falling 
inside the Hoechst 33342-low (side population) region were positively sorted for further 
analysis. At least 5x103 cells in the side population gated region were analysed per tube. 
Analysis was undertaken using Weasel v3 software.  
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7.2.2 RNA isolation from sorted cell populations and conventional RT-PCR analysis 
Isolated epithelial cells characterised as cytometrically from both side population and non-
side population regions were transferred to Eppendorf tubes and centrifuged at 13,000rpm 
(>10,000g) for 5 minutes followed by removal of the supernatant. Total RNA was isolated 
using the Qiagen RNeasy Plus Mini Kit (product 74134, Qiagen) as per the PDQXIDFWXUHU¶V
instructions (section 2.2). Samples of total RNA were labelled and stored at -80oC in 20µL 
aliquots. RNA samples were assessed using a Nanodrop® spectrophotometer (Thermo 
Scientific) (section 2.3.1).  
 
Side population cells were analysed for the expression of HPRT, TLR2 and TLR4 mRNA 
using the conventional RT-PCR primers and protocol described in section 2.4.3.2. However, 
45 PCR cycles were used in the protocol for TLR2 and TLR4 cDNA amplification, whereas 
the standard 40 cycles was used for HPRT cDNA PCR. In addition SP cells were analysed 
for the expression of TLR3, TLR5 and TLR9 mRNA transcripts using commercial primers 
(QuantiTect Primer Assay primers, Qiagen). Details of these commercial primers are shown 
in table 7.1. 
 
Table 7.1 Exon amplification and amplicon length for commercial TLR3, TLR5 and TLR9 
real-time RT-PCR primers 
Gene Qiagen product code Amplified exons Amplicon length (bp) 
TLR3 QT00007714 2/3 90bp 
TLR5 QT01682079 2/3 147bp 
TLR9 QT00015183 1/2 146bp 
Bp, base pairs; TLR, Toll-like receptor 
 
7KH3&5PDVWHUPL[ZDVPDGHDVIROORZVWRWDOȝ/[4XDQWL7HFW6<%5*UHHQ3&5
Mastermix ȝ/[4XDQWL7HFW3ULPHU$VVD\IRU7/57/5RU7/5ȝ/QXFOHDVH-
IUHHZDWHUȝ/DQGF'1$ȝ/7KHVDPSOHVZHUHWKRURXJKO\PL[HGEHIRUHEHLQJ
amplified on a Veriti rapid cycler (Applied Biosystems) using the following protocol: 95oC for 
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15 minutes (hot start); 45 cycles of 94oC for 15 seconds (denaturation), 55oC for 30 seconds 
(annealing) and 72oC for 30 seconds (elongation); and finally 72oC for 10 minutes to 
complete synthesis. Samples were then separated using 1% agarose gel electrophoresis 
and visualised using an ultraviolet (UV) trans-illuminator (section 2.4.3.3).  
 
7.2.3 Flow cytometric analysis of surface marker expression of sorted cell populations 
In some cases, to allow for sorting of SP/NSP cell populations (for subsequent RNA 
isolation) and to allow simultaneous measurement of surface marker expression, 
disaggregated crypt IEC were labelled with monoclonal antibodies to various cell surface 
markers following the Hoechst 33342 dye incubation step, but prior to cytometric sorting.  
In such cases, dye efflux properties were investigated using a modified protocol from that 
detailed in section 7.2.1. Following incubation in Hoechst 33342, cells were centrifuged at 
800rpm (300g) for 5 minutes at 4oC. The supernatants ZHUHUHPRYHGDQGȝ/PRXVHVHUXP
added for 15 minutes to block potential non-specific or FcR-binding. Thereafter, primary or 
isotype antibodies were added to the tubes in the following order: 
 
Tube 1: No primary antibody 
Tube 2: BerEP4-),7&ȝ/'DNR)-0860) 
Tube 3: BerEP4-),7&ȝ/,J*Dț-$3&LVRW\SHȝ/H%LRVFLHQFH-4724) 
Tube 4: BerEP4-),7&ȝ/Anti-TLR2-$3&ȝ/H%LRVFLHQFH-9922) 
Tube 5: BerEP4-),7&ȝ/Anti-TLR4-$3&ȝ/H%LRVFLHQFH-9917) 
Tube 6: Anti-CD45-$)ȝ/%LR/HJHQG 
 
These cells were incubated for 1 hour at 4oC in the dark. Next 0.5mL of cold HBSS (FACS) 
was added to each tube and the cells re-suspended. The tubes were centrifuged for 5 
minutes at 800rpm (300g) at 4oC and the supernatant removed. Finally the cells were re-
suspended in 0.5mL HBSS (FACS) and kept on ice in the dark until analysis.  
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During the analysis process, in addition to the identification of cells with SP/NSP 
characteristics (section 7.2.1), these cell populations were gated upon to allow simultaneous 
characterisation of the expression of surface BerEP4, TLR2, TLR4 and CD45 proteins by 
measuring fluorescent signal in the FITC, APC and AF488 channels, respectively. 
Expression of surface protein was expressed as the median fluorescent intensity difference 
between the primary antibody sample and either the isotype-control or the no-antibody 
control sample. At least 5x103 cells in the side population gated region were analysed and 
sorted per tube.  All analyses were undertaken using Weasel v3 software.   
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7.3 Results 
7.3.1 Isolated colonic crypt cells treated with Hoechst 33342 demonstrate a sub-
population of cells with side population characteristics 
The defining feature of side population (SP) cells is the ability to efflux the fluorescent 
nuclear dye Hoechst 33342 via the ABCG2 pump. SP cells derived from bone marrow and 
intestine are enriched with stem cells as demonstrated by their ability to save mice from 
lethal irradiation and to express markers of haematopoietic and intestinal stem cells, 
respectively. To define the SP required the blockage of the ABCG2 pump using an agent 
such as verapamil or fumitremorgin C.  
 
Intestinal crypt cells from healthy controls were isolated using EDTA/DTT and disaggregated 
using pancreatin (section 3.2.4). Cells were then incubated with Hoechst 33342 before being 
kept at 4oC until analysis on a MoFlo cytometer. Immediately prior to analysis on the flow 
cytometer, isolated cells were incubated with propidium iodide (PI) to assess cell viability.  
 
Hoechst 33342 efflux was assessed on the red and blue lasers. Abolition of Hoechst 33342 
efflux was assessed on samples containing isolated crypt cells pre-incubated with an 
ABCG2-blocking agent. A side population was considered present if pre-incubation with an 
ABCG2-blocking agent resulted in a reduction in cells numbers within the SP region of at 
least 75% (230).  
 
Within these criteria, a side population of cells was demonstrated in isolated intestinal 
epithelial cells from healthy subjects (n=6, figure 7.1). Although it was possible to resolve the 
SP using fumitremorgin C as the ABCG2-blocking agent, verapamil was observed to be a 
more efficient ABCG2-blocking agent. Of note, compared to Hoechst 33342-treated crypt 
cells, verapamil treatment resulted in a significant reduction in cell viability as assessed by PI 
staining (54.3% + 2.9 versus 36.8% + 2.4, respectively, p<0.001). On occasion, verapamil 
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treatment resulted in the total loss of all viable cells and in such cases resolution of the SP 
was not possible. Fumitremorgin C was observed to reduce cell viability noticeably less than 
verapamil (41.4% + 1.7, p=0.003 versus Hoechst 33342-treated cells), but was less effective 
at blocking the ABCG2 pump, as measured by a less than 75% reduction in SP region cell 
numbers following ABCG2-blockade (region 4, figure 7.1). Verapamil was therefore chosen 
as the ABCG2 pump-blocking agent of choice in subsequent experiments.  
 
7.3.2 DyeCycle Violet is an alternative fluorescent molecule capable of discriminating 
side population cells with ABCG2-mediated efflux properties 
Flow cytometric cell sorters with ultraviolet (UV) lasers (wavelength 350nm) are readily able 
to resolve a side population of cells from a variety of primary tissue types. However, such 
equipment is expensive and often unavailable to many laboratories. More commonly, flow 
cytometers are equipped with near-UV lasers (wavelength 370nm) or violet laser diodes 
(VLD, wavelength 408-401nm) which are smaller, less expensive and do not contain 
maintenance-intensive argon- or krypton-ion gas lasers. Near-UV lasers have been shown to 
resolve mouse bone marrow SP cells with excellent resolution, whereas VLD cytometers 
demonstrate poorer resolution and reduced ability to accurately discriminate the SP (288).  
 
DyeCycle Violet (DCV) is an alternative DNA-binding fluorescent molecule with similar 
emission characteristics to Hoechst 33342 but with a longer wavelength excitation maxima 
(369nm) (289). On isolated murine bone marrow cells, DCV has been shown to discriminate 
an equally precise SP of cells using a violet laser diode compared to that resolved using a 
traditional UV gas laser. Moreover, immunophenotyping of sorted cells from either the violet 
laser-resolved DCV SP or the UV laser-resolved Hoechst 33342 SP were identical in their 
stem cell lineage surface marker expression phenotypes (289).  
 
The ability of DCV to discriminate a SP of intestinal crypt epithelial cells using a violet laser 
diode was investigated using the Beckman Coulter MoFlo cell sorter. A protocol similar that 
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described in section 7.2.1 was used, but the addition of Hoechst 33342 was replaced by the 
DGGLWLRQRIȝ/'&9WRDFHOOVXVSHQVLRQRI[6 IEC in 1mL.  Using this modified 
protocol, a SP of intestinal crypt epithelial cells was discriminated (n=3, figure 7.2). The 
DGGLWLRQRIHLWKHUYHUDSDPLORUIXPLWUHPRUJLQ&ȝ/WRP/FHOOVXVSHQVLRQIRUERWK
resulted in a greater than four-fold reduction in cell numbers in the SP region (region 5, 
figure 7.2).  
 
7.3.3 Sorted side population and non-side population cells express BerEP4 but not 
CD45 
To investigate the expression of the epithelial marker BerEP4 and the haematopoietic 
marker CD45 on side population cells, healthy intestinal crypt cells were isolated and stained 
with Hoechst 33342 or DCV. Side population wells were resolved using verapamil ABCG2-
blockade and sorted into tubes containing FACS medium. Cells were collected following 
centrifugation and labelled with either anti-BerEP4-FITC or anti-CD45-AF488 monoclonal 
antibodies. Thereafter, cells were fixed in 0.5% formaldehyde until analysis. 
 
Side population cells were demonstrated to be BerEP4-positive (mean + SEM 97.9+2.1%, 
n=3, figure 7.3) but CD45-negative (0.35+0.35%, n=3, figure 7.4). Non-side population cells 
were immunophenotypically similar (BerEP4-positive 92.6+7.2%, n=3, and CD45-positive 
0.15+0.1%, n=3). 
 
 
7.3.4 Side population and non-side population cells express similar levels of surface 
TLR2 and TLR4 protein 
To investigate the expression of TLR2 and TLR4 on side population cells from healthy 
controls, large intestinal crypt cells were isolated and incubated with either Hoechst 33342 or 
DCV. Following fluorescent dye incubation, cells were chilled and centrifuged before staining 
with either anti-TLR2 or anti-TLR4 APC-conjugated monoclonal antibodies. Side population 
cells were resolved using verapamil-induced ABCG2-blockade.  
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At the time of SP discrimination using the MoFlo cytometer, cell events in the SP-gated sub-
population were simultaneously analysed for TLR2 and TLR4 expression by measuring APC 
median fluorescent intensity within the gated region. In addition, a sub-population of non-
side population of cells were also analysed for TLR2 and TLR4 expression and to act as a 
paired comparison group.  
 
Side population intestinal epithelial cells were observed to express both surface TLR2 and 
TLR4 protein (n=3, figure 7.5). Both TLR2 and TLR4 showed a trend towards higher 
expression in side population compared to non-side population sub-groups, but the 
differences were not statistically significant using a paired Wilcoxon test (TLR2: SP median 
[range] 7.1 [2.4-24] versus NSP 2.3 [1.3-3.9], p=0.25, n=3; TLR4: SP 7.7 [1.1-12.2] versus 
NSP 5.6 [3.2-6.8], p=0.59, n=3), figure 7.6.  
 
7.3.5 Sorted side population cells express TLR2, TLR3, TLR4 and TLR5 mRNA 
To investigate whether RNA could be isolated following their analysis and sorting by flow 
cytometry, side population and non-side population cells were demonstrated using the 
Hoechst 33342 fluorescent dye incubation and verapamil-mediated ABCG2-blockage of 
healthy control intestinal crypt cells. SP and NSP cells were sorted into cytometry tubes 
FRQWDLQLQJȝ/RI)$&6PHGLXP on ice. Following collection, cells were centrifuged and 
the supernatant discarded. RNA was isolated using the RNeasy Plus Mini kit and reverse-
transcribed into cDNA. The expression of HPRT, TLR2 and TLR4 mRNA was then 
investigated using conventional polymerase chain reaction.  
 
Three samples from healthy colon crypt epithelial cells were sorted into SP and NSP 
samples. Analysis of the quality of isolated RNA using the Nanodrop® spectrophotometer 
ZDVQRWSRVVLEOHGXHWRORZ51$FRQFHQWUDWLRQQJȝ/1RQHWKHOHVVDOOWKUHHVDPSOHV
expressed HPRT transcript, though expression appeared weaker in sample 3 than in 
samples 1 and 2 (figure 7.7A). Samples 1 and 2 also demonstrated mRNA expression for 
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TLR2 and TLR4 in both the SP and NSP isolates. However, there was no detectable 
expression of TLR2 or TLR4 mRNA in sample 3 (figure 7.7B and C).  
 
Side population samples were also analysed for expression of TLR5, TLR3 and TLR9 mRNA 
expression. Two of the three SP samples were shown to express TLR5 mRNA transcript, as 
did pooled mRNA samples from unsorted crypt intestinal epithelial cells from the small and 
large intestine, primary PBMC and T84 and THP-1 cell lines (figure 7.8A). All three SP 
samples expressed TLR3 mRNA, as did human primary PBMC and the T84 epithelial cell 
line, but not the THP-1 monocyte cell line (figure 7.8B). TLR3 RT-PCR amplification product 
bands were weaker than those of TLR5 RT-PCR amplification. Side population cells did not 
express transcripts for TLR9 mRNA (figure 7.8C). There was weak expression of TLR9 
mRNA by PBMC and the T84 epithelial cell line, but the THP-1 cell line did not express 
TLR9 mRNA (figure 7.8C).  
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7.4 Figures 
 
 
 
 
Figure 7.1 Isolated colonic intestinal crypt cells demonstrate a population of cells with side 
population characteristics. Isolated colonic crypt cells were incubated with the fluorescent 
dye Hoechst 33348 alone (left side) or following incubation with an ABDG2-blocking agent, 
either verapamil (right, top) or fumitremorgin C (right, bottom). The proportion of cells with 
low fluorescence in both the red (FL10) and blue (FL7) channels (region 4, R4) reduced from 
2.38% in unblocked cells to 0.37% or 1.11% with verapamil and fumitremorgin C, 
respectively. This region represents a population of cells which have the phenotype of 
Hoechst 33342 dye exclusion via the ABCG2 efflux pump and are known as side population 
cells.  
 
ABCG2, ATP binding cassette (ABC) transporter Bcrp1 
 
 
 
 
 
Red 
Blue 
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Figure 7.2 Isolated colonic intestinal crypt cells demonstrate a population of cells with side 
population characteristics using DyeCycle Violet. Isolated colonic crypt cells were incubated 
with the fluorescent molecule DyeCycle Violet alone (left side) or following incubation with an 
ABDG2-blocking agent, either verapamil (right, top) or fumitremorgin C (right, bottom). The 
proportion of cells with low fluorescence in both the red (FL10) and blue (FL7) channels 
(region 5, R5) reduced from 2.45% in unblocked cells to 0.58% or 0.54% with verapamil and 
fumitremorgin C, respectively. This region represents a population of cells which have the 
phenotype of ABCG2 efflux pump expression and are known as side population cells.  
 
ABCG2, ATP binding cassette (ABC) transporter Bcrp1 
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Red 
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Figure 7.3 Sorted side population cells express surface BerEP4 protein. Intestinal crypt 
epithelial cells were isolated and incubated with the fluorescent dye Hoechst 33342 or DCV. 
Side population cells were identified by demonstrating that their efflux of the fluorescent dye 
was ameliorated using the ABCG2-blocking agent verapamil. Side population cells were 
sorted and subsequently stained with (A) isotype control FITC-conjugated or (B) anti-BerEP4 
FITC-conjugated monoclonal antibodies, followed by analysis on a flow cytometer. Data 
were overlaid on a histogram (C) to illustrate comparative distribution of antibody 
fluorescence in each tube. The Y-axes in panels A and B represent unused gates.  
 
 
Black: Isotype-FITC control 
Purple: BerEP4-FITC 
 
ABCG2, ATP binding cassette (ABC) transporter Bcrp1; DCV, DyeCycle Violet; FITC, 
Fluorescein isothiocyanate 
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Figure 7.4 Sorted side population cells do not express CD45 protein. Intestinal crypt 
epithelial cells were isolated and incubated with the fluorescent dye Hoechst 33342 or DCV. 
Side population cells were identified by demonstrating that their efflux of the fluorescent dye 
was ameliorated using the ABCG2-blocking agent verapamil. Side population cells were 
sorted and subsequently stained with (A) isotype control AF488-conjugated or (B) anti-CD45 
AF488-conjugated monoclonal antibodies, followed by analysis on a flow cytometer. Data 
were overlaid on a histogram (C) to illustrate comparative distribution of antibody 
fluorescence in each tube. The Y-axes in panels A and B represent unused gates.  
 
 
Black: Isotype-AF488 control 
Yellow: CD45-AF488 
 
ABCG2, ATP binding cassette (ABC) transporter Bcrp1; AF488, Alexa Fluor-488; DCV, 
DyeCycle Violet 
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Figure 7.5 Side population cells express surface TLR2 andTLR4 protein. Isolated crypt 
intestinal cells were incubated with the fluorescent dye Hoechst 33342 or DCV followed by 
staining with either (A) anti-TLR2 APC-conjugated or (B) anti-TLR4 APC-conjugated 
monoclonal antibodies. Side population cells were identified by demonstrating that their 
efflux of the fluorescent dye was ameliorated using the ABCG2-blocking agent verapamil. 
Subsequently, cells with side population characteristics were gated, and the expression of 
TLR2 and TLR4 surface protein was characterised by measuring fluorescence in the APC 
channel at the time of cell sorting.  
 
 
Black: Isotype-APC control  
Red: TLR2-APC 
Blue: TLR4-APC 
 
ABCG2, ATP binding cassette (ABC) transporter Bcrp1; APC, Allophycocyanin; DCV, 
DyeCycle Violet 
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Figure 7.6 Side population cells express similar levels of TLR2 and TLR4 protein compared 
to non-side population cells. Isolated intestinal crypt cells were incubated with the 
fluorescent dye Hoechst 33342 or DCV, followed by staining with either (A) anti-TLR2 APC-
conjugated or (B) anti-TLR4 APC-conjugated monoclonal antibodies. Side population cells 
(SP) were identified by demonstrating that their efflux of the fluorescent dye was ameliorated 
using the ABCG2-blocking agent verapamil. In contrast, cells demonstrating no dye efflux 
properties in the red (FL10) and blue (FL7) channels following ABCG2-blockade were 
termed non-side population cells (NSP). Subsequently, cells with SP and NSP 
characteristics were gated, and the expression of TLR2 and TLR4 surface protein was 
calculated as the difference between the median fluorescence intensities of the primary and 
isotype antibodies in the APC channel. Subject numbers correspond to the subjects in 
figures 7.7 and 7.8.  
 
ABCG2, ATP binding cassette (ABC) transporter Bcrp1; APC, allophycocyanin; DCV, 
DyeCycle Violet; NSP, non-side population; SP, side population; TLR, Toll-like receptor 
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B 
Subject 1 
Case 3 
Subject 2 
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Subject 1 
Subject 3 
Subject 2 
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Figure 7.7 Sorted side population cells express TLR2 and TLR4 mRNA. Side population 
cells (SP) were identified from isolated intestinal crypt cells (n=3) by demonstrating that their 
efflux of a fluorescent dye (Hoechst 33342 or DCV) was ameliorated using the ABCG2-
blocking agent verapamil. Cells demonstrating no dye efflux properties were termed non-
side population cells (NSP). Subsequently, SP and NSP cells were cytometrically sorted and 
RNA isolated before conventional RT-PCR was undertaken. The mRNA expression of (A) 
HPRT (160bp), (B) TLR2 (599bp) and (C) TLR4 (507bp) was investigated using agarose gel 
electrophoresis and UV transillumination.  
 
Lanes 1-3: Side population cells (a) and non-side population cells (b) from subjects 1-3  
Lane 4: PBMC positive control 
Lane 5: No reverse transcriptase (negative) control 
Lane 6: No cDNA template (negative) control 
 
DCV, DyeCycle Violet; HPRT, Hypoxanthine guanine phosphoribosyltransferase; L 100 base 
pair ladder; PBMC, peripheral blood mononuclear cell; RT-PCR, reverse transcriptase 
polymerase chain reaction; TLR, Toll-like receptor; UV, ultra-violet light 
 
   L        1a        2a      3a                1b      2b      3b        5       6 
A 
B 
C 
   L         1a      1b       2a      2b       3a     3b         4       5       6 
500bp 
100bp 
500bp 
600bp 
600bp 
500bp 
    L        1a      1b       2a       2b      3a      3b       4        5        6 
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Figure 7.8 Sorted side population cells express transcripts for TLR5 and TLR3, but not TLR9 
mRNA. Side population cells (SP) were identified from isolated intestinal crypt cells (n=3) by 
demonstrating that their efflux of a fluorescent dye (Hoechst 33342 or DCV) was ameliorated 
using the ABCG2-blocking agent verapamil. Cells demonstrating no dye efflux properties 
were termed non-side population cells (NSP). Subsequently, SP and NSP cells were 
cytometrically sorted and RNA isolated before conventional RT-PCR was undertaken. The 
mRNA expression of (A) TLR5 (147bp), (B) TLR3 (90bp) and (C) TLR9 (146bp) was 
investigated using agarose gel electrophoresis and UV transillumination.  
 
Lanes 1-3: Side population cell from subjects 1-3  
Lane 4: PBMC 
Lane 5: T84 human epithelial cell line 
Lane 6: THP-1 human monocyte cell line 
Lane 7: Pooled healthy control small intestine unsorted crypt intestinal epithelial cells (n=7) 
Lane 8: Pooled healthy control colon unsorted crypt intestinal epithelial cells (n=13) 
Lane 9: No reverse transcriptase (negative) control 
Lane 10: No cDNA template (negative) control 
 
DCV, DyeCycle Violet; HPRT, Hypoxanthine guanine phosphoribosyltransferase; PBMC, 
peripheral blood mononuclear cell; RT-PCR, reverse transcriptase polymerase chain 
reaction; TLR, Toll-like receptor; UV, ultra-violet light
   1     2      3     4     5     6      7     8     9    10 
    1        2        3        4        5        6       9     10 
A 
B 
C 
    1        2       3       4        5        6       9      10 
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7.5 Discussion 
The demonstration of a side population of cells by their ability to efflux the DNA-binding 
fluorescent dye Hoechst 33342, which is ameliorated by pre-incubation of cells with an 
ABCG2-blocking agent such as verapamil or FTC, has allowed investigators to 
cytometrically sort a sub-population of cells enriched for stem cells. This technique was 
originally described using murine haematopoietic stem cells (202), and subsequently side 
population cells have been described in murine liver (205) and skeletal muscle (206, 207) 
and in human breast (203) and prostate (204). Prior to this discovery, intestinal stem cells 
were identifiable only by their label-retaining properties (193) or via immunohistochemical 
staining of a number of intracellular markers (174), and could not be sorted for down-stream 
analysis. SP cells expressing intestinal stem cell markers have been reported in the mouse 
jejunum (208) and more recently in the human colon (210).  
 
Traditionally, to be able to identify the SP cells it has been a requirement of flow cytometers 
that a UV laser is used at a wavelength of approximately 350nm for Hoechst 33342 dye 
excitation. The Beckman Coulter MoFlo cytometer contains a violet laser diode (VLD, 
wavelength 401-408nm) which is smaller, less expensive and does not contain a 
maintenance-intensive argon- or krypton-ion gas laser. It has been reported that VLD laser-
containing flow cytometers are still able to resolve the murine bone marrow SP cells using 
Hoechst 33342 dye, although discrimination of the target SP is poorer than with the use of 
near-UV (wavelength 370nm) and UV lasers (wavelength 350nm) (288).  
 
This study set out to investigate if a SP of colonic epithelial cells could be resolved using the 
Beckman Coulter MoFlo VLD laser cytometer. Indeed it was possible to discriminate a SP of 
intestinal crypt epithelial cells isolated from healthy colonic mucosa and it was also possible 
to selectively sort these cells directly into culture medium for down-stream analysis. Although 
both verapamil and FTC were shown to block the ABCG2 efflux pump and facilitate in the 
298 
 
identification of the SP cells, verapamil was consistently the more effective blocking agent. 
However, verapamil treatment was associated with a reduction in total isolated cell viability 
and, on occasion, verapamil incubation resulted in complete loss of all viable cells with 
failure to resolve the side population.  
 
To attempt to improve the discrimination of the SP cells using the VLD laser, an alternative 
DNA-binding fluorescent dye to replace Hoechst 33342 was sought. DyeCycle Violet (DCV) 
is reported to demonstrate similar emission characteristics to Hoechst 33342 under both UV 
and violet light, but has longer wavelength excitation maxima (369 nm), and allowed 
accurate identification of a SP of murine bone marrow cells which expressed the predicted 
haematopoietic stem cell markers Sca-1 and c-kit (289). Subsequently, DCV has been 
reported to discriminate the SP of an enriched stem cell population in benign and malignant 
primary prostate tissue and several prostate cancer cell lines (CWR-R1, DU-145 and RWPE-
1 cells) (290) and in a human bladder cancer cell line (SW780) (291). There is therefore 
good data to suggest that DCV dye exclusion is a valid reagent for identifying stem cell-
enriched SP cells.  
 
This study demonstrated that when using DCV dye it was possible to discriminate a side 
population of crypt intestinal epithelial cells from primary human colon, using both verapamil 
and FTC as ABCG2-blocking agents and using the VLD laser of the MoFlo cytometer. 
However, resolution of the SP of cells did not appear to be superior to the resolution of the 
SP using Hoechst 33342. Since DCV is significantly more expensive than Hoechst 33342 
and offered no improvement in SP cell resolution, Hoechst 33342 dye was used for all 
subsequent down-stream analyses of sorted SP cells.  
 
To allow further characterisation, SP cells isolated using Hoechst 33342 were sorted and 
stained with antibodies to the epithelial specific marker BerEP4 and the haematopoietic 
marker CD45. Isolated SP cells were shown to be exclusively BerEP4-positive and CD45-
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negative, suggesting that these isolated SP cells were epithelial and not haematopoietic in 
origin. Previous work in this laboratory has demonstrated that SP cells isolated by Hoechst 
33342 dye efflux express the putative ISC marker CD133 and over-express ȕ-integrin, but 
do not express the haematopoietic stem cell marker CD34 using flow cytometry. 
Furthermore, isolated SP cells express the ISC marker Msi-1 using immunocytochemical 
staining (210). Therefore, SP cells sorted by Hoechst 33342 express epithelial cell and 
intestinal stem cell markers, but not markers of haematopoietic stem cells, and are a suitable 
population of cells on which to further analyse ISC characteristics.  
 
Interestingly, sorted SP and NSP cells expressed surface TLR2 and TLR4 protein in all 
samples using flow cytometry. Moreover, when these SP cells were sorted and collected, 
transcripts for TLR2 and TLR4 mRNA were identified in two of the three samples. The third 
sample demonstrated mRNA of poor quality and low concentration, which may have been a 
contributing factor the lack of visible bands following conventional RT-PCR amplification.  
 
Myofibroblast-adherent epithelial cells are predominantly Msi-1-positive intestinal stem cells 
(210). Earlier in this study, un-sorted intestinal crypt cells were co-cultured with myofibroblast 
monolayers (section 6.2.3). Staining of these co-cultured cells demonstrated TLR2 and 
TLR4 expression by both MF and adherent cells, however the adherent IEC demonstrated 
more intense staining than the underlying MF cells (section 6.3.5).  
 
These data suggest that putative intestinal stem cells isolated by SP cell sorting or through 
their interaction with cultured intestinal myofibroblasts express TLR2 and TLR4 transcripts 
and protein, as identified using a variety of laboratory techniques. When the expression of 
surface TLR2 and TLR4 protein on SP cells was compared to expression on NSP (non-
stem) cells, there was no significant difference in absolute expression levels, though a trend 
towards higher expression was noted for both TLR2 and TLR4 in SP cells.  
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Side population cells also expressed transcripts for TLR5 and TLR3 mRNA. Agonists for 
TLR5 have been shown to protect against the induction of radiation-induced enteritis if given 
prior to radiation treatment (161). Furthermore, parenteral TLR3 ligands protect against the 
development of murine experimental colitis (159). These data further implicate the intestinal 
stem cell in directly sensing microbial ligands through the recognition of flagellated bacteria 
and microbial dsRNA, respectively.  
 
This is the first report to demonstrate TLR2, TLR3, TLR4 and TLR5 expression in a human 
ISC-enriched population. A recent abstract reported the epithelial-specific over-expression of 
TLR4 in mice expressing the green fluorescent protein-labelled ISC marker Lgr5 (292). 
Over-expression of epithelial TLR4 in mice resulted both in the expansion of the Lgr5-
positive stem cell population and in QXFOHDUDFFXPXODWLRQRIȕ-catenin, two events which are 
associated with tumorigenesis. Moreover, villin-TLR4 mice with DSS-induced colitis are 
highly susceptible to azoxymethane-induced neoplasia, which was inhibited using a 
TLR4/MD-2 antagonist (273) and which may signal through epidermal growth factor receptor 
ligands (293). This provides evidence that TLR4 signalling is directly important in ISC 
function and may play a role in neoplastic transformation.  
 
Interestingly, this group have also demonstrated increased immunostaining of TLR4 in 
human ulcerative colitis-associated dysplasia and cancer (273). To the contrary, the TLR4 
Asp299Gly gene polymorphism (which interrupts TLR4 signalling) is reported to confer a 
greater risk of advanced stage in sporadic human colonic adenocarcinoma, suggesting loss 
of TLR4 signalling may convey a worse prognosis in this setting (294).  
 
Stem cells are vital for replenishing the epithelial cell surface of the intestine, which turns 
over every five days in the healthy state (187). Following epithelial injury stem cell expansion 
is a key step in epithelial restitution and mucosal healing (295). Exposure to ligands for 
TLR2, TLR3, TLR4 and TLR9 are protective against various models of experimental colitis in 
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mice (159). Exposure to the TLR4 ligand LPS prior to radiation injury protects mice form 
radiation enteritis (160) and the TLR5 ligand flagellin has similar radio-protective effects on 
intestine and bone marrow in mice and primates (161). It was unclear from these 
publications if these ligands acted directly or indirectly on the intestinal stem cell population. 
 
My studies suggest that ISC may be able to directly sense intestinal Gram-positive, Gram-
negative and flagellated bacteria via their expression of TLR2, TLR3, TLR4 and TLR5, and 
imply that the protective effects of prior exposure to these ligands in experimental models of 
colitis and radiation enteritis may act via direct ligand interaction with these receptors on the 
stem cells themselves. Moreover, TLR4 signalling in intestinal stem cells may be an 
important pathway in colitis-associated tumorigenesis. It would be interesting to investigate if 
there is differential expression of TLR2, TLR4 and TLR5 by intestinal stem cells in patients 
with active IBD and in patients with IBD-associated dysplasia and cancer.  
 
Intestinal stem cells may therefore play a role in bacterial sensing, which is known to be 
important in maintaining intestinal homeostasis. These data also suggest that TLR-directed 
therapeutic interventions in inflammatory colonic diseases may act directly on the stem cells 
themselves, providing a possible future mechanism for influencing intestinal stem cell 
function. 
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Chapter 8: Discussion and conclusions 
7KHLQIODPPDWRU\ERZHOGLVHDVHVXOFHUDWLYHFROLWLVDQG&URKQ¶VGLVHDVHDUHLQFXUDEOH
chronic inflammatory conditions which primarily affect the distal ileum and colon. IBD is 
associated with significant morbidity. Current medical treatments are successful at inducing 
and maintaining disease remission in a proportion of patients, but many patients inevitably 
require surgical intervention. Although there have been significant advances in the treatment 
of IBD with the introduction of anti-tumour necrosis factor-alpha therapy, a significant 
number of patients either fail to respond or lose response to this treatment. A better 
understanding of the underlying pathogenesis of IBD may lead to more effective treatments 
in the future.  
 
Pathologically IBD results in a dense inflammatory cell infiltrate into the intestinal mucosa, 
resulting in the histopathological features of epithelial cell loss, crypt architectural distortion 
and dense peri- and intra-crypt inflammation, causing cryptitis and crypt abscesses. At the 
base of the crypts reside intestinal stem cells surrounded by the stromal cells, forming the 
stem cell niche. Interaction between the cells of the niche is important to the regulation of 
stem cell proliferation and differentiation, a vital process in restitution following epithelial 
injury.  
 
Toll-like receptors are innate immune system pattern recognition receptors expressed by a 
variety of cells, including intestinal epithelial cells. These receptors bind to highly conserved 
cellular molecules expressed by a number of micro-organisms, including commensal and 
pathogenic bacteria. The role of toll-like receptor signalling in the intestinal mucosa is 
complex. While toll-like receptor signalling is indispensable in the formation of a healthy 
mucosal immune system and in maintaining homeostasis, excessive receptor signalling 
results in and perpetuates intestinal inflammation and may play a role in carcinogenesis.  
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With this in mind, this study set out to characterise the expression of Toll-like receptors 2 
and 4 by crypt intestinal epithelial cells in patients with inflammatory bowel disease. The 
crypt epithelial cells were chosen specifically for a number of reasons. Firstly, the crypt 
lumen does not normally contain bacteria and it is only during intestinal inflammation that 
bacteria are present in the crypt. Secondly, cryptitis and crypt abscesses are pathological 
features of inflammatory bowel disease, implicating the crypt epithelium as a focal region of 
mucosal inflammation in inflammatory bowel disease. Thirdly, it is reported that the 
expression of Toll-like receptor 2 and 4 is greatest in the crypt epithelial cells, with down-
regulation of expression demonstrated as epithelial cells migrate to the intestinal luminal 
surface. Finally, the crypt is the location of the intestinal stem cells which are vital in 
responding to mucosal injury by replenishing the epithelium.  
 
Initially this study demonstrated that ethylenediaminetetraacetic acid (for the isolation of 
intestinal crypts) and pancreatin treatment (for the disaggregation of crypt epithelial cells) 
resulted in the isolation of a population of individual crypt epithelial cells. These crypt cells 
contained few non-epithelial cells. Moreover, isolated crypt cells from patients with 
inflammatory bowel disease did not result in haematopoietic cell contamination. This 
technique also isolated Paneth cells from mucosal samples of the small intestine.  
 
Quantitative analysis demonstrated up-regulation of Toll-like receptors 2 and 4 transcripts 
and cell surface proteins by crypt intestinal epithelial cells from patients with ulcerative colitis 
DQG&URKQ¶VFROLWLV7ROO-like receptor 4 transcript was also up-regulated in crypt cells from 
SDWLHQWVZLWK&URKQ¶VLOHLWLVThis data suggests that Toll-like receptors 2 and 4 play a role in 
the pathogenesis of inflammatory bowel disease and may offer a future therapeutic target for 
active disease. This is the first study to report surface toll-like receptor expression by primary 
intestinal epithelial cells using flow cytometry.  
 
304 
 
This study also demonstrated an up-regulation of the expression of Toll-like receptor 4 
transcript in histologically normal, un-inflamed crypt cells from patients with ulcerative colitis.  
Moreover, both Toll-like receptors 2 and 4 transcripts were similarly expressed in paired 
normal and inflamed specimens from patients with left-sided ulcerative colitis. These data 
suggest that Toll-like receptor 2 and 4 expression is constitutive in the crypt epithelial cells of 
patients with ulcerative colitis. This may indicate a primary predisposition to ulcerative colitis 
in these individuals and suggests up-regulated Toll-like receptor expression by intestinal 
epithelial cells is not purely a secondary phenomenon.  
 
Intestinal myofibroblasts are important mucosal cells which play a significant role in the 
regulation of intestinal stem cells in the stem cell niche. Myofibroblasts regulate the mucosal 
immune response by secreting a number of inflammatory mediators and sensing bacterial 
ligands. Myofibroblasts are also responsible for the formation of the intestinal fibrosis 
REVHUYHGLQLQIODPPDWRU\ERZHOGLVHDVHSDUWLFXODUO\&URKQ¶VLOHLWLVThis study has 
demonstrated expression of Toll-like receptors 2 and 4 by primary cultured intestinal 
myofibroblasts, which may be up-UHJXODWHGLQ&URKQ¶VLOHLWLVDQGPD\SOD\DUROHLQWKH
pathogenesis of intestinal fibrosis. Moreover, Toll-like receptor 2 transcript is down-regulated 
in ulcerative colitis, a condition where intestinal fibrosis is less common.  
 
Isolated crypt cells adhere to cultured primary intestinal myofibroblasts and these adherent 
cells are highly enriched for intestinal stem cells. This study reports that adherent crypt cells 
express Toll-like receptors 2 and 4 proteins, suggesting intestinal stem cells express these 
receptors.  
 
Efflux of the fluorescent dye Hoechst 33342 via the ATP binding cassette transporter Bcrp1 
allows identification of a group of cells referred to as side population cells. These cells are 
highly enriched for epithelial and intestinal stem cells markers. This study has demonstrated 
that side population cells expressed the epithelial-specific marker BerEP4 but not the 
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haematopoietic marker CD45. Furthermore side population cells expressed Toll-like 
receptors 2 and 4 transcripts and protein, and expressed TLR3 and TLR5 transcripts.  
 
Together with the observations from the myofibroblast-adherent crypt cell experiments, 
these data suggest intestinal stem cells are able to directly sense microbial products through 
Toll-like receptors 2, 3, 4 and 5. Signalling through toll-like receptors has been reported to 
protect mice from experimental colitis and radiation-induced enteritis. The demonstration of 
Toll-like receptors 2, 3, 4 and 5 expression by intestinal stem cells suggests this protective 
effect may act directly on intestinal stem cells and provides a mechanism through which 
intestinal stem cell function may be manipulated in health and during mucosal inflammation. 
This may have wider reaching implications given the observation that Toll-like receptor 4 
signalling is implicated in experimental colitis-induced colonic cancer and manipulation of 
Toll-like receptor 4 signalling may become an important future cancer chemo-protective 
therapy in inflammatory bowel disease.  
 
There are limitations to the current study which warrant discussion. The histological 
assessment of the activity of mucosal inflammation was undertaken by a Clinical 
Histopathologist blinded to the underlying diagnosis and disease activity of each study 
participant. In all cases, the mucosal samples from which the intestinal crypt cells were 
isolated, and from which the histological assessment was made, were taken from 
immediately adjacent regions of the bowel (with macroscopically similar degrees of 
inflammation), but not from the exact same site. It is likely Toll-like receptors expression data 
from the isolated crypt cells were representative of those from adjacent tissue (on which the 
histological activity of severity was assessed). However this may not always have been the 
FDVHSDUWLFXODUO\LQVXEMHFWVZLWK&URKQ¶VGLVHDVHZKLFKLVFKDUDFWHULVHGE\VNLSOHVLRQVLQ
disease extent.  
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The magnitude of the differences in the differential expression of Toll-like receptors 2 and 4 
at the transcript levels and the protein level were dissimilar. Surface protein expression was 
several-fold greater than the corresponding mRNA expression when comparing subjects 
with IBD and healthy controls. One explanation for this observation is that the rate of 
degradation of cellular mRNA was more rapid than that of surface protein, resulting in a 
reduction in the observed differential expression in the former. It is also possible that, 
because the subjects contributing to the real-time RT-PCR and flow cytometry data were not 
taken from the same cohort of individuals, there may have been differences amongst these 
groups which explain the differences in Toll-like receptor 2 and 4 expression rather than 
mRNA degradation. Ideally, analysis of transcript and surface protein expression would have 
been undertaken on the same group of subjects to allow a more meaningful discussion on 
the magnitude of Toll-like receptor expression.  
 
Investigation of the expression of Toll-like receptors 2 and 4 in crypt cells from patients with 
&URKQ¶VLOHLWLVZDVOLPLWHGto the mRNA level. Similarly, specimens from subjects with acute 
severe colitis were also limited to the mRNA level. It would have been desirable to have 
been able to investigate the expression of Toll-like receptors 2 and 4 at the surface protein 
level in these groups for completeness. Likewise, the observed greater expression of Toll-
like receptors 2 and 4 transcripts in crypt cells from histologically normal regions of mucosa 
in patients with left-sided UC compared to healthy controls was only investigated at the 
transcript level. Analysis of surface expression at the protein level in this unique group of 
patients would be very interesting.  
 
In chapter 6, the expression of Toll-like receptors 2 and 4 was investigated in cultured 
myofibroblasts from healthy control and patients with IBD. The sample sizes for IBD subjects 
were limited to three cases in each group. This was in part due to the lengthy and complex 
myofibroblast acquisition and culture protocol, which limited the number of specimens which 
could be cultured over several months, and partly due to tissue availability in the latter period 
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of the study. Therefore, while there appeared to be trends in the differential expression of 
Toll-like receptors in myofibroblaVWVIURPSDWLHQWVZLWK&URKQ¶VLOHLWLVDQGXOFHUDWLYHFROLWLV
larger sample groups are required to definitively answer this issue. The data reported in his 
chapter should be regarded as preliminary data.  
 
A significant number of samples were required to optimise the protocol for identifying side 
population cells using both Hoechst 33342 and DyeCycle Violet fluorescent dyes. However, 
the expression of Toll-like receptors in the side population cells were reported in a group of 
three healthy large intestine control specimens. Further investigation using a larger sample 
size, including healthy samples from the small intestine, would be required to more 
definitively address the issue of Toll-like receptor expression in the intestinal stem cells 
population.  
 
All crypt cell samples were isolated the day following acquisition of the mucosal tissue from 
the study participant. In many cases, primary tissue was not available for collection until late 
in the working day. It was not possible to isolate crypt cells and undertake flow cytometric 
analysis on live cells the same day due to time constraints. Therefore, all acquired tissue 
was maintained in tissue culture medium overnight and the cell isolation protocol undertaken 
at the beginning of the following day. This allowed continuity in the handling of all specimens 
and allowed the acquisition of live cells for flow cytometric analysis and sorting. However, 
there was a risk that cell viability, mRNA quality and protein quality would decline during the 
overnight storage step. Therefore interpretation of the Toll-like receptor mRNA and protein 
expression data should be undertaken with this born in mind.  
 
This study had a number of strengths. Care was taken to phenotypically characterise the 
isolated crypt cell population, ensuring that only epithelial cells and intestinal myofibroblasts, 
but not haematopoietic cells were included in the Toll-like receptor expression data analysis. 
CD45-positive cells were excluded from all flow cytometric analyses, allowing only BerEP4-
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positive (i.e. epithelial) cells to be analysed. This is the first study to positively gate for 
epithelial cells in this way using flow cytometry.  
 
Extensive demographic data was obtained for each subject enabling the investigation of 
factors which may have explained the observed differences between groups. Apart from age 
and immunosuppressant drug therapies, all groups were well matched. Moreover, an age-
related decline in Toll-like receptor expression was excluded as an explanation for the 
differential expression between the younger IBD groups and the older healthy control groups 
using a sub-group analysis of the healthy control subjects.  
 
The study included subjects with IBD of varying degrees of histological disease activity, as 
assessed by a blinded Clinical Histopathologist using a published and well-reported method. 
This allowed assessment of the effect of disease activity and local mucosal inflammation on 
Toll-like receptor expression, a novel aspect of this study. Moreover, the inclusion of a sub-
group of patients with left-sided colitis allowed assessment of the expression of Toll-like 
receptors in histologically normal mucosal from patients with UC. This data has provided 
insights into the primary expression of Toll-like receptors in this unique group.  
 
The assessments of both mRNA and protein expression were undertaken using more than 
one technique for each molecule, providing greater confidence in the observed differences 
amongst IBD and healthy control groups. Transcript and protein assays were undertaken 
using well established and widely reported techniques. These techniques were highly 
reproducible and provided mRNA of high quality, as assessed by spectrophotometry and 
micro-fluid capillary electrophoresis. All primers and antibodies used in the analyses were 
extensively tested for functionality using established control templates.  
 
The analyses of primary crypt intestinal cells from human samples of patients with IBD using 
quantitative methods, including real-time RT-PCR and flow cytometry, were both novel to 
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this study and allowed accurate quantification of Toll-like receptor expression. This is the first 
study to quantitatively demonstrate up-regulation of Toll-like receptors 2 and 4 in crypt 
intestinal epithelial cells in human IBD.  
 
Future studies in this field should aim to determine if the Toll-like receptors expressed by 
primary human intestinal epithelial cells are functional when exposed to their respective 
ligands. Although this has been demonstrated in human epithelial cancer cell lines, primary 
intestinal epithelial Toll-like receptor function has not been reported. Demonstration of their 
functionality would strengthen the evidence suggesting that Toll-like receptors play important 
roles in maintaining intestinal homeostasis in humans and in the pathogenesis of human 
inflammatory bowel disease.  
 
The role of Toll-like receptor expression and signalling in intestinal myofibroblasts, 
particularly in myofibroblasts GHULYHGIURPSDWLHQWVZLWKVWULFWXULQJ&URKQ¶VLOHLWLVDOVR
warrants further investigation in a larger cohort of patients, particularly as a stricturing 
SKHQRW\SHLVFRPPRQWR&URKQ¶VGLVHDVH. Investigation of sustained or diminished Toll-like 
receptor expression with successive primary cell culture passage would be interesting to 
undertake. It has been demonstrated that transforming growth factor-ȕLVRIRUPVDUH
consistently expressed during successive passages during myofibroblast culture, but this 
has not been reported for Toll-like receptors.  
 
Finally, the role of Toll-like receptor signalling in intestinal stem cell regulation is likely to be 
of great scientific interest over the next few years. Toll-like receptor-mediated regulation of 
intestinal stem cell function may have implications beyond mucosal inflammation to that of 
preventing radiation-induced enteritis and to a better understanding of colitis-associated 
cancer in the future.  
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